Any feedback?
Information on EC 3.2.1.18 - exo-alpha-sialidase and Organism(s) Homo sapiens and UniProt Accession Q9UQ49
for references in articles please use BRENDA:EC3.2.1.18Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.2.1.18 exo-alpha-sialidaseIUBMB Comments
The enzyme does not act on 4-O-acetylated sialic acids. endo-alpha-Sialidase activity is listed as EC 3.2.1.129, endo-alpha-sialidase. See also EC 4.2.2.15 anhydrosialidase.
Specify your search results
Word Map
- 3.2.1.18
- influenza
-
sialic
- viruses
- vaccine
- pandemic
- oseltamivir
- lectin
-
sialylated
- oligosaccharide
- subtype
- epitope
- erythrocyte
- gangliosides
- lymphocyte
-
reassortant
-
hemagglutination
-
anti-influenza
- chicken
- glycans
-
surveillance
- galactose
- cholera
-
desialylation
- hn
- glycoconjugates
-
outbreak
- cruzi
-
poultry
- virion
- bird
- pronase
- parainfluenza
-
epidemic
-
n-acetylneuraminic
- trypanosoma
- peanut
- mucin
-
n-linked
- newcastle
-
agglutination
- perfringens
- nucleoprotein
-
prophylaxis
-
concanavalin
- medicine
-
drift
-
sendai
- analysis
- n-acetylgalactosamine
- ferret
- nutrition
-
endoglycosidase
- molecular biology
- diagnostics
- gm3
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
The enzyme appears in selected viruses and cellular organisms
Synonyms
neuraminidase, sialidase, glycosyl hydrolase, trans-sialidase, hemagglutinin-neuraminidase, major surface antigen, alpha2,6-sialyltransferase, cytosolic sialidase, endosialidase, neuraminidase 1, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
Neu3
acetylneuraminidase
-
-
-
-
Acetylneuraminyl hydrolase
acylneuraminyl glycohydrolase
-
-
-
-
alpha-neuraminidase
-
-
-
-
Cytosolic sialidase
G9 sialidase
Ganglioside sialidase
-
-
-
-
Lysosomal sialidase
Major 85 kDa surface antigen
-
-
-
-
Major surface antigen
-
-
-
-
Membrane sialidase
-
-
-
-
Mouse skeletal muscle sialidase
-
-
-
-
MSS
-
-
-
-
MTS
-
-
-
-
mucopolysaccharide N-acetylneuraminylhydrolase
-
-
-
-
Murine thymic sialidase
-
-
-
-
N-acylneuraminate glycohydrolase
-
-
-
-
NANase
-
-
-
-
NEU1
NEU2
Neu3
NEU4
neuraminidase
SA85-1.1 protein
-
-
-
-
SA85-1.2 protein
-
-
-
-
SA85-1.3 protein
-
-
-
-
sialidase
STNA
-
-
-
-
Acetylneuraminyl hydrolase
-
-
-
-
Cytosolic sialidase
-
-
-
-
G9 sialidase
-
-
-
-
Lysosomal sialidase
-
-
-
-
neuraminidase
-
-
-
-
sialidase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates
catalytic mechanism, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of O-glycosyl bond
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
acetylneuraminyl hydrolase
The enzyme does not act on 4-O-acetylated sialic acids. endo-alpha-Sialidase activity is listed as EC 3.2.1.129, endo-alpha-sialidase. See also EC 4.2.2.15 anhydrosialidase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9001-67-6
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
N-glycolylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)Galbeta-p-nitrophenol + H2O
N-glycolylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
2'-(4-methyl-umbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) 9-O-acetyl-alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + 9-O-acetyl-alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(3-methoxyphenyl)-N-acetylneuraminic acid + H2O
3-methoxyphenol + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
about 1% activity compared to ganglioside GD3
-
-
?
4-methylumbelliferyl alpha-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-NeuAc + H2O
4-methylumbelliferone + alpha-neuAc
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
5-acetylneuraminic acid-(alpha2,3)Galbeta-4-nitrophenol + H2O
N-acetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-acetylneuraminic acid-(alpha2,6)Galbeta-4-nitrophenol + H2O
N-acetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-azidoacetylneuraminic acid-(alpha2,3)Galbeta-4-nitrophenol + H2O
N-azidoacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-azidoacetylneuraminic acid-(alpha2,6)Galbeta-4-nitrophenol + H2O
N-azidoacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-fluoroacetylneuraminic acid-(alpha2,3)Galbeta-4-nitrophenol + H2O
N-fluoroacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-fluoroacetylneuraminic acid-(alpha2,6)Galbeta-4-nitrophenol + H2O
N-fluoroacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
ganglioside GD3 + H2O
N-acetylneuraminate + ganglioside GM3
-
100% activity
-
-
?
ganglioside GM3 + H2O
N-acetylneuraminate + beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
Neu5(4-[(2,4-dinitrophenoxy)methyl]-1H-1,2,3-triazol-1-yl)Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-CH2(CH3)CH2CH2CH3 + H2O
?
-
-
-
-
?
Neu5Ac9(2,4-dinitrobenzoyl)N-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
O-(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->3)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->6)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-acetamido-9-O-acetyl-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->3)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-acetamido-9-O-acetyl-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->6)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-glycolylamido-3,5,-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->3)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-glycolylamido-3,5,-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->6)-O-(beta-D-galactopyranosyl)-(1-> 4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
-
i.e. NeuAcalpha(2-3)-Galbeta(1-3)-GalNAcbeta(1-4)-NeuAcalpha(2-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer, isozyme Neu-3, no activity with Neu-1
-
-
?
ganglioside GM3 + H2O
N-acetylneuraminate + beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
-
-
-
-
?
ganglioside GM3 + H2O
N-acetylneuraminate + beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
-
about 60% activity compared to ganglioside GD3
-
-
?
additional information
?
-
sialidase-3 is a key enzyme for ganglioside hydrolysis. Neu3 is an important regulator of insulin sensitivity and glucose tolerance
-
-
?
additional information
?
-
the Neu3 gene represents a physiological modulator of vascular smooth muscle cells responses that may contribute to plaque instability in atherosclerosis
-
-
?
additional information
?
-
the key catalytic residues of the enzyme consist of the general acid-base D50 and the nucleophilic Y370-E225 pair, molecular modeling to predict residues involved in the recognition and hydrolysis of glycolipid substrates, homology modeling and molecular docking of NEU3, overview
-
-
?
additional information
?
-
-
the key catalytic residues of the enzyme consist of the general acid-base D50 and the nucleophilic Y370-E225 pair, molecular modeling to predict residues involved in the recognition and hydrolysis of glycolipid substrates, homology modeling and molecular docking of NEU3, overview
-
-
?
additional information
?
-
sialidase NEU3 shows high enzymatic specificity toward gangliosides
-
-
?
additional information
?
-
-
enzyme is required for cellular signaling and for the production of cytokine interleukin-4 by activated T-lymphocytes, inherited enzyme defiency results in sialidosis or galactosialidosis, both severe metaboic disorders associated with lysosomal storage of oligosaccharides and glycopeptides
-
-
?
additional information
?
-
-
ganglioside substrate specificity of the isozymes, overview
-
-
?
additional information
?
-
-
hardly any activities on alpha(2-6)-sialyllactose and ganglioside GM1 and GM2
-
-
?
additional information
?
-
-
increased CD15 and decreased CD15s expression during myeloid differentiation is sialidase dependent. Both CD15s synthesis and sialidase activity are induced by CD44 ligation, but the increase in sialidase activity dominates, such that the overall expression pattern upon CD44 ligation is a decrease in CD15s expression with an accompanying increase in CD15. The observed increase in CD15 results predominantly from conversion of CD15s to CD15 on glycoproteins
-
-
?
additional information
?
-
-
neuraminidase causes the desialylation of both PDGF and IGF-1 receptors and diminishes the intracellular signals induced by the mitogenic ligands PDGF-BB and IGF-2
-
-
?
additional information
?
-
-
the induction of hST3Gal V, which synthesizes ganglioside GM3 and reduction of Neu3 by phorbol 12-myristate 13-acetate, are linked for the expression of differentiation marker protein, CD41b surface antigen. Neu3 overexpression inhibits the PMA-induced ERK1/2 and p38 MAPK phosphorylation in the K-562 cells. Down-regulation of expression of CD41b surface antigen is dependent on expression of Neu3 gene. Neu3 inhibitor 2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid induces morphological changes, showing megakaryocytic differentiation of K-562 cells, with expression of CD41b surface antigen, while specific glucosylceramide synthase inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol inhibits megakaryocytic differentiation of K-562 cells
-
-
?
additional information
?
-
-
both alpha2-3- and alpha2-6-linked sialosides are suitable substrates for NEU2 although it cleaves alpha2-3-linked sialosides more efficiently. Twenty 4-nitrophenyl-tagged alpha(2,3)- or alpha(2,6)-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid, non-human N-glycolylneuraminic acid, 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid, or their C5-derivatives are used as substrates, overview
-
-
?
additional information
?
-
-
substrate recognition of the membrane-associated sialidase NEU3 requires a hydrophobic aglycone, two-site model for enzyme recognition, requiring interaction at both the Neu5Ac residue and the hydrophobic aglycone. Evaluation of series of 11 synthetic trisaccharides. NEU3 substrate activity is directly dependent upon the hydrophobicity of the aglycone but has no apparent requirement for features of the ceramide headgroup. Trisaccharides with incorporated azide groups in the Neu5Ac residue at either C9 or the N5-Ac position are substrates, and in the case of the N5-azidoacetyl derivative, the activity is superior to that of GM3. Incorporation of larger aryl groups is tolerated only at C9, but not at N5-Ac
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
-
i.e. NeuAcalpha(2-3)-Galbeta(1-3)-GalNAcbeta(1-4)-NeuAcalpha(2-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer, isozyme Neu-3, no activity with Neu-1
-
-
?
additional information
?
-
sialidase-3 is a key enzyme for ganglioside hydrolysis. Neu3 is an important regulator of insulin sensitivity and glucose tolerance
-
-
?
additional information
?
-
the Neu3 gene represents a physiological modulator of vascular smooth muscle cells responses that may contribute to plaque instability in atherosclerosis
-
-
?
additional information
?
-
sialidase NEU3 shows high enzymatic specificity toward gangliosides
-
-
?
additional information
?
-
-
enzyme is required for cellular signaling and for the production of cytokine interleukin-4 by activated T-lymphocytes, inherited enzyme defiency results in sialidosis or galactosialidosis, both severe metaboic disorders associated with lysosomal storage of oligosaccharides and glycopeptides
-
-
?
additional information
?
-
-
increased CD15 and decreased CD15s expression during myeloid differentiation is sialidase dependent. Both CD15s synthesis and sialidase activity are induced by CD44 ligation, but the increase in sialidase activity dominates, such that the overall expression pattern upon CD44 ligation is a decrease in CD15s expression with an accompanying increase in CD15. The observed increase in CD15 results predominantly from conversion of CD15s to CD15 on glycoproteins
-
-
?
additional information
?
-
-
neuraminidase causes the desialylation of both PDGF and IGF-1 receptors and diminishes the intracellular signals induced by the mitogenic ligands PDGF-BB and IGF-2
-
-
?
additional information
?
-
-
the induction of hST3Gal V, which synthesizes ganglioside GM3 and reduction of Neu3 by phorbol 12-myristate 13-acetate, are linked for the expression of differentiation marker protein, CD41b surface antigen. Neu3 overexpression inhibits the PMA-induced ERK1/2 and p38 MAPK phosphorylation in the K-562 cells. Down-regulation of expression of CD41b surface antigen is dependent on expression of Neu3 gene. Neu3 inhibitor 2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid induces morphological changes, showing megakaryocytic differentiation of K-562 cells, with expression of CD41b surface antigen, while specific glucosylceramide synthase inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol inhibits megakaryocytic differentiation of K-562 cells
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
4,5-diacetamido-2-fluorobenzoic acid
23% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-(2-naphthamido)-2-fluorobenzoic acid
8% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
8% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-pentanamido-2-fluorobenzoic acid
13% inhibition of isoform NEU3 at 1 mM
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(acetylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(benzoylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(butyrylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-[(cyclopropylcarbonyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
2,6-anhydro-3,5-dideoxy-5-glycolylamido-D-glycero-D-galactonon-2-enonic acid
-
-
2,6-anhydro-5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid
-
induces morphological changes, showing megakaryocytic differentiation of K-562 cells, with expression of CD41b surface antigen
4,5-diacetamido-2-fluorobenzoate
8% inhibition of isoform NEU4 at 1 mM
4,5-diacetamido-2-fluorobenzoic acid
37% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-(2-methylbutanamido)-2-fluorobenzoic acid
7% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-benzamido-2-fluorobenzoic acid
17% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-pivalamido-2-fluorobenzoic acid
less than 5% inhibition of isoform NEU4 at 1 mM
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-(pentanoylamino)-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-[(3-methylbutanoyl)amino]-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-2,6-anhydro-9-[(cyclopentylcarbonyl)amino]-3,5,9-trideoxy-L-glycero-L-altro-non-2-enonic acid
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
-
-
plant extract
-
extracts of Laminaria saccharina, Fucus vesiculosus, Achillea millefolium, Allium cepa and Hypericum perforatum decrease activity. Extracts of pollen and garlic powder (Allium sativum) produce maximum inhibitory effect, 2fold inhibition after preoral administration
-
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
-
treatment of cultured human aortic smooth muscle cells induces significant up-regulation in smooth muscle cell proliferation in response to fetal bovine serum
4-acetamido-5-(2-ethylbutanamido)-2-fluorobenzoic acid
23% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-(2-ethylbutanamido)-2-fluorobenzoic acid
less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-(2-naphthamido)-2-fluorobenzoic acid
10% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-(2-naphthamido)-2-fluorobenzoic acid
33% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
10% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
60% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-cyclohexanecarboxamido-2-fluorobenzoic acid
17% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-cyclohexanecarboxamido-2-fluorobenzoic acid
6% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-cyclopropanecarboxamido-2-fluorobenzoic acid
20% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-cyclopropanecarboxamido-2-fluorobenzoic acid
less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-isobutyramido-2-fluorobenzoic acid
11% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-isobutyramido-2-fluorobenzoic acid
15% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-pentanamido-2-fluorobenzoic acid
25% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-pentanamido-2-fluorobenzoic acid
less than 5% inhibition of isoform NEU4 at 1 mM
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM
-
additional information
-
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM
-
additional information
-
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM
-
additional information
-
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
-
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
-
design of a sialidase inhibitor selective against human NEU2, inhibitor docking using also the crystal structure of the enzyme, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
protective protein/cathepsin A
-
because of its association with protective protein/cathepsin A, which acts as a molecular chaperone, NEU1 is transported to the lysosomal compartment, catalytically activated, and stabilized
-
sodium deoxycholate
-
highest activation (1.1-1.8.5fold) at 0.03% w/v concentration
additional information
-
isozymes Neu-1 and Neu-3 are induced in T-cells by CD3/CD28 co-stimulation, Neu-3 is the major inducible form in stimulated T-cells, specificity of induction, overview
-
additional information
-
the enzyme is activated at 37°C and acidic pH, activation is dependent on time, pH and temperature, activation is inhibited by amastatin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice.
Abscess
A Sialidase-Deficient Porphyromonas gingivalis Mutant Strain Induces Less IL-1? and TNF? in epi4 Cells than the W83 Strain Through Regulation of the JNK Pathway.
Abscess
[Neuraminidase as a pathogenetic factor in an abscess caused by Bacteroides fragilis]
Acidosis, Lactic
Alterations in the ganglioside composition of rat cortical brain slices during experimental lactic acidosis: implications of an enzymatic process independent of the oxidative stress.
Acne Vulgaris
Neuraminidase production by Propionibacterium acnes-strains isolated from patients with acne vulgaris, seborrheic eczema and healthy subjects.
Acne Vulgaris
Vaccination Targeting a Surface Sialidase of P. acnes: Implication for New Treatment of Acne Vulgaris.
Acquired Immunodeficiency Syndrome
AML1 protein interacts with influenza A virus neuraminidase and upregulates IFN-? response in infected mammalian cells.
Acquired Immunodeficiency Syndrome
Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby canine kidney cells.
Acquired Immunodeficiency Syndrome
Defensive role of pleural mesothelial cell sialomucins in tumor metastasis.
Acquired Immunodeficiency Syndrome
Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.
Acquired Immunodeficiency Syndrome
Influenza A virus neuraminidase protein enhances cell survival through interaction with CEACAM6.
Acquired Immunodeficiency Syndrome
Influenza viruses with receptor-binding n1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.
Acquired Immunodeficiency Syndrome
Recombinant sialidase NanA (rNanA) cleaves ?2-3 linked sialic acid of host cell surface N-linked glycoprotein to promote Edwardsiella tarda infection.
Acute Kidney Injury
Hepatocellular injury in Streptococcus pneumoniae-associated hemolytic uremic syndrome in children.
Acute Lung Injury
Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Acute Lung Injury
Neuraminidase Reprograms Lung Tissue and Potentiates Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Adenocarcinoma
Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.
Adenocarcinoma
Enzymically-mediated changes in murine mammary adenocarcinoma cell membrane induces changes in lymphoid tissue immune ribonucleic acids.
Adenocarcinoma
Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Adenocarcinoma
Histochemical and biochemical aspects of lectin binding glycoproteins in primary and metastatic adenocarcinoma in the lung.
Adenocarcinoma
Human colon sialidase: characterization and activity levels in normal mucosa and colonic adenocarcinoma.
Adenocarcinoma
Immunohistochemical localization of T antigen-like substance in benign hyperplasia and adenocarcinoma of the prostate.
Adenocarcinoma
Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2.
Adenocarcinoma
Preparation of fixed antigenic, non-oncogenic and protective neoplastic cells.
Adenocarcinoma
Production and characterization of monoclonal antibody to a 60-kD glycoprotein in ovarian carcinoma.
Adenocarcinoma
Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study.
Adenocarcinoma
The loss of lectin reactivity from human endometrium is a feature of malignant change.
Adenocarcinoma
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Adenocarcinoma
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Adenocarcinoma
Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression.
Adenocarcinoma
Variation of leukocyte neuraminidase with Duke stage in patients with adenocarcinoma of the colon and rectum.
Adenocarcinoma
[Successful liver metastasis model with neuraminidase treated colon 26 adenocarcinoma via portal vein: preliminary report]
Adenocarcinoma of Lung
Mutations in the Neuraminidase-Like Protein of Bat Influenza H18N11 Virus Enhance Virus Replication in Mammalian Cells, Mice, and Ferrets.
Adenocarcinoma, Clear Cell
Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Adenocarcinoma, Mucinous
[Histochemical characteristics of the mucus in pseudomyxoma peritonei]
Adenoma
Cellular localization of PNA binding in colorectal adenomas: comparison with differentiation, nuclear:cell height ratio and effect of desialylation.
Adenoma
Enhancement of carcinoembryonic antigen (CEA) expression in colorectal tumors by neuraminidase.
Adenoma
Human colorectal carcinoma-specific glycoconjugates detected by pokeweed mitogen lectin.
Adenoma
Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study.
Adenoma, Pleomorphic
[Lectin-histochemical analysis of pleomorphic adenoma of the lacrimal gland]
Adrenal Hyperplasia, Congenital
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
Albuminuria
Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes.
Albuminuria
Removal of heparan sulfate from the glomerular basement membrane blocks protein passage.
alpha-n-acetylglucosaminidase deficiency
The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis.
Alzheimer Disease
Pharmacological activities and structure-modification of resveratrol analogues.
Amebiasis
Characterization of sialidase from Entamoaeba hystolitica and possible pathogenic role in amebiasis.
Anemia
A bloodstream Trypanosoma congolense sialidase could be involved in anemia during experimental trypanosomiasis.
Anemia
Bacterial neuraminidase-mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure.
Anemia
Erythrocyte surface sialic acid levels of clinically healthy mongrel and exotic (alsatian and terrier) breeds of dogs.
Anemia
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Anemia
Production, purification and crystallization of a trans-sialidase from Trypanosoma vivax.
Anemia
Stigmasterol retards the proliferation and pathological features of Trypanosoma congolense infection in rats and inhibits trypanosomal sialidase in vitro and in silico.
Anemia
The therapeutic potential of phytol towards Trypanosoma congolense infection and the inhibitory effects against trypanosomal sialidase.
Anemia
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.
Anemia
Trypanostatic activity of geranylacetone: Mitigation of Trypanosoma congolense-associated pathological pertubations and insight into the mechanism of anaemia amelioration using in vitro and in silico models.
Anemia
Trypanosuppresive effects of ellagic acid and amelioration of the trypanosome-associated pathological features coupled with inhibitory effects on trypanosomal sialidase in vitro and in silico.
Anemia
Variation in erythrocyte surface and free serum sialic acid concentrations during experimental Trypanosoma vivax infection in cattle.
Anemia, Hemolytic
Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion.
Anemia, Hemolytic
Monoclonal antibodies for the detection of desialylation of erythrocyte membranes during haemolytic disease and haemolytic uraemic syndrome caused by the in vivo action of microbial neuraminidase.
Anemia, Hemolytic
[Neuraminidase induced hemolytic anemia. Experimental and clinical observations (author's transl)]
Anemia, Hemolytic, Autoimmune
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications]
Angiokeratoma
beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum.
Anthrax
Investigation of spore surface antigens in the genus Bacillus by the use of polyclonal antibodies in immunofluorescence tests.
Anthrax
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Arteriosclerosis
Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids.
Arteritis
Adhesion of Erysipelothrix rhusiopathiae to cultured rat aortic endothelial cells. Role of bacterial neuraminidase in the induction of arteritis.
Arteritis
An experimental model of arteritis: periarteritis induced by Erysipelothrix rhusiopathiae in young rats.
Arteritis
Possible role of neuraminidase in the pathogenesis of arteritis and thrombocytopenia induced in rats by Erysipelothrix rhusiopathiae.
Arthritis, Experimental
Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis.
Arthritis, Rheumatoid
?-2,3-Sialyltransferase 1 and neuraminidase-3 from monocytes in patients with rheumatoid arthritis correlate with disease activity measures: A pilot study.
Arthritis, Rheumatoid
Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study.
aspartoacylase deficiency
Coincident neuraminidase and aspartoacylase deficiency associated with chromosome 9Q paracentric inversion in a Saudi family.
Asthma
A crucial role of sialidase Neu1 in hyaluronan receptor function of CD44 in T helper type 2-mediated airway inflammation of murine acute asthmatic model.
Asthma
The isoelectric focusing pattern of desialylated alpha 1-antichymotrypsin of heterozygous alpha 1-antichymotrypsin deficiency and of acute phase plasma.
Ataxia
Identification of a homozygous deletion of the NEU1 gene in a patient with type II sialidosis presenting isolated fetal ascites and central nervous system hypoplasia.
Ataxia
Lysosomal enzymes in ataxia: discovery of two new cases of late onset hexosaminidase A and B deficiency (adult Sandhoff disease) in French Canadians.
Atherosclerosis
Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis.
Atherosclerosis
Commentary: Comparison of the Protective Effects of Individual Components of Particulated trans-Sialidase (PTCTS), PTC and TS, against High Cholesterol Diet-Induced Atherosclerosis in Rabbits.
Atherosclerosis
Comparison of the Protective Effects of Individual Components of Particulated trans-Sialidase (PTCTS), PTC and TS, against High Cholesterol Diet-Induced Atherosclerosis in Rabbits.
Atherosclerosis
Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein.
Atherosclerosis
Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages.
Atherosclerosis
Overexpression of membrane sialic acid-specific sialidase Neu3 inhibits matrix metalloproteinase-9 expression in vascular smooth muscle cells.
Atherosclerosis
Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study.
Atherosclerosis
Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice.
Atherosclerosis
Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology.
Autoimmune Diseases
Comparative Biochemistry of GH3, GH20 and GH84 ?-N-acetyl-D-hexosaminidases and Recent Progress in Selective Inhibitor Discovery.
Autoimmune Diseases
NEU1 is more abundant in uveitic retina with concomitant desialylation of retinal cells.
Avian Leukosis
Retroviral expressed hemagglutinin-neuraminidase protein protects chickens from Newcastle disease virus induced disease.
Bacteremia
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Bacterial Infections
CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.
Bacterial Infections
Chitinase 3-like-1 deficient donor splenocytes accentuated the pathogenesis of acute graft-versus-host diseases through regulating T cell expansion and type I inflammation.
Bacterial Infections
Design, synthesis, and evaluation of curcumin analogues as potential inhibitors of bacterial sialidase.
Bacterial Infections
Evaluation of microbial enzymes in normal and abnormal cervicovaginal fluids of cervical dysplasia: a case control study.
Bacterial Infections
Factors associated with fatality due to avian influenza A(H7N9) infection in China.
Bacterial Infections
Highly potent bacterial neuraminidase inhibitors, chromenone derivatives from Flemingia philippinensis.
Bacterial Infections
Identification and evaluation of flavone-glucosides isolated from barley sprouts and their inhibitory activity against bacterial neuraminidase.
Bacterial Infections
Modelling, synthesis and biological evaluation of novel glucuronide-based probes of Vibrio cholerae sialidase.
Bacterial Infections
Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
beta-galactosidase deficiency
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
beta-galactosidase deficiency
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
beta-galactosidase deficiency
Biochemical comparison of the dysmorphic type with the normosomatic type of sialidosis.
beta-galactosidase deficiency
Carrier detection of sialidosis with partial beta-galactosidase deficiency by the assay of lysosomal sialidase in lymphocytes.
beta-galactosidase deficiency
Combined sialidase (neuraminidase) and beta-galactosidase deficiency. Clinical, morphological and enzymological observations in a patient.
beta-galactosidase deficiency
Homologous modeling of the lysosomal protective protein/carboxypeptidase L: structural and functional implications of mutations identified in galactosialidosis patients.
beta-galactosidase deficiency
Immunoelectron microscopical localization of lysosomal beta-galactosidase and its precursor forms in normal and mutant human fibroblasts.
beta-galactosidase deficiency
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
beta-galactosidase deficiency
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
beta-galactosidase deficiency
Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies.
beta-galactosidase deficiency
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
beta-galactosidase deficiency
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
beta-galactosidase deficiency
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
beta-galactosidase deficiency
Partial characterization and studies of fibroblast and leucocyte neuraminidase activities towards sialyloligosaccharides in adult sialidosis and mucolipidosis II and III.
beta-galactosidase deficiency
Prenatal diagnosis of sialidosis with combined neuraminidase and beta-galactosidase deficiency.
beta-galactoside alpha-2,3-sialyltransferase deficiency
Sialyltransferase specificity in selectin ligand formation.
Blindness
Altered expression of ?-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.
Blister
Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes.
Blister
Rounding and steroidogenesis of enzyme- and ACTH-treated Y-l mouse adrenal tumor cells.
Brain Abscess
Production of specific glycosidase activities by Streptococcus intermedius strain UNS35 grown in the presence of mucin.
Brain Diseases
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Brain Diseases
Salla disease variants. Sialoylaciduric encephalopathy with increased sialidase activity in two non-Finnish children.
Brain Neoplasms
Cell surface glycoproteins of human tumor cell lines: unusual characteristics of malignant melanoma.
Breast Neoplasms
Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.
Breast Neoplasms
Biochemical and immunochemical analysis of a breast carcinoma associated antigen defined by the monoclonal antibody NCRC-11.
Breast Neoplasms
Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin--comparison of antigen MUSE11 with CA15-3.
Breast Neoplasms
Correlation between low neuraminidase blood levels and a predisposition toward family-related breast cancer.
Breast Neoplasms
Enzymically-modified human mammary carcinoma cells: modulators of macrophage functions.
Breast Neoplasms
Epitope analysis of monoclonal antibody NCRC-11 defined antigen isolated from human ovarian and breast carcinomas.
Breast Neoplasms
Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.
Breast Neoplasms
Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines.
Breast Neoplasms
Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Breast Neoplasms
Macrophage-mediated tumor cytotoxicity: role of macrophage surface sialic acid.
Breast Neoplasms
MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 ?1,6-N-acetylglucosaminyltransferase and ?-galactoside ?2,3-sialyltransferase.
Breast Neoplasms
Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.
Breast Neoplasms
Overexpression of ?2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis.
Breast Neoplasms
Pulsed Low-Frequency Magnetic Fields Induce Tumor Membrane Disruption and Altered Cell Viability.
Bronchial Spasm
Neuraminidase inhibitors for preventing and treating influenza in children.
Bronchitis
Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays.
Bronchitis
Neuraminidase treatment of avian infectious bronchitis coronavirus reveals a hemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytes.
Bronchitis
Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge.
Burkitt Lymphoma
Glycosidases from the interferon producing lymphoid cell line Namalva and from three other lymphoid cell lines.
Canavan Disease
Coincident neuraminidase and aspartoacylase deficiency associated with chromosome 9Q paracentric inversion in a Saudi family.
Candidiasis
Immunoglobulin A response against Gardnerella vaginalis hemolysin and sialidase activity in bacterial vaginosis.
Carcinogenesis
Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Carcinogenesis
Detection of hepatitis B virus DNA in hepatocellular carcinoma: analysis by hybridization with subgenomic DNA fragments.
Carcinogenesis
Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers.
Carcinogenesis
Monoclonal antibodies recognizing normal and retrovirus-transformed chicken hematopoietic cells.
Carcinogenesis
NEU3 sialidase protein interactors in the plasma membrane and in the endosomes.
Carcinogenesis
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
Carcinogenesis
Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival.
Carcinogenesis
Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells.
Carcinogenesis
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Carcinogenesis
Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase.
Carcinogenesis
Regulation of plasma-membrane-associated sialidase NEU3 gene by Sp1/Sp3 transcription factors.
Carcinogenesis
[Action of Vibrio cholera neuraminidase on chemically induced carcinogenesis]
Carcinogenesis
[Use of the enzyme neuraminidase for immunotherapeutic treatment of chemically induced carcinogenesis]
Carcinoma
Alkaline phosphatase isoenzymes in intestinal metaplasia and carcinoma of rat stomach induced by N-methyl-N'-nitro-N-nitrosoguanidine.
Carcinoma
Analysis of carbohydrate composition and sialidase activity in oral secretions of patients with tumors in the upper aerodigestive tract.
Carcinoma
Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity.
Carcinoma
Blood group ABH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas.
Carcinoma
CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas.
Carcinoma
Cellular site of synthesis and dynamics of cell surface re-expression of polysialic acid of the neural cell adhesion molecule.
Carcinoma
Characterization of variant gamma-glutamyl transpeptidase produced by pancreatocholangiocarcinoma cell lines in a protein-free, chemically defined medium.
Carcinoma
Colonic oligosaccharide structures deduced from lectin-binding studies before and after desialylation.
Carcinoma
Correlation between glycoconjugate expression and fucosyltransferase activity in human colorectal carcinoma.
Carcinoma
Difference of hyaluronidase produced by human tumor cell lines with hyaluronidase present in human serum as revealed by zymography.
Carcinoma
Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
Carcinoma
Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody.
Carcinoma
Effect of neuraminidase on electrophoretic mobility and immune cytolysis of human uterine cervix carcinoma cells.
Carcinoma
Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas.
Carcinoma
Enzymatic modulation of the cell surface in malignant transformation of normal human mammary epithelial cells and in conversion of mammary carcinoma cells.
Carcinoma
Enzymically-modified human mammary carcinoma cells: modulators of macrophage functions.
Carcinoma
Experimental cancer immunotherapy: modification of tumor cells to increase immunogenicity.
Carcinoma
Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
Carcinoma
Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines.
Carcinoma
Histochemical and morphologic studies of mucosa bordering rectosigmoid carcinomas: comparisons with normal, diseased, and malignant colonic epithelium.
Carcinoma
Human colorectal carcinoma-specific glycoconjugates detected by pokeweed mitogen lectin.
Carcinoma
Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen.
Carcinoma
Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma.
Carcinoma
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Carcinoma
Isolation and partial characterization of surface components of cell line MDA-MB-231 derived from a human metastatic breast carcinoma.
Carcinoma
Lymphocyte blastogenic response to autologous tumor cells pretreated with neuraminidase in patients with gastric carcinoma.
Carcinoma
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
Carcinoma
Mucoid carcinomas of the breast: a study using mucin histochemistry and peanut lectin.
Carcinoma
Neuraminidase 1 regulates proliferation, apoptosis and the expression of Cadherins in mammary carcinoma cells.
Carcinoma
Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture.
Carcinoma
Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility.
Carcinoma
Regression of spontaneous mammary carcinomas using direct injections of neuraminidase and BCG.
Carcinoma
Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines.
Carcinoma
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling ?1 integrin internalization and recycling.
Carcinoma
The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells.
Carcinoma
The Thomsen-Friedenreich antigen on human urothelial cell lines detectable by peanut lectin and monoclonal antibody raised against human glycophorin A.
Carcinoma
The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, upregulates interleukin 6 secretion in normal human intestinal microvascular endothelial cells and peripheral blood mononuclear cells.
Carcinoma
Thomsen-Friedenreich-related antigen in human endometrium. An immunohistochemical study employing the monoclonal antibody 49H.8. A preliminary report.
Carcinoma
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Carcinoma
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Carcinoma
Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma.
Carcinoma
[Establishment of a method to detect multiple antennae carcinoembryonic antigen (MA-CEA) and MA-CEA level in the sera of patients with malignant tumors]
Carcinoma
[Expression of human membrane associated sialidase gene in prostate carcinoma PC-3 cell line].
Carcinoma
[Immunohistochemical studies of bronchial carcinoma using monoclonal antibody A63-C/A3]
Carcinoma, Bronchogenic
[Immunohistochemical studies of bronchial carcinoma using monoclonal antibody A63-C/A3]
Carcinoma, Ehrlich Tumor
Curcumin's effects on sialic acid level and sialidase activity in Ehrlich ascites tumor bearing mice.
Carcinoma, Ehrlich Tumor
On the lysosomal occurrence and the properties of the neuraminidase of rat liver and of Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
[Action of x-rays and neuraminidase on pinocytotic activity and microtubule-microfilament system of Ehrlich ascites tumor cells in monolayer culture (author's transl)]
Carcinoma, Ehrlich Tumor
[Effect of neuraminidase and x-rays (2 Gy and 8 Gy) on microvilli and membrane invaginations of Ehrlich ascites tumor cells in monolayer culture]
Carcinoma, Hepatocellular
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
Carcinoma, Hepatocellular
Alpha-fetoprotein antibody-lectin enzyme immunoassay to characterize sugar chains for the study of liver diseases.
Carcinoma, Hepatocellular
Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 crosstalk to induce transactivation of insulin receptor signaling.
Carcinoma, Hepatocellular
Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines.
Carcinoma, Hepatocellular
Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines.
Carcinoma, Hepatocellular
Effect of neuraminidase and papain treatment on lectin-induced agglutination of Novikoff tumor cells and assay of lectin receptor activity of the glycopeptides released from the cell surface by papain.
Carcinoma, Hepatocellular
Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis.
Carcinoma, Hepatocellular
Increased binding and killing of neuraminidase-galactose oxidase-treated tumor cells by normal macrophages.
Carcinoma, Hepatocellular
Killing Effects of IFN R-/- Mouse NK Cells Activated by HN Protein of NDV on Mouse Hepatoma Cells and Possible Mechanism with Syk and NF-?B.
Carcinoma, Hepatocellular
Localization of membrane glycoproteins by in situ neuraminidase treatment of rat hepatoma tissue culture cells and two-dimensional gel electrophoretic analysis of the modified proteins.
Carcinoma, Hepatocellular
Membrane-associated sialidase of rat liver and its decrease in hepatomas.
Carcinoma, Hepatocellular
Modulation of expression of the hepatitis B virus surface antigen gene by the viral X-gene product.
Carcinoma, Hepatocellular
Multiple forms of mammalian sialidase: altered expression in carcinogenesis.
Carcinoma, Hepatocellular
Neoplastic alteration of a membrane-associated sialidase of rat liver.
Carcinoma, Hepatocellular
Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.
Carcinoma, Hepatocellular
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.
Carcinoma, Hepatocellular
Sialidase of rat hepatomas: qualitative and quantitative comparison with rat liver sialidase.
Carcinoma, Hepatocellular
Targeting of loaded Sendai virus envelopes by covalently attached insulin molecules to virus receptor-depleted cells: fusion-mediated microinjection of ricin A and simian virus 40 DNA.
Carcinoma, Hepatocellular
Unique structural properties of apolipoprotein B in low-density lipoproteins produced by several human hepatoma-derived cell lines.
Carcinoma, Hepatocellular
[On the activity of neuraminic acid aldolase and neuraminidase in the cells of ascite and solid forms of hepatoma 22 in mice]
Carcinoma, Hepatocellular
[STUDIES ON NEURAMINIC ACID DERIVATIVES SEPARABLE WITH NEURAMINIDASE FROM SURFACE MEMBRANES OF NORMAL LIVER CELLS AND ASCITES HEPATOMA CELLS IN RATS.]
Carcinoma, Non-Small-Cell Lung
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Carcinoma, Papillary
[Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens]
Carcinoma, Renal Cell
A novel gamma-glutamyl transpeptidase in renal carcinoma in comparison with normal kidney enzyme.
Carcinoma, Renal Cell
Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility.
Carcinoma, Renal Cell
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling ?1 integrin internalization and recycling.
Carcinoma, Squamous Cell
Epidermal growth factor-induced mobilization of a ganglioside-specific sialidase (NEU3) to membrane ruffles.
Carcinoma, Squamous Cell
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Carcinoma, Squamous Cell
Role of sialoglycan structures for the function of the epidermal growth factor receptor and the in vitro proliferation of head and neck cancer.
Carcinoma, Squamous Cell
Sialidase gene transfection enhances epidermal growth factor receptor activity in an epidermoid carcinoma cell line, A431.
Carcinoma, Squamous Cell
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Carcinoma, Squamous Cell
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Carcinoma, Squamous Cell
Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma.
Cardiomyopathy, Hypertrophic
Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
Cardiovascular Diseases
Neuraminidase 1 and its Inhibitors from Chinese Herbal Medicines: An Emerging Role for Cardiovascular Diseases.
Cataract
Kidney sialidase and sialyltransferase activities in spontaneously and experimentally diabetic rats. Influence of insulin and sorbinil treatments.
Cerebellar Ataxia
Adult type GMl-gangliosidosis: a complementation study on somatic cell hybrids.
Cerebellar Ataxia
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Cerebrovascular Disorders
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Cervical Intraepithelial Neoplasia
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
Chagas Disease
A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase.
Chagas Disease
A new class of mechanism-based inhibitors for Trypanosoma cruzi trans-sialidase and their influence on parasite virulence.
Chagas Disease
A proteolytic fragment of Trypanosoma cruzi trans-sialidase lacking the carboxyl-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity.
Chagas Disease
A trypanosomal protein synergizes with the cytokines ciliary neurotrophic factor and leukemia inhibitory factor to prevent apoptosis of neuronal cells.
Chagas Disease
An influenza virus model for Trypanosoma cruzi infection: interactive roles for neuraminidase and lectin.
Chagas Disease
Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
Chagas Disease
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.
Chagas Disease
Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase.
Chagas Disease
Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
Chagas Disease
Costimulation of host T lymphocytes by a trypanosomal trans-sialidase: involvement of CD43 signaling.
Chagas Disease
Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: Screening for novel inhibitor scaffolds.
Chagas Disease
Diagnostic Applicability of Neutralizing Antibodies to Trypanosoma cruzi Trans-sialidase.
Chagas Disease
Discovery of novel inhibitors of Trypanosoma cruzitrans-sialidase from in silico screening.
Chagas Disease
Effect of primary structure modifications in Trypanosoma cruzi neuraminidase/trans-sialidase activities.
Chagas Disease
Effect of the Tc13Tul antigen from Trypanosoma cruzi on splenocytes from naïve mice.
Chagas Disease
Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Chagas Disease
Endothelial cell signalling induced by trans-sialidase from Trypanosoma cruzi.
Chagas Disease
Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.
Chagas Disease
Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.
Chagas Disease
Evidence of ternary complex formation in Trypanosoma cruzi trans-sialidase catalysis.
Chagas Disease
Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the Michaelis complex to the covalent intermediate.
Chagas Disease
Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype.
Chagas Disease
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Chagas Disease
Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence.
Chagas Disease
HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8 T Cells in Chronic Chagas Disease.
Chagas Disease
Identification and characterization of a sialidase released by the salivary gland of the hematophagous insect Triatoma infestans.
Chagas Disease
Identification of glycoproteins targeted by Trypanosoma cruzi trans-sialidase, a virulence factor that disturbs lymphocyte glycosylation.
Chagas Disease
Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
Chagas Disease
Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
Chagas Disease
Immunological and pathological responses in BALB/c mice induced by genetic administration of Tc 13 Tul antigen of Trypanosoma cruzi.
Chagas Disease
Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase.
Chagas Disease
Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients.
Chagas Disease
Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.
Chagas Disease
Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.
Chagas Disease
Machine Learning Techniques for the Automated Classification of Adhesin-Like Proteins in the Human Protozoan Parasite Trypanosoma cruzi.
Chagas Disease
Medium scale production and purification to homogeneity of a recombinant trans-sialidase from Trypanosoma cruzi.
Chagas Disease
Metabolic Labeling of Surface Neo-sialylglyconjugates Catalyzed by Trypanosoma cruzi trans-Sialidase.
Chagas Disease
Modulation of catalytic function by differential plasticity of the active site: case study of Trypanosoma cruzi trans-sialidase and Trypanosoma rangeli Sialidase.
Chagas Disease
Parasite-host glycan interactions during Trypanosoma cruzi infection: trans-Sialidase rides the show.
Chagas Disease
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease.
Chagas Disease
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.
Chagas Disease
Probing molecular function of trypanosomal sialidases: single point mutations can change substrate specificity and increase hydrolytic activity.
Chagas Disease
Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
Chagas Disease
Proton transfer facilitated by ligand binding. An energetic analysis of the catalytic mechanism of Trypanosoma cruzi trans-sialidase.
Chagas Disease
Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease.
Chagas Disease
Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi.
Chagas Disease
Serum neuraminidase activity and hematological alterations in acute human Chagas' disease.
Chagas Disease
Sialic acid C-glycosides with aromatic residues: Investigating enzyme binding and inhibition of Trypanosoma cruzi trans-sialidase.
Chagas Disease
Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.
Chagas Disease
Synthesis of a model trisaccharide for studying the interplay between the anti ?-Gal antibody and the trans-sialidase reactions in Trypanosoma cruzi.
Chagas Disease
Synthesis of PEGylated lactose analogs for inhibition studies on T.cruzi trans-sialidase.
Chagas Disease
T rypanosoma cruzi trans-sialidase as a multifunctional enzyme in Chagas' disease.
Chagas Disease
Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of Trypanosoma cruzi trans-sialidase.
Chagas Disease
The role of natural selection in shaping genetic variation in a promising Chagas disease drug target: Trypanosoma cruzi trans-sialidase.
Chagas Disease
The synthesis and kinetic evaluation of aryl ?-aminophosphonates as novel inhibitors of T. cruzi trans-sialidase.
Chagas Disease
The trans-sialidase from Trypanosoma cruzi efficiently transfers alpha-(2-->3)-linked N-glycolylneuraminic acid to terminal beta-galactosyl units.
Chagas Disease
The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.
Chagas Disease
Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.
Chagas Disease
trans-Sialidase from Trypanosoma cruzi binds host T-lymphocytes in a lectin manner.
Chagas Disease
Trans-sialidase from Trypanosoma cruzi induces apoptosis in cells from the immune system in vivo.
Chagas Disease
Trans-sialidase inhibition assay detects Trypanosoma cruzi infection in different wild mammal species.
Chagas Disease
Trans-sialidase inhibition assay for the detection of Trypanosoma cruzi infection in blood donor samples from Argentina.
Chagas Disease
trans-sialidase inhibition assay, a highly sensitive and specific diagnostic test for Chagas' disease.
Chagas Disease
Trypanosoma cruzi trans-sialidase as a drug target against Chagas disease (American trypanosomiasis).
Chagas Disease
Trypanosoma cruzi trans-sialidase inhibits human lymphocyte proliferation by nonapoptotic mechanisms: implications in pathogenesis and transplant immunology.
Chagas Disease
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Chagas Disease
Trypanosoma cruzi: the effect of nitric oxide synthesis inhibition on the CD4 T cell response to the trans-sialidase superfamily.
Chagas Disease
Tryptophan as a molecular shovel in the glycosyl transfer activity of Trypanosoma cruzi trans-sialidase.
Chagas Disease
Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.
Chagas Disease
Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes.
Chickenpox
Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine.
Chlamydia Infections
Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia.
Cholera
A rapid and sensitive assay for neuraminidase using peanut lectin hemagglutination: application to Vibrio cholera and Trypanosoma cruzi.
Cholera
A sialidase-susceptible ganglioside, IV3 alpha(NeuGc alpha 2-8NeuGc)-Gg4Cer, is a major disialoganglioside in WHT/Ht mouse thymoma and thymocytes.
Cholera
Action of alpha-galactosidase from Clostridium sporogenes and coffee beans on blood group B antigen of erythrocytes. The effect on the viability of erythrocytes in circulation.
Cholera
Characterization of Vibrio cholerae neuraminidase by a novel mechanism-based fluorescent labeling reagent.
Cholera
Chemical and histochemical studies of normal and diseased human gastrointestinal tract. I. A comparison between histologically normal colon, colonic tumours, ulcerative colitis and diverticular disease of the colon.
Cholera
Cloning and characterization of sialidases with 2-6' and 2-3' sialyl lactose specificity from Pasteurella multocida.
Cholera
Coexpression of lactosyl and gangliotetraosyl gangliosides in rat cerebellar radial glial cells in culture.
Cholera
Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer.
Cholera
Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells.
Cholera
Correlation between plasminogen activator activity of immunizing tumor cells and complement-mediated cytotoxic antibodies secreted by cloned hybrid cells.
Cholera
Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
Cholera
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Cholera
Crystal structure of Vibrio cholerae neuraminidase reveals dual lectin-like domains in addition to the catalytic domain.
Cholera
Dependence of cardiac cell Ca2+ permeability on sialic acid-containing sarcolemmal gangliosides.
Cholera
Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase.
Cholera
Desialylation of extracellular GD1a-neoganglioprotein suggests cell surface orientation of the plasma membrane-bound ganglioside sialidase activity in human neuroblastoma cells.
Cholera
Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique.
Cholera
Effects of cell surface receptor-altering agents on the binding and biological activity of 12-O-tetradecanoylphorbol-13-acetate in isolated epidermal cells.
Cholera
Endogenous GM1 ganglioside of the plasma membrane promotes neuritogenesis by two mechanisms.
Cholera
Enzymically-mediated changes in murine mammary adenocarcinoma cell membrane induces changes in lymphoid tissue immune ribonucleic acids.
Cholera
Enzymically-modified human mammary carcinoma cells: modulators of macrophage functions.
Cholera
Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract.
Cholera
Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
Cholera
Expression of gangliosides as receptors at the cell surface controls infection of NCTC 2071 cells by Sendai virus.
Cholera
Expression of gangliosides in neuronal development of P19 embryonal carcinoma stem cells.
Cholera
Fibrillar organization of fibronectin is expressed coordinately with cell surface gangliosides in a variant murine fibroblast.
Cholera
Further studies on the gangliosidic nature of the cholinergic-specific antigen, Chol-1.
Cholera
Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture.
Cholera
Gangliosides and sulphatide in human cerebrospinal fluid: quantitation with immunoaffinity techniques.
Cholera
Glycosylation Characterization of an Influenza H5N7 Hemagglutinin Series with Engineered Glycosylation Patterns: Implications for Structure-Function Relationships.
Cholera
Hepatic and pancreatic glycosphingolipid phenotypes of the neurological different rat strains.
Cholera
Heterogeneity in the specificity of the islet cell cytoplasmic antibody response in insulin-dependent diabetes mellitus.
Cholera
Immunofluorescent studies on antibodies directed to a buried membrane structure present in lymphocytes and erythrocytes.
Cholera
Inhibition of neurite outgrowth of neuroblastoma Neuro-2a cells by cholera toxin B-subunit and anti-GM1 antibody.
Cholera
Interaction of ganglioside GM1 with the B subunit of cholera toxin modulates growth and differentiation of neuroblastoma N18 cells.
Cholera
Intestinal epithelium brush border and microsome chemistry. II. Cholera exoenterotoxin and neuramindase effects.
Cholera
Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Cholera
Isolation and structural characterization of N-acetyl- and N-glycolylneuraminic-acid-containing GalNAc-GD1a isomers, IV4GalNAcIV3Neu5AcII3Neu5GcGgOse4Cer and IV4GalNAcIV3Neu5GcII3Neu5AcGgOse4Cer, from bovine brain.
Cholera
Micro-necrotic foci in regression of a murine calvarium transplantable tumor. 2. Enzymatic modification of the transformed calvarium cell immunological characteristics.
Cholera
Micro-necrotic foci in regression of a murine calvarium transplantable tumor. 3. Histological characteristics of the micro-necrotic foci.
Cholera
Neuraminidase treatment of adrenal cells increases their response to cholera enterotoxin.
Cholera
Occurrence of gangliosides in the common squid and pacific octopus among protostomia.
Cholera
Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming.
Cholera
Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh.
Cholera
Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies.
Cholera
Regeneration of membrane sialic acid after neuraminidase treatment of leukemic granulocytes.
Cholera
Removal of O-acetylated sialic acids from rat colonic epithelial glycoproteins by cell-free extracts of rat faeces.
Cholera
Saturation transfer difference (STD) 1H-NMR experiments and in silico docking experiments to probe the binding of N-acetylneuraminic acid and derivatives to Vibrio cholerae sialidase.
Cholera
Serum sialic acid levels in Vibrio cholera serotype Hikojima infected Nigerian patients.
Cholera
Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.
Cholera
Structural analysis and functional role of the carbohydrate component of somatostatin receptors.
Cholera
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Cholera
Surface distribution of monosialoganglioside GM1 on human blood cells and the effect of exogenous GM1 and neuraminidase on cholera toxin surface labeling. A quantitative immunocytochemical study.
Cholera
Terminal glycosylation of bovine uroplakin III, one of the major integral-membrane glycoproteins of mammalian bladder.
Cholera
Three pathogenicity islands of Vibrio cholerae can excise from the chromosome and form circular intermediates.
Cholera
Unmasking of actual and potential receptor sites for cholera toxin in intestinal mucosal homogenates.
Cholera
Upregulation of nuclear GM1 accompanies axon-like, but not dendrite-like, outgrowth in NG108-15 cells.
Cholera
Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
Cholera
[A comparison of biological and chemical methods of determining fecal neuraminidase in cholera studies]
Cholera
[Analysis of toxin genetic determinants of Vibrio cholerae virulence cassette and neuraminidase with DNA probes]
Cholera
[Biochemical and immunochemical characteristics of a new oral, chemical cholera bivalent vaccine and results of a trial of the preparation on volunteers]
Cholera
[Cholera vibrios lectins as main pathogenicity and persistence factors (biotechnological aspects of use)].
Cholera
[Inhibitory effect of combined administration of neuraminidase and interferon in mice with Rauscher leukemia]
Cholera
[On the effect of cholera neuraminidase in comparison with other neuraminic acid splitting enzymes of plant and animal origin on a few physico-chemical properties of human erythrocytes]
Cholera
[Reduction of the biological activity of Vibrio cholerae culture filtrates exposed to neuraminidase inhibitors]
Cholera
[Role of enterotoxin and neuraminidase in the biological activity of E1 Tor vibrios]
Cholera
[Role of neuraminidase from cholera vibrions in the pathogenesis of experimental cholera]
Cholera
[Role of neuraminidase in the pathogenicity of Vibrio cholera 01 and Vibrio cholerae not 01]
Cholera
[Serological study of the neuraminidase activity of cholera filtrate and influenza virus]
Cholera
[Use of the aggregate hemagglutination method for determining cholera vibrio neuraminidase]
Chordoma
Lectin histochemistry of human fetal notochord, ecchordosis physaliphora, and chordomas.
Choriocarcinoma
Lectin binding in tissues from hydatidiform mole, invasive mole and choriocarcinoma to concanavalin-A, wheat germ agglutinin and peanut agglutinin.
Chromoblastomycosis
Exploring the genomic diversity of black yeasts and relatives (Chaetothyriales, Ascomycota).
Clostridium Infections
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation.
Coinfection
Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Co-infection Model of the Human Airway Epithelium.
Coinfection
Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.
Coinfection
Expression of cDNA encoding the Sendai virus hemagglutinin-neuraminidase gene: characterization of wild-type and mutant gene products.
Coinfection
Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis.
Coinfection
Influenza A Viruses from Overwintering and Spring-Migrating Waterfowl in the Lake Erie Basin, United States.
Coinfection
Influenza and Community-acquired Pneumonia Interactions: The Impact of Order and Time of Infection on Population Patterns.
Coinfection
Influenza viral neuraminidase primes bacterial coinfection through TGF-?-mediated expression of host cell receptors.
Coinfection
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Coinfection
Modulation of vaginal immune response among pregnant women with bacterial vaginosis by Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and yeast.
Coinfection
Mutations to A/Puerto Rico/8/34 PB1 gene improves seasonal reassortant influenza A virus growth kinetics.
Coinfection
Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.
Coinfection
Simultaneous Differentiation of the N1 to N9 Neuraminidase Subtypes of Avian Influenza Virus by a GeXP Analyzer-Based Multiplex Reverse Transcription PCR Assay.
Coinfection
The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia.
Coinfection
Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia.
Coinfection
Use of hemagglutinin and neuraminidase amplicon-based high-throughput sequencing with variant analysis to detect co-infection and resolve identical consensus sequences of seasonal influenza in a university setting.
Colitis
Neu3 neuraminidase induction triggers intestinal inflammation and colitis in a model of recurrent human food-poisoning.
Colitis
Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice.
Colitis
Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources.
Colitis, Ulcerative
Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts.
Colitis, Ulcerative
The roles of enteric bacterial sialidase, sialate O-acetyl esterase and glycosulfatase in the degradation of human colonic mucin.
Colonic Neoplasms
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4.
Colonic Neoplasms
Detection of 4-O-acetyl-N-glycolylneuraminyl lactosylceramide as one of tumor-associated antigens in human colon cancer tissues by specific antibody.
Colonic Neoplasms
Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers.
Colonic Neoplasms
Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice.
Colonic Neoplasms
Plasma-membrane-associated sialidase (NEU3) differentially regulates integrin-mediated cell proliferation through laminin- and fibronectin-derived signalling.
Colonic Neoplasms
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.
Colonic Neoplasms
Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4.
Colonic Neoplasms
Sialidase NEU3 contributes neoplastic potential on colon cancer cells as a key modulator of gangliosides by regulating Wnt signaling.
Colonic Neoplasms
Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression.
Colorectal Neoplasms
Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients.
Colorectal Neoplasms
Enhancement of carcinoembryonic antigen (CEA) expression in colorectal tumors by neuraminidase.
Colorectal Neoplasms
Human colorectal carcinoma-specific glycoconjugates detected by pokeweed mitogen lectin.
Colorectal Neoplasms
NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels.
Communicable Diseases
A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
Communicable Diseases
Bakkenolides and Caffeoylquinic Acids from the Aerial Portion of Petasites japonicus and Their Bacterial Neuraminidase Inhibition Ability.
Communicable Diseases
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Communicable Diseases
Genotyping of a nosocomial outbreak of pandemic influenza A/H1N1 2009.
Communicable Diseases
Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies.
Communicable Diseases
Proposition of real-time precise prediction model of infectious disease patients from Prescription Surveillance using the National Database of Electronic Medical Claims.
Communicable Diseases
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Communicable Diseases, Emerging
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Congenital Abnormalities
A case of neuraminidase deficiency associated with a partial beta-galactosidase defect. Clinical, biochemical and radiological studies.
Congenital Abnormalities
Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
High-resolution capillary zone electrophoresis and mass spectrometry for distinction of undersialylated and hypoglycosylated transferrin glycoforms in body fluids.
Conjunctivitis
Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.
Conjunctivitis
Characterisation of an avian influenza A virus isolated from a human--is an intermediate host necessary for the emergence of pandemic influenza viruses?
Conjunctivitis
Effect of polycations, polyanions and neuraminidase on the infectivity of trachoma-inclusin conjunctivitis and lymphogranuloma venereum organisms HeLa cells: sialic acid residues as possible receptors for trachoma-inclusion conjunction.
Contracture
Changes in contractility and calcium binding of guinea pig taenia coli by treatment with enzymes which hydrolyze sialic acid.
Contracture
Dependence of cardiac cell Ca2+ permeability on sialic acid-containing sarcolemmal gangliosides.
Coronary Artery Disease
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Coronary Artery Disease
Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages.
Coronary Disease
Carbohydrate-deficient transferrin and sialidase levels in coronary heart disease.
Coronary Disease
The relationship between the electrophoretic mobility of lipoproteins and coronary heart disease.
Coronavirus Infections
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells.
COVID-19
Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.
COVID-19
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19.
COVID-19
Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181.
Crohn Disease
Chemical and histochemical studies of normal and diseased human gastrointestinal tract. II. A comparison between histologically normal small intestine and Crohn's disease of the small intestine.
Crohn Disease
Elevated liver isoenzymes of alkaline phosphatase and disease activity in patients with Crohn's disease.
Crohn Disease
Histochemical comparison of the epithelial mucins in the ileum in Crohn's disease and in normal controls.
Crohn Disease
Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts.
Cross Infection
[Control of hospital infection of influenza: administration of neuraminidase inhibitor and cohort isolation of influenza patients]
Cryptorchidism
The oligosaccharidic content of the glycoconjugates of the prepubertal descended and undescended testis: lectin histochemical study.
Cystic Fibrosis
Cobalamin R binder as a possible model molecule for glycoprotein study in cystic fibrosis.
Cystic Fibrosis
Extracellular neuraminidase production by a strain of Pseudomonas aeruginosa isolated from cystic fibrosis.
Cystic Fibrosis
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
Cystic Fibrosis
Pseudomonas aeruginosa and cystic fibrosis: correlation between exoenzyme production and patient's clinical state.
Cystic Fibrosis
Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition.
Cystic Fibrosis
Susceptibility to neuraminidase of alpha-L-fucosidase and N-acetyl-beta-D-glucosaminidase of cystic fibrosis, I-cell and neuraminidase-deficient fibroblasts.
Cysts
Identification and Characterization of the Most Abundant Cellulases in Stylet Secretions from Globodera rostochiensis
Cysts
Identification and characterization of the most abundant cellulases in stylet secretions from Globodera rostochiensis.
Deafness
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.
Deficiency Diseases
Human beta-galactosidase and alpha-neuraminidase deficient mucolipidosis: genetic complementation analysis of the neuraminidase deficiency.
Deficiency Diseases
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
Dehydration
Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
Delirium
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Dementia
Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies.
Dementia
Sialidase (alpha-n-acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia.
Dengue
Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue.
Dengue
Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
Dental Plaque
Occurrence of haemophili in dental plaque and their association with neuraminidase activity.
Diabetes Complications
Decreased sialidase activity in mononuclear leucocytes of type 1 diabetic subjects: relationship to diabetic complications and glycaemic control.
Diabetes Mellitus
Acidic and neutral sialidase in the erythrocyte membrane of type 2 diabetic patients.
Diabetes Mellitus
Antiviral therapy for influenza : a clinical and economic comparative review.
Diabetes Mellitus
Sialic acid content and sialidase activity of polymorphonuclear leucocytes in diabetes mellitus.
Diabetes Mellitus
[Analysis of sialic acid-related substances. 1. Platelet sialidase and blood sialic acid analysis, with special reference to the fluctuations in diabetes mellitus]
Diabetes Mellitus, Type 1
Target antigen of islet cell antibody in Japanese insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Acidic and neutral sialidase in the erythrocyte membrane of type 2 diabetic patients.
Diabetes Mellitus, Type 2
Acidic and neutral sialidase in the erythrocytes of patients with type 2 diabetes: an answer to comments by Richard et al.
Diabetes Mellitus, Type 2
Acidic and neutral sialidase in the erythrocytes of patients with Type 2 diabetes: influence on erythrocyte lifespan.
Diabetes Mellitus, Type 2
Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy.
Diabetic Nephropathies
Significance of serum and urine neuraminidase activity and serum and urine level of sialic acid in diabetic nephropathy.
Diphtheria
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin.
Diphtheria
Interaction of transferrin, haptoglobin and other serum proteins with neuraminidase of diphtheria toxin.
Diphtheria
Modification of the cell surface with neuraminidase increases the sensitivities of cells to diphtheria toxin and Pseudomonas aeruginosa exotoxin.
Diphtheria
Treatment of FL cells with neuraminidase stimulating the sensitivities to diphtheria toxin and ricin toxin [proceedings]
Diphtheria
[The effect of neuraminidase of C. diphtheriae on the functional capacity of the peritoneal exudate cells of guinea pigs to diphtheria bacilli]
Disseminated Intravascular Coagulation
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
Eczema
Neuraminidase production by Propionibacterium acnes-strains isolated from patients with acne vulgaris, seborrheic eczema and healthy subjects.
Encephalitis
Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.
Encephalomyelitis, Venezuelan Equine
Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
Encephalomyelitis, Venezuelan Equine
[Inhibition of the infectivity of enveloped viruses while retaining the specific biological activity of the viral proteins]
Endocarditis
Metabolism of glycoprotein-derived sialic acid and N-acetylglucosamine by Streptococcus oralis.
Endocarditis, Subacute Bacterial
Neuraminidase production by a Streptococcus sanguis strain associated with subacute bacterial endocarditis.
Endometrial Neoplasms
Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers.
Endometrial Neoplasms
Immunohistochemical localization of blood group substances in normal and neoplastic endometrial tissues--with special reference to type 1 core chain expression.
Endometrial Neoplasms
Thomsen-Friedenreich-related antigen in human endometrium. An immunohistochemical study employing the monoclonal antibody 49H.8. A preliminary report.
Endometrial Neoplasms
[Effects of Sialidase Inhibitor on Proliferation and Apoptosis of Endometrial Cancer Cells].
Endotoxemia
Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1.
Enteritis
Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease.
Enteritis
Sialidase Production and Genetic Diversity in Clostridium perfringens Type A Isolated from Chicken with Necrotic Enteritis in Brazil.
Enterocolitis, Necrotizing
Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources.
Ependymoma
Localization and significance of peanut agglutinin-binding sites on ependymoma cells.
Epilepsy
[Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]
Esophageal Neoplasms
Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
exo-alpha-sialidase deficiency
A case of neuraminidase deficiency associated with a partial beta-galactosidase defect. Clinical, biochemical and radiological studies.
exo-alpha-sialidase deficiency
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
exo-alpha-sialidase deficiency
A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts.
exo-alpha-sialidase deficiency
A point mutation in the neu1 promoter recruits an ectopic repressor, Nkx3.2 and results in a mouse model of sialidase deficiency.
exo-alpha-sialidase deficiency
A Sialidase-Deficient Porphyromonas gingivalis Mutant Strain Induces Less IL-1? and TNF? in epi4 Cells than the W83 Strain Through Regulation of the JNK Pathway.
exo-alpha-sialidase deficiency
Abnormal pattern electroretinograms with macular cherry-red spots: evidence for selective ganglion cell damage.
exo-alpha-sialidase deficiency
Acid alpha-neuraminidase deficiency: a nephropathic phenotype?
exo-alpha-sialidase deficiency
Adult mucolipidosis with beta-galactosidase and neuraminidase deficiencies.
exo-alpha-sialidase deficiency
Adult type beta-galactosidase and neuraminidase deficiency in three siblings.
exo-alpha-sialidase deficiency
Adult type GMl-gangliosidosis: a complementation study on somatic cell hybrids.
exo-alpha-sialidase deficiency
Adult type mucolipidosis with beta-galactosidase and sialidase deficiency. Histological and biochemical studies.
exo-alpha-sialidase deficiency
Adult type neuronal storage disease with neuraminidase deficiency.
exo-alpha-sialidase deficiency
An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca2+ dynamics.
exo-alpha-sialidase deficiency
Anesthetic management for mastectomy and total hysterectomy in a 49-year-old woman with type 1 sialidosis: a case report.
exo-alpha-sialidase deficiency
beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum.
exo-alpha-sialidase deficiency
Biochemical comparison of the dysmorphic type with the normosomatic type of sialidosis.
exo-alpha-sialidase deficiency
Biological consequences of neuraminidase deficiency in Newcastle disease virus.
exo-alpha-sialidase deficiency
Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II).
exo-alpha-sialidase deficiency
Cell disease: desialylation of beta-hexosaminidase and its effect on uptake by fibroblasts.
exo-alpha-sialidase deficiency
Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.
exo-alpha-sialidase deficiency
Chronic GM1 gangliosidosis presenting as dystonia: II. Biochemical studies.
exo-alpha-sialidase deficiency
Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation.
exo-alpha-sialidase deficiency
Cloning and characterization of a sialidase from the murine histocompatibility-2 complex: low levels of mRNA and a single amino acid mutation are responsible for reduced sialidase activity in mice carrying the Neu1a allele.
exo-alpha-sialidase deficiency
Cloning of the cDNA and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse SM/J fibroblasts.
exo-alpha-sialidase deficiency
Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases).
exo-alpha-sialidase deficiency
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
exo-alpha-sialidase deficiency
Complementation analysis of human sialidase deficiency using natural substrates.
exo-alpha-sialidase deficiency
Complementation, cross correction, and drug correction studies of combined beta-galactosidase neuraminidase deficiency in human fibroblasts.
exo-alpha-sialidase deficiency
Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients.
exo-alpha-sialidase deficiency
Diagnostics and Therapy of human diseases - Focus on sialidases.
exo-alpha-sialidase deficiency
Effect of the co-existence of galactosyl and phosphomannosyl residues on beta-hexosaminidase on the processing and transport of the enzyme in mucolipidosis I fibroblasts.
exo-alpha-sialidase deficiency
Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
exo-alpha-sialidase deficiency
Electrophoretic analysis of glycoprotein enzymes in the sialidoses and mucolipidoses.
exo-alpha-sialidase deficiency
Electrophysiological studies of myoclonus in sialidosis type 2.
exo-alpha-sialidase deficiency
Enhanced proteolytic degradation of normal beta-galactosidase in the lysosomal storage disease with combined beta-galactosidase and neuraminidase deficiency.
exo-alpha-sialidase deficiency
Galactosialidosis: molecular heterogeneity among distinct clinical phenotypes.
exo-alpha-sialidase deficiency
Ganglioside GM1 metabolism in living human fibroblasts with beta-galactosidase deficiency.
exo-alpha-sialidase deficiency
Human beta-galactosidase and alpha-neuraminidase deficient mucolipidosis: genetic complementation analysis of the neuraminidase deficiency.
exo-alpha-sialidase deficiency
Human neuraminidase is a 60 kDa-processing product of prosaposin.
exo-alpha-sialidase deficiency
I-cell disease. A hypothesis for the structure of the carbohydrate recognition site on beta-D-N-acetylhexosaminidase.
exo-alpha-sialidase deficiency
Increased levels of sialic acid associated with a sialidase deficiency in I-cell disease (mucolipidosis II) fibroblasts.
exo-alpha-sialidase deficiency
Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings.
exo-alpha-sialidase deficiency
Infantile type 2 sialidosis in a Pakistani family--a clinical and biochemical study.
exo-alpha-sialidase deficiency
Isolated acid neuraminidase deficiency: a distinct lysosomal storage disease.
exo-alpha-sialidase deficiency
Isolation and structural characterization of sialic acid-containing storage material from mucolipidosis I (sialidosis) fibroblasts.
exo-alpha-sialidase deficiency
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
exo-alpha-sialidase deficiency
Liver neuraminidase deficiency inherited as a single gene on mouse chromosome 17.
exo-alpha-sialidase deficiency
Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors.
exo-alpha-sialidase deficiency
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
exo-alpha-sialidase deficiency
Lysosomal sialidase deficiency: increased ganglioside content in autopsy tissues of a sialidosis patient.
exo-alpha-sialidase deficiency
Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man.
exo-alpha-sialidase deficiency
Molecular heterogeneity in human beta-galactosidase and neuraminidase deficiency.
exo-alpha-sialidase deficiency
Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation.
exo-alpha-sialidase deficiency
Mucolipidosis I, the cherry red-spot--myoclonus syndrome and neuraminidase deficiency.
exo-alpha-sialidase deficiency
Mucolipidosis I: studies of sialidase activity and a prenatal diagnosis.
exo-alpha-sialidase deficiency
Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency.
exo-alpha-sialidase deficiency
Multimodality evoked potentials and EEG in a case of cherry red spot-myoclonus syndrome and alpha-neuraminidase deficiency (sialidosis type 1)
exo-alpha-sialidase deficiency
Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex.
exo-alpha-sialidase deficiency
Neuraminidase assay in cultured human fibroblasts: in situ versus in vitro procedures.
exo-alpha-sialidase deficiency
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
exo-alpha-sialidase deficiency
Neuraminidase deficiency in the cherry red spot-myoclonus syndrome.
exo-alpha-sialidase deficiency
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
exo-alpha-sialidase deficiency
Neuraminidase deficiency presenting as a nephrosialidosis: the first case detected in Poland.
exo-alpha-sialidase deficiency
Neuraminidase deficiency presenting as non-immune hydrops fetalis.
exo-alpha-sialidase deficiency
Neuraminidase deficiency: case report and review of the phenotype.
exo-alpha-sialidase deficiency
Neuraminidase in cultured fibroblasts and leucocytes of homozygotes and heterozygotes for the mucolipidosis II gene (I-cell disease).
exo-alpha-sialidase deficiency
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
exo-alpha-sialidase deficiency
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
exo-alpha-sialidase deficiency
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
exo-alpha-sialidase deficiency
Neuropathological findings of an autopsy case of adult beta-galactosidase and neuraminidase deficiency.
exo-alpha-sialidase deficiency
Pathological study on a severe sialidosis (alpha-neuraminidase deficiency).
exo-alpha-sialidase deficiency
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
exo-alpha-sialidase deficiency
Polymorphisms of apolipoprotein C-III in two cases with sialidase deficiency.
exo-alpha-sialidase deficiency
Post-translational modification of enzymes: processing genes.
exo-alpha-sialidase deficiency
Radioassay method of neuraminidase towards N-acetylneuraminosyl hexasaccharides.
exo-alpha-sialidase deficiency
Revertant analysis of a temperature-sensitive mutant of Newcastle disease virus with defective glycoproteins: implication of the fusion glycoprotein in cell killing and isolation of a neuraminidase-deficient hemagglutinating virus.
exo-alpha-sialidase deficiency
Sialidase (alpha-n-acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia.
exo-alpha-sialidase deficiency
Sialidase Deficiency in Porphyromonas gingivalis Increases IL-12 Secretion in Stimulated Macrophages Through Regulation of CR3, IncRNA GAS5 and miR-21.
exo-alpha-sialidase deficiency
Sialidosis (neuraminidase deficiency) types I and II: neuro-ophthalmic manifestations.
exo-alpha-sialidase deficiency
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobilities of some enzymes known to be glycoproteins. 1. Clinical findings.
exo-alpha-sialidase deficiency
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobility of some enzymes known to be glycoproteins. II. Enzymes studies.
exo-alpha-sialidase deficiency
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia.
exo-alpha-sialidase deficiency
Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.
exo-alpha-sialidase deficiency
Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan.
exo-alpha-sialidase deficiency
Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis.
exo-alpha-sialidase deficiency
The cherry red spot-myoclonus syndrome: a newly recognized inherited lysosomal storage disease due to acid neuraminidase deficiency.
exo-alpha-sialidase deficiency
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
exo-alpha-sialidase deficiency
The structure of sialyl-glycopeptides of the O-glycosidic type, isolated from sialidosis (mucolipidosis I) urine.
exo-alpha-sialidase deficiency
Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency.
exo-alpha-sialidase deficiency
Turnover of beta-galactosidase in fibroblasts from patients with genetically different types of beta-galactosidase deficiency.
exo-alpha-sialidase deficiency
Ultrastructural and immunocytochemical study of skin fibroblasts from normal and sialidosis patients.
exo-alpha-sialidase deficiency
[Adult type beta-galactosidase and neuraminidase deficiency in 3 siblings]
exo-alpha-sialidase deficiency
[Genetic disorders of N-acetylneuraminic acid metabolism: sialurias and sialidoses]
exo-alpha-sialidase deficiency
[Mucolipidosis type I. Sialidosis due to alpha-2-6-neuraminidase deficiency with neurological symptoms]
exo-alpha-sialidase deficiency
[Ocular findings in a peculiar type of mucolipidosis called nephrosialidosis]
exo-alpha-sialidase deficiency
[Sialidosis due to alpha-2-6 neuraminidase deficiency: a heterogeneous group]
exo-alpha-sialidase deficiency
[Skin and conjunctival biopsies in adult type beta-galactosidase neuraminidase deficiency]
Eye Diseases
Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies.
Eye Infections
Experimental ocular toxoplasmosis in genetically susceptible and resistant mice.
Fabry Disease
beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum.
Fabry Disease
[Angiokeratoma and fucosidosis. Immunohistochemical and ultrastructural study]
Fetal Death
[Prognostic value of neuraminidase activity in mammary gland secretion in fetal death]
Fibrosarcoma
Antitumor immunity. II. Viability, tumorigenicity, and immunogenicity of neuraminidase-treated tumor cells: effective immunization of animals with a tumor vaccine.
Fibrosarcoma
Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice.
Fibrosarcoma
Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
Fibrosarcoma
Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.
Fibrosarcoma
Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.
Fibrosarcoma
Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. II. Intratumor injections of neuraminidase.
Fibrosarcoma
Sialylation of 3-Methylcholanthrene-Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting.
Fibrosarcoma
The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
Foodborne Diseases
Antibiotic Sensitivity of Clostridium perfringens Isolated From Faeces in Tabriz, Iran.
Foodborne Diseases
The production of neuraminidase by food poisoning strains of Clostridium welchii (C. perfringens).
Fowlpox
A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV.
Fowlpox
Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV.
Fowlpox
Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants.
Fowlpox
Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses.
Fowlpox
Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes.
Fowlpox
Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus.
Fowlpox
Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene.
Fowlpox
Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses.
Fowlpox
Vaccination of chickens with a recombinant fowlpox virus containing the hemagglutinin-neuraminidase gene of Newcastle disease virus under the control of the fowlpox virus thymidine kinase promoter.
Friedreich Ataxia
Lysosomal enzymes in ataxia: discovery of two new cases of late onset hexosaminidase A and B deficiency (adult Sandhoff disease) in French Canadians.
Fructose Intolerance
Two-dimensional electrophoresis highlights haptoglobin beta chain as an additional biomarker of congenital disorders of glycosylation.
Galactorrhea
[Prognostic value of neuraminidase activity in mammary gland secretion in fetal death]
Gallstones
Intestinal alkaline phosphatase in bile: evidence for an enterohepatic circulation.
Gangliosidoses
Complementation, cross correction, and drug correction studies of combined beta-galactosidase neuraminidase deficiency in human fibroblasts.
Gangliosidoses
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Gangliosidoses, GM2
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Gangliosidosis, GM1
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
Gangliosidosis, GM1
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Gangliosidosis, GM1
Biochemical comparison of the dysmorphic type with the normosomatic type of sialidosis.
Gangliosidosis, GM1
Biochemical, immunological, and structural studies on a sphingolipid activator protein (SAP-1).
Gangliosidosis, GM1
Carrier detection of sialidosis with partial beta-galactosidase deficiency by the assay of lysosomal sialidase in lymphocytes.
Gangliosidosis, GM1
Chronic GM1 gangliosidosis presenting as dystonia: II. Biochemical studies.
Gangliosidosis, GM1
Combined sialidase (neuraminidase) and beta-galactosidase deficiency. Clinical, morphological and enzymological observations in a patient.
Gangliosidosis, GM1
Inherited lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase in sheep.
Gangliosidosis, GM1
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
Gangliosidosis, GM1
Lysosomal multienzymatic complex-related diseases: a genetic study among Portuguese patients.
Gangliosidosis, GM1
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
Gangliosidosis, GM1
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
Gangliosidosis, GM1
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Gangliosidosis, GM1
Partial characterization and studies of fibroblast and leucocyte neuraminidase activities towards sialyloligosaccharides in adult sialidosis and mucolipidosis II and III.
Gangliosidosis, GM1
Prenatal diagnosis of sialidosis with combined neuraminidase and beta-galactosidase deficiency.
Gas Gangrene
Sialidase activity in the sera of patients and rabbits with clostridial myonecrosis.
Gas Gangrene
The production of neuraminidase by food poisoning strains of Clostridium welchii (C. perfringens).
Gas Gangrene
[Neuraminidase as a pathogenic factor in gas gangrene infections with Clostridium perfringens]
Gastroenteritis
Insight into host cell carbohydrate-recognition by human and porcine rotavirus from crystal structures of the virion spike associated carbohydrate-binding domain (VP8*).
Gastrointestinal Diseases
NanI Sialidase Contributes to the Growth and Adherence of Clostridium perfringens Type F Strain F4969 in the Presence of Adherent Mucus.
Gaucher Disease
Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors.
Gaucher Disease
Increased lung surfactant phosphatidylcholine in patients affected by lysosomal storage diseases.
Genetic Diseases, Inborn
A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts.
Genetic Diseases, Inborn
A point mutation in the neu1 promoter recruits an ectopic repressor, Nkx3.2 and results in a mouse model of sialidase deficiency.
Genetic Diseases, Inborn
Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.
Glioblastoma
Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells.
Glioblastoma
Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins.
Glioma
alpha2,6-Sialyltransferase gene transfection into a human glioma cell line (U373 MG) results in decreased invasivity.
Glioma
Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
Glioma
Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents.
Glioma
Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells.
Glioma
Overexpression of ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits glioma growth in vivo.
Glioma
Receptor-mediated uptake of beta-glucuronidase into primary astrocytes and C6 glioma cells from rat brain.
Glioma
Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins.
Glioma
[Sensitivity of human glial tumor cells of different grade of anaplasia to lysis due to natural killers depending on some characteristics of the glycoprotein structure of tumor cell membranes]
Glioma
[The composition of glycosphingolipids and the effect of neuraminidase on cultured glioma cell lines]
Glomerulonephritis
Extracellular neuraminidase production of streptococci associated with acute nephritis.
Glomerulonephritis
Glomerular binding sites for peanut agglutinin in acute poststreptococcal glomerulonephritis.
Glomerulonephritis
Histological evidence of neuraminidase involvement in acute nephritis: desialized leukocytes infiltrate the kidney in acute post-streptococcal glomerulonephritis.
Glomerulonephritis
Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis.
Glomerulonephritis
Neuraminidase and free sialic acid levels in acute poststreptococcal glomerulonephritis.
Glomerulonephritis
Neuraminidase production by streptococci from patients with glomerulonephritis.
Glomerulonephritis
The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis.
Glomerulonephritis
Viral infections, their influence on some parts of the immune system and glomerulonephritis development.
Glomerulonephritis
[Structure and properties of neuraminidase originating from various sources]
Glomerulonephritis, IGA
Activity of alpha2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy.
Glomerulonephritis, IGA
Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy.
Glomerulonephritis, IGA
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.
Glomerulonephritis, IGA
Neuraminidase treatment abrogates the binding abnormality of IgA1 from IgA nephropathy patients and the differential charge distribution of its alpha-heavy chains.
Glomerulonephritis, Membranous
Expression of sialidase and dystroglycan in human glomerular diseases.
Graft vs Host Disease
Modification of graft-versus-host disease by neuraminidase treatment of donor cells. Decreased tolerogenicity of neuraminidase-treated cells.
Graft vs Host Disease
Neuraminidase pretreatment of donor lymphocytes and graft-versus-host disease.
Granuloma
A role for Bacteroides fragilis neuraminidase in bacterial growth in two model systems.
Hearing Loss
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.
Hearing Loss
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1- deficient mice.
Hearing Loss
[Morphological and functional alterations of ear in lysosomal neuraminidase gene deficient mouse]
Heart Failure
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Heart Failure
Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma.
Heart Failure
Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages.
Hemangioma
Phenotypic characterization of normal and neoplastic canine endothelial cells by lectin histochemistry.
Hemangiosarcoma
Phenotypic characterization of normal and neoplastic canine endothelial cells by lectin histochemistry.
Hematuria
Relationship between IgA1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in IgA nephropathy.
Hemolytic-Uremic Syndrome
Determination of neuraminidase activity in serum or plasma. Relevance to the pathogenic diagnosis of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion.
Hemolytic-Uremic Syndrome
High-resolution capillary zone electrophoresis and mass spectrometry for distinction of undersialylated and hypoglycosylated transferrin glycoforms in body fluids.
Hemolytic-Uremic Syndrome
Streptococcus pneumoniae-induced hemolytic uremic syndrome: a case for early diagnosis.
Hemolytic-Uremic Syndrome
The use of a rapid fluorogenic neuraminidase assay to differentiate acute Streptococcus pneumoniae-associated hemolytic uremic syndrome (HUS) from other forms of HUS.
Hemolytic-Uremic Syndrome
[Neuraminidase induced hemolytic anemia. Experimental and clinical observations (author's transl)]
Hepatitis
Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors.
Hepatitis
Hepatic infections. Part II. The effect of acute and chronic hepatitis B antigenaemia on the reaction to antibodies to sheep red cells (microbial antigens) and human T-activated cells (exposed autologous tissue antigens).
Hepatitis B
A functional hepatocyte nuclear factor 3 binding site is a critical component of the duck hepatitis B virus major surface antigen promoter.
Hepatitis B
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus.
Hepatitis B
Cell surface display of hepatitis B virus surface antigen by using Pseudomonas syringae ice nucleation protein.
Hepatitis B
Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines.
Hepatitis B
Characterization of the hepatitis B virus major surface antigen promoter hepatocyte nuclear factor 3 binding site.
Hepatitis B
Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.
Hepatitis B
Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines.
Hepatitis B
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Hepatitis B
Detection of hepatitis B virus DNA in hepatocellular carcinoma: analysis by hybridization with subgenomic DNA fragments.
Hepatitis B
Development of imaged capillary isoelectric focusing method and use of capillary zone electrophoresis in hepatitis B vaccine RECOMBIVAX HB®.
Hepatitis B
Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis.
Hepatitis B
Integrated hepatitis B virus DNA sequences specifying the major viral core polypeptide are methylated in PLC/PRF/5 cells.
Hepatitis B
Large hepatitis B surface antigen polypeptides of Dane particles with the receptor for polymerized human serum albumin.
Hepatitis B
Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Hepatitis B
Mapping the major transcripts of ground squirrel hepatitis virus: the presumptive template for reverse transcriptase is terminally redundant.
Hepatitis B
Modulation of expression of the hepatitis B virus surface antigen gene by the viral X-gene product.
Hepatitis B
Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line.
Hepatitis B
Prediction of transmembrane segments in proteins utilising multiple sequence alignments.
Hepatitis B
Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment.
Hepatitis B
Regulation of secretion of the hepatitis B virus major surface antigen by the preS-1 protein.
Hepatitis B
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.
Hepatitis B
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.
Hepatitis B
The nature of polypeptides larger in size than the major surface antigen components of hepatitis b and like viruses in ground squirrels, woodchucks, and ducks.
Hepatitis B
The properties of an HBV surface antigen protein carrying the binding site for the receptor of hepatocytes--its formation of surface antigen particles and secretion from discrete cell lines.
Hepatitis B, Chronic
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Hepatitis C
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus.
Hepatitis C
Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques.
Hepatitis C
Development of anti-viral agents using molecular modeling and virtual screening techniques.
Hepatitis C
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Hepatitis, Chronic
Alpha-fetoprotein antibody-lectin enzyme immunoassay to characterize sugar chains for the study of liver diseases.
Hepatoblastoma
Characterization of hepatitis B virus major surface antigen gene transcriptional regulatory elements in differentiated hepatoma cell lines.
Hepatoblastoma
Interaction between desialylated hepatitis B virus and asialoglycoprotein receptor on hepatocytes may be indispensable for viral binding and entry.
Herpes Simplex
Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells.
Herpes Simplex
Effect of neuraminidase on Fc and C3b receptors on rabbit corneal cells infected with herpes simplex virus.
Herpes Simplex
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
Herpes Simplex
Neuraminidase reversal of resistance to lysis of herpes simplex virus-infected cells by antibody and complement.
Herpes Simplex
Removal of N-linked carbohydrates decreases the infectivity of herpes simplex virus type 1.
Herpes Zoster
Glycohistochemistry of the zona pellucida of developing oocytes in the rabbit and hare.
Herpes Zoster
Sialidases on mammalian sperm mediate deciduous sialylation during capacitation.
Herpes Zoster
Sperm penetration of rabbit zona pellucida inhibited by treatment of ova with neuraminidase.
Herpes Zoster
Structural characterization of the N-linked carbohydrate chains of the zona pellucida glycoproteins from bovine ovarian and fertilized eggs.
Herpes Zoster
Variations in lectin-binding on the zona pellucida during oocyte growth in some wild ungulates.
Herpesviridae Infections
A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
Herpesviridae Infections
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.
Herpesviridae Infections
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Herpesviridae Infections
CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
Herpesviridae Infections
Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
Herpesviridae Infections
Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Co-infection Model of the Human Airway Epithelium.
Herpesviridae Infections
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Herpesviridae Infections
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.
Herpesviridae Infections
Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.
Herpesviridae Infections
MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.
Herpesviridae Infections
Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance.
Herpesviridae Infections
Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.
Herpesviridae Infections
Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Herpesviridae Infections
Protection against influenza B virus infection by immunization with DNA vaccines.
Herpesviridae Infections
Sequential Influenza B Viral Load and Susceptibility in Children Treated with Oseltamivir and Zanamivir.
Herpesviridae Infections
The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
Herpesviridae Infections
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
HIV Infections
Electrostatic Surface Properties of Blood and Semen Extracellular Vesicles: Implications of Sialylation and HIV-Induced Changes on EV Internalization.
HIV Infections
Pneumococcus virulence factor sialidase: a new direction in neuro-AIDS research?
Hodgkin Disease
Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Homocystinuria
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Hydatidiform Mole, Invasive
Lectin binding in tissues from hydatidiform mole, invasive mole and choriocarcinoma to concanavalin-A, wheat germ agglutinin and peanut agglutinin.
Hydrocephalus
Ependymal denudation, aqueductal obliteration and hydrocephalus after a single injection of neuraminidase into the lateral ventricle of adult rats.
Hydrops Fetalis
Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase.
Hyperalgesia
Intraplantar injection of sialidase reduces mechanical allodynia during inflammatory pain.
Hyperalgesia
Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice.
Hyperalgesia
Reversal of neuropathic pain in diabetes by targeting glycosylation of CaV3.2 T-type calcium channels.
Hyperalgesia
Targeting of CaV3.2 T-type calcium channels in peripheral sensory neurons for the treatment of painful diabetic neuropathy.
Hypersensitivity
Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy.
Hypersensitivity
Enhancement of delayed skin hypersensitivity by neuraminidase in cancer patients.
Hypersensitivity
Prevention of suppression of alloreactive capacity following intravenous injection of neuraminidase-treated allogeneic cells by co-injection of agents competing for asialoglycoprotein receptor.
Hypersensitivity
[Determination of ten stilbenes and their antioxidant activity of peony seed coat, seed kernel and seed coat extracts].
Hypersensitivity
[Enhancement of the immune response to surface antigens of the influenza B virus as a result of their covalent binding with a synthetic polymer carrier]
Hypertension
Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.
Hypertension
Recombinant neuraminidase pseudotyped baculovirus: a dual vector for delivery of Angiotensin II peptides and DNA vaccine.
Hyperthyroidism
Tissue sources of serum alkaline phosphatase in 34 hyperthyroid cats: a qualitative and quantitative study.
Hypervitaminosis A
[Enzymatic activity of glycoprotein catabolism in the organs of rats with hyper- and hypovitaminosis A]
Hypoglycemia
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Hypoglycemia
The sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid is a glucose-dependent potentiator of insulin secretion.
Hypothyroidism
Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients.
Hypothyroidism
Hormonal control of postnatal development of ileal neuraminidase and acid beta-galactosidase.
Idiopathic Pulmonary Fibrosis
Elevated Expression of NEU1 Sialidase in Idiopathic Pulmonary Fibrosis Provokes Pulmonary Collagen Deposition, Lymphocytosis, and Fibrosis.
Idiopathic Pulmonary Fibrosis
Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis.
Immune System Diseases
Detection of anti-red blood cell antibodies by treatment of the cells with neuraminidase.
Infant, Newborn, Diseases
Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model.
Infections
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
Infections
?2-3 Sialic acid glycoconjugate loss and its effect on infection with Toxoplasma parasites.
Infections
A 65-kDa trypsin-sensible membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells.
Infections
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
Infections
A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus.
Infections
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
Infections
A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase.
Infections
A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
Infections
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa.
Infections
A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
Infections
A new in vitro hemagglutinin inhibitor screening system based on a single-vesicle fusion assay.
Infections
A novel method for detection of Newcastle disease virus with a fluorescent sialidase substrate.
Infections
A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.
Infections
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
Infections
A plant extract of Ribes nigrum folium possesses anti-influenza virus activity in vitro and in vivo by preventing virus entry to host cells.
Infections
A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals.
Infections
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus.
Infections
A rapid-plate hemagglutination assay for the detection of infectious bronchitis virus.
Infections
A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza.
Infections
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.
Infections
A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.
Infections
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
Infections
A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus.
Infections
Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children.
Infections
Activation of brain endothelium by pneumococcal neuraminidase NanA promotes bacterial internalization.
Infections
Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008).
Infections
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
Infections
Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India.
Infections
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.
Infections
Aminopeptidase-N-independent entry of porcine epidemic diarrhea virus into Vero or porcine small intestine epithelial cells.
Infections
An alternative route of infection for viruses: entry by means of the asialoglycoprotein receptor of a Sendai virus mutant lacking its attachment protein.
Infections
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Infections
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Infections
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
Infections
An influenza virus model for Trypanosoma cruzi infection: interactive roles for neuraminidase and lectin.
Infections
An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.
Infections
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Infections
Anti N1 Cross-Protecting Antibodies Against H5N1 Detected in H1N1 Infected People.
Infections
Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.
Infections
Anti-Neuraminidase Bioactives from Manggis Hutan (Garcinia celebica L.) Leaves: Partial Purification and Molecular Characterization.
Infections
Anti-SAG1 peptide antibodies inhibit the penetration of Toxoplasma gondii tachyzoites into enterocyte cell lines.
Infections
Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
Infections
Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection.
Infections
Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
Infections
Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
Infections
Antibody to Trypanosoma cruzi neuraminidase enhances infection in vitro and identifies a subpopulation of trypomastigotes.
Infections
Antigen variability in Anaplasma phagocytophilum during chronic infection of a reservoir host.
Infections
Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection.
Infections
Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.
Infections
Antiviral Activity of Chrysin against Influenza Virus Replication via Inhibition of Autophagy.
Infections
Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.
Infections
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Infections
Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies.
Infections
Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.
Infections
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Infections
Attachment and infection to MA104 cells of avian rotaviruses require the presence of sialic acid on the cell surface.
Infections
Autoimmune reactions against liver cells by syngeneic neuraminidase-treated lymphocytes.
Infections
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Infections
Avian influenza viruses infect primary human bronchial epithelial cells unconstrained by sialic acid ?2,3 residues.
Infections
Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses.
Infections
Avian paramyoxvirus-8 immunization reduces viral shedding after homologous APMV-8 challenge but fails to protect against Newcastle disease.
Infections
Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production.
Infections
Bacterial neuraminidase increases IL-8 production in lung epithelial cells via NF-kappaB-dependent pathway.
Infections
Bacterial neuraminidase inhibitory effects of prenylated isoflavones from roots of Flemingia philippinensis.
Infections
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.
Infections
Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.
Infections
Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Infections
Beyond personal protective equipment: adjunctive methods for control of healthcare-associated respiratory viral infections.
Infections
Biochemical studies on the production of neuraminidase by environmental isolates of Vibrio cholerae non-O1 from Bulgaria.
Infections
Both ?2,3- and ?2,6-linked sialic acids on o-linked glycoproteins act as functional receptors for porcine sapovirus.
Infections
Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells.
Infections
Capnocytophaga canimorsus: a human pathogen feeding at the surface of epithelial cells and phagocytes.
Infections
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.
Infections
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes.
Infections
Cell surface alterations induced by vaccinia and Newcastle disease viruses (38486).
Infections
Characteristics of human infection with avian influenza viruses and development of new antiviral agents.
Infections
Characterization of a novel chromosomal virulence locus involved in expression of a major surface flagellar sheath antigen of the fish pathogen Vibrio anguillarum.
Infections
Characterization of a recombinant Bacteroides fragilis sialidase expressed in Escherichia coli.
Infections
Characterization of canine parvovirus (CPV) interactions with 3201 T cells: involvement of GPI-anchored protein(s) in binding and infection.
Infections
Characterization of neuraminidase-resistant mutants derived from rotavirus porcine strain OSU.
Infections
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Infections
Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.
Infections
Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Infections
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
Infections
Clinical Features of Bacterial Vaginosis in a Murine Model of Vaginal Infection with Gardnerella vaginalis.
Infections
Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016.
Infections
Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients.
Infections
Clinical, epidemiological and virological characteristics of the first detected human case of avian influenza A(H5N6) virus.
Infections
Cloning and characterization of sialidases with 2-6' and 2-3' sialyl lactose specificity from Pasteurella multocida.
Infections
Clostridium perfringens Sialidases: Potential Contributors to Intestinal Pathogenesis and Therapeutic Targets.
Infections
Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens.
Infections
Combination activity of neuraminidase inhibitor oseltamivir and ?-tocopherol in influenza virus A (H3N2) infection in mice.
Infections
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Infections
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Infections
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.
Infections
Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.
Infections
Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.
Infections
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
Infections
Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
Infections
Comparison of human, simian, and bovine rotaviruses for requirement of sialic acid in hemagglutination and cell adsorption.
Infections
Complement Decay-Accelerating Factor is a modulator of influenza A virus lung immunopathology.
Infections
Comprehensive Analysis and Characterization of Linear Antigenic Domains on HN Protein from Genotype VII Newcastle Disease Virus Using Yeast Surface Display System.
Infections
Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme.
Infections
Construction and comparison of different source neuraminidase candidate vaccine strains for human infection with Eurasian avian-like influenza H1N1 virus.
Infections
Continuous non-radioactive method for screening trypanosomal trans-sialidase activity and its inhibitors.
Infections
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein.
Infections
Correlation between levels of apoptosis, levels of infection and haemagglutinin receptor binding interaction of various subtypes of influenza virus: does the viral neuraminidase have a role in these associations.
Infections
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Infections
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Infections
Current usage and effectiveness of influenza medications and factors regarding the time taken to alleviate fever based on postcard questionnaire survey.
Infections
Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity.
Infections
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.
Infections
Deacetylation of sialic acid by esterases potentiates pneumococcal neuraminidase activity for mucin utilization, colonization and virulence.
Infections
Deficiency of Antigen-Specific B Cells Results in Decreased Trypanosoma cruzi Systemic but Not Mucosal Immunity Due to CD8 T Cell Exhaustion.
Infections
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.
Infections
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.
Infections
Desialylation by Edwardsiella tarda is the initial step in the regulation of its invasiveness.
Infections
Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.
Infections
Desialylation of O-glycans on glycoprotein Ib? drives receptor signaling and platelet clearance.
Infections
Detailed genetic analysis of hemagglutinin-neuraminidase glycoprotein gene in human parainfluenza virus type 1 isolates from patients with acute respiratory infection between 2002 and 2009 in Yamagata prefecture, Japan.
Infections
Detection and Titration of Influenza A Virus Neuraminidase Inhibiting (NAI) Antibodies Using an Enzyme-Linked Lectin Assay (ELLA).
Infections
Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
Infections
Detection of Toxoplasma gondii soluble antigen, SAG-1(p30), antibody and immune complex in the cerebrospinal fluid of HIV positive or negative individuals.
Infections
Development and evaluation of a real-time nucleic acid sequence based amplification assay for rapid detection of influenza A.
Infections
Development of antibodies to neuraminidase of A2-Hong Kong and A2-Taiwan influenza viruses after administration of different Hong Kong vaccines and after natural infection in humans.
Infections
Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
Infections
Developmental disturbances in the hamster retina caused by a mutant of mumps virus.
Infections
Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells.
Infections
Differential immune response in mice immunized with the A, R or C domain from TcSP protein of Trypanosoma cruzi or with the coding DNAs.
Infections
Differential infection of receptor-modified host cells by receptor-specific influenza viruses.
Infections
Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
Infections
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Infections
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Infections
Direct adverse effects of Sendai virus DI particles on virus budding and on M protein fate and stability.
Infections
Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase.
Infections
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Infections
Discovery of Potent Neuraminidase Inhibitors Using a Combination of Pharmacophore-Based Virtual Screening and Molecular Simulation Approach.
Infections
Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.
Infections
Diverse Epitope Specificity, Immunodominance Hierarchy, and Functional Avidity of Effector CD4 T Cells Established During Priming Is Maintained in Lung After Influenza A Virus Infection.
Infections
DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.
Infections
Dual Specificity of Human Plasma Lactose-Binding Immunoglobulin to Anomers of Terminal Galactose Enables Recognition of Desialylated Lipoprotein(a) and Xenoantigens.
Infections
Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues.
Infections
Dynamics of functional maturation and inactivation of HN glycoprotein in NDV-infected chick embryo fibroblasts.
Infections
Dynamics of viral growth, viral enzymatic activity, and antigenicity in murine lungs during the course of influenza pneumonia.
Infections
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus.
Infections
Early oseltamivir after hospital admission is associated with shortened hospitalization: A five-year analysis of oseltamivir timing and clinical outcomes.
Infections
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
Infections
Effect of 4-amino-3-nitrobenzoic acid on the expression level of the trans-sialidase gene in Trypanosoma cruzi epimastigotes.
Infections
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
Infections
Effect of sialidase fusion protein (DAS 181) on human metapneumovirus infection of Hep-2 cells.
Infections
Effect of various digestive enzymes on the interaction of Toxoplasma gondii with macrophages.
Infections
Effectiveness of neuraminidase inhibitors to prevent mortality in patients with laboratory-confirmed avian influenza A H7N9.
Infections
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Infections
Effects of cell differentiation on replication of A/WS/33, WSN, and A/PR/8/34 influenza viruses in mouse brain cell cultures: biological and immunological characterization of products.
Infections
Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A(H7N9) virus in guinea pigs.
Infections
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
Infections
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Infections
Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.
Infections
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Infections
Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Infections
Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.
Infections
Efficient infection of buffalo rat liver-resistant cells by encephalomyocarditis virus requires binding to cell surface sialic acids.
Infections
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Infections
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-? for infection control and treatment.
Infections
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.
Infections
Energy metabolic disorder is a major risk factor in severe influenza virus infection: Proposals for new therapeutic options based on animal model experiments.
Infections
Entry of influenza virus into a glycosphingolipid-deficient mouse skin fibroblast cell line.
Infections
Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.
Infections
Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.
Infections
EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo.
Infections
Establishment of Adequate Functional Cellular Immune Response in Chicks Is Age Dependent.
Infections
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
Infections
Evaluation of BioStar FLU OIA assay for rapid detection of influenza A and B viruses in respiratory specimens.
Infections
Evaluation of different serologic markers for the early detection of avian influenza infection in chickens.
Infections
Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
Infections
Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo.
Infections
Evolution of antigen variation in the tick-borne pathogen Anaplasma phagocytophilum.
Infections
Exosome-Driven Antigen Transfer for MHC Class II Presentation Facilitated by the Receptor Binding Activity of Influenza Hemagglutinin.
Infections
Experimental ocular toxoplasmosis in genetically susceptible and resistant mice.
Infections
Experimental validation and computational modeling of anti-influenza effects of quercetin-3-O-?-L-rhamnopyranoside from indigenous south African medicinal plant Rapanea melanophloeos.
Infections
Exploring cell tropism as a possible contributor to influenza infection severity.
Infections
Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
Infections
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
Infections
Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A.
Infections
Expression of cDNA encoding the Sendai virus hemagglutinin-neuraminidase gene: characterization of wild-type and mutant gene products.
Infections
Expression of gangliosides as receptors at the cell surface controls infection of NCTC 2071 cells by Sendai virus.
Infections
First reported detection of influenza A (H1N1)pdm09 in turkeys in the United Kingdom.
Infections
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Infections
Fluorescent Neuraminidase Assay Based on Supramolecular Dye Capture After Enzymatic Cleavage.
Infections
Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the Michaelis complex to the covalent intermediate.
Infections
Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses.
Infections
Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion.
Infections
Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1.
Infections
Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses.
Infections
Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis.
Infections
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.
Infections
Genetic analysis of H9N2 avian influenza viruses circulated in broiler flocks: a case study in Iraq in 2014-2015.
Infections
Genetic analysis of influenza virus NS1 gene: a temperature-sensitive mutant shows defective formation of virus particles.
Infections
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Infections
Genetic vaccination against experimental infection with myotropic parasite strains of Trypanosoma cruzi.
Infections
Geniposide demonstrates anti-inflammatory and antiviral activity against pandemic A/Jiangsu/1/2009 (H1N1) influenza virus infection in vitro and in vivo.
Infections
Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase.
Infections
Group C rotavirus requires sialic acid for erythrocyte and cell receptor binding.
Infections
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus pandemrix(®) -vaccination.
Infections
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Infections
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Infections
Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.
Infections
Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence.
Infections
Heterosubtypic immunity to influenza A virus infections in mallards may explain existence of multiple virus subtypes.
Infections
Heterotypic protective immune reactions in mice infected with distinct serotypes of human influenza virus.
Infections
High polymeric IgA content facilitates recognition of microbial polysaccharide-natural serum antibody immune complexes by immobilized human galectin-1.
Infections
High Seroprevalence of Toxoplasmosis Detected by RDT among the Residents of Seokmo-do (Island) in Ganghwa-Gun, Incheon City, Korea.
Infections
High- and low-density lipoproteins enhance infection of Trypanosoma cruzi in vitro.
Infections
High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses.
Infections
Highly sensitive detection of influenza virus by boron-doped diamond electrode terminated with sialic acid-mimic peptide.
Infections
HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8 T Cells in Chronic Chagas Disease.
Infections
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Infections
Human and most animal rotavirus strains do not require the presence of sialic acid on the cell surface for efficient infectivity.
Infections
Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.
Infections
Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces.
Infections
Hybrid- and complex-type N-glycans are not essential for Newcastle disease virus infection and fusion of host cells.
Infections
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
Infections
Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent neuraminidase inhibitor.
Infections
I-cell disease: intracellular desialylation of lysosomal enzymes using an influenza virus vector.
Infections
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
Infections
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.
Infections
Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.
Infections
Identification of novel E347Q and G362K amino acid substitutions in HN neutralization epitope and major antigenic difference in novel sub-genotype VIIj isolates.
Infections
IFIT1 Expression Patterns Induced by H9N2 Virus and Inactivated Viral Particle in Human Umbilical Vein Endothelial Cells and Bronchus Epithelial Cells.
Infections
IL-10 inhibits neuraminidase-activated TGF-? and facilitates Th1 phenotype during early phase of infection.
Infections
Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections.
Infections
Immunity to influenza in ferrets. 13. Protection against influenza infection by serum antibody to homologous haemagglutinin or neuraminidase antigens.
Infections
Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
Infections
Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
Infections
Immunoelectron microscopic study of the detection of the glycoproteins of influenza and Sendai viruses in infected cells by the immunoperoxidase method.
Infections
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Infections
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.
Infections
Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza.
Infections
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis.
Infections
Implication of Sialidases in Salmonella Infection: Genome Release of Sialidase Knockout Strains from Salmonella enterica Serovar Typhimurium LT2.
Infections
Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies.
Infections
Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.
Infections
In planta transcriptome analysis reveals tissue-specific expression of pathogenicity genes and microRNAs during rice-Magnaporthe interactions.
Infections
In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.
Infections
In situ molecular identification of the influenza A (H1N1) 2009 Neuraminidase in patients with severe and fatal infections during a pandemic in Mexico City.
Infections
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Infections
In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors.
Infections
In vivo production of neuraminidase by Pasteurella haemolytica A1 in goats after transthoracic challenge.
Infections
In vivo production of neuraminidase by Pasteurella haemolytica in market stressed cattle after natural infection.
Infections
In vivo production of neuraminidase by Pasteurella multocida A:3 in goats after transthoracic challenge.
Infections
Inactivation of influenza A virus via exposure to silver nanoparticle-decorated silica hybrid composites.
Infections
Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus.
Infections
Infection of bovine well-differentiated airway epithelial cells by Pasteurella multocida: actions and counteractions in the bacteria-host interactions.
Infections
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.
Infections
Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids.
Infections
Infection of human airway epithelium by human and avian strains of influenza a virus.
Infections
Infection of the tracheal epithelium by infectious bronchitis virus is sialic acid dependent.
Infections
Infection with Listeria monocytogenes impairs sialic acid addition to host cell glycoproteins.
Infections
Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance.
Infections
Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice.
Infections
Infectious subvirion particles of reovirus type 3 Dearing exhibit a loss in infectivity and contain a cleaved sigma 1 protein.
Infections
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.
Infections
Influenza A and methicillin-resistant Staphylococcus aureus co-infection in rhesus macaques - A model of severe pneumonia.
Infections
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Infections
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Infections
Influenza virus proteins: identity, synthesis, and modification analyzed by two-dimensional gel electrophoresis.
Infections
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
Infections
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Infections
Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children.
Infections
Inhibition of H9N2 Virus Invasion into Dendritic Cells by the S-Layer Protein from L. acidophilus ATCC 4356.
Infections
Inhibition of influenza A virus infection in vitro by peptides designed in silico.
Infections
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Infections
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Infections
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection.
Infections
Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir.
Infections
Intracellular synthesis of neuraminidase following infection of charioallantoic membranes with influenza virus.
Infections
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Infections
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Infections
Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
Infections
Invasive phenotype of Trypanosoma cruzi restricted to a population expressing trans-sialidase.
Infections
Isolation and characterisation of sialidase from a strain of Streptococcus oralis.
Infections
Isolation and characterization of influenza A viruses from wild ducks in northern Japan: appearance of HSW1 antigens in the Japanese duck population.
Infections
Isolation of Separate Ureaplasma Species From Endotracheal Secretions of Twin Patients.
Infections
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Infections
Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
Infections
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Infections
Latex fetuin spheres as probes for influenza virus neuraminidase in productively and abortively infected cells.
Infections
Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand.
Infections
Levels of immunoglobulins and antibodies to haemaglutinin and neuraminidase of influenza virus in nasal secretions after natural infection.
Infections
Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells.
Infections
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Infections
Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients.
Infections
Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.
Infections
Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.
Infections
Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.
Infections
Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Infections
Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans.
Infections
Macaque proteome response to highly pathogenic avian influenza and 1918 reassortant influenza virus infections.
Infections
Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus-infected insect cells.
Infections
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Infections
Management of respiratory viral infections in hematopoietic cell transplant recipients.
Infections
Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus.
Infections
Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.
Infections
Mechanism of cell invasion by Trypanosoma cruzi: importance of sialidase activity.
Infections
Mechanism of interference mediated by human parainfluenza virus type 3 infection.
Infections
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Infections
Modified sialic acids on mucus and erythrocytes inhibit influenza A HA and NA functions.
Infections
Molecular and genetic characteristics of hemagglutinin and neuraminidase in Iranian 2009 pandemic influenza A(H1N1) viruses.
Infections
Molecular characterisation of a predominant antigenic region of Giardia lamblia variant surface protein H7.
Infections
Molecular characterization of the surface glycoprotein genes of an H5N1 influenza virus isolated from a human in Guangdong, China.
Infections
Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.
Infections
Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.
Infections
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Infections
Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013.
Infections
Monoclonal antibodies against Trypanosoma cruzi neuraminidase reveal enzyme polymorphism, recognize a subset of trypomastigotes, and enhance infection in vitro.
Infections
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
Infections
Mucin-like glycoprotein genes are closely linked to members of the trans-sialidase super-family at multiple sites in the Trypanosoma cruzi genome.
Infections
Multiple clusters of A(H1N1)pdm09 virus circulating in severe cases of influenza during the 2010-2011 season: a phylogenetic and molecular analysis of the neuraminidase gene.
Infections
N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN.
Infections
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
Infections
Naringenin suppresses Edwardsiella tarda infection in GAKS cells by NanA sialidase inhibition.
Infections
Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children.
Infections
NEU1 Sialidase Regulates the Sialylation State of CD31 and Disrupts CD31-driven Capillary-like Tube Formation in Human Lung Microvascular Endothelia.
Infections
Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against Pseudomonas aeruginosa lung infection.
Infections
Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies.
Infections
Neuraminidase activity of influenza virus-infected cells: localization and properties.
Infections
Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.
Infections
Neuraminidase decreases in vitro adherence of slime-forming coagulase-negative staphylococci to biosynthetic ovine collagen vascular graft.
Infections
Neuraminidase enhances the initial steps of human T-cell leukemia virus type 1 replication.
Infections
Neuraminidase from a bacterial source enhances both HIV-1-mediated syncytium formation and the virus binding/entry process.
Infections
Neuraminidase Gene Variations in Influenza A(H1N1)pdm09 Virus among Patients Admitted to Refferal Pulmonary Hospital, Tehran, Iran in 2009-2013.
Infections
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Infections
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Infections
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
Infections
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Infections
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.
Infections
Neuraminidase inhibitors for preventing and treating influenza in children.
Infections
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
Infections
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19.
Infections
Neuraminidase produces a decrease of adherence of slime-forming Staphylococcus aureus to gelatin-impregnated polyester fiber graft fabric: an experimental study.
Infections
Neuraminidase treatment of respiratory syncytial virus-infected cells or virions, but not target cells, enhances cell-cell fusion and infection.
Infections
Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection.
Infections
Neuraminidase-deficient Sendai virus HN mutants provide protection from homologous superinfection.
Infections
Neuraminidase-producing oral mitis group streptococci potentially contribute to influenza viral infection and reduction in antiviral efficacy of zanamivir.
Infections
NEUTRALIZING ANTIBODIES TO TYPE A INFLUENZA VIRUSES IN SHOREBIRDS AT DELAWARE BAY, NEW JERSEY, USA.
Infections
Newcastle disease virus (NDV) vaccine based on immunization with avian cells expressing the NDV hemagglutinin-neuraminidase glycoprotein.
Infections
Newcastle disease virus F and HN proteins contribute to its macrophage host range.
Infections
Novel baculovirus expression vectors that provide sialylation of recombinant glycoproteins in lepidopteran insect cells.
Infections
Novel correlates of protection against pandemic H1N1 influenza A virus infection.
Infections
Nucleotide and predicted amino acid sequence analysis of the fusion protein and hemagglutinin-neuraminidase protein genes among Newcastle disease virus isolates. Phylogenetic relationships among the Paramyxovirinae based on attachment glycoprotein sequences.
Infections
Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses.
Infections
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Infections
Oseltamivir therapy in two low birth-weight premature infants born to women with H1N1 influenza.
Infections
Oseltamivir use in pregnancy: Risk of birth defects, preterm delivery, and small for gestational age infants.
Infections
Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation.
Infections
Over-expression of mammalian sialidase NEU3 reduces Newcastle disease virus entry and propagation in COS7 cells.
Infections
Parasite-host glycan interactions during Trypanosoma cruzi infection: trans-Sialidase rides the show.
Infections
Pathogenesis and pathology of blackleg in ruminants: the role of toxins and neuraminidase. A short review.
Infections
Pathogenesis and Transmission of Genetically Diverse Swine-Origin H3N2 Variant Influenza A Viruses from Multiple Lineages Isolated in the United States, 2011-2016.
Infections
Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
Infections
Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach.
Infections
Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
Infections
Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Infections
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
Infections
Periodic appearance of a predominant variant antigen type during a chronic Giardia lamblia infection in a mouse model.
Infections
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.
Infections
Persistent infection with human parainfluenza virus 3 in CV-1 cells: analysis of the role of defective interfering particles.
Infections
Phylogenetic analysis of human influenza A/H3N2 viruses isolated in 2015 in Germany indicates significant genetic divergence from vaccine strains.
Infections
PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
Infections
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease.
Infections
Plant polyphenolic complex inhibits the reproduction of influenza and herpes simplex viruses.
Infections
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.
Infections
Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus.
Infections
Porcine arterivirus infection of alveolar macrophages is mediated by sialic acid on the virus.
Infections
Possible Reason for Cross-Species and Cross-Subtype Reassortment in Polymerase Basic Protein 2 from Influenza A Virus.
Infections
Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK.
Infections
Potent inhibition of bacterial neuraminidase activity by pterocarpans isolated from the roots of Lespedeza bicolor.
Infections
Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol.
Infections
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.
Infections
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
Infections
Prevalence of Capnocytophaga canimorsus in dogs and occurrence of potential virulence factors.
Infections
Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice.
Infections
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.
Infections
Prior infection of pigs with swine influenza viruses is a barrier to infection with avian influenza viruses.
Infections
Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods.
Infections
Production and characterization of a monoclonal antibody against the sialidase of Gardnerella vaginalis using a synthetic peptide in a MAP8 format.
Infections
Production of the 57 kDa major surface antigen by a non-agglutinating strain of the fish pathogen Renibacterium salmoninarum.
Infections
Productive penetration of rotavirus in cultured cells induces coentry of the translation inhibitor alpha-sarcin.
Infections
Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine.
Infections
Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.
Infections
Protection of chickens against challenge with virulent influenza A viruses of Hav5 subtype conferred by prior infection with influenza A viruses of Hsw1 subtype.
Infections
Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
Infections
Protective immunity and safety of a genetically modified influenza virus vaccine.
Infections
Proton transfer facilitated by ligand binding. An energetic analysis of the catalytic mechanism of Trypanosoma cruzi trans-sialidase.
Infections
Purification of the Porcine rubulavirus attachment protein by liquid isoelectric focusing.
Infections
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
Infections
Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Infections
Rab11 regulates trafficking of trans-sialidase to the plasma membrane through the contractile vacuole complex of Trypanosoma cruzi.
Infections
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.
Infections
Rapid identification and isolation of neuraminidase inhibitors from mockstrawberry (Duchesnea indica Andr.) based on ligand fishing combined with HR-ESI-Q-TOF-MS.
Infections
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection.
Infections
Recent Advances in the Structure-based Design of Neuraminidase Inhibitors as Anti-influenza Agents.
Infections
Recent progress and challenges in the discovery of new neuraminidase inhibitors.
Infections
Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro.
Infections
Recombinant sialidase NanA (rNanA) cleaves ?2-3 linked sialic acid of host cell surface N-linked glycoprotein to promote Edwardsiella tarda infection.
Infections
Reduced glycosylation of human cell lines increases susceptibility to CD4-independent infection by human immunodeficiency virus type 2 (LAV-2/B).
Infections
Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
Infections
Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.
Infections
Relative Roles of GM1 Ganglioside, N-Acylneuraminic Acids, and ?2?1 Integrin in Mediating Rotavirus Infection.
Infections
Reovirus preferentially infects the basolateral surface and is released from the apical surface of polarized human respiratory epithelial cells.
Infections
Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia.
Infections
Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.
Infections
Retroviral infection of Syrian hamster BHK cells depends on age and susceptibility toward sialidase.
Infections
Risk factors for poor outcomes and therapeutic strategies for seasonal and pandemic influenza.
Infections
Role of Porcine Aminopeptidase N and Sialic Acids in Porcine Coronavirus Infections in Primary Porcine Enterocytes.
Infections
Role of sialidase in Mycoplasma alligatoris-induced pulmonary fibroblast apoptosis.
Infections
Rotaviruses require basolateral molecules for efficient infection of polarized MDCKII cells.
Infections
Salmonella Degrades the Host Glycocalyx Leading to Altered Infection and Glycan Remodeling.
Infections
Secreted Alpha-N-Arabinofuranosidase B Protein Is Required for the Full Virulence of Magnaporthe oryzae and Triggers Host Defences.
Infections
Sendai virus infection in the brains of mice: distribution of viral antigens studied with monoclonal antibodies.
Infections
Sendai virus utilizes specific sialyloligosaccharides as host cell receptor determinants.
Infections
Serological response to Pasteurella multocida NanH sialidase in persistently colonized rabbits.
Infections
Seroprevalence of Toxoplasmosis Detected by RDT in Residents near the DMZ (demilitarized zone) of Cheorwon-gun, Gangwon-do, Korea.
Infections
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic ?/California/07/2009(H1N1) influenza in healthy volunteers.
Infections
Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016.
Infections
Shikimic acid, a base compound for the formulation of swine/avian flu drug: statistical optimization, fed-batch and scale up studies along with its application as an antibacterial agent.
Infections
Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus.
Infections
Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells.
Infections
Sialic acid removal by trans-sialidase modulates MMP-2 activity during Trypanosoma cruzi infection.
Infections
Sialidase activity in the sera of patients and rabbits with clostridial myonecrosis.
Infections
Sialidase of Glaesserella parasuis Augments Inflammatory Response via Desialylation and Abrogation of Negative Regulation of Siglec-5.
Infections
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Infections
Simultaneous detection of avian influenza virus NP and H5 antibodies in chicken sera using a fluorescence microsphere immunoassay.
Infections
Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE.
Infections
Single radial complement fixation test for assaying antibody to influenza virus type-specific antigens.
Infections
Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.
Infections
Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors.
Infections
Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents.
Infections
Stigmasterol retards the proliferation and pathological features of Trypanosoma congolense infection in rats and inhibits trypanosomal sialidase in vitro and in silico.
Infections
Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
Infections
Streptococcus pneumoniae Enhances Human Respiratory Syncytial Virus Infection In Vitro and In Vivo.
Infections
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
Infections
Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines.
Infections
Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin.
Infections
Substrate Specificity of Equine and Human Influenza A Virus Sialidase to Molecular Species of Sialic Acid.
Infections
Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin.
Infections
Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Infections
Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Infections
Suppression subtractive hybridization and comparative expression of a pore-forming toxin and glycosyl hydrolase genes in Rhizoctonia solani during potato sprout infection.
Infections
Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets.
Infections
Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
Infections
Suspected Oseltamivir-induced bradycardia in a pediatric patient: A case report from King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia.
Infections
Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain.
Infections
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.
Infections
The action of Trypanosoma cruzi trans-sialidase on glycolipids and glycoproteins.
Infections
The bird flu: a new emerging pandemic threat and its pharmacological intervention.
Infections
The detection of influenza A virus antigens in cultured cells by enzyme-linked immunosorbent assay.
Infections
The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
Infections
The effects of monoclonal antibodies against the hemagglutinin-neuraminidase and fusion protein on the release of Sendai virus from infected cells.
Infections
The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
Infections
The evolutionary genetics and emergence of avian influenza viruses in wild birds.
Infections
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Infections
The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence.
Infections
The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.
Infections
The influence of 150-cavity binders on the dynamics of influenza a neuraminidases as revealed by molecular dynamics simulations and combined clustering.
Infections
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation.
Infections
The Low-pH Resistance of Neuraminidase Is Essential for the Replication of Influenza A Virus in Duck Intestine following Infection via the Oral Route.
Infections
The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation.
Infections
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
Infections
The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
Infections
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
Infections
The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis.
Infections
The SA85-1.1 protein of the Trypanosoma cruzi trans-sialidase superfamily is a dominant T-cell antigen.
Infections
The subclass IgG responses of mice to influenza surface proteins formulated into liposomes.
Infections
The surface receptor is a major determinant of the cell tropism of influenza C virus.
Infections
The therapeutic potential of phytol towards Trypanosoma congolense infection and the inhibitory effects against trypanosomal sialidase.
Infections
The Trypanosoma cruzi trans-sialidase, through its COOH-terminal tandem repeat, upregulates interleukin 6 secretion in normal human intestinal microvascular endothelial cells and peripheral blood mononuclear cells.
Infections
The use of a radial haemolysis test for neuraminidase antibodies in the diagnosis of influenza A infection.
Infections
The use of enzyme-linked immunosorbent assay to determine the appearance, specificity and immunoglobulin class of antibodies to the structural proteins of influenza A virus in mice.
Infections
The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
Infections
Theiler's murine encephalomyelitis virus attachment to the gastrointestinal tract is associated with sialic acid binding.
Infections
Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein.
Infections
Thomsen-Friedenreich antigen exposure as a cause of Streptococcus pyogenes-associated hemolytic-uremic syndrome.
Infections
Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.
Infections
Trans-sialidase inhibition assay detects Trypanosoma cruzi infection in different wild mammal species.
Infections
Trans-sialidase inhibition assay for the detection of Trypanosoma cruzi infection in blood donor samples from Argentina.
Infections
Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
Infections
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Infections
Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic.
Infections
Trypanosoma cruzi subverts host cell sialylation and may compromise antigen-specific CD8+ T cell responses.
Infections
Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia.
Infections
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Infections
Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes.
Infections
Trypanosoma cruzi: the effect of nitric oxide synthesis inhibition on the CD4 T cell response to the trans-sialidase superfamily.
Infections
Trypanosoma rangeli sialidase: lack of activity in stocks from Panama and other regions.
Infections
Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
Infections
Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi).
Infections
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.
Infections
Use of trans-Sialidase inhibition assay in a population serologically negative for Trypanosoma cruzi but at a high risk of infection.
Infections
Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children.
Infections
Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
Infections
Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.
Infections
Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes.
Infections
WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.
Infections
Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry.
Infections
[Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors]
Infections
[Antigenic and biochemical analysis of the proteins of influenza virus A/USSR/Alma-Ata/13/81 with hemagglutinin H1]
Infections
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Infections
[Epitope analysis of mumps virus proteins in a persistent cell culture infection: changes in the hemagglutinin-neuraminidase polypeptide]
Infections
[Evaluation of Newcastle disease virus with derivated hemagglutinin-neuraminidase gene of mesogenic strain]
Infections
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications]
Infections
[Homologous and heterologous antibody induction in influenzal infection and immunization]
Infections
[Immunity against Erysipelothrix rhusiopathiae infection by means of active immunization using homologous neuraminidase (author's transl)]
Infections
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
Infections
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
Infections
[Neuraminidase as a pathogenic factor in gas gangrene infections with Clostridium perfringens]
Infections
[Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations]
Infections
[Neuraminidase neutralizing antibodies in pigs with chronic Erysipelothrix rhusiopathiae infection (author's transl)]
Infections
[Protective action of liposome-incorporated surface antigens of the influenza virus by different methods of immunization]
Infections
[Role of neuraminidase from cholera vibrions in the pathogenesis of experimental cholera]
Infections
[The virulence of Streptococcus pneumoniae strains--the causative agents of pneumococcal infection at different sites]
Infections
[Treatment for viral respiratory infections: Principles of action, strategies, and future prospects]
Infertility
[Prognostic value of neuraminidase activity in mammary gland secretion in fetal death]
Infertility, Male
Identification of novel putative causative genes and genetic marker for male sterility in Japanese cedar (Cryptomeria japonica D.Don).
Inflammatory Bowel Diseases
Degradation by bacterial enzymes of colonic mucus from normal subjects and patients with inflammatory bowel disease: the role of sialic acid metabolism and the detection of a novel O-acetylsialic acid esterase.
Inflammatory Bowel Diseases
Histochemical demonstration of desialation and desulphation of normal and inflammatory bowel disease rectal mucus by faecal extracts.
Influenza in Birds
2D-SAR, Topomer CoMFA and molecular docking studies on avian influenza neuraminidase inhibitors.
Influenza in Birds
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
Influenza in Birds
4-Methylumbelliferyl-alpha-glycosides of partially O-acetylated N-acetylneuraminic acids as substrates of bacterial and viral sialidases.
Influenza in Birds
A 20-amino-acid deletion in the neuraminidase stalk and a five-amino-acid deletion in the NS1 protein both contribute to the pathogenicity of H5N1 avian influenza viruses in mallard ducks.
Influenza in Birds
A complete molecular diagnostic procedure for applications in surveillance and subtyping of avian influenza virus.
Influenza in Birds
A Computational Model for Docking of Noncompetitive Neuraminidase Inhibitors and Probing their Binding Interactions with Neuraminidase of Influenza Virus H5N1.
Influenza in Birds
A cross-sectional serological survey of the Dutch commercial poultry population for the presence of low pathogenic avian influenza virus infections.
Influenza in Birds
A heterologous neuraminidase subtype strategy for the differentiation of infected and vaccinated animals (DIVA) for avian influenza virus using an alternative neuraminidase inhibition test.
Influenza in Birds
A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.
Influenza in Birds
A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
Influenza in Birds
A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase.
Influenza in Birds
A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza.
Influenza in Birds
A real-time TaqMan RT-PCR method for neuraminidase type 1 (N1) gene detection of H5N1 Eurasian strains of avian influenza virus.
Influenza in Birds
A reverse transcription-PCR for subtyping of the neuraminidase of avian influenza viruses.
Influenza in Birds
A sandwich ELISA for the detection of neuraminidase of avian influenza A(H7N9) virus.
Influenza in Birds
Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses.
Influenza in Birds
Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase.
Influenza in Birds
Amino acid residues at positions 222 and 227 of the hemagglutinin together with the neuraminidase determine binding of H5 avian influenza viruses to sialyl Lewis X.
Influenza in Birds
Amino Acid Substitutions in PB1 of Avian Influenza Viruses Influence Pathogenicity and Transmissibility in Chickens.
Influenza in Birds
Amino acid substitutions in the neuraminidase protein of an H9N2 avian influenza virus affect its airborne transmission in chickens.
Influenza in Birds
An in situ Pt Staining Method for Simple, Stable, and Sensitive Pressure-based Bioassays.
Influenza in Birds
An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.
Influenza in Birds
An outbreak of avian influenza subtype H9N8 among chickens in South Korea.
Influenza in Birds
Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Influenza in Birds
Antibody and T cell responses induced in chickens immunized with avian influenza virus N1 and NP DNA vaccine with chicken IL-15 and IL-18.
Influenza in Birds
Antibody Titer Has Positive Predictive Value for Vaccine Protection against Challenge with Natural Antigenic-Drift Variants of H5N1 High-Pathogenicity Avian Influenza Viruses from Indonesia.
Influenza in Birds
Antigenic relationship between the surface antigens of avian and equine influenze viruses.
Influenza in Birds
Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
Influenza in Birds
Assessing the efficacy of a recombinant H9N2 avian influenza virus-inactivated vaccine.
Influenza in Birds
Attenuation of pathogenicity of fowl plague virus by recombination with other influenza A viruses nonpathogenic for fowl: nonexculsive dependence of pathogenicity on hemagglutinin and neuraminidase of the virus.
Influenza in Birds
Authors' response: Sequencing bias for residue 28 of the neuraminidase of the recent highly pathogenic avian influenza virus A(H5N8).
Influenza in Birds
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Influenza in Birds
Avian influenza A/H5N1 neuraminidase expressed in yeast with a functional head domain.
Influenza in Birds
Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways.
Influenza in Birds
Avian Influenza Virus with Hemagglutinin-Neuraminidase Combination H3N6, Isolated from a Domestic Pigeon in Guangxi, Southern China.
Influenza in Birds
Avian Influenza Virus with Hemagglutinin-Neuraminidase Combination H8N8, Isolated in Russia.
Influenza in Birds
Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses.
Influenza in Birds
B cell epitopes in the intrinsically disordered regions of neuraminidase and hemagglutinin proteins of H5N1 and H9N2 avian influenza viruses for peptide-based vaccine development.
Influenza in Birds
Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus.
Influenza in Birds
Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and its Implication for Drug Design.
Influenza in Birds
Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives.
Influenza in Birds
Biosynthesis, intracellular transport and enzymatic activity of an avian influenza A virus neuraminidase: role of unpaired cysteines and individual oligosaccharides.
Influenza in Birds
Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
Influenza in Birds
Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy.
Influenza in Birds
Characterisation of an avian influenza A virus isolated from a human--is an intermediate host necessary for the emergence of pandemic influenza viruses?
Influenza in Birds
Characterization of a cold-sensitive (cs) recombinant between two influenza A strains.
Influenza in Birds
Characterization of a new avian-like influenza A virus from horses in China.
Influenza in Birds
Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules.
Influenza in Birds
Characterization of H3 subtype avian influenza viruses isolated from poultry in Vietnam.
Influenza in Birds
Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses.
Influenza in Birds
Characterization of pseudoparticles paired with hemagglutinin and neuraminidase from highly pathogenic H5N1 influenza and avian influenza A (H7N9) viruses.
Influenza in Birds
Characterization of virulent and avirulent A/chicken/Pennsylvania/83 influenza A viruses: potential role of defective interfering RNAs in nature.
Influenza in Birds
Clinical and Pathologic Characterization of an Outbreak of Highly Pathogenic Avian Influenza H7N8 in Commercial Turkeys in Southern Indiana.
Influenza in Birds
Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens.
Influenza in Birds
Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance.
Influenza in Birds
Comparative analysis of virulence of a novel, avian-origin H3N2 canine influenza virus in various host species.
Influenza in Birds
Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Influenza in Birds
Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus.
Influenza in Birds
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Influenza in Birds
Comparison of the pathogenesis of two genetically different H3N2 influenza A viruses in pigs.
Influenza in Birds
Compatibility between haemagglutinin and neuraminidase drives the recent emergence of novel clade 2.3.4.4 H5Nx avian influenza viruses in China.
Influenza in Birds
Complete Genome Sequence of a Novel Reassortant Avian Influenza H1N2 Virus Isolated from a Domestic Sparrow in 2012.
Influenza in Birds
Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase.
Influenza in Birds
Computational assay of Zanamivir binding affinity with original and mutant influenza neuraminidase 9 using molecular docking.
Influenza in Birds
Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
Influenza in Birds
Computational identification of reassortments in avian influenza viruses.
Influenza in Birds
Computational Method for Classification of Avian Influenza A Virus Using DNA Sequence Information and Physicochemical Properties.
Influenza in Birds
Computational Study of Dispersion and Extent of Mutated and Duplicated Sequences of the H5N1 Influenza Neuraminidase over the Period 1997-2008.
Influenza in Birds
Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.
Influenza in Birds
Construction of Multilevel Structure for Avian Influenza Virus System Based on Granular Computing.
Influenza in Birds
Construction of Recombinant Marek's Disease Virus (rMDV) Co-Expressing AIV-H9N2-NA and NDV-F Genes under Control of MDV's Own Bi-Directional Promoter.
Influenza in Birds
Continuing evolution of highly pathogenic H5N1 viruses in Bangladeshi live poultry markets.
Influenza in Birds
Control of highly pathogenic avian influenza in Quang Tri province, Vietnam: voices from the human-animal interface.
Influenza in Birds
Conventional H5N9 vaccine suppresses shedding in specific-pathogen-free birds challenged with HPAI H5N1 A/chicken/Yamaguchi/7/2004.
Influenza in Birds
Correction for Jeong et al., "In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility".
Influenza in Birds
Could a deletion in neuraminidase stalk strengthen human tropism of the novel avian influenza virus H7N9 in China, 2013?
Influenza in Birds
Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase.
Influenza in Birds
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.
Influenza in Birds
Degenerate primers for PCR amplification and sequencing of the avian influenza A neuraminidase gene.
Influenza in Birds
Deletions in the Neuraminidase Stalk Region of H2N2 and H9N2 Avian Influenza Virus Subtypes Do Not Affect Postinfluenza Secondary Bacterial Pneumonia.
Influenza in Birds
Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant.
Influenza in Birds
Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Influenza in Birds
Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays.
Influenza in Birds
Detection of highly pathogenic zoonotic influenza virus H5N6 by reverse-transcriptase quantitative polymerase chain reaction.
Influenza in Birds
Detection of NP, N3 and N7 antibodies to avian influenza virus by indirect ELISA using yeast-expressed antigens.
Influenza in Birds
Determination of hemagglutinin and neuraminidase subtypes of avian influenza A viruses in urban pigeons by a new nested RT-PCR.
Influenza in Birds
Development and evaluation of an avian influenza, neuraminidase subtype 1, indirect enzyme-linked immunosorbent assay for poultry using the differentiation of infected from vaccinated animals control strategy.
Influenza in Birds
Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza.
Influenza in Birds
Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Influenza in Birds
Diagnostics-in-a-Suitcase: Development of a portable and rapid assay for the detection of the emerging avian influenza A (H7N9) virus.
Influenza in Birds
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.
Influenza in Birds
Direct and label-free influenza virus detection based on multisite binding to sialic acid receptors.
Influenza in Birds
Discover binding pathways using the sliding binding-box docking approach: application to binding pathways of oseltamivir to avian influenza H5N1 neuraminidase.
Influenza in Birds
Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design.
Influenza in Birds
Drugs against Avian Influenza A Virus: Design of Novel Sulfonate Inhibitors of Neuraminidase N1.
Influenza in Birds
Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues.
Influenza in Birds
Effectiveness of neuraminidase inhibitors to prevent mortality in patients with laboratory-confirmed avian influenza A H7N9.
Influenza in Birds
Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza.
Influenza in Birds
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Influenza in Birds
Efficacy of a high-yield attenuated vaccine strain wholly derived from avian influenza viruses by use of reverse genetics.
Influenza in Birds
Efficacy of avian influenza neuraminidase-specific vaccines in chickens.
Influenza in Birds
Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model.
Influenza in Birds
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Influenza in Birds
Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques.
Influenza in Birds
Emergence and genetic variation of neuraminidase stalk deletions in avian influenza viruses.
Influenza in Birds
Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic.
Influenza in Birds
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease.
Influenza in Birds
Enhancement of DNA vaccine efficacy by intracellular targeting strategies.
Influenza in Birds
Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.
Influenza in Birds
Establishment of Adequate Functional Cellular Immune Response in Chicks Is Age Dependent.
Influenza in Birds
Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.
Influenza in Birds
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers.
Influenza in Birds
Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Influenza in Birds
Evaluation of neuraminidase antigen based competitive enzyme-linked immunosorbent assay in chickens vaccinated with avian influenza inactivated vaccine.
Influenza in Birds
Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
Influenza in Birds
Evaluation of transmission route and replication efficiency of H9N2 avian influenza virus.
Influenza in Birds
Evolutionary interactions between haemagglutinin and neuraminidase in avian influenza.
Influenza in Birds
Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.
Influenza in Birds
Field monitoring of avian influenza viruses: whole-genome sequencing and tracking of neuraminidase evolution using 454 pyrosequencing.
Influenza in Birds
Full sequence analysis of hemagglutinin and neuraminidase genes and proteins of highly pathogenic avian influenza H5N1 virus detected in Iran, 2015.
Influenza in Birds
Functional defects of fowl plague virus temperature-sensitive mutant having mutation in the neuraminidase.
Influenza in Birds
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Influenza in Birds
Further studies on the role of neuraminidase and the mechanism of low pH dependence in influenza virus-induced membrane fusion.
Influenza in Birds
Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
Influenza in Birds
Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.
Influenza in Birds
Generation of a recombinant chickenized monoclonal antibody against the neuraminidase of H9N2 avian influenza virus.
Influenza in Birds
Generation of highly productive and mammalian nonpathogenic recombinant H9N2 avian influenza viruses by optimization of 3'end promoter and NS genome.
Influenza in Birds
Genetic analysis of a novel reassortant H11N9 Isolated from waterfowl in South Korea in 2016.
Influenza in Birds
Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013.
Influenza in Birds
Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro.
Influenza in Birds
Genetic characterization of an H2N2 influenza virus isolated from a muskrat in Western Siberia.
Influenza in Birds
Genetic characterization of H1N1, H1N2 and H3N2 swine influenza virus in Thailand.
Influenza in Birds
Genetic Characterization of Highly Pathogenic Avian Influenza A(H5N8) Virus in Pakistani Live Bird Markets Reveals Rapid Diversification of Clade 2.3.4.4b Viruses.
Influenza in Birds
Genome Sequence of an H9N2 Avian Influenza Virus Strain with Hemagglutinin-Neuraminidase Combination, Isolated from a Quail in Guangxi, Southern China.
Influenza in Birds
Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture.
Influenza in Birds
Graphical representation and numerical characterization of H5N1 avian flu neuraminidase gene sequence.
Influenza in Birds
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Influenza in Birds
Haemagglutinin and neuraminidase characterization of low pathogenic H5 and H7 avian influenza viruses isolated from Northern pintails (Anas acuta) in Japan, with special reference to genomic and biogeographical aspects.
Influenza in Birds
Hemagglutinin-Neuraminidase Balance Influences the Virulence Phenotype of a Recombinant H5N3 Influenza A Virus Possessing a Polybasic HA0 Cleavage Site.
Influenza in Birds
High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses.
Influenza in Birds
Highly Pathogenic and Low Pathogenic Avian Influenza H5 Subtype Viruses in Wild Birds in Ukraine.
Influenza in Birds
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Influenza in Birds
Highly pathogenic avian influenza viruses H5N2, H5N3, and H5N8 in Taiwan in 2015.
Influenza in Birds
Human H7N9 avian influenza virus infection: a review and pandemic risk assessment.
Influenza in Birds
Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin.
Influenza in Birds
I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.
Influenza in Birds
Identification of a Divergent Avian Influenza H3N2 Virus from Domestic Ducks in France.
Influenza in Birds
In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility.
Influenza in Birds
Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus.
Influenza in Birds
Independent-Trajectories Thermodynamic-Integration Free-Energy Changes for Biomolecular Systems: Determinants of H5N1 Avian Influenza Virus Neuraminidase Inhibition by Peramivir.
Influenza in Birds
Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression.
Influenza in Birds
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Influenza in Birds
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Influenza in Birds
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Influenza in Birds
Influenza virus: association of mouse-lung virulence with plaque formation in mouse kidney cells.
Influenza in Birds
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
Influenza in Birds
Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Influenza in Birds
Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid.
Influenza in Birds
Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus.
Influenza in Birds
Interaction of N-acetyl-4-epi-D-neuraminic acid with key enzymes of sialic acid metabolism.
Influenza in Birds
Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice.
Influenza in Birds
Isolation and Characterization of Avian Influenza H9N2 Viruses from Different Avian Species in Pakistan 2016-17.
Influenza in Birds
Isolation and characterization of influenza A viruses from wild ducks in northern Japan: appearance of HSW1 antigens in the Japanese duck population.
Influenza in Birds
Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India.
Influenza in Birds
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Influenza in Birds
Letter to the editor: Sequencing bias for residue 28 of the neuraminidase of the recent highly pathogenic avian influenza virus A(H5N8).
Influenza in Birds
Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
Influenza in Birds
Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities.
Influenza in Birds
MiR674 inhibits the neuraminidase-stimulated immune response on dendritic cells via down-regulated Mbnl3.
Influenza in Birds
Molecular analysis of highly pathogenic avian influenza virus of subtype H5N1 isolated from wild birds and mammals in northern Germany.
Influenza in Birds
Molecular cloning and analysis of the N5 neuraminidase subtype from an avian influenza virus.
Influenza in Birds
Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus.
Influenza in Birds
Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Influenza in Birds
Monoclonal antibody based ELISA tests to detect antibodies against neuraminidase subtypes 1, 2 and 3 of avian influenza viruses in avian sera.
Influenza in Birds
Mutation signature in neuraminidase gene of avian influenza H9N2/G1 in Egypt.
Influenza in Birds
N1 neuraminidase of H5N1 avian influenza A virus complexed with sialic acid and zanamivir - A study by molecular docking and molecular dynamics simulation.
Influenza in Birds
Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses.
Influenza in Birds
Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Influenza in Birds
Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses.
Influenza in Birds
Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks.
Influenza in Birds
Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Influenza in Birds
Neuraminidase is essential for fowl plague virus hemagglutinin to show hemagglutinating activity.
Influenza in Birds
Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
Influenza in Birds
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.
Influenza in Birds
Neuraminidase subtyping of avian influenza viruses with PrimerHunter-designed primers and quadruplicate primer pools.
Influenza in Birds
Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
Influenza in Birds
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Influenza in Birds
Novel antiviral activity of neuraminidase inhibitors against an avian influenza A virus.
Influenza in Birds
Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.
Influenza in Birds
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
Influenza in Birds
Novel post-translational modifications of the hemagglutinin and neuraminidase proteins of avian influenza virus expressed by Kluyveromyces lactis.
Influenza in Birds
Novel reassortant highly pathogenic H5N2 avian influenza viruses in poultry in China.
Influenza in Birds
Novel use of a N2-specific enzyme-linked immunosorbent assay for differentiation of infected from vaccinated animals (DIVA)-based identification of avian influenza.
Influenza in Birds
On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Influenza in Birds
Optimal attenuation of a PR8-derived mouse pathogenic H5N1 recombinant virus for testing antigenicity and protective efficacy in mice.
Influenza in Birds
Oseltamivir activity against avian influenza H9N2 strain with different point mutations in their neuraminidase.
Influenza in Birds
Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?
Influenza in Birds
Passive immune neutralization strategies for prevention and control of influenza A infections.
Influenza in Birds
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Influenza in Birds
Phylogenetic analysis of H and N2 genes of avian influenza viruses detected in Ireland between 2003 and 2007.
Influenza in Birds
Phylogenetic analysis of hemagglutinin and neuraminidase genes of highly pathogenic avian influenza H5N1 Egyptian strains isolated from 2006 to 2008 indicates heterogeneity with multiple distinct sublineages.
Influenza in Birds
Phylogenetic analysis of hemagglutinin, neuraminidase, and nucleoprotein genes of H9N2 avian influenza viruses isolated in Israel during the 2000-2005 epizootic.
Influenza in Birds
Phylogenetic analysis of neuraminidase gene of H9N2 avian influenza viruses isolated from chicken in Iran during 2010-2011.
Influenza in Birds
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Influenza in Birds
Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
Influenza in Birds
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses.
Influenza in Birds
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Influenza in Birds
Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Influenza in Birds
Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes.
Influenza in Birds
Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam.
Influenza in Birds
Proteome Response of Chicken Embryo Fibroblast Cells to Recombinant H5N1 Avian Influenza Viruses with Different Neuraminidase Stalk Lengths.
Influenza in Birds
Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.
Influenza in Birds
QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR.
Influenza in Birds
R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses.
Influenza in Birds
Rapid and highly sensitive neuraminidase subtyping of avian influenza viruses by use of a diagnostic DNA microarray.
Influenza in Birds
Rapid molecular subtyping by reverse transcription polymerase chain reaction of the neuraminidase gene of avian influenza A viruses.
Influenza in Birds
Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1.
Influenza in Birds
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys.
Influenza in Birds
Receptor recognition mechanism of human influenza A H1N1 (1918), avian influenza A H5N1 (2004), and pandemic H1N1 (2009) neuraminidase.
Influenza in Birds
Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes.
Influenza in Birds
Review analysis and impact of co-circulating H5N1 and H9N2 avian influenza viruses in Bangladesh.
Influenza in Birds
Role of domestic ducks in the emergence of a new genotype of highly pathogenic H5N1 avian influenza A viruses in Bangladesh.
Influenza in Birds
Safety and pharmacokinetics of oseltamivir at standard and high dosages.
Influenza in Birds
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Influenza in Birds
Seasonal and pandemic influenza preparedness: science and countermeasures.
Influenza in Birds
Selection of avian influenza A (H9N2) virus with reduced susceptibility to neuraminidase inhibitors oseltamivir and zanamivir.
Influenza in Birds
Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase.
Influenza in Birds
Sequence analysis of recent H7 avian influenza viruses associated with three different outbreaks in commercial poultry in the United States.
Influenza in Birds
Sequence analysis of the neuraminidase genes of avian influenza A viruses isolated from live bird markets in the United States.
Influenza in Birds
Sequence and phylogenetic analysis of neuraminidase genes of H9N2 avian influenza viruses isolated from commercial broiler chicken in Iran (2008 and 2009).
Influenza in Birds
Sequence of the neuraminidase gene of an avian influenza A virus (A/parrot/ulster/73, H7N1).
Influenza in Birds
Shikimic Acid Production in Escherichia coli: From Classical Metabolic Engineering Strategies to Omics Applied to Improve Its Production.
Influenza in Birds
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
Influenza in Birds
Sialivac: An intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.
Influenza in Birds
Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses.
Influenza in Birds
Simultaneous detection of four different neuraminidase types of avian influenza A H5 viruses by multiplex reverse transcription PCR using a GeXP analyser.
Influenza in Birds
Simultaneous Differentiation of the N1 to N9 Neuraminidase Subtypes of Avian Influenza Virus by a GeXP Analyzer-Based Multiplex Reverse Transcription PCR Assay.
Influenza in Birds
Simultaneous genotyping of all hemagglutinin and neuraminidase subtypes of avian influenza viruses by use of padlock probes.
Influenza in Birds
Single Electrode Genosensor for Simultaneous Determination of Sequences Encoding Hemagglutinin and Neuraminidase of Avian Influenza Virus (AIV) type H5N1.
Influenza in Birds
Single PA mutation as a high yield determinant of avian influenza vaccines.
Influenza in Birds
Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
Influenza in Birds
Spatiotemporal analysis of the genetic diversity of seal influenza A(H10N7) virus, Northwestern Europe.
Influenza in Birds
Specific antibody response of mice after immunization with COS-7 cell derived avian influenza virus (H5N1) recombinant proteins.
Influenza in Birds
Spot-scan imaging of microcrystals of an influenza neuraminidase-antibody fragment complex.
Influenza in Birds
Studies with avian influenza A viruses: serological relations of the haemagglutinin and neuraminidase antigens of ten virus isolates.
Influenza in Birds
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
Influenza in Birds
Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir.
Influenza in Birds
Susceptibility of Chickens to Low Pathogenic Avian Influenza (LPAI) Viruses of Wild Bird- and Poultry-Associated Subtypes.
Influenza in Birds
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Influenza in Birds
SYBR green-based real-time reverse transcription-PCR for typing and subtyping of all hemagglutinin and neuraminidase genes of avian influenza viruses and comparison to standard serological subtyping tests.
Influenza in Birds
Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
Influenza in Birds
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.
Influenza in Birds
The Appropriate Combination of Hemagglutinin and Neuraminidase Prompts the Predominant H5N6 Highly Pathogenic Avian Influenza Virus in Birds.
Influenza in Birds
The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling.
Influenza in Birds
The fit of codon usage of human-isolated avian influenza A viruses to human.
Influenza in Birds
The molecular characterizations of surface proteins hemagglutinin and neuraminidase from recent H5Nx avian influenza viruses.
Influenza in Birds
The Neuraminidase Stalk Deletion Serves as Major Virulence Determinant of H5N1 Highly Pathogenic Avian Influenza Viruses in Chicken.
Influenza in Birds
The neuraminidases of the virulent and avirulent A/Chicken/Pennsylvania/83 (H5N2) influenza A viruses: sequence and antigenic analyses.
Influenza in Birds
The Short Stalk Length of Highly Pathogenic Avian Influenza H5N1 Virus Neuraminidase Limits Transmission of Pandemic H1N1 Virus in Ferrets.
Influenza in Birds
The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.
Influenza in Birds
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.
Influenza in Birds
The virulence of the 1918 pandemic influenza virus: unraveling the enigma.
Influenza in Birds
Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Influenza in Birds
Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.
Influenza in Birds
Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic.
Influenza in Birds
Truncation or Deglycosylation of the Neuraminidase Stalk Enhances the Pathogenicity of the H5N1 Subtype Avian Influenza Virus in Mallard Ducks.
Influenza in Birds
Understanding the complex pathobiology of high pathogenicity avian influenza viruses in birds.
Influenza in Birds
Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Influenza in Birds
Use of RT-PCR to Subtype N1 to N9 Neuraminidase Genes of Avian Influenza Viruses.
Influenza in Birds
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.
Influenza in Birds
Variable impact of the hemagglutinin polybasic cleavage site on virulence and pathogenesis of avian influenza H7N7 virus in chickens, turkeys and ducks.
Influenza in Birds
Viral neuraminidase and cellular ectosialyltransferase in human lymphoblastoid cells infected with influenza virus.
Influenza in Birds
Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.
Influenza in Birds
Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry.
Influenza in Birds
[1H-NMR spectroscopy--a potent method for the determination of substrate specificity of sialidases (author's transl)]
Influenza in Birds
[A preclinical trial of the reassortant influenza virus vaccine strain A/17/Quail/Hong Kong/97/84 (H9N2)].
Influenza in Birds
[Change in the influenza virus upon multiplication in the presence of high concentrations of remantadine]
Influenza in Birds
[Chitosan as an adjuvant for inactivated vaccines against avian influenza viruses]
Influenza in Birds
[Distribution of avian influenza virus subtypes among domestic ducks in eastern China]
Influenza in Birds
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
Influenza in Birds
[Effect of low pH values on the infectivity and neuraminidase activity of human and animal strains of influenza virus type A]
Influenza in Birds
[Effect of neuraminidase treatment of chick embryo fibroblasts on the adsorption and reproduction of the fowl plague virus]
Influenza in Birds
[Electrophoretic characteristics of the proteins and the preparative production of neuraminidase from the A/turkey/Wisconsin/66 (Hav6N2) strain of the avian influenza virus]
Influenza in Birds
[Epidemiology, clinical picture, prevention and treatment of avian influenza.]
Influenza in Birds
[Establishing a high-titer infectious avian influenza A (H5N1) pseudotyped viral particle].
Influenza in Birds
[Factors that cause a change in the antigenic structure of of the influenza virus hemagglutinin]
Influenza in Birds
[Fowl plague and avian influenza A viruses of poultry and birds. Diagnosis, control measures and practical experiences].
Influenza in Birds
[Genetic characteristics of hemagglutinin and neuraminidase of avian influenza A (H7N9) virus in Guizhou province, 2014-2017].
Influenza in Birds
[H-NMR spectroscopy. Specificity of microbial sialidases against complex substrates]
Influenza in Birds
[Impact of avian influenza virus H5N1 neuraminidase mutations on the activity of neuraminidase and the sensibility to neuraminidase inhibitors].
Influenza in Birds
[Influence of antibody-mediated immune pressure on neuraminidase gene mutations of avian influenza virus H9N2].
Influenza in Birds
[Molecular analysis of hemagglutinin and neuraminidase genes of avian influenza virus H5N6 subtype in the border of Yunnan Province from 2014 to 2015].
Influenza in Birds
[Neuraminidase inhibitors and their potential use in the avian influenza pandemic]
Influenza in Birds
[Optimization of the gene composition of influenza H5 virus hemagglutinin-containing reassortants and their efficacy in immune cross-protection experiments]
Influenza in Birds
[Prediction of the B cell epitopes of hemagglutinin and neuraminidase of human infected avian influenza A H7N9 virus].
Influenza in Birds
[Primary structure of the full-length DNA copy of the neuraminidase gene in the avian influenza virus of the N7 antigenic subtype]
Influenza in Birds
[Properties of the influenza viruses isolated in 1976 from gulls in Astrakhan Province]
Influenza in Birds
[Rapid detection of novel avian influenza virus subtype H7N9 by multiplex real-time RT-PCR].
Influenza in Birds
[Relationship between eluting and neuraminidase activity of human, mammalian and avian influenza type A viruses]
Influenza in Birds
[Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]
Influenza, Human
"Late" Treatment With Neuraminidase Inhibitors for Severely Ill Patients With Influenza: Better Late Than Never?
Influenza, Human
"Will they just pack up and leave?" - attitudes and intended behaviour of hospital health care workers during an influenza pandemic.
Influenza, Human
1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses.
Influenza, Human
2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus.
Influenza, Human
2009 H1N1 influenza: a twenty-first century pandemic with roots in the early twentieth century.
Influenza, Human
2009 update in prevention, evaluation, and outpatient treatment of influenza.
Influenza, Human
3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
Influenza, Human
3D-quantitative structure-activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase.
Influenza, Human
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
Influenza, Human
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
Influenza, Human
5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication.
Influenza, Human
A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: determination of molecular size and subunit composition of the active unit.
Influenza, Human
A 27-amino-acid deletion in the neuraminidase stalk supports replication of an avian H2N2 influenza A virus in the respiratory tract of chickens.
Influenza, Human
A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase.
Influenza, Human
A baculovirus dual expression vector derived from the Autographa californica nuclear polyhedrosis virus polyhedrin and p10 promoters: co-expression of two influenza virus genes in insect cells.
Influenza, Human
A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.
Influenza, Human
A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus.
Influenza, Human
A benzoic acid inhibitor induces a novel conformational change in the active site of Influenza B virus neuraminidase.
Influenza, Human
A binary QSAR model for classifying neuraminidase inhibitors of influenza A viruses (H1N1) using the combined minimum redundancy maximum relevancy criterion with the sparse support vector machine.
Influenza, Human
A broad spectrum, one-step reverse-transcription PCR amplification of the neuraminidase gene from multiple subtypes of influenza A virus.
Influenza, Human
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
Influenza, Human
A cell-free assay for the insertion of a viral glycoprotein into the plasma membrane.
Influenza, Human
A changing trend in diagnostic methods of Influenza A (H3N2) virus in human: a review.
Influenza, Human
A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase.
Influenza, Human
A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region.
Influenza, Human
A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010-2011.
Influenza, Human
A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus.
Influenza, Human
A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses.
Influenza, Human
A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
Influenza, Human
A competitive-inhibition radioimmunoassay for influenza virus envelope antigens.
Influenza, Human
A comprehensive deep sequencing strategy for full-length genomes of influenza A.
Influenza, Human
A Computational Assay that Explores the Hemagglutinin/Neuraminidase Functional Balance Reveals the Neuraminidase Secondary Site as a Novel Anti-Influenza Target.
Influenza, Human
A Computational Model for Docking of Noncompetitive Neuraminidase Inhibitors and Probing their Binding Interactions with Neuraminidase of Influenza Virus H5N1.
Influenza, Human
A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase.
Influenza, Human
A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.
Influenza, Human
A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
Influenza, Human
A Cost-Effectiveness Analysis of Neuraminidase Inhibitors for Influenza Virus Infections in an Adult-Outpatient Setting in Japan.
Influenza, Human
A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.
Influenza, Human
A designer drug against influenza: the NA inhibitor oseltamivir (Tamiflu).
Influenza, Human
A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin.
Influenza, Human
A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.
Influenza, Human
A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(iii) complexes.
Influenza, Human
A Dynamic, Supramolecular View on the Multivalent Interaction between Influenza Virus and Host Cell.
Influenza, Human
A fluorometric procedure for measuring the neuraminidase activity: its application to the determination of this activity in influenza and parainfluenza viruses.
Influenza, Human
A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
Influenza, Human
A generic system for the expression and purification of soluble and stable influenza neuraminidase.
Influenza, Human
A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens.
Influenza, Human
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.
Influenza, Human
A high-throughput screening system targeting the nuclear export pathway via the third nuclear export signal of influenza A virus nucleoprotein.
Influenza, Human
A human cell polarity protein Lgl2 regulates influenza A virus nucleoprotein exportation from nucleus in MDCK cells.
Influenza, Human
A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.
Influenza, Human
A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.
Influenza, Human
A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model.
Influenza, Human
A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment.
Influenza, Human
A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
Influenza, Human
A microplate assay for sialidase activity using plant lectin binding to N-acetyllactosamine.
Influenza, Human
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens.
Influenza, Human
A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes.
Influenza, Human
A molecular mechanism for the low-pH stability of sialidase activity of influenza A virus N2 neuraminidases.
Influenza, Human
A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains.
Influenza, Human
A Monte Carlo sampling method of amino acid sequences adaptable to given main-chain atoms in the proteins.
Influenza, Human
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.
Influenza, Human
A multiplex real-time PCR assay for detection of oseltamivir-resistant strains of influenza virus.
Influenza, Human
A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein.
Influenza, Human
A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations.
Influenza, Human
A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
Influenza, Human
A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.
Influenza, Human
A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines.
Influenza, Human
A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.
Influenza, Human
A new in vitro hemagglutinin inhibitor screening system based on a single-vesicle fusion assay.
Influenza, Human
A new method for detection of pandemic influenza virus using High Resolution Melting analysis of the neuraminidase gene.
Influenza, Human
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
Influenza, Human
A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action.
Influenza, Human
A new series of C3-aza carbocyclic influenza neuraminidase inhibitors: synthesis and inhibitory activity.
Influenza, Human
A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group.
Influenza, Human
A novel aqueous extract from rice fermented with Aspergillus oryzae and Saccharomyces cerevisiae possesses an anti-influenza A virus activity.
Influenza, Human
A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.
Influenza, Human
A novel genotyping and quantitative analysis of neuraminidase inhibitor-resistance associated mutations in influenza A viruses by single nucleotide polymorphism analysis.
Influenza, Human
A Novel I221L Substitution in Neuraminidase Confers High-Level Resistance to Oseltamivir in Influenza B Viruses.
Influenza, Human
A novel lamprey antibody sequence to multimerize and increase the immunogenicity of recombinant viral and bacterial vaccine antigens.
Influenza, Human
A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.
Influenza, Human
A novel lung explant model for the ex vivo study of efficacy and mechanisms of anti-influenza drugs.
Influenza, Human
A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
Influenza, Human
A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles.
Influenza, Human
A novel mutation in the neuraminidase gene of the 2009 pandemic H1N1 influenza A virus confers multidrug resistance.
Influenza, Human
A Novel Natural Influenza A H1N1 Virus Neuraminidase Inhibitory Peptide Derived from Cod Skin Hydrolysates and Its Antiviral Mechanism.
Influenza, Human
A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
Influenza, Human
A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
Influenza, Human
A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
Influenza, Human
A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.
Influenza, Human
A novel small molecule displays two different binding modes during inhibiting H1N1 influenza A virus neuraminidases.
Influenza, Human
A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
Influenza, Human
A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.
Influenza, Human
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
Influenza, Human
A phospha-oseltamivir-biotin conjugate as a strong and selective adhesive for the influenza virus.
Influenza, Human
A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.
Influenza, Human
A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs.
Influenza, Human
A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals.
Influenza, Human
A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase.
Influenza, Human
A probable model of the inhibitory action of ceruloplasmin on the multiplication of some myxo- and paramyxoviruses.
Influenza, Human
A proline-based neuraminidase inhibitor: DFT studies on the zwitterion conformation, stability and formation.
Influenza, Human
A QSAR classification model for neuraminidase inhibitors of influenza A viruses (H1N1) based on weighted penalized support vector machine.
Influenza, Human
A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
Influenza, Human
A randomized study of standard versus double dose oseltamivir for treating influenza in the community.
Influenza, Human
A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza.
Influenza, Human
A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination.
Influenza, Human
A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
Influenza, Human
A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK.
Influenza, Human
A re-examination of the single radial haemolysis technique for the assay of influenza anti-neuraminidase antibodies in human sera.
Influenza, Human
A reassortant between influenza A viruses (H7N2) synthesizing an enzymatically inactive neuraminidase at 40 degrees which is not incorporated into infectious particles.
Influenza, Human
A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site.
Influenza, Human
A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
Influenza, Human
A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA.
Influenza, Human
A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Influenza, Human
A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.
Influenza, Human
A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.
Influenza, Human
A rigid bicyclic platform for the generation of conformationally locked neuraminidase inhibitors.
Influenza, Human
A robust quantitative structure-activity relationship modelling of influenza neuraminidase a/PR/8/34 (H1N1) inhibitors based on the rank-bridge estimator.
Influenza, Human
A Screening of Neuraminidase Inhibition Activities of Isoquinolone Alkaloids in Coptis chinensis Using Molecular Docking and Pharmacophore Analysis.
Influenza, Human
A secondary sialic Acid binding site on influenza virus neuraminidase: fact or fiction?
Influenza, Human
A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein.
Influenza, Human
A Sero-Survey of Subtype H3 Influenza A Virus Infection in Dogs and Cats in Japan.
Influenza, Human
A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF.
Influenza, Human
A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies.
Influenza, Human
A sialosyl sulfonate as a potent inhibitor of influenza virus replication.
Influenza, Human
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
Influenza, Human
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.
Influenza, Human
A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge.
Influenza, Human
A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
Influenza, Human
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Influenza, Human
A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
Influenza, Human
A single sequence change destabilizes the influenza virus neuraminidase tetramer.
Influenza, Human
A single-radial haemolysis technique for measurement of antibody to influenza virus neuraminidase in equine sera.
Influenza, Human
A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis.
Influenza, Human
A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.
Influenza, Human
A structural and energetics analysis of the binding of a series of N-acetylneuraminic-acid-based inhibitors to influenza virus sialidase.
Influenza, Human
A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs.
Influenza, Human
A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus.
Influenza, Human
A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.
Influenza, Human
A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
Influenza, Human
A Synonymous Change in the Influenza A Virus Neuraminidase Gene Interferes with PCR-Based Subtyping and Oseltamivir Resistance Mutation Detection.
Influenza, Human
A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.
Influenza, Human
A topographic map of the enzyme active center and antigenic sites on the neuraminidase of influenza virus A/Tokyo/3/67 (H2N2).
Influenza, Human
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
Influenza, Human
A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Influenza, Human
A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus.
Influenza, Human
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Influenza, Human
A Virtual Screening Approach For Identifying Plants with Anti H5N1 Neuraminidase Activity.
Influenza, Human
A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies.
Influenza, Human
A9?Deep sequencing analysis to investigate the importance of within host genetic diversity and evolution of influenza A viruses for the development of resistance against neuraminidase inhibitors.
Influenza, Human
Abnormal behavior during influenza in Japan during the last seven seasons: 2006-2007 to 2012-2013.
Influenza, Human
Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans.
Influenza, Human
Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
Influenza, Human
ACP Journal Club. Review: Extended-duration chemoprophylaxis with neuraminidase inhibitors prevents symptomatic influenza.
Influenza, Human
ACP Journal Club. Review: Neuraminidase inhibitors relieve influenza symptoms and reduce laboratory-confirmed influenza in healthy adults.
Influenza, Human
Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.
Influenza, Human
Action of influenza virus neuraminidase on gangliosides. Haemagglutinin inhibits viral neuraminidase.
Influenza, Human
Action of ortho- and paramyxovirus neuraminidase on gangliosides. Hydrolysis of ganglioside GM1 by Sendai virus neuraminidase.
Influenza, Human
Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
Influenza, Human
Active influenza virus neuraminidase is expressed in monkey cells from cDNA cloned in simian virus 40 vectors.
Influenza, Human
Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells.
Influenza, Human
Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: study on the mechanism of action.
Influenza, Human
Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Influenza, Human
Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.
Influenza, Human
Acyl amino acid derivatives as novel inhibitors of influenza neuraminidase.
Influenza, Human
Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Influenza, Human
Adamantane and neuraminidase inhibitor resistance among circulating human influenza A viruses in Cuba during 2006-2010.
Influenza, Human
Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.
Influenza, Human
Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008).
Influenza, Human
Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009.
Influenza, Human
Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity.
Influenza, Human
Adaptation of the influenza neuraminidase and neuraminidase-inhibition assays to the microtitrator system.
Influenza, Human
Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses.
Influenza, Human
Addition of a prominent epitope affects influenza A virus-specific CD8+ T cell immunodominance hierarchies when antigen is limiting.
Influenza, Human
Additional treatment with clarithromycin reduces fever duration in patients with influenza.
Influenza, Human
Adherence to Oseltamivir Guidelines during Influenza Pandemic, the Netherlands.
Influenza, Human
Adjunctive therapies and immunomodulatory agents in the management of severe influenza.
Influenza, Human
Adjustment of receptor-binding and neuraminidase substrate specificities in avian-human reassortant influenza viruses.
Influenza, Human
Administration of neuraminidase inhibitors for the treatment of Japanese patients infected with the novel influenza A (H1N1).
Influenza, Human
Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents.
Influenza, Human
Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
Influenza, Human
Advances in the prophylaxis and treatment of influenza illness. Based on a presentation by Frederick G. Hayden, MD.
Influenza, Human
Advances in the structure-based design of the influenza A neuraminidase inhibitors.
Influenza, Human
Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
Influenza, Human
Affinity chromatography of influenza virus on immobilized alpha- and beta-ketosides of neuraminic acid derivatives.
Influenza, Human
Affinity ranking of influenza neuraminidase mutants with monoclonal antibodies using an optical biosensor. Comparison with ELISA and slot blot assays.
Influenza, Human
Agathisflavone, a Biflavonoid from Anacardium occidentale L., Inhibits Influenza Virus Neuraminidase.
Influenza, Human
Allo-cross-reactivity of a human neuraminidase-specific T cell clone dependent on presentation of an endogenous B cell-specific antigen.
Influenza, Human
Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions.
Influenza, Human
Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene.
Influenza, Human
Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials.
Influenza, Human
Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India.
Influenza, Human
Amino acid 316 of hemagglutinin and the neuraminidase stalk length influence virulence of H9N2 influenza virus in chickens and mice.
Influenza, Human
Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase.
Influenza, Human
Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase.
Influenza, Human
Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase.
Influenza, Human
Amino acid sequence of the Pronase-released heads of neuraminidase subtype N2 from the Asian strain A/Tokyo/3/67 of influenza virus.
Influenza, Human
Amino acids responsible for the absolute sialidase activity of the influenza A virus neuraminidase: relationship to growth in the duck intestine.
Influenza, Human
Amino-terminal anchored surface display in insect cells and budded baculovirus using the amino-terminal end of neuraminidase.
Influenza, Human
AML1 protein interacts with influenza A virus neuraminidase and upregulates IFN-? response in infected mammalian cells.
Influenza, Human
Amplification of four genes of influenza A viruses using a degenerate primer set in a one step RT-PCR method.
Influenza, Human
An activity-integrated strategy of the identification, screening and determination of potential neuraminidase inhibitors from Radix Scutellariae.
Influenza, Human
An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity.
Influenza, Human
An analysis of the role of neuraminidase in the receptor-binding activity of influenza B virus: the inhibitory effect of Zanamivir on haemadsorption.
Influenza, Human
An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac.
Influenza, Human
An effect of phloridzin on influenza virus elution and on neuraminidase activity.
Influenza, Human
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
Influenza, Human
An enzymatic virus-like particle assay for sensitive detection of virus entry.
Influenza, Human
An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex.
Influenza, Human
An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
Influenza, Human
An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
Influenza, Human
An Infant Mouse Model of Influenza Virus Transmission Demonstrates the Role of Virus-Specific Shedding, Humoral Immunity, and Sialidase Expression by Colonizing Streptococcus pneumoniae.
Influenza, Human
An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus.
Influenza, Human
An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice.
Influenza, Human
An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
Influenza, Human
An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.
Influenza, Human
An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir.
Influenza, Human
An influenza virus model for Trypanosoma cruzi infection: interactive roles for neuraminidase and lectin.
Influenza, Human
An inhibition test for identifying the neuraminidase antigen on influenza viruses.
Influenza, Human
An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.
Influenza, Human
An integrated microfluidic system for rapid detection and multiple subtyping of influenza A viruses by using glycan-coated magnetic beads and RT-PCR.
Influenza, Human
An investigation of antigenic drift of neuraminidases of influenza A (H1N1) viruses.
Influenza, Human
An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality.
Influenza, Human
An iron carbonyl approach to the influenza neuraminidase inhibitor oseltamivir.
Influenza, Human
An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.
Influenza, Human
An NA-deficient 2009 pandemic H1N1 influenza virus mutant can efficiently replicate in cultured cells.
Influenza, Human
An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses.
Influenza, Human
An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.
Influenza, Human
An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.
Influenza, Human
Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Influenza, Human
Analyses of structural polypeptides of seven different isolates of influenza C virus.
Influenza, Human
Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation of drug unbinding and rebinding in simulation.
Influenza, Human
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Influenza, Human
Analysis of Glycosyl-Enzyme Intermediate Formation in the Catalytic Mechanism of Influenza Virus Neuraminidase Using Molecular Modeling.
Influenza, Human
Analysis of influenza A virus neuraminidase using lectin test and monoclonal antibodies.
Influenza, Human
Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.
Influenza, Human
Analysis of the binding of the Fab fragment of monoclonal antibody NC10 to influenza virus N9 neuraminidase from tern and whale using the BIAcore biosensor: effect of immobilization level and flow rate on kinetic analysis.
Influenza, Human
Analysis of the desialidation process of the haemagglutinin protein of influenza B virus: the host-dependent desialidation step.
Influenza, Human
Analysis of the Evolution of Pandemic Influenza A(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics.
Influenza, Human
Analysis of the hemagglutinin and neuraminidase genes of human Influenza A/H3N2 viruses circulating in iran between 2005 and 2007: antigenic and phylogenetic relationships to vaccine strains.
Influenza, Human
Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
Influenza, Human
Analysis of the signals for polarized transport of influenza virus (A/WSN/33) neuraminidase and human transferrin receptor, type II transmembrane proteins.
Influenza, Human
Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft association.
Influenza, Human
Analysis of viral and cellular parameters which affect the fusion process of influenza viruses.
Influenza, Human
Analyzing swine sera for functional antibody titers against influenza A neuraminidase proteins using an enzyme-linked lectin assay (ELLA).
Influenza, Human
Ancestral and Compensatory Mutations that Promote Antiviral Resistance in Influenza N1 Neuraminidase Revealed by a Phylonumerics Approach.
Influenza, Human
Animal influenza virus neuraminidase: studies on dependence of some of its properties on its association with hemagglutinin.
Influenza, Human
Anomeric specificity and protein-substrate interactions support the 3D model for the hemagglutinin-neuraminidase from sendai virus.
Influenza, Human
Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV).
Influenza, Human
Anti-Influenza Activity of an Ethyl Acetate Fraction of a Rhus verniciflua Ethanol Extract by Neuraminidase Inhibition.
Influenza, Human
Anti-influenza effect of the major flavonoids from Salvia plebeia R.Br. via inhibition of influenza H1N1 virus neuraminidase.
Influenza, Human
Anti-Influenza Virus (H5N1) Activity Screening on the Phloroglucinols from Rhizomes of Dryopteris crassirhizoma.
Influenza, Human
Anti-influenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa.
Influenza, Human
Anti-Influenza Virus Activity and Constituents. Characterization of Paeonia delavayi Extracts.
Influenza, Human
Anti-influenza virus activity of peramivir in mice with single intramuscular injection.
Influenza, Human
Anti-influenza virus phytochemicals from Radix Paeoniae Alba and characterization of their neuraminidase inhibitory activities.
Influenza, Human
Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.
Influenza, Human
Anti-neuraminidase antibodies: which substrate should be used to test their effect on influenza virus neuraminidase.
Influenza, Human
Anti-Neuraminidase Bioactives from Manggis Hutan (Garcinia celebica L.) Leaves: Partial Purification and Molecular Characterization.
Influenza, Human
Anti-pandemic influenza A(H1N1) virus potential of catechin and gallic acid.
Influenza, Human
Anti-Viral Inhibitor Binding to Influenza Neuraminidase by MALDI Mass Spectrometry.
Influenza, Human
Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Influenza, Human
Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry.
Influenza, Human
Antibody against Microbial Neuraminidases Recognizes Human Sialidase 3 (NEU3): the Neuraminidase/Sialidase Superfamily Revisited.
Influenza, Human
Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.
Influenza, Human
Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.
Influenza, Human
Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
Influenza, Human
Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98).
Influenza, Human
Antibody formation after vaccination with adsorbed and non-adsorbed A/New Jersey/8/76 influenza vaccines.
Influenza, Human
Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding.
Influenza, Human
Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination.
Influenza, Human
Antibody response in humans to neuraminidase of A2-Aichi-68 and B-Mass-66 influenza viruses.
Influenza, Human
Antibody response in man to influenza virus neuraminidase following influenza.
Influenza, Human
Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
Influenza, Human
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
Influenza, Human
Antibody-free digital influenza virus counting based on neuraminidase activity.
Influenza, Human
Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice.
Influenza, Human
Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection.
Influenza, Human
Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies.
Influenza, Human
ANTIGENIC AND GENETIC CHARACTERIZATION OF INFLUENZA B VIRUSES IN 2012 FROM SLUMS, DHAKA, BANGLADESH.
Influenza, Human
Antigenic and genomic relation between human influenza A (H3N2) viruses circulating in Argentina during 1998 and the H3N2 vaccine component.
Influenza, Human
Antigenic characterisation of influenza B virus with a new microneutralisation assay: comparison to haemagglutination and sequence analysis.
Influenza, Human
Antigenic characterization of an H3N2 swine influenza virus isolated from pigs with proliferative and necrotizing pneumonia in Quebec.
Influenza, Human
Antigenic characterization of recombinant hemagglutinin proteins derived from different avian influenza virus subtypes.
Influenza, Human
Antigenic Drift of Hemagglutinin and Neuraminidase in seasonal H1N1 influenza Viruses from Saudi Arabia in 2014-2015.
Influenza, Human
Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Influenza, Human
Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.
Influenza, Human
Antigenic relationship between the surface antigens of avian and equine influenze viruses.
Influenza, Human
Antigenic relationships among influenza virua A neuraminidase (N2) antigens by immunodiffusion and postinfection neutralization tests.
Influenza, Human
Antigenic variability in Neuraminidase protein of Influenza A/H3N2 vaccine strains (1968 - 2009).
Influenza, Human
Antigenic variation of neuraminidase of human type A influenza (H3N2) viruses isolated in Berlin (West).
Influenza, Human
Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins.
Influenza, Human
Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase.
Influenza, Human
Antineuraminidase antibody response of man to influenza virus neuraminidase N2: results obtained with an improved hemagglutination inhibition technique and an enzyme inhibition test.
Influenza, Human
Antiviral Activities of Compounds from Aerial Parts of Salvia plebeia R. Br.
Influenza, Human
Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism.
Influenza, Human
Antiviral activity of antiserum specific for an influenza virus neuraminidase.
Influenza, Human
Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.
Influenza, Human
Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Influenza, Human
Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition.
Influenza, Human
Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase.
Influenza, Human
Antiviral Activity of Chrysin against Influenza Virus Replication via Inhibition of Autophagy.
Influenza, Human
Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition.
Influenza, Human
Antiviral Activity of Isoimperatorin Against Influenza A Virus in vitro and its Inhibition of Neuraminidase.
Influenza, Human
Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase.
Influenza, Human
Antiviral Activity of the Long Chain Pentraxin PTX3 against Influenza Viruses.
Influenza, Human
Antiviral activity of the plant extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii against influenza virus A/PR/8/34.
Influenza, Human
Antiviral adhesion molecular mechanisms for influenza: W. G. Laver's lifetime obsession.
Influenza, Human
Antiviral agents for influenza, hepatitis C and herpesvirus, enterovirus and rhinovirus infections.
Influenza, Human
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.
Influenza, Human
Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?
Influenza, Human
Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.
Influenza, Human
Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.
Influenza, Human
Antiviral drugs in influenza. An adjunct to vaccination in some situations.
Influenza, Human
Antiviral drugs in the immunocompetent host: part II. Treatment of influenza and respiratory syncytial virus infections.
Influenza, Human
Antiviral effect of flavonol glycosides isolated from the leaf of Zanthoxylum piperitum on influenza virus.
Influenza, Human
Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai.
Influenza, Human
Antiviral prophylaxis during pandemic influenza may increase drug resistance.
Influenza, Human
Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.
Influenza, Human
Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
Influenza, Human
Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Influenza, Human
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
Influenza, Human
Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers.
Influenza, Human
Antiviral resistance markers in influenza virus sequences in Mexico, 2000-2017.
Influenza, Human
Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007.
Influenza, Human
Antiviral strategies against influenza virus: towards new therapeutic approaches.
Influenza, Human
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Influenza, Human
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Influenza, Human
Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
Influenza, Human
Antiviral therapy for influenza : a clinical and economic comparative review.
Influenza, Human
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Influenza, Human
Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Influenza, Human
Antivirals for the treatment and prevention of epidemic and pandemic influenza.
Influenza, Human
Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Influenza, Human
Apical budding of a recombinant influenza A virus expressing a hemagglutinin protein with a basolateral localization signal.
Influenza, Human
Apical Trafficking Pathways of Influenza A Virus HA and NA via Rab17- and Rab23-Positive Compartments.
Influenza, Human
Apigenin suppresses influenza A virus-induced RIG-I activation and viral replication.
Influenza, Human
Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis.
Influenza, Human
Application of a Seven-Target Pyrosequencing Assay To Improve the Detection of Neuraminidase Inhibitor-Resistant Influenza A(H3N2) Viruses.
Influenza, Human
Application of the single radial diffusion test for assay of antibody to influenza type A viruses.
Influenza, Human
Application of three duplex real-time PCR assays for simultaneous detection of human seasonal and avian influenza viruses.
Influenza, Human
Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions.
Influenza, Human
Approach to the involvement of influenza B neuraminidase in the cleavage of HA by host cell protease using low pH-induced cell fusion reaction.
Influenza, Human
Approaches and strategies for the treatment of influenza virus infections.
Influenza, Human
Aptamers to hemagglutinin: a novel tool for influenza virus recognition and neutralization.
Influenza, Human
Are neuraminidase inhibitors effective for preventing and treating influenza in healthy adults and children?
Influenza, Human
Aromatic sialic acid analogues as potential inhibitors of influenza virus neuraminidase.
Influenza, Human
Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays.
Influenza, Human
Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.
Influenza, Human
Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains.
Influenza, Human
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Influenza, Human
Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model.
Influenza, Human
Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
Influenza, Human
Assessing the susceptibility of highly pathogenic avian influenza H5N1 viruses to oseltamivir using embryonated chicken eggs.
Influenza, Human
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Influenza, Human
Assessment of Anti-Influenza Activity and Hemagglutination Inhibition of Plumbago indica and Allium sativum Extracts.
Influenza, Human
Assessment of immunity to influenza using artifical challenge of normal volunteers with influenza virus.
Influenza, Human
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Influenza, Human
Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Influenza, Human
Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks.
Influenza, Human
Association of severe abnormal behavior and acetaminophen with/without neuraminidase inhibitors.
Influenza, Human
Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.
Influenza, Human
Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry.
Influenza, Human
Attenuated influenza B virus recombinants obtained by crossing of B/England/2608/76 virus with a cold-adapted B/Leningrad/14/17/55 strain.
Influenza, Human
Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice.
Influenza, Human
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.
Influenza, Human
Attenuation and phenotypic stability of influenza B/Texas/1/84 cold-adapted reassortant virus: studies in hamsters and chimpanzees.
Influenza, Human
Attenuation of an influenza A virus due to alteration of its hemagglutinin-neuraminidase functional balance in mice.
Influenza, Human
Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.
Influenza, Human
Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase.
Influenza, Human
Attenuation of pathogenicity of fowl plague virus by recombination with other influenza A viruses nonpathogenic for fowl: nonexculsive dependence of pathogenicity on hemagglutinin and neuraminidase of the virus.
Influenza, Human
Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin.
Influenza, Human
Author Correction: Structural restrictions for influenza neuraminidase activity promote adaptation and diversification.
Influenza, Human
Auto-antibody dependent activation of the autologous classical complement pathway by guinea-pig red cells treated with influenza virus or neuraminidase: in vitro and in vivo study.
Influenza, Human
Automatic detection of rate change in large data sets with an unsupervised approach: the case of influenza viruses.
Influenza, Human
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Influenza, Human
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.
Influenza, Human
Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses.
Influenza, Human
Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process.
Influenza, Human
B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.
Influenza, Human
Bacterial and viral sialidases: contribution of the conserved active site glutamate to catalysis.
Influenza, Human
Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production.
Influenza, Human
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.
Influenza, Human
Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.
Influenza, Human
Baculovirus-Produced Influenza Virus-like Particles in Mammalian Cells Protect Mice from Lethal Influenza Challenge.
Influenza, Human
Baicalein, Ethyl Acetate, and Chloroform Extracts of Scutellaria baicalensis Inhibit the Neuraminidase Activity of Pandemic 2009 H1N1 and Seasonal Influenza A Viruses.
Influenza, Human
Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.
Influenza, Human
Balancing societal needs and regulatory certainty: the case study of peramivir in Japan.
Influenza, Human
Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone.
Influenza, Human
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
Influenza, Human
Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Influenza, Human
Baloxavir marboxil treatment of nude mice infected with influenza A virus.
Influenza, Human
Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Influenza, Human
Basolateral sorting signals differ in their ability to redirect apical proteins to the basolateral cell surface.
Influenza, Human
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Influenza, Human
Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus.
Influenza, Human
Benzoic acid and pyridine derivatives as inhibitors of Trypanosoma cruzi trans-sialidase.
Influenza, Human
Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
Influenza, Human
Berberine-piperazine conjugates as potent influenza neuraminidase blocker.
Influenza, Human
Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Influenza, Human
Beyond personal protective equipment: adjunctive methods for control of healthcare-associated respiratory viral infections.
Influenza, Human
Binding affinity of influenza virus N9 neuraminidase with Fab fragments of monoclonal antibodies NC10 and NC41.
Influenza, Human
Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Influenza, Human
Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and its Implication for Drug Design.
Influenza, Human
Binding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometry.
Influenza, Human
Binding of antibodies to isolated haemagglutinin and neuraminidase molecules of influenza virus observed in the electron microscope.
Influenza, Human
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form.
Influenza, Human
Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
Influenza, Human
Bioactive compounds derived from the marine-derived fungus MCCC3A00951 and their influenza neuraminidase inhibition activity in vitro and in silico.
Influenza, Human
Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors.
Influenza, Human
Biochemical Methods for the Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.
Influenza, Human
Bioinformatics studies of Influenza A hemagglutinin sequence data indicate recombination-like events leading to segment exchanges.
Influenza, Human
Biological and immunological properties of haemagglutinin and neuraminidase expressed from cloned cDNAs in prokaryotic and eukaryotic cells.
Influenza, Human
Biological and protective properties of immune sera directed to the influenza virus neuraminidase.
Influenza, Human
Biological properties of N-acyl and N-haloacetyl neuraminic acids: processing by enzymes of sialic acid metabolism, and interaction with influenza virus.
Influenza, Human
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza drug susceptibility in clinical specimens.
Influenza, Human
Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities.
Influenza, Human
Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus.
Influenza, Human
Biotin-, fluorescein- and 'clickable' conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase.
Influenza, Human
Birds, migration and emerging zoonoses: west nile virus, lyme disease, influenza A and enteropathogens.
Influenza, Human
Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.
Influenza, Human
Bivalent vaccine platform based on ca influenza virus vaccine elicits protective immunity against human adenoviruses.
Influenza, Human
Block deletions in the neuraminidase genes from some influenza A viruses of the N1 subtype.
Influenza, Human
Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza.
Influenza, Human
BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses.
Influenza, Human
Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Influenza, Human
Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.
Influenza, Human
Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
Influenza, Human
Broadly Protective CD8+ T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine.
Influenza, Human
Broadly protective human antibodies that target the active site of influenza virus neuraminidase.
Influenza, Human
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.
Influenza, Human
Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
Influenza, Human
Budding capability of the influenza virus neuraminidase can be modulated by tetherin.
Influenza, Human
Burden of influenza B virus infection and considerations for clinical management.
Influenza, Human
C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase.
Influenza, Human
C-Terminally tagged NA in replication-competent influenza A viruses reveals differences in glycan profiles between NA and HA.
Influenza, Human
Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors.
Influenza, Human
Calcium is needed for the thermostability of influenza B virus neuraminidase.
Influenza, Human
Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?
Influenza, Human
Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles.
Influenza, Human
Carbocyclic influenza neuraminidase inhibitors possessing a C3-cyclic amine side chain: synthesis and inhibitory activity.
Influenza, Human
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.
Influenza, Human
Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.
Influenza, Human
Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
Influenza, Human
Catalytic properties of the A/H3N2 influenza neuraminidases: influence of antigenic variations.
Influenza, Human
Catechin inhibiting the H1N1 influenza virus associated with the regulation of autophagy.
Influenza, Human
Catechin inhibition of influenza neuraminidase and its molecular basis with mass spectrometry.
Influenza, Human
Cationic Lipid/DNA Complex-Adjuvanted Influenza A Vaccination Induces Robust Cross-Protective Immunity.
Influenza, Human
CD4+ follicular regulatory T cells optimize the influenza virus-specific B cell response.
Influenza, Human
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Influenza, Human
Cell surface transport, oligomerization, and endocytosis of chimeric type II glycoproteins: role of cytoplasmic and anchor domains.
Influenza, Human
Cell-mediated immune responses to the hemagglutinin and neuraminidase antigens of influenza A virus after immunization in humans.
Influenza, Human
Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
Influenza, Human
Challenges and options in the management of viral infections after stem cell transplantation.
Influenza, Human
Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.
Influenza, Human
Changes in Hemagglutinin and Neuraminidase Genes of pH1N1 Influenza Virus Strains Collected from a North Indian Tertiary Care Hospital during 2015.
Influenza, Human
Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Influenza, Human
Changes in temperature-sensitivity of haemagglutinin and neuraminidase during adaptation of influenza virus to mice.
Influenza, Human
Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons.
Influenza, Human
Changes in the Length of the Neuraminidase Stalk Region Impact H7N9 Virulence in Mice.
Influenza, Human
Characterisation of an avian influenza virus nucleoprotein expressed in E. coli and in insect cells.
Influenza, Human
Characterisation of an ionisable group involved in binding and catalysis by sialidase from influenza virus.
Influenza, Human
Characterisation of influenza viruses isolated from turkeys in Great Britain during 1963--1977.
Influenza, Human
Characteristic of alkylated chalcones from Angelica keiskei on influenza virus neuraminidase inhibition.
Influenza, Human
Characteristics of a cell-free assay for the delivery of proteins to the plasma membrane.
Influenza, Human
Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine.
Influenza, Human
Characteristics of influenza HA-NA interdependence determined through a graphical technique.
Influenza, Human
Characterization and mutational analysis of haemagglutinin and neuraminidase of H3N2 and H1N1pdm09 human influenza A viruses in Egypt.
Influenza, Human
Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.
Influenza, Human
Characterization of a 1980-swine recombinant influenza virus possessing H1 hemagglutinin and N2 neuraminidase similar to that of the earliest Hong Kong (H3N2) virus.
Influenza, Human
Characterization of a cold-sensitive (cs) recombinant between two influenza A strains.
Influenza, Human
Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
Influenza, Human
Characterization of a large cluster of influenza A(H1N1)pdm09 virus cross-resistant to oseltamivir and peramivir during the 2013/2014 influenza season in Japan.
Influenza, Human
Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.
Influenza, Human
Characterization of a newly emerged genetic cluster of H1N1 and H1N2 swine influenza virus in the United States.
Influenza, Human
Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls.
Influenza, Human
Characterization of a temperature-sensitive influenza B virus mutant defective in neuraminidase.
Influenza, Human
Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.
Influenza, Human
Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
Influenza, Human
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
Influenza, Human
Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Influenza, Human
Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Influenza, Human
Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Influenza, Human
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.
Influenza, Human
CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
Influenza, Human
Characterization of influenza virus neuraminidase with hemagglutinin activity and its comparison with that of viral neuraminidase.
Influenza, Human
Characterization of influenza virus-induced leukocyte adherence to human umbilical vein endothelial cell monolayers.
Influenza, Human
Characterization of mAb6-9-1 monoclonal antibody against hemagglutinin of avian influenza virus H5N1 and its engineered derivative, single-chain variable fragment antibody.
Influenza, Human
Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.
Influenza, Human
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Influenza, Human
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Influenza, Human
Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses.
Influenza, Human
Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses.
Influenza, Human
Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
Influenza, Human
Characterization of pseudoparticles paired with hemagglutinin and neuraminidase from highly pathogenic H5N1 influenza and avian influenza A (H7N9) viruses.
Influenza, Human
Characterization of recent H5 subtype avian influenza viruses from US poultry.
Influenza, Human
Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
Influenza, Human
Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.
Influenza, Human
Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity.
Influenza, Human
Characterization of sialyltransferases from serum of normal and hepatoma Mc-29 bearing chickens.
Influenza, Human
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Influenza, Human
Characterization of temperature sensitive influenza virus mutants defective in neuraminidase.
Influenza, Human
Characterization of the 1918 "Spanish" influenza virus neuraminidase gene.
Influenza, Human
Characterization of the hemagglutinin and neuraminidase genes of recent influenza virus isolates from different avian species in Thailand.
Influenza, Human
Characterization of the hemagglutinin receptor specificity and neuraminidase substrate specificity of clinical isolates of human influenza A viruses.
Influenza, Human
Characterization of the neuraminidase genes from human influenza A viruses circulating in Iran from 2010 to 2015.
Influenza, Human
Characterization of the neuraminidase of the H1N1/09 pandemic influenza virus.
Influenza, Human
Characterization of the ribonucleoprotein and neuraminidase of influenza A viruses by immunodiffusion.
Influenza, Human
Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses.
Influenza, Human
Characterization of Variations in PB2, NS1, M, Neuraminidase and Hemagglutinin of Influenza A (H3N2) Viruses in Iran.
Influenza, Human
Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations.
Influenza, Human
Charged amino acid variability related to N-glyco -sylation and epitopes in A/H3N2 influenza: Hem -agglutinin and neuraminidase.
Influenza, Human
Chemical and antigenic characterization of the carbohydrate side chains of an Asian (N2) influenza virus neuraminidase.
Influenza, Human
Chemical insight into the emergence of influenza virus strains that are resistant to relenza.
Influenza, Human
Chemical probes for drug-resistance assessment by binding competition (RABC): oseltamivir susceptibility evaluation.
Influenza, Human
Chemoenzymatic site-specific labeling of influenza glycoproteins as a tool to observe virus budding in real time.
Influenza, Human
Chemoenzymatic Syntheses of Sialylated Oligosaccharides Containing C5-Modified Neuraminic Acids for Dual Inhibition of Hemagglutinins and Neuraminidases.
Influenza, Human
Chemoenzymatic synthesis of an N-acetylneuraminic acid analogue having a carbamoylmethyl group at C-4 as an inhibitor of sialidase from influenza virus.
Influenza, Human
Chemoenzymatic synthesis of neuraminic acid analogs structurally varied at C-5 and C-9 as potential inhibitors of the sialidase from influenza virus.
Influenza, Human
Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract.
Influenza, Human
Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin.
Influenza, Human
Circulating pattern and genomic characteristics of influenza B viruses in Taiwan from 2003 to 2014.
Influenza, Human
Cirsimaritin inhibits influenza A virus replication by downregulating the NF-?B signal transduction pathway.
Influenza, Human
Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells.
Influenza, Human
Class I H-2d-restricted cytotoxic T lymphocytes recognize the neuraminidase glycoprotein of influenza virus subtype N1.
Influenza, Human
Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis.
Influenza, Human
ClassyFlu: classification of influenza A viruses with Discriminatively trained profile-HMMs.
Influenza, Human
Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan.
Influenza, Human
Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.
Influenza, Human
Clinical and Pathologic Characterization of an Outbreak of Highly Pathogenic Avian Influenza H7N8 in Commercial Turkeys in Southern Indiana.
Influenza, Human
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Influenza, Human
Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations.
Influenza, Human
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Influenza, Human
Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Influenza, Human
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Influenza, Human
Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
Influenza, Human
Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients.
Influenza, Human
Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.
Influenza, Human
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
Influenza, Human
Clinical Efficacy of Peramivir in Adult Patients with Seasonal Influenza during the winter of 2012 in Japan.
Influenza, Human
Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
Influenza, Human
Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States.
Influenza, Human
Clinical findings in 10 children with H275Y influenza A(H1N1)pdm09 virus infection.
Influenza, Human
Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy.
Influenza, Human
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
Influenza, Human
Clinical trials with a new influenza subunit vaccine in adults and children.
Influenza, Human
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.
Influenza, Human
Co-evolution analysis to predict protein-protein interactions within influenza virus envelope.
Influenza, Human
Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
Influenza, Human
Codon optimization of the major antigen encoding genes of diverse strains of influenza a virus.
Influenza, Human
Codon usage bias and recombination events for neuraminidase and hemagglutinin genes in Chinese isolates of influenza A virus subtype H9N2.
Influenza, Human
Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge.
Influenza, Human
Cold-adapted recombinant influenza A virus vaccines in seronegative young children.
Influenza, Human
Combination activity of neuraminidase inhibitor oseltamivir and ?-tocopherol in influenza virus A (H3N2) infection in mice.
Influenza, Human
Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.
Influenza, Human
Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.
Influenza, Human
Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model.
Influenza, Human
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Influenza, Human
Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.
Influenza, Human
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Influenza, Human
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
Influenza, Human
Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
Influenza, Human
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Influenza, Human
Combinatorial effect of two E119V+I222L framework mutations in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
Influenza, Human
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.
Influenza, Human
Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.
Influenza, Human
Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Influenza, Human
Combined MS/MS-NMR Annotation Guided Discovery of Iris lactea var. chinensis Seed as a Source of Viral Neuraminidase Inhibitory Polyphenols.
Influenza, Human
Combined quantum mechanics/molecular mechanics (QM/MM) simulations for protein-ligand complexes: free energies of binding of water molecules in influenza neuraminidase.
Influenza, Human
Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition.
Influenza, Human
Combining Molecular Docking and Molecular Dynamics to Predict the Binding Modes of Flavonoid Derivatives with the Neuraminidase of the 2009 H1N1 Influenza A Virus.
Influenza, Human
Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
Influenza, Human
Comment on 'Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)"'.
Influenza, Human
Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Influenza, Human
Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Influenza, Human
Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.
Influenza, Human
Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016.
Influenza, Human
Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.
Influenza, Human
Comparable Fitness and Transmissibility between Oseltamivir-Resistant Pandemic 2009 and Seasonal H1N1 Influenza Viruses with the H275Y Neuraminidase Mutation.
Influenza, Human
Comparative analysis of virulence of a novel, avian-origin H3N2 canine influenza virus in various host species.
Influenza, Human
Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes.
Influenza, Human
Comparative Co-Evolution Analysis Between the HA and NA Genes of Influenza A Virus.
Influenza, Human
Comparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors.
Influenza, Human
Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
Influenza, Human
Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.
Influenza, Human
Comparative evaluation of effectiveness of IAVchip DNA microarray in influenza A diagnosis.
Influenza, Human
Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts.
Influenza, Human
Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.
Influenza, Human
Comparative nucleotide sequences at the 3' end of the neuraminidase gene from eleven influenza type A viruses.
Influenza, Human
Comparative phyloinformatics of virus genes at micro and macro levels in a distributed computing environment.
Influenza, Human
Comparative sequence, antigenic and phylogenetic analysis of avian influenza (H9N2) surface proteins isolated in Pakistan between 1999 and 2008.
Influenza, Human
Comparative studies on influenza B virus. I. Biological properties and polypeptide composition of strains isolated in different years.
Influenza, Human
Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.
Influenza, Human
Comparative study of lymphocytes from individuals that were vaccinated and unvaccinated against the pandemic 2009-2011 H1N1 influenza virus in Southern Brazil.
Influenza, Human
Comparative study of the hemagglutinin and neuraminidase genes of influenza A virus H3N2, H9N2, and H5N1 subtypes using bioinformatics techniques.
Influenza, Human
Comparative study of the nucleotide bias between the novel H1N1 and H5N1 subtypes of influenza A viruses using bioinformatics techniques.
Influenza, Human
Comparative thermostability analysis of zoonotic and human influenza virus A and B neuraminidase.
Influenza, Human
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
Influenza, Human
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
Influenza, Human
Comparison of biological and physical properties of human and animal A(H1N1) influenza viruses.
Influenza, Human
Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies.
Influenza, Human
Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Influenza, Human
Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Influenza, Human
Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
Influenza, Human
Comparison of in vitro replication features of H7N3 influenza viruses from wild ducks and turkeys: potential implications for interspecies transmission.
Influenza, Human
Comparison of influenza virus hemagglutinin, neuraminidase and their antibody responses in infected patients.
Influenza, Human
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine.
Influenza, Human
Comparison of neuraminidase activity of influenza A virus subtype H5N1 and H1N1 using reverse genetics virus.
Influenza, Human
Comparison of neuraminidases of the same subtype but from different species using a new method of titration.
Influenza, Human
Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.
Influenza, Human
Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: A phase III randomized, double-blind study.
Influenza, Human
Comparison of substrate specificities of sialidase activity between purified enzymes from influenza virus A (H1N1 and H3N2 subtypes) and B strains and their original viruses.
Influenza, Human
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Influenza, Human
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Influenza, Human
Comparison of the antiviral effect of solid-state copper and silver compounds.
Influenza, Human
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Influenza, Human
Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
Influenza, Human
Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
Influenza, Human
Comparison of the pathogenesis of two genetically different H3N2 influenza A viruses in pigs.
Influenza, Human
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.
Influenza, Human
Competitive Cooperation of Hemagglutinin and Neuraminidase during Influenza A Virus Entry.
Influenza, Human
Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets.
Influenza, Human
Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Co-infection Model of the Human Airway Epithelium.
Influenza, Human
Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Influenza, Human
Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus.
Influenza, Human
Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant.
Influenza, Human
Complete nucleotide sequence of a human influenza neuraminidase gene of subtype N2 (A/Victoria/3/75).
Influenza, Human
Complete nucleotide sequence of the neuraminidase gene of human influenza virus A/WSN/33.
Influenza, Human
Complete nucleotide sequence of the neuraminidase gene of influenza B virus.
Influenza, Human
Complete nucleotide sequence of the neuraminidase gene of the human influenza virus A/Chile/1/83 (H1N1). Brief report.
Influenza, Human
Complexity in influenza virus targeted drug design: interaction with human sialidases.
Influenza, Human
Composition of Hemagglutinin and Neuraminidase Affects the Antigen Yield of Influenza A(H1N1)pdm09 Candidate Vaccine Viruses.
Influenza, Human
Comprehensive N-glycosylation analysis of the influenza A virus proteins HA and NA from adherent and suspension MDCK cells.
Influenza, Human
Comprehensive profiling of translation initiation in influenza virus infected cells.
Influenza, Human
Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase.
Influenza, Human
Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential.
Influenza, Human
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Influenza, Human
Computational assay of Zanamivir binding affinity with original and mutant influenza neuraminidase 9 using molecular docking.
Influenza, Human
Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme.
Influenza, Human
Computational model for analyzing the evolutionary patterns of the neuraminidase gene of influenza A/H1N1.
Influenza, Human
Computational modeling and validation studies of 3-D structure of neuraminidase protein of H1N1 influenza A virus and subsequent in silico elucidation of piceid analogues as its potent inhibitors.
Influenza, Human
Computational studies of influenza a virus at three important targets: hemagglutinin, neuraminidase and m2 protein.
Influenza, Human
Computational Study of Dispersion and Extent of Mutated and Duplicated Sequences of the H5N1 Influenza Neuraminidase over the Period 1997-2008.
Influenza, Human
Computational Study of Drug Binding Affinity to Influenza A Neuraminidase Using Smooth Reaction Path Generation (SRPG) Method.
Influenza, Human
Computational Study of Interdependence Between Hemagglutinin and Neuraminidase of Pandemic 2009 H1N1.
Influenza, Human
Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.
Influenza, Human
Computer-Guided Approach to Access the Anti-influenza Activity of Licorice Constituents.
Influenza, Human
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Influenza, Human
Conformational Free Energy Surface of alpha-N-Acetylneuraminic Acid: An Interplay Between Hydrogen Bonding and Solvation.
Influenza, Human
Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.
Influenza, Human
Conservation region finding for influenza A viruses by machine learning methods of N-linked glycosylation sites and B-cell epitopes.
Influenza, Human
Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies.
Influenza, Human
Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses.
Influenza, Human
Construction and comparison of different source neuraminidase candidate vaccine strains for human infection with Eurasian avian-like influenza H1N1 virus.
Influenza, Human
Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases.
Influenza, Human
Construction of recombinant fusion protein of influenza, a virus neuraminidase and heat shock protein 70 gene: expression in baculovirus and bioactivity.
Influenza, Human
Contacts between influenza virus N9 neuraminidase and monoclonal antibody NC10.
Influenza, Human
Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
Influenza, Human
Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays.
Influenza, Human
Contribution of neuraminidase of influenza viruses to the sensitivity to sera inhibitors and reassortment efficiency.
Influenza, Human
Contribution to the standardization of influenza neuraminidase inhibition tests, based on enzyme- antienzyme kinetic studies.
Influenza, Human
Control of highly pathogenic avian influenza in Quang Tri province, Vietnam: voices from the human-animal interface.
Influenza, Human
Cooperation between distinct viral variants promotes growth of H3N2 influenza in cell culture.
Influenza, Human
Core-6 fucose and the oligomerization of the 1918 pandemic influenza viral neuraminidase.
Influenza, Human
Correction: Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Influenza, Human
Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice.
Influenza, Human
Correlation Analyses on Binding Affinity of Sialic Acid Analogues and Antiinfluenza Drugs with Human Neuraminidase Using ab Initio MO Calculations on Their Complex Structures - LERE-QSAR Analysis (IV).
Influenza, Human
Correlation analyses on binding affinity of sialic acid analogues with influenza virus neuraminidase-1 using ab initio MO calculations on their complex structures.
Influenza, Human
Correlation between levels of apoptosis, levels of infection and haemagglutinin receptor binding interaction of various subtypes of influenza virus: does the viral neuraminidase have a role in these associations.
Influenza, Human
Corticosteroids as adjunctive therapy in the treatment of influenza.
Influenza, Human
Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
Influenza, Human
Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.
Influenza, Human
Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.
Influenza, Human
Critical care management of adults with community-acquired severe respiratory viral infection.
Influenza, Human
Critical interactions in binding antibody NC41 to influenza N9 neuraminidase: amino acid contacts on the antibody heavy chain.
Influenza, Human
Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
Influenza, Human
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.
Influenza, Human
Cross-protective immune responses elicited by live attenuated influenza vaccines.
Influenza, Human
Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Influenza, Human
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.
Influenza, Human
Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase.
Influenza, Human
Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6.
Influenza, Human
Crystal structure of phage P22 tailspike protein complexed with Salmonella sp. O-antigen receptors.
Influenza, Human
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Influenza, Human
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Influenza, Human
Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface.
Influenza, Human
Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site.
Influenza, Human
Crystalline monoclonal fab fragment with specificity towards an influenza virus neuraminidase.
Influenza, Human
Crystallization and peptide maps of neuraminidase "heads" from H2N2 and H3N2 influenza virus strains.
Influenza, Human
Crystallization and preliminary X-ray analyses of two neuraminidases from influenza B virus strains B/Hong Kong/8/73 and B/Lee/40.
Influenza, Human
Crystallization and preliminary X-ray analysis of type B influenza virus neuraminidase complexed with antibody Fab fragments.
Influenza, Human
Crystallization and preliminary X-ray studies of influenza A virus neuraminidase of subtypes N5, N6, N8 and N9.
Influenza, Human
Crystals of antibodies complexed with influenza virus neuraminidase show isosteric binding of antibody to wild-type and variant antigens.
Influenza, Human
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Influenza, Human
Current and future antiviral therapy of severe seasonal and avian influenza.
Influenza, Human
Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses.
Influenza, Human
Current usage and effectiveness of influenza medications and factors regarding the time taken to alleviate fever based on postcard questionnaire survey.
Influenza, Human
Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.
Influenza, Human
Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase.
Influenza, Human
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.
Influenza, Human
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.
Influenza, Human
Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains.
Influenza, Human
Db-binding peptides from influenza virus: effect of non-anchor residues on stability and immunodominance.
Influenza, Human
Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.
Influenza, Human
Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.
Influenza, Human
Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase.
Influenza, Human
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.
Influenza, Human
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus.
Influenza, Human
Defining the requirements for an antibody epitope on influenza virus neuraminidase: how tolerant are protein epitopes?
Influenza, Human
Deletion mutation in the signal anchor domain activates cleavage of the influenza virus neuraminidase, a type II transmembrane protein.
Influenza, Human
Deletions in the Neuraminidase Stalk Region of H2N2 and H9N2 Avian Influenza Virus Subtypes Do Not Affect Postinfluenza Secondary Bacterial Pneumonia.
Influenza, Human
Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.
Influenza, Human
Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice.
Influenza, Human
Demonstration of antibodies to both hemagglutinin and neuraminidase antigens of H3N2 influenza A virus in domestic dogs.
Influenza, Human
Depression of luminol-enhanced chemiluminescence of guinea pig polymorphonuclear leukocytes by influenza virus with special reference to neuraminidase.
Influenza, Human
Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.
Influenza, Human
Design and expression of a QconCAT protein to validate Hi3 protein quantification of influenza vaccine antigens.
Influenza, Human
Design and one-pot synthesis of 2-thiazolylhydrazone derivatives as influenza neuraminidase inhibitors.
Influenza, Human
Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
Influenza, Human
Design and Synthesis of 4-Alkyl-2-amino(acetamino)-6-aryl-1,3-thiazine Derivatives as Influenza Neuraminidase Inhibitors.
Influenza, Human
Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors.
Influenza, Human
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Influenza, Human
Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase.
Influenza, Human
Design of a mechanism-based probe for neuraminidase to capture influenza viruses.
Influenza, Human
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
Influenza, Human
Design of N-acetyl-6-sulfo-beta-d-glucosaminide-based inhibitors of influenza virus sialidase.
Influenza, Human
Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections.
Influenza, Human
Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Influenza, Human
Design of peptide epitope from the neuraminidase protein of influenza A and influenza B towards short peptide vaccine development.
Influenza, Human
Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Influenza, Human
Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors.
Influenza, Human
Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors.
Influenza, Human
Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors.
Influenza, Human
Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
Influenza, Human
Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
Influenza, Human
Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
Influenza, Human
Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.
Influenza, Human
Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors.
Influenza, Human
Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.
Influenza, Human
Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors.
Influenza, Human
Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.
Influenza, Human
Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.
Influenza, Human
Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Influenza, Human
Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors.
Influenza, Human
Design, Synthesis, Molecular Docking, and Biological Evaluation of New Emodin Anthraquinone Derivatives as Potential Antitumor Substances.
Influenza, Human
Desorption electrospray ionization reactions between host crown ethers and the influenza neuraminidase inhibitor oseltamivir for the rapid screening of Tamiflu((R)).
Influenza, Human
Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient.
Influenza, Human
Detection and characterization of type B influenza virus from influenza-like illness cases during the 2017-2018 winter influenza season in Beijing, China.
Influenza, Human
Detection and identification of human influenza viruses by the polymerase chain reaction.
Influenza, Human
Detection and isolation of highly pathogenic H5N1 avian influenza A viruses from blow flies collected in the vicinity of an infected poultry farm in Kyoto, Japan, 2004.
Influenza, Human
Detection and Titration of Influenza A Virus Neuraminidase Inhibiting (NAI) Antibodies Using an Enzyme-Linked Lectin Assay (ELLA).
Influenza, Human
Detection of a transient R292K mutation in Influenza A/H3N2 viruses shed for several weeks by an immunocompromised patient.
Influenza, Human
Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs.
Influenza, Human
Detection of antigenic variation in influenza virus neuraminidase by the ESSEN-NIT and the WHO standard procedure.
Influenza, Human
Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.
Influenza, Human
Detection of D151G/N mutations in the neuraminidase gene of influenza A (H3N2) viruses by real-time RT-PCR allelic discrimination assay.
Influenza, Human
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
Influenza, Human
Detection of evolutionarily distinct avian influenza a viruses in antarctica.
Influenza, Human
Detection of Hemagglutinin Variants of the Pandemic Influenza A (H1N1) 2009 Virus by Pyrosequencing.
Influenza, Human
Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Influenza, Human
Detection of influenza A virus neuraminidase and PB2 gene segments by one step reverse transcription polymerase chain reaction.
Influenza, Human
Detection of influenza B viruses with reduced sensitivity to neuraminidase inhibitor in Morocco during 2014/15 season.
Influenza, Human
Detection of influenza virus neuraminidase-specific antibodies by an enzyme-linked immunosorbent assay.
Influenza, Human
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Influenza, Human
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
Influenza, Human
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.
Influenza, Human
Detection of neuraminidase inhibitor-resistant influenza A (H1N1)pdm09 viruses obtained from influenza surveillance in Indonesia.
Influenza, Human
Detection of neuraminidase stalk motifs associated with enhanced N1 subtype influenza A virulence via Raman spectroscopy.
Influenza, Human
Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test.
Influenza, Human
Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds.
Influenza, Human
Determinants of oligomeric structure in the chicken liver glycoprotein receptor.
Influenza, Human
Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate.
Influenza, Human
Determination of relative binding affinity of influenza virus N9 sialidases with the Fab fragment of monoclonal antibody NC41 using biosensor technology.
Influenza, Human
Determination of the novel sialic acid analog GG167 (GR121167X) in human urine by liquid chromatography: direct injection with column switching.
Influenza, Human
Determination of viral neuraminidase specificity for membrane-bound sialic acids by cell electrophoresis.
Influenza, Human
Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry.
Influenza, Human
Development and clinical testing of a simple, low-density gel element array for influenza identification, subtyping, and H275Y detection.
Influenza, Human
Development and evaluation of a real-time nucleic acid sequence based amplification assay for rapid detection of influenza A.
Influenza, Human
Development and fit-for-purpose verification of an LC-MS method for quantitation of hemagglutinin and neuraminidase proteins in influenza virus-like particle vaccine candidates.
Influenza, Human
Development and implementation of influenza a virus subtyping and detection of genotypic resistance to neuraminidase inhibitors.
Influenza, Human
Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Influenza, Human
Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.
Influenza, Human
Development of 6E3 antibody-mediated SERS immunoassay for drug-resistant influenza virus.
Influenza, Human
Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
Influenza, Human
Development of a multiplex probe combination-based one-step real-time reverse transcription-PCR for NA subtype typing of avian influenza virus.
Influenza, Human
Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates.
Influenza, Human
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
Influenza, Human
Development of a real-time RT-PCR assay for detection of resistance to oseltamivir in influenza A pandemic (H1N1) 2009 virus using single nucleotide polymorphism probes.
Influenza, Human
Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Influenza, Human
Development of a surface plasmon resonance assay to measure the binding affinity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drug zanamivir.
Influenza, Human
Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus.
Influenza, Human
Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract.
Influenza, Human
Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques.
Influenza, Human
Development of anti-viral agents using molecular modeling and virtual screening techniques.
Influenza, Human
Development of antibodies to neuraminidase of A2-Hong Kong and A2-Taiwan influenza viruses after administration of different Hong Kong vaccines and after natural infection in humans.
Influenza, Human
Development of multiplex rt-PCR assays for rapid detection and subtyping of influenza type A viruses from clinical specimens.
Influenza, Human
Development of new stereodiverse diaminocyclitols as inhibitors of influenza virus neuraminidase.
Influenza, Human
Development of recombinant protein-based influenza vaccine. Expression and affinity purification of H1N1 influenza virus neuraminidase.
Influenza, Human
Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
Influenza, Human
Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Influenza, Human
Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes.
Influenza, Human
Diastereoselective tandem reactions of substituted 3-sulfolenes with bis-vinyl ketones leading to highly functionalized bicyclic and tricyclic frameworks.
Influenza, Human
Dietary Flavonoid Aglycones and Their Glycosides: Which Show Better Biological Significance?
Influenza, Human
Differences between influenza virus receptors on target cells of duck and chicken.
Influenza, Human
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Influenza, Human
Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor.
Influenza, Human
Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.
Influenza, Human
Differential action of Aspergillus glycosidases on the hemagglutinating and neuraminidase activities of influenza and Newcastle disease viruses.
Influenza, Human
Differential effect of guanidine hydrochloride and heat on the haemagglutinin and neuraminidase of influenza viruses.
Influenza, Human
Differential expression of influenza N protein and neuraminidase antigenic determinants in Escherichia coli.
Influenza, Human
Differential expression of sialylglycoconjugates and sialidase activity in distinct morphological stages of Fonsecaea pedrosoi.
Influenza, Human
Differential release of sialic acid from normal and malignant cells by Vibrio cholerae neuraminidase or influenza virus neuraminidase.
Influenza, Human
Differential transport of Influenza A neuraminidase signal anchor peptides to the plasma membrane.
Influenza, Human
Differing epidemiological dynamics of influenza B lineages in Guangzhou, southern China, 2009-2010.
Influenza, Human
Difficulties in standardizing the neuraminidase content of influenza vaccines.
Influenza, Human
Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
Influenza, Human
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Influenza, Human
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
Influenza, Human
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.
Influenza, Human
Diospyros anisandra phytochemical analysis and anti-hemagglutinin-neuraminidase activity on influenza AH1N1pdm09 virus.
Influenza, Human
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Influenza, Human
Direct and label-free influenza virus detection based on multisite binding to sialic acid receptors.
Influenza, Human
Directed selection of amino acid changes in the influenza hemagglutinin and neuraminidase affecting protein antigenicity.
Influenza, Human
Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.
Influenza, Human
Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase.
Influenza, Human
Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.
Influenza, Human
Discovery of (E)-1-amino-4-phenylbut-3-en-2-ol derivatives as novel neuraminidase inhibitors.
Influenza, Human
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Influenza, Human
Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase.
Influenza, Human
Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.
Influenza, Human
Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
Influenza, Human
Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
Influenza, Human
Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.
Influenza, Human
Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models.
Influenza, Human
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Influenza, Human
Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
Influenza, Human
Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
Influenza, Human
Discovery of Novel Neuraminidase Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
Influenza, Human
Discovery of Novel Pyrazole Derivatives as Potent Neuraminidase Inhibitors against Influenza H1N1 Virus.
Influenza, Human
Discovery of novel thiophene derivatives as potent neuraminidase inhibitors.
Influenza, Human
Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae.
Influenza, Human
Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design.
Influenza, Human
Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein.
Influenza, Human
Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.
Influenza, Human
Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition.
Influenza, Human
Distribution of hemagglutinin and neuraminidase on influenza virions as revealed by immunoelectron microscopy.
Influenza, Human
Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies.
Influenza, Human
Divalent oseltamivir analogues as potent influenza neuraminidase inhibitors.
Influenza, Human
Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada.
Influenza, Human
Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity.
Influenza, Human
Divergent genetic evolution of hemagglutinin in influenza A H1N1 and A H1N2 subtypes isolated in the south-France since the winter of 2001-2002.
Influenza, Human
Diverse and Unexpected Roles of Human Monocytes/Macrophages in the Immune Response to Influenza Virus.
Influenza, Human
DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors.
Influenza, Human
Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase.
Influenza, Human
Docking and 3D-QSAR investigations of pyrrolidine derivatives as potent neuraminidase inhibitors.
Influenza, Human
Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.
Influenza, Human
Docking study of flavonoid derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
Influenza, Human
Does the availability of a neuraminidase inhibitor impair influenza vaccination? A report from Austria.
Influenza, Human
Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.
Influenza, Human
Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus.
Influenza, Human
Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.
Influenza, Human
Drift of the sialyl-linkage specific recognition of the sialidase of influenza B virus isolates.
Influenza, Human
Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
Influenza, Human
Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.
Influenza, Human
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Influenza, Human
Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Influenza, Human
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.
Influenza, Human
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.
Influenza, Human
Drug under test: influenza--Relenza in daily practice. Experience during the influenza season 1999/2000.
Influenza, Human
Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.
Influenza, Human
Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing.
Influenza, Human
Drugs against Avian Influenza A Virus: Design of Novel Sulfonate Inhibitors of Neuraminidase N1.
Influenza, Human
Dual Acting Neuraminidase Inhibitors Open New Opportunities to Disrupt the Lethal Synergism between Streptococcus pneumoniae and Influenza Virus.
Influenza, Human
Duck and human pandemic influenza A viruses retain sialidase activity under low pH conditions.
Influenza, Human
Dynamic patterns of circulating influenza virus from 2005 to 2012 in Shandong Province, China.
Influenza, Human
Dynamic residue interaction network analysis of the oseltamivir binding site of N1 neuraminidase and its H274Y mutation site conferring drug resistance in influenza A virus.
Influenza, Human
Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008.
Influenza, Human
Dynamics of viral growth, viral enzymatic activity, and antigenicity in murine lungs during the course of influenza pneumonia.
Influenza, Human
Early administration of neuraminidase inhibitors in adult patients hospitalized for influenza does not benefit survival: a retrospective cohort study.
Influenza, Human
Early detection of influenza virus by using a fluorometric assay of infected tissue culture.
Influenza, Human
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
Influenza, Human
Early oseltamivir after hospital admission is associated with shortened hospitalization: A five-year analysis of oseltamivir timing and clinical outcomes.
Influenza, Human
Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.
Influenza, Human
Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection.
Influenza, Human
Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.
Influenza, Human
Economic consequence of immediate testing for C-reactive protein and leukocyte count in new outpatients with acute infection.
Influenza, Human
Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
Influenza, Human
Effect of a single inhalation of laninamivir octanoate in children with influenza.
Influenza, Human
Effect of a single mutation in neuraminidase on the properties of Influenza B virus isolates.
Influenza, Human
Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza.
Influenza, Human
Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Influenza, Human
Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial.
Influenza, Human
Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus.
Influenza, Human
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
Influenza, Human
Effect of blood group determinants on binding of human salivary mucous glycoproteins to influenza virus.
Influenza, Human
Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multi-season cohort study.
Influenza, Human
Effect of fever on hospital presentation, diagnosis, and treatment in patients with H1N1/09 influenza.
Influenza, Human
Effect of four neuraminidase inhibitors on influenza in Osaka, Japan: An eight-year survey.
Influenza, Human
Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins.
Influenza, Human
Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.
Influenza, Human
Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
Influenza, Human
Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
Influenza, Human
Effect of modification of N-acetylneuraminic acid on the binding of glycoproteins to influenza virus and on susceptibility to cleavage by neuraminidase.
Influenza, Human
Effect of monoclonal anti-neuraminidase antibodies on the kinetic behavior of influenza virus neuraminidase.
Influenza, Human
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Influenza, Human
Effect of neuraminidase on potency of inactivated influenza virus vaccines in mice.
Influenza, Human
Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.
Influenza, Human
Effect of specific immunity to viral neuraminidase on subsequent influenza virus infection in man.
Influenza, Human
Effect of substitution of hemagglutinin-neuraminidase with influenza hemagglutinin on Sendai virus F protein mediated membrane fusion.
Influenza, Human
Effect of substrate aglycon on enzyme mechanism in the reaction of sialidase from influenza virus.
Influenza, Human
Effect of syngeneic anti-idiotypic antibody on influenza virus neuraminidase antibody response.
Influenza, Human
Effect of Tea Catechins on Influenza Infection and the Common Cold with a Focus on Epidemiological/Clinical Studies.
Influenza, Human
Effect of temperature on the order of electrophoretic migration of influenza virus neuraminidase and nucleoprotein genes in acrylamide gels lacking denaturing agents.
Influenza, Human
Effect of the fourth nucleotide at the 3' end of neuraminidase and matrix viral genomic RNA on the pathogenicity of influenza virus A/PR/8/34.
Influenza, Human
Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
Influenza, Human
Effectiveness and role of zanamivir in the treatment of influenza infection.
Influenza, Human
Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.
Influenza, Human
Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons.
Influenza, Human
Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.
Influenza, Human
Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza.
Influenza, Human
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Influenza, Human
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Influenza, Human
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
Influenza, Human
Effects of Biomolecular Flexibility on Alchemical Calculations of Absolute Binding Free Energies.
Influenza, Human
Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus.
Influenza, Human
Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A(H7N9) virus in guinea pigs.
Influenza, Human
Effects of single-point amino acid substitutions on the structure and function neuraminidase proteins in influenza A virus.
Influenza, Human
Effects of site-specific mutation on structure and activity of influenza virus B/Lee/40 neuraminidase.
Influenza, Human
Effects of substitutions in the binding surface of an antibody on antigen affinity.
Influenza, Human
Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza.
Influenza, Human
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
Influenza, Human
Effects of windowing and zero-padding on Complex Resonant Recognition Model for protein sequence analysis.
Influenza, Human
Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
Influenza, Human
Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study.
Influenza, Human
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
Influenza, Human
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Influenza, Human
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.
Influenza, Human
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Influenza, Human
Efficacy and safety of zanamivir in patients with influenza--impact of age, severity of infections and specific risk factors.
Influenza, Human
Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
Influenza, Human
Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
Influenza, Human
Efficacy of a single intravenous dose of the neuraminidase inhibitor peramivir in the treatment of equine influenza.
Influenza, Human
Efficacy of hemagglutinin and neuraminidase antigens presented in ISCOMs as vaccine for influenza in turkeys.
Influenza, Human
Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Influenza, Human
Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model.
Influenza, Human
Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Influenza, Human
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Influenza, Human
Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
Influenza, Human
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Influenza, Human
Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.
Influenza, Human
Efficient Method for the Preparation of Peracetylated Neu5Ac2en by Flash Vacuum Pyrolysis.
Influenza, Human
Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins.
Influenza, Human
Efficient synthesis of highly active phospha-isosteres of the influenza neuraminidase inhibitor oseltamivir.
Influenza, Human
Electrochemical assay to detect influenza viruses and measure drug susceptibility.
Influenza, Human
Electron and X-ray diffraction studies of influenza neuraminidase complexed with monoclonal antibodies.
Influenza, Human
Electroporation of influenza virus ribonucleoprotein complexes for rescue of the nucleoprotein and matrix genes.
Influenza, Human
Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10.
Influenza, Human
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Influenza, Human
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-? for infection control and treatment.
Influenza, Human
Emergence of a young case infected with avian influenza A (H5N6) in Anhui Province, East China during the COVID-19 pandemic.
Influenza, Human
Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly receiving a suboptimal dose of antiviral prophylaxis.
Influenza, Human
Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Influenza, Human
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Influenza, Human
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
Influenza, Human
Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Influenza, Human
Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.
Influenza, Human
Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors.
Influenza, Human
Emerging from the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination.
Influenza, Human
Endogenously-expressed influenza A M1 and NP proteins are efficiently presented by class-I and -II major histocompatibility complexes.
Influenza, Human
Enhanced Anti-influenza Agents Conjugated with Anti-inflammatory Activity.
Influenza, Human
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.
Influenza, Human
Enhanced expression of secretable influenza virus neuraminidase in suspension mammalian cells by influenza virus nonstructural protein 1.
Influenza, Human
Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Influenza, Human
Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.
Influenza, Human
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
Influenza, Human
Enhanced Reliability of Avian Influenza Virus (AIV) and Newcastle Disease Virus (NDV) Identification Using Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry (MALDI-MS).
Influenza, Human
Enhanced replication of avian-origin H3N2 canine influenza virus in eggs, cell cultures and mice by a two-amino acid insertion in neuraminidase stalk.
Influenza, Human
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.
Influenza, Human
Enhancement of neuraminidase activity with influenza virus by anti-influenza virus drug.
Influenza, Human
Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).
Influenza, Human
Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
Influenza, Human
Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor.
Influenza, Human
Envelope Proteins Pertain with Evolution and Adaptive Mechanism of the Novel Influenza A/H1N1 in Humans.
Influenza, Human
Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.
Influenza, Human
Environmental resistance development to influenza antivirals: a case exemplifying the need for a multidisciplinary One Health approach including physicians.
Influenza, Human
Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.
Influenza, Human
ENZYMATIC VARIANTS OF INFLUENZA VIRUS. III. FUNCTION OF NEURAMINIDASE IN THE VIRAL GROWTH CYCLE.
Influenza, Human
Enzymological heterogeneity of influenza B virus neuraminidase demonstrated by the fluorometric assay method.
Influenza, Human
Epidemiological and genetic characteristics of influenza virus and the effects of air pollution on laboratory-confirmed influenza cases in Hulunbuir, China, from 2010 to 2019.
Influenza, Human
Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017.
Influenza, Human
Epidemiological survey and genetic evolution of H3N2 subtype influenza viruses from stray dogs in Shanghai, China.
Influenza, Human
Epidemiological, Clinical and Virological Characteristics of Influenza B Virus from Patients at the Hospital Tertiary Care Units in Bangkok during 2011-2014.
Influenza, Human
Epidemiology and virology of influenza illness. Based on a presentation by Arnold S. Monto, MD.
Influenza, Human
Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses.
Influenza, Human
Epitope mapping of diverse influenza Hemagglutinin drug candidates using HDX-MS.
Influenza, Human
Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies.
Influenza, Human
Epitope peptides of influenza H3N2 virus neuraminidase gene designed by immunoinformatics.
Influenza, Human
EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo.
Influenza, Human
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.
Influenza, Human
Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection.
Influenza, Human
Establishment and lineage replacement of H6 influenza viruses in domestic ducks in southern China.
Influenza, Human
Estimating influenza vaccine effectiveness in an outbreak when anti-viral medications were used as a control measure.
Influenza, Human
Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses.
Influenza, Human
Estimation of seroprevalence of the pandemic H1N1 2009 influenza virus using a novel virus-free ELISA assay for the detection of specific antibodies.
Influenza, Human
Estimation of the molecular weights of the polypeptide chains from the isolated hemagglutinin and neuraminidase subunits of influenza viruses.
Influenza, Human
Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography.
Influenza, Human
Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis.
Influenza, Human
Ethanolic Extract of Melia Fructus Has Anti-influenza A Virus Activity by Affecting Viral Entry and Viral RNA Polymerase.
Influenza, Human
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS and ELN.
Influenza, Human
Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.
Influenza, Human
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
Influenza, Human
Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.
Influenza, Human
Evaluation of a neuraminidase detection assay for the rapid detection of influenza A and B virus in children.
Influenza, Human
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.
Influenza, Human
Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors.
Influenza, Human
Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.
Influenza, Human
Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
Influenza, Human
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers.
Influenza, Human
Evaluation of BioStar FLU OIA assay for rapid detection of influenza A and B viruses in respiratory specimens.
Influenza, Human
Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
Influenza, Human
Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
Influenza, Human
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.
Influenza, Human
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.
Influenza, Human
Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets.
Influenza, Human
Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A.
Influenza, Human
Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates.
Influenza, Human
Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study.
Influenza, Human
Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo.
Influenza, Human
Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
Influenza, Human
Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
Influenza, Human
Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers.
Influenza, Human
Evaluation of the methodological quality of the Health Protection Agency's 2009 guidance on neuraminidase inhibitors.
Influenza, Human
Evaluation of the potential defensive strategy against Influenza A in cell line models.
Influenza, Human
Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza season.
Influenza, Human
Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.
Influenza, Human
Evaluation of Twelve Real-Time Reverse Transcriptase PCR Primer-Probe Sets for Detection of Pandemic Influenza A/H1N1 2009 Virus.
Influenza, Human
Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus.
Influenza, Human
Evidence for Deleterious Antigenic Imprinting in SARS-CoV-2 Immune Response.
Influenza, Human
Evidence for influenza B virus lineage shifts and reassortants circulating in Thailand in 2014-2016.
Influenza, Human
Evidence for segment-nonspecific packaging of the influenza a virus genome.
Influenza, Human
Evidence for the contribution of the host species to the extent of antigenic variation of N1 influenza virus neuraminidase.
Influenza, Human
Evidence for wild waterfowl origin of H7N3 influenza A virus detected in captive-reared New Jersey pheasants.
Influenza, Human
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.
Influenza, Human
Evidence of a cross-protective immune response to influenza A in the cotton rat model.
Influenza, Human
Evidence of a fixed internal gene constellation in influenza A viruses isolated from wild birds in Argentina (2006-2016).
Influenza, Human
Evidence of selection pressures of neuraminidase gene (NA) of influenza A virus subtype H5N1 on different hosts in Guangxi Province of China.
Influenza, Human
Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage.
Influenza, Human
Evolution and antigenic advancement of N2 neuraminidase of swine influenza A viruses circulating in the United States following two separate introductions from human seasonal viruses.
Influenza, Human
Evolution of influenza neuraminidase and the detection of antiviral resistant strains using mass trees.
Influenza, Human
Evolution of influenza viral neuraminidase (NA) revealed by large-scale sequence analysis.
Influenza, Human
Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
Influenza, Human
Evolution of surface and nonstructural-1 genes of influenza B viruses isolated in the Province of Québec, Canada, during the 1998-2001 period.
Influenza, Human
Evolution of the influenza virus neuraminidase gene during drift of the N2 subtype.
Influenza, Human
Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.
Influenza, Human
Evolutional analysis of human influenza A virus N2 neuraminidase genes based on the transition of the low-pH stability of sialidase activity.
Influenza, Human
Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival.
Influenza, Human
Evolutionary analysis of human-origin influenza A virus (H3N2) genes associated with the codon usage patterns since 1993.
Influenza, Human
Evolutionary changes in influenza B are not primarily governed by antibody selection.
Influenza, Human
Evolutionary characterization of the six internal genes of H5N1 human influenza A virus.
Influenza, Human
Evolutionary dynamics of highly pathogenic avian influenza A/H5N1 HA clades and vaccine implementation in Vietnam.
Influenza, Human
Evolutionary dynamics of the N1 neuraminidases of the main lineages of influenza A viruses.
Influenza, Human
Evolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analyses.
Influenza, Human
Evolutionary interactions between haemagglutinin and neuraminidase in avian influenza.
Influenza, Human
Evolutionary pathways of N2 neuraminidases of swine and human influenza A viruses: origin of the neuraminidase genes of two reassortants (H1N2) isolated from pigs.
Influenza, Human
Evolutionary, genetic, structural characterization and its functional implications for the influenza A (H1N1) infection outbreak in India from 2009 to 2017.
Influenza, Human
Examining the use of antiviral prophylaxis for influenza outbreaks in residential aged care facilities in NSW, Australia.
Influenza, Human
Exosome-Driven Antigen Transfer for MHC Class II Presentation Facilitated by the Receptor Binding Activity of Influenza Hemagglutinin.
Influenza, Human
Experimental validation and computational modeling of anti-influenza effects of quercetin-3-O-?-L-rhamnopyranoside from indigenous south African medicinal plant Rapanea melanophloeos.
Influenza, Human
Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes.
Influenza, Human
Exploitation of the Catalytic Site and 150 Cavity for Design of Influenza A Neuraminidase Inhibitors.
Influenza, Human
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
Influenza, Human
Exploring cell tropism as a possible contributor to influenza infection severity.
Influenza, Human
Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
Influenza, Human
Exploring the interactions of unsaturated glucuronides with influenza virus sialidase.
Influenza, Human
Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study.
Influenza, Human
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
Influenza, Human
Expression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based Assay.
Influenza, Human
Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.
Influenza, Human
Expression of the influenza M2 protein in three different eukaryotic cell lines.
Influenza, Human
Expression, purification and characterization of low-glycosylation influenza neuraminidase in ?-1,6-mannosyltransferase defective Pichia pastoris.
Influenza, Human
Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
Influenza, Human
Extraction of catalytically active neuraminidase of H5N1 influenza virus using thrombin proteolytic cleavage.
Influenza, Human
Fc? Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.
Influenza, Human
Fight against H1N1 Influenza A Virus: Recent Insights towards the Development of Druggable Compounds.
Influenza, Human
Filament-producing mutants of influenza A/Puerto Rico/8/1934 (H1N1) virus have higher neuraminidase activities than the spherical wild-type.
Influenza, Human
Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors.
Influenza, Human
Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews.
Influenza, Human
Finding a Maximum Common Subgraph from Molecular Structural Formulas through the Maximum Clique Approach Combined with the Ising Model.
Influenza, Human
First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection.
Influenza, Human
Fitness Costs for Influenza B Viruses Carrying Neuraminidase Inhibitor-Resistant Substitutions: Underscoring the Importance of E119A and H274Y.
Influenza, Human
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
Influenza, Human
Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.
Influenza, Human
Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
Influenza, Human
Flavonoids from Matteuccia struthiopteris and Their Anti-influenza Virus (H1N1) Activity.
Influenza, Human
Flocculation of influenza virus by a neuraminidase inhibitor, neuraminin, produced by Streptomyces sp.
Influenza, Human
Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals.
Influenza, Human
Fluorescent assays to quantitate enzymatic activities yielding as end product an aqueous-insoluble indigo-blue dye.
Influenza, Human
Fluorescent Neuraminidase Assay Based on Supramolecular Dye Capture After Enzymatic Cleavage.
Influenza, Human
Fluorometric assay for measurement of viral neuraminidase--application to the rapid detection of influenza virus in nasal wash specimens.
Influenza, Human
Fluorometric assay for the measurement of viral neuraminidase in influenza vaccines.
Influenza, Human
FluTyper-an algorithm for automated typing and subtyping of the influenza virus from high resolution mass spectral data.
Influenza, Human
Force Spectroscopy Shows Dynamic Binding of Influenza Hemagglutinin and Neuraminidase to Sialic Acid.
Influenza, Human
Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase.
Influenza, Human
Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins.
Influenza, Human
Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
Influenza, Human
Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Influenza, Human
Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
Influenza, Human
From the National Institutes of Health. Summary of a meeting on the origin of pandemic influenza viruses.
Influenza, Human
Full length sequencing of all nine subtypes of the neuraminidase gene of influenza A viruses using subtype specific primer sets.
Influenza, Human
Functional and structural analysis of influenza virus neuraminidase n3 offers further insight into the mechanisms of oseltamivir resistance.
Influenza, Human
Functional balance between haemagglutinin and neuraminidase in influenza virus infections.
Influenza, Human
Functional balance between neuraminidase and haemagglutinin in influenza viruses.
Influenza, Human
Functional balance between the hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 HA D222 variants.
Influenza, Human
Functional Balance of the Hemagglutinin and Neuraminidase Activities Accompanies the Emergence of the 2009 H1N1 Influenza Pandemic.
Influenza, Human
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Influenza, Human
Functional reconstitution of the integral membrane proteins of influenza virus into phospholipid liposomes.
Influenza, Human
Functional significance of neuraminidase in the replication cycle of influenza viruses.
Influenza, Human
Functional significance of sialidase during influenza virus multiplication: an electron microscope study.
Influenza, Human
Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses.
Influenza, Human
Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors.
Influenza, Human
Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.
Influenza, Human
Further studies on the role of neuraminidase and the mechanism of low pH dependence in influenza virus-induced membrane fusion.
Influenza, Human
Fusion of enveloped viruses with sperm cells: interaction of Sendai, influenza, and Semliki Forest viruses with bull spermatozoa.
Influenza, Human
Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.
Influenza, Human
Galectins promote the interaction of influenza virus with its target cell.
Influenza, Human
Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity.
Influenza, Human
General practitioners' management of influenza with or without neuraminidase inhibitors.
Influenza, Human
Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate.
Influenza, Human
Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.
Influenza, Human
Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.
Influenza, Human
Generation and Characterization of Recombinant Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors.
Influenza, Human
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
Influenza, Human
Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.
Influenza, Human
Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Influenza, Human
Generation of live attenuated novel influenza A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs.
Influenza, Human
Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segment.
Influenza, Human
Generation of Stable Influenza Virus Hemagglutinin through Structure-Guided Recombination.
Influenza, Human
Genetic analysis and evaluation of the reassortment of influenza B viruses isolated in Taiwan during the 2004-2005 and 2006-2007 epidemics.
Influenza, Human
Genetic analysis of influenza A/H3N2 and A/H1N1 viruses circulating in Vietnam from 2001 to 2006.
Influenza, Human
Genetic analysis of neuraminidase gene of influenza A(H1N1)pdm09 virus circulating in Southwest India from 2009 to 2012.
Influenza, Human
Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013.
Influenza, Human
Genetic Analysis of the Neuraminidase (NA) Gene of Equine Influenza Virus (H3N8) from Epizootic of 2008-2009 in India.
Influenza, Human
Genetic and antigenic characterization of influenza A(H1N1)pdm09 in Yantai, China, during the 2009-2017 influenza season.
Influenza, Human
Genetic changes in influenza A(H3N2) viruses circulating during 2011 to 2013 in northern India (Lucknow).
Influenza, Human
Genetic characterisation of influenza A(H1N1)pdm09 viruses circulating in Assam, Northeast India during 2009-2015.
Influenza, Human
Genetic Characterisation of Influenza A(H1N1)pdm09 Viruses Circulating in Assam, Northeast India during 2009-2015.
Influenza, Human
Genetic characterisation of the influenza viruses circulating in Bulgaria during the 2019-2020 winter season.
Influenza, Human
Genetic characterization of an H2N2 influenza virus isolated from a muskrat in Western Siberia.
Influenza, Human
Genetic characterization of H3N2 influenza viruses isolated from pigs in North America, 1977-1999: evidence for wholly human and reassortant virus genotypes.
Influenza, Human
Genetic characterization of influenza virus circulating in Brazilian pigs during 2009 and 2010 reveals a high prevalence of the pandemic H1N1 subtype.
Influenza, Human
Genetic composition of a high-yielding influenza A virus recombinant: a vaccine strain against "Swine" influenza.
Influenza, Human
Genetic diversity of influenza A(H3N2) viruses in Northern Cameroon during the 2014-2016 influenza seasons.
Influenza, Human
Genetic diversity of the pandemic influenza A (H1N1) virus in Saudi Arabia.
Influenza, Human
Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution.
Influenza, Human
Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.
Influenza, Human
Genetic Predisposition To Acquire a Polybasic Cleavage Site for Highly Pathogenic Avian Influenza Virus Hemagglutinin.
Influenza, Human
Genetic relatedness between influenza A (H1N1) viruses isolated from humans and pigs.
Influenza, Human
Genetic relatedness of the neuramindase of influenza A strains Nav2, Nav3, and Nav6.
Influenza, Human
Genetic sequencing of influenza A (H1N1) pdm09 isolates from South India, collected between 2011 and 2015 to detect mutations affecting virulence and resistance to oseltamivir.
Influenza, Human
Genetic Sequencing of Influenza A (H1N1) pdm09 Isolates from South India, Collected between 2011 and 2015 to Detect Mutations Affecting Virulence and Resistance to Oseltamivir.
Influenza, Human
Genetic subtyping of influenza A viruses using RT-PCR with a single set of primers based on conserved sequences within the HA2 coding region.
Influenza, Human
Genetic tuning of the novel avian influenza A(H7N9) virus during interspecies transmission, China, 2013.
Influenza, Human
Genetic variability of the neuraminidase gene of influenza A(H1N1)pdm09 viruses circulating from the 2012/2013 to 2017/2018 season in Vojvodina Province, Serbia.
Influenza, Human
Genome Stability of Pandemic Influenza A (H1N1) 2009 Based on Analysis of Hemagglutinin and Neuraminidase Genes.
Influenza, Human
Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases.
Influenza, Human
Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Influenza, Human
Genotypic evolution and epidemiological characteristics of H9N2 influenza virus in Shandong Province, China.
Influenza, Human
GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets.
Influenza, Human
Global Assessment of Resistance to Neuraminidase Inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS).
Influenza, Human
Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus.
Influenza, Human
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Influenza, Human
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
Influenza, Human
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Influenza, Human
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Influenza, Human
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.
Influenza, Human
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Influenza, Human
Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase.
Influenza, Human
Glycan binding and specificity of viral influenza neuraminidases by classical molecular dynamics and replica exchange molecular dynamics simulations.
Influenza, Human
Glycosylation and surface expression of the influenza virus neuraminidase requires the N-terminal hydrophobic region.
Influenza, Human
Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture.
Influenza, Human
Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs.
Influenza, Human
Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus.
Influenza, Human
Grid-enabled high-throughput in silico screening against influenza A neuraminidase.
Influenza, Human
GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains.
Influenza, Human
Guanidinothiosialoside-Human Serum Albumin Conjugate Mimics mucin Barrier to Restrict Influenza Infection.
Influenza, Human
Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe.
Influenza, Human
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.
Influenza, Human
H1N1 influenza virus-like particles: Physical degradation pathways and identification of stabilizers.
Influenza, Human
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus pandemrix(®) -vaccination.
Influenza, Human
H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site.
Influenza, Human
H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes.
Influenza, Human
H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies in humans that preferentially bind to oligomeric form of influenza hemagglutinin.
Influenza, Human
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Influenza, Human
Haemagglutinin and neuraminidase sequencing delineate nosocomial influenza outbreaks with accuracy equivalent to whole genome sequencing.
Influenza, Human
HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.
Influenza, Human
Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.
Influenza, Human
HEL-Flu: an influenza virus containing the hen egg lysozyme epitope recognized by CD4+ T cells from mice transgenic for an alphabeta TCR.
Influenza, Human
Hemagglutinating and sialidase activities of subpopulations of influenza A viruses.
Influenza, Human
Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections.
Influenza, Human
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Influenza, Human
Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
Influenza, Human
Hemagglutinin and neuraminidase genes of influenza B viruses circulating in Riyadh, Saudi Arabia during 2010-2011: Evolution and sequence analysis.
Influenza, Human
Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics.
Influenza, Human
Hemagglutinin and neuraminidase specific cell-mediated immune responses to influenza A virus following immunization in guinea pigs.
Influenza, Human
Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities.
Influenza, Human
Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses.
Influenza, Human
Hemagglutinin stalk domain from H5N1 strain as a potentially universal antigen.
Influenza, Human
Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance.
Influenza, Human
Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets.
Influenza, Human
Hemagglutinin-Neuraminidase Balance Influences the Virulence Phenotype of a Recombinant H5N3 Influenza A Virus Possessing a Polybasic HA0 Cleavage Site.
Influenza, Human
Hemagglutinin-neuraminidase protein of the paramyxovirus simian virus 5: nucleotide sequence of the mRNA predicts an N-terminal membrane anchor.
Influenza, Human
Hemolysis and fusion by influenza viruses with heat-inactivated neuraminidase activity.
Influenza, Human
Heterogeneity of neuraminidase genetic information in an H1N2 reassortant influenza virus [X-7 (F1)]. Brief report.
Influenza, Human
Heterogeneity of the cytotoxic response of thymus-derived lymphocytes after immunization with influenza viruses.
Influenza, Human
Heterologous viral protein interactions within licensed seasonal influenza virus vaccines.
Influenza, Human
Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.
Influenza, Human
Heterotypic Neuraminidase Antibodies Against Different A(H1N1) Strains are Elicited after Seasonal Influenza Vaccination.
Influenza, Human
Heterotypic protective immune reactions in mice infected with distinct serotypes of human influenza virus.
Influenza, Human
High antiviral effects of hibiscus tea extract on the H5 subtypes of low and highly pathogenic avian influenza viruses.
Influenza, Human
High efficiency method of detection and isolation of neuraminidase inhibitor resistant influenza viruses by fluorescence sialidase imaging.
Influenza, Human
High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.
Influenza, Human
High molecular weight constituents of cranberry interfere with influenza virus neuraminidase activity in vitro.
Influenza, Human
High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity.
Influenza, Human
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
Influenza, Human
High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors.
Influenza, Human
High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde.
Influenza, Human
High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses.
Influenza, Human
High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines.
Influenza, Human
Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations.
Influenza, Human
Highly lethal H5N1 influenza virus in asia: Genesis and options for control.
Influenza, Human
Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
Influenza, Human
Highly specific and rapid glycan based amperometric detection of influenza viruses.
Influenza, Human
Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
Influenza, Human
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Influenza, Human
Host mediated variation and receptor binding specificity of influenza viruses.
Influenza, Human
Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses, Germany, 2007-8.
Influenza, Human
How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency.
Influenza, Human
How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.
Influenza, Human
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
Influenza, Human
Human Clade 2.3.4.4 A/H5N6 Influenza Virus Lacks Mammalian Adaptation Markers and Does Not Transmit via the Airborne Route between Ferrets.
Influenza, Human
Human genetics and responses to influenza vaccination: clinical implications.
Influenza, Human
Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.
Influenza, Human
Human influenza viral neuraminidases augment cell-mediated cytotoxicity in vitro.
Influenza, Human
Human influenza virus neuraminidase, but not hemagglutinin, induces murine macrophage interleukin 1 in vivo and in vitro.
Influenza, Human
Human monoclonal ScFv specific to NS1 protein inhibits replication of influenza viruses across types and subtypes.
Influenza, Human
Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
Influenza, Human
Human sera possess a limited antibody repertoire to influenza neuraminidase antigenic variants selected in vitro.
Influenza, Human
Human trachea primary epithelial cells express both sialyl(alpha2-3)Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl(alpha2-6)Gal receptor for human influenza viruses.
Influenza, Human
Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Influenza, Human
Hydration of ligands of influenza virus neuraminidase studied by the fragment molecular orbital method.
Influenza, Human
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
Influenza, Human
Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
Influenza, Human
Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent neuraminidase inhibitor.
Influenza, Human
I-cell disease: intracellular desialylation of lysosomal enzymes using an influenza virus vector.
Influenza, Human
I223R Mutation in Influenza A(H1N1)pdm09 Neuraminidase Confers Reduced Susceptibility to Oseltamivir and Zanamivir and Enhanced Resistance with H275Y.
Influenza, Human
Ia-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysozyme-specific T cells.
Influenza, Human
Identification and characterization of H2N3 avian influenza virus from backyard poultry and comparison with novel H2N3 swine influenza virus.
Influenza, Human
Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.
Influenza, Human
Identification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus.
Influenza, Human
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Influenza, Human
Identification of a linear epitope on the haemagglutinin protein of pandemic A/H1N1 2009 influenza virus using monoclonal antibodies.
Influenza, Human
Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity.
Influenza, Human
Identification of amino acids in H9N2 influenza virus neuraminidase that are critical for the binding of two mouse monoclonal antibodies.
Influenza, Human
Identification of amino acids in the HA of H3 influenza viruses that determine infectivity levels in primary swine respiratory epithelial cells.
Influenza, Human
Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors.
Influenza, Human
Identification of coevolution sites and evolution history for neuraminidase of human influenza A viruses.
Influenza, Human
Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase.
Influenza, Human
Identification of Critical Residues in the Hemagglutinin and Neuraminidase of Influenza Virus H1N1pdm for Vaccine Virus Replication in Embryonated Chicken Eggs.
Influenza, Human
Identification of critical residues of influenza neuraminidase in viral particle release.
Influenza, Human
Identification of defects in the neuraminidase gene of four temperature-sensitive mutants of A/WSN/33 influenza virus.
Influenza, Human
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
Influenza, Human
Identification of equine influenza virus infection in Asian wild horses (Equus przewalskii).
Influenza, Human
Identification of genetic determinants of influenza A virus resistance to adamantanes and neuraminidase inhibitors using biological microarray.
Influenza, Human
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
Influenza, Human
Identification of hemagglutinin and neuraminidase genes of influenza B virus.
Influenza, Human
Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
Influenza, Human
Identification of influenza A pandemic (H1N1) 2009 variants during the first 2009 influenza outbreak in Mexico City.
Influenza, Human
Identification of key residues involved in the neuraminidase antigenic variation of H9N2 influenza virus.
Influenza, Human
Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.
Influenza, Human
Identification of nonavid influenza A viruses containing human subtypes of hemagglutinin and neuraminidase isolated from poultry in Hong Kong.
Influenza, Human
Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening.
Influenza, Human
Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method.
Influenza, Human
Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation.
Influenza, Human
Identification of Potential Inhibitors of H5N1 Influenza A Virus Neuraminidase by Ligand-Based Virtual Screening Approach.
Influenza, Human
Identification of pyrrolo[3,2-c]pyridin-4-amine compounds as a new class of entry inhibitors against influenza viruses in vitro.
Influenza, Human
Identification of residues that affect oligomerization and/or enzymatic activity of influenza virus H5N1 neuraminidase proteins.
Influenza, Human
Identification of single amino acid substitutions (SAAS) in neuraminidase from influenza a virus (H1N1) via mass spectrometry analysis coupled with de novo peptide sequencing.
Influenza, Human
Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking.
Influenza, Human
Identification of the 5'-Terminal Packaging Signal of the H1N1 Influenza A Virus Neuraminidase Segment at Single-Nucleotide Resolution.
Influenza, Human
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection.
Influenza, Human
Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes.
Influenza, Human
Immune response to influenza vaccine in hemodialysis patients with chronic renal failure.
Influenza, Human
Immunity to influenza in ferrets. 13. Protection against influenza infection by serum antibody to homologous haemagglutinin or neuraminidase antigens.
Influenza, Human
Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Influenza, Human
Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.
Influenza, Human
Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.
Influenza, Human
Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Influenza, Human
Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Influenza, Human
Immunobiological properties of influenza A (H7N9) hemagglutinin and neuraminidase proteins.
Influenza, Human
Immunochemistry of variants of influenza virus hemagglutinin and neuraminidase.
Influenza, Human
Immunodominance of Antigenic Site B over Site A of Hemagglutinin of Recent H3N2 Influenza Viruses.
Influenza, Human
Immunoelectron microscopic study of the detection of the glycoproteins of influenza and Sendai viruses in infected cells by the immunoperoxidase method.
Influenza, Human
Immunoelectron microscopy of influenza A virus neuraminidase glycoprotein topography.
Influenza, Human
Immunogenic peptides of influenza virus subtype N1 neuraminidase identify a T-cell determinant used in class II major histocompatibility complex-restricted responses to infectious virus.
Influenza, Human
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
Influenza, Human
Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets.
Influenza, Human
Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants.
Influenza, Human
Immunohistochemical Findings of an Autopsied Lung Specimen from a Patient with Pandemic Influenza (A/H1N1pdm) Virus Infection.
Influenza, Human
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial.
Influenza, Human
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.
Influenza, Human
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice.
Influenza, Human
Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
Influenza, Human
Immunological consequences of infection and vaccination in South American trypanosomiasis.
Influenza, Human
Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.
Influenza, Human
Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis.
Influenza, Human
Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
Influenza, Human
Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
Influenza, Human
Impact assessment of the rational selection of training and test sets on the predictive ability of QSAR models.
Influenza, Human
Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.
Influenza, Human
Impact of a potential glycosylation site at neuraminidase amino acid 264 of influenza A/H9N2 virus.
Influenza, Human
Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.
Influenza, Human
Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study.
Influenza, Human
Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein.
Influenza, Human
Impact of Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodiafiltration on the Pharmacokinetics of Oseltamivir Carboxylate in Critically Ill Patients With Pandemic (H1N1) Influenza.
Influenza, Human
Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.
Influenza, Human
Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors.
Influenza, Human
Impact of mutations at residue i223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Influenza, Human
Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.
Influenza, Human
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.
Influenza, Human
Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Influenza, Human
Impact of Oseltamivir Treatment on Influenza A and B Virus Dynamics in Human Volunteers.
Influenza, Human
Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an Individual Participant Data (IPD) meta-analysis.
Influenza, Human
Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.
Influenza, Human
Impact of tetramerization on the ligand recognition of N1 influenza neuraminidase via MMGBSA approach.
Influenza, Human
Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment.
Influenza, Human
Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.
Influenza, Human
Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).
Influenza, Human
Impairment of the M-protein and unmasking of a superficial type-specific antigen by proteolytic treatment of influenza A virions with preservation of host-specific antigenicity.
Influenza, Human
Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.
Influenza, Human
Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics.
Influenza, Human
Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34.
Influenza, Human
Improving influenza virus backbones by including terminal regions of MDCK-adapted strains on hemagglutinin and neuraminidase gene segments.
Influenza, Human
Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015.
Influenza, Human
In search of effective H1N1 neuraminidase inhibitor by molecular docking, antiviral evaluation and membrane interaction studies using NMR.
Influenza, Human
In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.
Influenza, Human
In silico analysis of genes nucleoprotein, neuraminidase and hemagglutinin: A comparative study on different strains of influenza A (Bird Flu) virus sub-type H5N1.
Influenza, Human
In silico design of a multi-epitope peptide construct as a potential vaccine candidate for Influenza A based on neuraminidase protein.
Influenza, Human
In Silico Identification of the Potential Drug Resistance Sites over 2009 Influenza A (H1N1) Virus Neuraminidase.
Influenza, Human
In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1.
Influenza, Human
In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.
Influenza, Human
In silico prediction of influenza vaccine effectiveness by sequence analysis.
Influenza, Human
In silico study of rotavirus VP7 surface accessible conserved regions for antiviral drug/vaccine design.
Influenza, Human
In silico study on multidrug resistance conferred by I223R/H275Y double mutant neuraminidase.
Influenza, Human
In situ molecular identification of the influenza A (H1N1) 2009 Neuraminidase in patients with severe and fatal infections during a pandemic in Mexico City.
Influenza, Human
In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.
Influenza, Human
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Influenza, Human
In vitro and in vivo assay systems for study of influenza virus inhibitors.
Influenza, Human
In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.
Influenza, Human
In vitro and in vivo characterization of novel neuraminidase substitutions in influenza A(H1N1)pdm09 identified using Laninamivir-mediated in vitro selection.
Influenza, Human
In vitro and in vivo inhibitory effects of disodium cromoglycate on influenza virus infection.
Influenza, Human
In vitro anti-influenza A activity of interferon (IFN)-?1 combined with IFN-? or oseltamivir carboxylate.
Influenza, Human
In vitro Anti-viral Activity of Psoraleae Semen Water Extract against Influenza A Viruses.
Influenza, Human
In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase.
Influenza, Human
In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients.
Influenza, Human
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Influenza, Human
In vitro enhancement of human natural cell-mediated cytotoxicity by purified influenza virus glycoproteins.
Influenza, Human
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
Influenza, Human
In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection.
Influenza, Human
In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
Influenza, Human
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
Influenza, Human
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Influenza, Human
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Influenza, Human
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Influenza, Human
In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility.
Influenza, Human
In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors.
Influenza, Human
In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.
Influenza, Human
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Influenza, Human
In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
Influenza, Human
In vivo anti-influenza virus activity of kampo (Japanese herbal) medicine "sho-seiryu-to" and its mode of action.
Influenza, Human
In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase.
Influenza, Human
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
Influenza, Human
In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir.
Influenza, Human
In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain.
Influenza, Human
In-silico structural analysis of the influenza A subtype H7N9 neuraminidase and molecular docking with different neuraminidase inhibitors.
Influenza, Human
Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age-Dependent Manner.
Influenza, Human
Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
Influenza, Human
Inactivation and stability of viral diagnostic reagents treated by gamma radiation.
Influenza, Human
Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.
Influenza, Human
Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Influenza, Human
Increase in titer of the naturally occurring human antibody to neuraminidase-treated lymphocytes after influenza.
Influenza, Human
Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation.
Influenza, Human
Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains.
Influenza, Human
Increased influenza A virus sialidase activity with N-acetyl-9-O-acetylneuraminic acid-containing substrates resulting from influenza C virus O-acetylesterase action.
Influenza, Human
Increased resistance of vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity avian influenza virus.
Influenza, Human
Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
Influenza, Human
Increasing appearance of reassortant influenza B virus in Taiwan from 2002 to 2005.
Influenza, Human
Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.
Influenza, Human
Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus.
Influenza, Human
Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding.
Influenza, Human
Induction of long-term protective immune responses by influenza H5N1 virus-like particles.
Influenza, Human
Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
Influenza, Human
Infection of human airway epithelium by human and avian strains of influenza a virus.
Influenza, Human
Infection of influenza virus neuraminidase-vaccinated mice with homologous influenza virus leads to strong protection against heterologous influenza viruses.
Influenza, Human
Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice.
Influenza, Human
Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104.
Influenza, Human
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.
Influenza, Human
Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies.
Influenza, Human
Influenza A and methicillin-resistant Staphylococcus aureus co-infection in rhesus macaques - A model of severe pneumonia.
Influenza, Human
Influenza A H1N1 Virus 2009 Synthetic Hemagglutinin and Neuraminidase Peptides for Antibody Detection.
Influenza, Human
Influenza A H1N1pdm 2009 Virus in Paraguay: Nucleotide Point Mutations in Hemagglutinin and Neuraminidase Genes are not Associated with Drug Resistance.
Influenza, Human
Influenza A neuraminidase antibodies in children and young adults studied by serum absorption.
Influenza, Human
Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase.
Influenza, Human
Influenza a virus encoding secreted gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins.
Influenza, Human
Influenza A virus enhances allergic histamine release. Effect of neuraminidase.
Influenza, Human
Influenza A virus enhances IgE-mediated histamine release from human basophil leukocytes. Examination of the effect of viral neuraminidase and haemagglutinin.
Influenza, Human
Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery.
Influenza, Human
Influenza A virus hemagglutinin and neuraminidase mutually accelerate their apical targeting through clustering of lipid rafts.
Influenza, Human
Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance.
Influenza, Human
Influenza A virus hemagglutinin containing basolateral localization signal does not alter the apical budding of a recombinant influenza A virus in polarized MDCK cells.
Influenza, Human
Influenza A Virus Hemagglutinin is Required for the Assembly of Viral Components Including Bundled vRNPs at the Lipid Raft.
Influenza, Human
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.
Influenza, Human
Influenza A virus hemagglutinin specific antibodies interfere with virion neuraminidase activity via two distinct mechanisms.
Influenza, Human
Influenza A Virus Infection of Intestinal Epithelial Cells Enhances the Adhesion Ability of Crohn's Disease Associated Escherichia coli Strains.
Influenza, Human
Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules.
Influenza, Human
Influenza A virus neuraminidase protein enhances cell survival through interaction with CEACAM6.
Influenza, Human
Influenza A virus neuraminidase protein interacts with Hsp90, to stabilize itself and enhance cell survival.
Influenza, Human
Influenza A virus neuraminidase: regions of the protein potentially involved in virus-host interactions.
Influenza, Human
Influenza A virus nucleoprotein selectively decreases neuraminidase gene-segment packaging while enhancing viral fitness and transmissibility.
Influenza, Human
Influenza A virus survival in water is influenced by the origin species of the host cell.
Influenza, Human
Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice.
Influenza, Human
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Influenza, Human
Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components.
Influenza, Human
Influenza A viruses: combinations of hemagglutinin and neuraminidase subtypes isolated from animals and other sources.
Influenza, Human
Influenza A viruses: combinations of hemagglutinin and neuraminidase subtypes isolated from animals and other sources. Brief review.
Influenza, Human
Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Influenza, Human
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.
Influenza, Human
Influenza A(H1N1)pdm09 virus: viral characteristics and genetic evolution.
Influenza, Human
Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.
Influenza, Human
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Influenza, Human
Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
Influenza, Human
Influenza and Community-acquired Pneumonia Interactions: The Impact of Order and Time of Infection on Population Patterns.
Influenza, Human
Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity.
Influenza, Human
Influenza antiviral resistance testing in new york and wisconsin, 2006 to 2008: methodology and surveillance data.
Influenza, Human
Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.
Influenza, Human
Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface.
Influenza, Human
Influenza B virus BM2 protein is transported through the trans-Golgi network as an integral membrane protein.
Influenza, Human
Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
Influenza, Human
Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.
Influenza, Human
Influenza chemotherapy: a review of the present state of art and of new drugs in development.
Influenza, Human
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.
Influenza, Human
Influenza Hemagglutinin and Neuraminidase: Yin?Yang Proteins Coevolving to Thwart Immunity.
Influenza, Human
Influenza in the Emergency Department: Vaccination, Diagnosis, and Treatment: Clinical Practice Paper Approved by American Academy of Emergency Medicine Clinical Guidelines Committee.
Influenza, Human
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
Influenza, Human
Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
Influenza, Human
Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.
Influenza, Human
Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Influenza, Human
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.
Influenza, Human
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
Influenza, Human
Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.
Influenza, Human
Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity.
Influenza, Human
Influenza neuraminidase is delivered directly to the apical surface of MDCK cell monolayers.
Influenza, Human
Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors.
Influenza, Human
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Influenza, Human
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.
Influenza, Human
Influenza pH1N1 Virus Accumulated H275Y Mutation in Neuraminidase during Propagation in MDCK Cells.
Influenza, Human
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Influenza, Human
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review.
Influenza, Human
Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.
Influenza, Human
Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding.
Influenza, Human
Influenza type B neuraminidase can replace the function of type A neuraminidase.
Influenza, Human
Influenza vaccination and antiviral therapy: is there a role for concurrent administration in the institutionalised elderly?
Influenza, Human
Influenza Vaccine: An effective preventive vaccine for developing countries.
Influenza, Human
Influenza vaccine: progress in a vaccine that elicits a broad immune response.
Influenza, Human
Influenza viral glycoproteins induced cell-mediated cytotoxicity by an interferon-independent mechanism.
Influenza, Human
Influenza Viral Load and Peramivir Kinetics after Single Administration and Proposal of Regimens for Peramivir Administration against Resistant Variants.
Influenza, Human
Influenza viral neuraminidase primes bacterial coinfection through TGF-?-mediated expression of host cell receptors.
Influenza, Human
Influenza virus A(H1N1)pdm09 hemagglutinin polymorphism and associated disease in southern Germany during the 2010/11 influenza season.
Influenza, Human
Influenza virus antigens conjugated with a synthetic polyelectrolyte: a novel model of vaccines.
Influenza, Human
Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins.
Influenza, Human
Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins.
Influenza, Human
Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein.
Influenza, Human
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.
Influenza, Human
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Influenza, Human
Influenza virus changes cell-surface glycoproteins including major histocompatibility complex determinants on lymphocytes.
Influenza, Human
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape.
Influenza, Human
Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein.
Influenza, Human
Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles.
Influenza, Human
Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.
Influenza, Human
Influenza virus infection of mouse lymphoblasts alters the binding affinity of anti-H-2 antibody: requirement for viral neuraminidase.
Influenza, Human
Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections.
Influenza, Human
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.
Influenza, Human
Influenza virus neuraminidase activates latent transforming growth factor beta.
Influenza, Human
Influenza virus neuraminidase contributes to secondary bacterial pneumonia.
Influenza, Human
Influenza virus neuraminidase contributes to the dextran sulfate-dependent suppressive replication of some influenza A virus strains.
Influenza, Human
Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening.
Influenza, Human
Influenza virus neuraminidase inhibitory activity of phlorotannins from the edible brown alga Ecklonia cava.
Influenza, Human
Influenza virus neuraminidase regulates host CD8+ T-cell response in mice.
Influenza, Human
Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors.
Influenza, Human
Influenza virus partially counteracts restriction imposed by tetherin/BST-2.
Influenza, Human
Influenza virus PB1 and neuraminidase gene segments can cosegregate during vaccine reassortment driven by interactions in the PB1 coding region.
Influenza, Human
Influenza virus proteins: identity, synthesis, and modification analyzed by two-dimensional gel electrophoresis.
Influenza, Human
Influenza virus resistance to neuraminidase inhibitors: implications for treatment.
Influenza, Human
Influenza virus sialidase: effect of calcium on steady-state kinetic parameters.
Influenza, Human
Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans.
Influenza, Human
Influenza Virus Uses Its Neuraminidase Protein to Evade the Recognition of Two Activating NK Cell Receptors.
Influenza, Human
Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay.
Influenza, Human
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
Influenza, Human
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Influenza, Human
Influenza virus-like particles harboring H9N2 HA and NA proteins induce a protective immune response in chicken.
Influenza, Human
Influenza virus-related critical illness: prevention, diagnosis, treatment.
Influenza, Human
Influenza virus: association of mouse-lung virulence with plaque formation in mouse kidney cells.
Influenza, Human
Influenza viruses differ in recognition of 4-O-acetyl substitution of sialic acid receptor determinant.
Influenza, Human
Influenza viruses from avian and porcine sources and their possible role in the origin of human pandemic strains.
Influenza, Human
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
Influenza, Human
Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
Influenza, Human
Influenza viruses with receptor-binding n1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice.
Influenza, Human
Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children.
Influenza, Human
Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design.
Influenza, Human
Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity.
Influenza, Human
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
Influenza, Human
Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies.
Influenza, Human
Inhibition effect of flavonoid compounds against neuraminidase expressed in Pichia pastoris.
Influenza, Human
Inhibition of cellular invasive parameters in influenza A virus-infected MDCK and Vero cells by a nutrient mixture.
Influenza, Human
Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways.
Influenza, Human
Inhibition of Influenza A Virus Infection by Fucoidan Targeting Viral Neuraminidase and Cellular EGFR Pathway.
Influenza, Human
Inhibition of influenza A virus infection in vitro by peptides designed in silico.
Influenza, Human
Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812).
Influenza, Human
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Influenza, Human
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Influenza, Human
Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action.
Influenza, Human
Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids.
Influenza, Human
Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design.
Influenza, Human
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
Influenza, Human
Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion.
Influenza, Human
Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Influenza, Human
Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position.
Influenza, Human
Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: A comparative structural analysis by the ScrewFit algorithm.
Influenza, Human
Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
Influenza, Human
Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo.
Influenza, Human
Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.
Influenza, Human
Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Influenza, Human
Inhibitory Effect and Possible Mechanism of Action of Patchouli Alcohol against Influenza A (H2N2) Virus.
Influenza, Human
Inhibitory effect of microalgae and cyanobacteria extracts on influenza virus replication and neuraminidase activity.
Influenza, Human
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
Influenza, Human
Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Influenza, Human
Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
Influenza, Human
Insights from QM/MM Modeling the 3D Structure of the 2009 H1N1 Influenza A Virus Neuraminidase and Its Binding Interactions with Antiviral Drugs.
Influenza, Human
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Influenza, Human
Intact Glycopeptide Analysis of Influenza A/H1N1/09 Neuraminidase Revealing the Effects of Host and Glycosite Location on Site-Specific Glycan Structures.
Influenza, Human
Intact sphingomyelin biosynthetic pathway is essential for intracellular transport of influenza virus glycoproteins.
Influenza, Human
Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus.
Influenza, Human
Integrating sequence variation and protein structure to identify sites under selection.
Influenza, Human
Intensive care management of influenza-associated pulmonary aspergillosis.
Influenza, Human
Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5.
Influenza, Human
Interaction of Hsp40 with influenza virus M2 protein: implications for PKR signaling pathway.
Influenza, Human
Interaction of influenza virus proteins with planar bilayer lipid membranes. I. Characterization of their adsorption and incorporation into lipid bilayers.
Influenza, Human
Intercontinental circulation of human influenza A(H1N2) reassortant viruses during the 2001-2002 influenza season.
Influenza, Human
Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics.
Influenza, Human
Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity.
Influenza, Human
Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir.
Influenza, Human
Intergenic HA-NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes.
Influenza, Human
Intra-host viral variability in children clinically infected with H1N1 (2009) pandemic influenza.
Influenza, Human
Intracellular synthesis of neuraminidase following infection of charioallantoic membranes with influenza virus.
Influenza, Human
Intragastric delivery of recombinant Lactococcus lactis displaying ectodomain of influenza matrix protein 2 (M2e) and neuraminidase (NA) induced focused mucosal and systemic immune responses in chickens.
Influenza, Human
Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient.
Influenza, Human
Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.
Influenza, Human
Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
Influenza, Human
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Influenza, Human
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Influenza, Human
Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Influenza, Human
Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses.
Influenza, Human
Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Influenza, Human
Intravenous peramivir for treatment of influenza in hospitalized patients.
Influenza, Human
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Influenza, Human
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
Influenza, Human
Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice.
Influenza, Human
Introduction of site-specific mutations into the genome of influenza virus.
Influenza, Human
Introductions and evolution of human-origin seasonal influenza a viruses in multinational swine populations.
Influenza, Human
Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1.
Influenza, Human
Investigation of genetic variation: Neuraminidase gene of influenza A virus H1N1/pdm09, Shiraz, Iran (2015-2016).
Influenza, Human
Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations.
Influenza, Human
Investigation of the binding and cleavage characteristics of N1 neuraminidases from avian, seasonal, and pandemic influenza viruses using saturation transfer difference nuclear magnetic resonance.
Influenza, Human
Involvement of the mannose receptor in infection of macrophages by influenza virus.
Influenza, Human
In Vitro Evaluation of Synergistic Inhibitory Effects of Neuraminidase Inhibitors and Methylglyoxal Against Influenza Virus Infection.
Influenza, Human
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
Influenza, Human
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors against clinical isolates of the influenza viruses circulating in the 2010-2011 to 2014-2015 Japanese influenza seasons.
Influenza, Human
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2015-16 season: Comparison with the 2010-11 to 2014-15 seasons.
Influenza, Human
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016-17 season: Comparison with the 2010-11 to 2015-16 seasons.
Influenza, Human
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2017-18 season: Comparison with the 2010-11 to 2016-17 seasons.
Influenza, Human
In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018-19 season: Comparison with the 2010-11 to 2017-18 seasons.
Influenza, Human
Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study.
Influenza, Human
Is the influenza vaccine effective in decreasing infection, hospitalization, pneumonia, and mortality in healthy adults?
Influenza, Human
Isocorilagin, isolated from Canarium album (Lour.) Raeusch, as a potent neuraminidase inhibitor against influenza A virus.
Influenza, Human
Isoelectric focusing studies of A2-1957 influenza neuraminidase and its subunits.
Influenza, Human
Isolation and characterization of a transfectant influenza B virus altered in RNA segment 6.
Influenza, Human
Isolation and characterization of influenza A viruses from wild ducks in northern Japan: appearance of HSW1 antigens in the Japanese duck population.
Influenza, Human
Isolation and characterization of influenza a viruses from wild free-flying ducks in Hokkaido, Japan.
Influenza, Human
Isolation and characterization of influenza virus recombinants with high and low neuraminidase activity. Use of 2-(3'-methoxyphenyl)-n-acetylneuraminic acid to identify cloned populations.
Influenza, Human
Isolation and genetic characterization of avian influenza viruses and a Newcastle disease virus from wild birds in Barbados: 2003-2004.
Influenza, Human
Isolation of a biologically active soluble form of the hemagglutinin-neuraminidase protein of Sendai virus.
Influenza, Human
Isolation of a low molecular weight sialidase (neuraminidase) from influenza virus.
Influenza, Human
Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.
Influenza, Human
Isolation of biologically active components from rabies and other envelope viruses.
Influenza, Human
Isolation of influenza A virus from budgerigars and its serological characterization.
Influenza, Human
Isolation of novel triple-reassortant swine H3N2 influenza viruses possessing the hemagglutinin and neuraminidase genes of a seasonal influenza virus in Vietnam in 2010.
Influenza, Human
Isolation, sequencing and phylogenetic analysis of the hemagglutinin, neuraminidase and nucleoprotein genes of the Chilean equine influenza virus subtypes H7N7 and H3N8.
Influenza, Human
Isometrically invariant and allosterically aware description of deformable macromolecular surfaces: Application to the viral neuraminidase.
Influenza, Human
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Influenza, Human
Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.
Influenza, Human
Key amino acid residues of neuraminidase involved in influenza A virus entry.
Influenza, Human
Kinetic studies on the sialidase of three influenza B and three influenza A virus strains.
Influenza, Human
Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza.
Influenza, Human
Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus.
Influenza, Human
Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland.
Influenza, Human
Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
Influenza, Human
L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo.
Influenza, Human
Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines.
Influenza, Human
Labeling of influenza viruses with synthetic fluorescent and biotin-labeled lipids.
Influenza, Human
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Influenza, Human
Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
Influenza, Human
Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.
Influenza, Human
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Influenza, Human
Laninamivir Octanoate and Artificial Surfactant Combination Therapy Significantly Increases Survival of Mice Infected with Lethal Influenza H1N1 Virus.
Influenza, Human
Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
Influenza, Human
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Influenza, Human
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Influenza, Human
Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone.
Influenza, Human
Large outbreak of swine influenza in southern Japan caused by reassortant (H1N2) influenza viruses: its epizootic background and characterization of the causative viruses.
Influenza, Human
Latex fetuin spheres as probes for influenza virus neuraminidase in productively and abortively infected cells.
Influenza, Human
Lattice-translocation defects in specific crystals of the catalytic head domain of influenza neuraminidase.
Influenza, Human
Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses.
Influenza, Human
Length variations in the NA stalk of an H7N1 influenza virus have opposite effects on viral excretion in chickens and ducks.
Influenza, Human
Levels of immunoglobulins and antibodies to haemaglutinin and neuraminidase of influenza virus in nasal secretions after natural infection.
Influenza, Human
Limited effect of recombinant human mannose-binding lectin on the infection of novel influenza A (H7N9) virus in vitro.
Influenza, Human
Lipid-dependence of target membrane stability during influenza viral fusion.
Influenza, Human
Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
Influenza, Human
Live attenuated H5N1 vaccine with H9N2 internal genes protects chickens from infections by both Highly Pathogenic H5N1 and H9N2 Influenza Viruses.
Influenza, Human
Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.
Influenza, Human
Live Imaging of Virus-Infected Cells by Using a Sialidase Fluorogenic Probe.
Influenza, Human
Live temperature-sensitive equine influenza virus vaccine: generation of the virus and efficacy in hamsters.
Influenza, Human
Live tissue culture influenza vaccine for oral administration. I. Specific immune response to monovaccine A (H3N2) in volunteers.
Influenza, Human
Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets.
Influenza, Human
Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
Influenza, Human
Localization of the Ts defect in two Ts mutants of influenza A virus: evidence for the occurrence of intracistronic complementation between Ts mutants of influenza A virus coding for the neuraminidase and nucleoprotein polypeptides.
Influenza, Human
Locally Acquired Human Infection with Swine-Origin Influenza A(H3N2) Variant Virus, Australia, 2018.
Influenza, Human
Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase.
Influenza, Human
Location on the evolutionary trees of the non-structural protein (NS) and neuraminidase (NA) genes of late human influenza A (H2N2) viruses: parental viruses of the NS and NA genes of Hong Kong influenza A (H3N2) viruses.
Influenza, Human
Locking the 150-cavity open: in silico design and verification of influenza neuraminidase inhibitors.
Influenza, Human
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care.
Influenza, Human
Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Influenza, Human
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection.
Influenza, Human
Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
Influenza, Human
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Influenza, Human
Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.
Influenza, Human
Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
Influenza, Human
Longitudinal sampling is required to maximize detection of intrahost A/H3N2 virus variants.
Influenza, Human
Loss of enzyme activity in a site-directed mutant of influenza neuraminidase compared to expressed wild-type protein.
Influenza, Human
Loss of glycosylation at Asn144 alters the substrate preference of the N8 influenza A virus neuraminidase.
Influenza, Human
Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Influenza, Human
Low Pathogenic Avian Influenza Viruses in Wild Migratory Waterfowl in a Region of High Poultry Production, Delmarva, Maryland.
Influenza, Human
Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
Influenza, Human
Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic.
Influenza, Human
Low-pathogenicity avian influenza virus (H6N2) in chickens in California, 2000-02.
Influenza, Human
Low-pH Stability of Influenza A Virus Sialidase Contributing to Virus Replication and Pandemic.
Influenza, Human
Lymphocyte responses to hemagglutinin and neuraminidase subunits of influenza virus.
Influenza, Human
Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models.
Influenza, Human
Magnetic beads-based neuraminidase enzyme microreactor as a drug discovery tool for screening inhibitors from compound libraries and fishing ligands from natural products.
Influenza, Human
Mallards and highly pathogenic avian influenza ancestral viruses, northern Europe.
Influenza, Human
Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.
Influenza, Human
Management of influenza in patients with asthma or chronic obstructive pulmonary disease.
Influenza, Human
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.
Influenza, Human
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Influenza, Human
Management of respiratory viral infections in hematopoietic cell transplant recipients.
Influenza, Human
Manipulation of neuraminidase packaging signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influenza vaccine virus yield in eggs.
Influenza, Human
Many human RNA viruses show extraordinarily stringent selective constraints on protein evolution.
Influenza, Human
Mapping of the influenza virus genome: identification of the hemagglutinin and the neuraminidase genes.
Influenza, Human
Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites.
Influenza, Human
Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies.
Influenza, Human
Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines.
Influenza, Human
Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan.
Influenza, Human
Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice.
Influenza, Human
Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus.
Influenza, Human
Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.
Influenza, Human
Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.
Influenza, Human
MD simulation of the interaction between sialoglycans and the second sialic acid binding site of influenza A virus N1 neuraminidase.
Influenza, Human
Measurement of antibodies to influenza virus neuraminidase by an enzyme-linked immunosorbent assay.
Influenza, Human
Measurement of antibody to influenza virus neuraminidase by single radial hemolysis in agarose gels.
Influenza, Human
Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.
Influenza, Human
Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay.
Influenza, Human
Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay.
Influenza, Human
Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Influenza, Human
Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase.
Influenza, Human
Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins.
Influenza, Human
Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene.
Influenza, Human
Mechanism-Based Covalent Neuraminidase Inhibitors with Broad Spectrum Influenza Antiviral Activity.
Influenza, Human
Mechanisms of antiviral resistance in influenza neuraminidase revealed by a mass spectrometry based phylonumerics approach.
Influenza, Human
Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities.
Influenza, Human
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Influenza, Human
MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.
Influenza, Human
Mesoscale All-Atom Influenza Virus Simulations Suggest New Substrate Binding Mechanism.
Influenza, Human
Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids Confers Neuraminidase Resistance and Inhibits Influenza Reproduction.
Influenza, Human
Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
Influenza, Human
Method for Sequencing the Whole Genome of the Highly Pathogenic Avian Influenza A(H5N6) Virus.
Influenza, Human
MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
Influenza, Human
Microglial activation by microbial neuraminidase through TLR2 and TLR4 receptors.
Influenza, Human
Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants.
Influenza, Human
Mild to moderate influenza activity in Europe and the detection of novel A(H1N2) and B viruses during the winter of 2001-02.
Influenza, Human
Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses.
Influenza, Human
Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Influenza, Human
Mobility-Based Quantification of Multivalent Virus-Receptor Interactions: New Insights Into Influenza A Virus Binding Mode.
Influenza, Human
Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.
Influenza, Human
Modification of infectious bursal disease virus antigen VP2 for cell surface location fails to enhance immunogenicity.
Influenza, Human
Modified sialic acids on mucus and erythrocytes inhibit influenza A HA and NA functions.
Influenza, Human
Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.
Influenza, Human
Modulation of murine macrophage responses stimulated with influenza glycoproteins.
Influenza, Human
Molecular analysis of hemagglutinin, neuraminidase, matrix genes provide insight into the genetic diversity of seasonal H3N2 human influenza a viruses in Bangladesh during July-August, 2012.
Influenza, Human
Molecular analysis of isolates from influenza B outbreaks in the U.S. and Nepal, 2005.
Influenza, Human
Molecular and genetic characteristics of hemagglutinin and neuraminidase in Iranian 2009 pandemic influenza A(H1N1) viruses.
Influenza, Human
Molecular and phylogenetic analyses of influenza B viruses isolated from pediatric inpatients in South Korea during the 2011-2012 winter season.
Influenza, Human
Molecular and phylogenetic analysis and vaccine strain match of human influenza A(H3N2) viruses isolated in Northern Greece between 2004 and 2008.
Influenza, Human
Molecular and phylogenetic analysis of haemagglutinin and neuraminidase sequences from recent human influenza type A (H3N2) viral isolates in Southern Greece.
Influenza, Human
Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations.
Influenza, Human
Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.
Influenza, Human
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Influenza, Human
Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
Influenza, Human
Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013.
Influenza, Human
Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018-2019.
Influenza, Human
Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand.
Influenza, Human
Molecular characterization of the hemagglutinin and neuraminidase genes of H5N1 influenza A viruses isolated from poultry in Vietnam from 2004 to 2005.
Influenza, Human
Molecular characterization of the influenza A(H1N1)pdm09 isolates collected in the 2015-2016 season and comparison of HA mutations detected in Turkey since 2009.
Influenza, Human
Molecular cloning and analysis of the N5 neuraminidase subtype from an avian influenza virus.
Influenza, Human
Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.
Influenza, Human
Molecular docking analysis of zanamavir with haem agglutinin neuraminidase of human para influenza virus type 3.
Influenza, Human
Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Influenza, Human
Molecular Docking, 3D-QSAR studies and in-silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Influenza, Human
Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012-2013 in Beijing, China.
Influenza, Human
Molecular epidemiology and evolution of influenza A and B viruses during winter 2013-2014 in Beijing, China.
Influenza, Human
Molecular epidemiology and genetic characterization of influenza B virus in Lebanon during 2016-2018.
Influenza, Human
Molecular epidemiology and glycomics of swine influenza viruses circulating in commercial swine farms in the southeastern and midwest United States.
Influenza, Human
Molecular Epidemiology of a novel re-assorted epidemic strain of equine influenza virus in Pakistan in 2015-16.
Influenza, Human
Molecular epidemiology of influenza A virus infection in Cyprus in four consecutive seasons (2009 pandemic-2013).
Influenza, Human
Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons.
Influenza, Human
Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011.
Influenza, Human
Molecular findings from influenza A(H1N1)pdm09 detected in patients from a Brazilian equatorial region during the pandemic period.
Influenza, Human
Molecular footprints of selective pressure in the neuraminidase gene of currently circulating human influenza subtypes and lineages.
Influenza, Human
Molecular hybridization with DNA probes as a laboratory diagnosis test for influenza viruses: further investigations on the possibilities of the method.
Influenza, Human
Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Influenza, Human
Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Influenza, Human
Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.
Influenza, Human
Molecular modeling of sialyloligosaccharide fragments into the active site of influenza virus N9 neuraminidase.
Influenza, Human
Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase.
Influenza, Human
Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis.
Influenza, Human
Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
Influenza, Human
Molecular point-of-care testing for influenza to improve early neuraminidase inhibitor treatment and outcomes in hospitalised adults.
Influenza, Human
Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach.
Influenza, Human
Molecular simulation study of the binding mechanism of [?-PTi2W10O40]7- for its promising broad-spectrum inhibitory activity to FluV-A neuraminidase.
Influenza, Human
Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013.
Influenza, Human
Monitoring genetic diversity of influenza A(H1N1)pdm09 virus circulating during the post-pandemic period in Turkey.
Influenza, Human
Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity.
Influenza, Human
Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons.
Influenza, Human
Monoclonal antibodies against avian paramyxovirus-3: antigenic mapping and functional analysis of the haemagglutinin-neuraminidase protein and the characterization of nonspecific monoclonal antibodies.
Influenza, Human
Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines.
Influenza, Human
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
Influenza, Human
Monomeric inhibitors of influenza neuraminidase enhance the hemagglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups.
Influenza, Human
Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus.
Influenza, Human
Morin Hydrate Inhibits Influenza Virus entry into Host Cells and Has Anti-inflammatory Effect in Influenza-infected Mice.
Influenza, Human
Morphology of the isolated hemagglutinin and neuraminidase subunits of influenza virus.
Influenza, Human
Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants.
Influenza, Human
Mouse Saliva Inhibits Transit of Influenza Virus to the Lower Respiratory Tract by Efficiently Blocking Influenza Virus Neuraminidase Activity.
Influenza, Human
Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
Influenza, Human
Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs.
Influenza, Human
Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection.
Influenza, Human
Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
Influenza, Human
Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child.
Influenza, Human
Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic.
Influenza, Human
Multiple clusters of A(H1N1)pdm09 virus circulating in severe cases of influenza during the 2010-2011 season: a phylogenetic and molecular analysis of the neuraminidase gene.
Influenza, Human
Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
Influenza, Human
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.
Influenza, Human
Multiple viral introductions: molecular characterization of influenza B virus in Wenzhou, Zhejiang, China, from 2011 to 2014 based on hemagglutinin and neuraminidase genes.
Influenza, Human
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies.
Influenza, Human
Multiplex Reverse Transcription-PCR for Simultaneous Surveillance of Influenza A and B Viruses.
Influenza, Human
Multiplex rt-PCR and indirect immunofluorescence assays for detection and subtyping of human influenza virus in Tunisia.
Influenza, Human
Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase.
Influenza, Human
Multivalent Affinity Profiling: Direct Visualization of the Superselective Binding of Influenza Viruses.
Influenza, Human
Multivalent S-sialoside protein conjugates block influenza hemagglutinin and neuraminidase.
Influenza, Human
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.
Influenza, Human
Murine TH response to influenza virus: recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins.
Influenza, Human
Mutants of an influenza A reassortant which are cold-sensitive (cs) as well as temperature-sensitive (ts): on the role of the neuraminidase activity for influenza virus infection.
Influenza, Human
Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme.
Influenza, Human
Mutation of neuraminidase cysteine residues yields temperature-sensitive influenza viruses.
Influenza, Human
Mutation of the 2(nd) Sialic Acid-Binding Site Resulting in Reduced Neuraminidase Activity Preceded Emergence of H7N9 Influenza A Virus.
Influenza, Human
Mutation of the second sialic acid-binding site of influenza A virus neuraminidase drives compensatory mutations in hemagglutinin.
Influenza, Human
Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
Influenza, Human
Mutational analysis of the signal-anchor domain of influenza virus neuraminidase.
Influenza, Human
Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Influenza, Human
Mutations at highly conserved residues in influenza A(H1N1)pdm09 virus affect neuraminidase activity.
Influenza, Human
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Influenza, Human
Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses.
Influenza, Human
Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
Influenza, Human
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir).
Influenza, Human
Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody.
Influenza, Human
Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic.
Influenza, Human
Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions.
Influenza, Human
Mutations in the ectodomain of newcastle disease virus fusion protein confer a hemagglutinin-neuraminidase-independent phenotype.
Influenza, Human
Mutations in the Neuraminidase-Like Protein of Bat Influenza H18N11 Virus Enhance Virus Replication in Mammalian Cells, Mice, and Ferrets.
Influenza, Human
Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation.
Influenza, Human
Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
Influenza, Human
N-Linked Glycan Sites on the Influenza A Virus Neuraminidase Head Domain Are Required for Efficient Viral Incorporation and Replication.
Influenza, Human
N-Linked Glycosylation Plays an Important Role in Budding of Neuraminidase Protein and Virulence of Influenza Viruses.
Influenza, Human
N1 neuraminidase of H5N1 avian influenza A virus complexed with sialic acid and zanamivir - A study by molecular docking and molecular dynamics simulation.
Influenza, Human
N1 neuraminidase of influenza virus A/FPV/Rostock/34 has haemadsorbing activity.
Influenza, Human
N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free energy calculations capture specificity trends observed with mutant binding data.
Influenza, Human
NA proteins of influenza A viruses H1N1/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion.
Influenza, Human
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
Influenza, Human
Nanomicroarray and multiplex next-generation sequencing for simultaneous identification and characterization of influenza viruses.
Influenza, Human
Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season.
Influenza, Human
Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Influenza, Human
Natural infection with influenza A (H3N2). The development, persistance and effect of antibodies to the surface antigens.
Influenza, Human
Natural Products as Promising Therapeutics for Treatment of Influenza Disease.
Influenza, Human
NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets.
Influenza, Human
Neuraminidase activity and specificity of influenza A virus are influenced by haemagglutinin-receptor binding.
Influenza, Human
Neuraminidase Activity and The Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Influenza, Human
Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus.
Influenza, Human
Neuraminidase activity is not the cause of influenza virus-induced neutrophil dysfunction.
Influenza, Human
Neuraminidase activity of blue eye disease porcine rubulavirus: Specificity, affinity and inhibition studies.
Influenza, Human
Neuraminidase activity of influenza virus-infected cells: localization and properties.
Influenza, Human
Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
Influenza, Human
Neuraminidase Amino Acid Sequences of Influenza A/H3N2 and B Viruses Isolated from Influenza Patients in the 2014/15 Japanese Influenza Season.
Influenza, Human
Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Influenza, Human
Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses.
Influenza, Human
Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines.
Influenza, Human
Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis.
Influenza, Human
Neuraminidase antibodies and H5N1: geographic-dependent influenza epidemiology could determine cross-protection against emerging strains.
Influenza, Human
Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
Influenza, Human
Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
Influenza, Human
Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding.
Influenza, Human
Neuraminidase as an enzymatic marker for detecting airborne Influenza virus and other viruses.
Influenza, Human
Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.
Influenza, Human
Neuraminidase characterisation reveals very low levels of antiviral resistance and the presence of mutations associated with reduced antibody effectiveness in the Irish influenza 2018/2019 season.
Influenza, Human
Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.
Influenza, Human
Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.
Influenza, Human
Neuraminidase from Influenza A and B Viruses is Susceptible to the Compound 4-(4-Phenyl-1H-1,2,3-Triazol-1-yl)-2,2,6,6-Tetramethylpiperidine-1- Oxyl.
Influenza, Human
Neuraminidase from influenza virus A (H3N2): specificity towards several substrates and procedure of activity determination.
Influenza, Human
Neuraminidase gene from the early Asian strain of human influenza virus, A/RI/5-/57 (H2N2).
Influenza, Human
Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library.
Influenza, Human
Neuraminidase Gene Variations in Influenza A(H1N1)pdm09 Virus among Patients Admitted to Refferal Pulmonary Hospital, Tehran, Iran in 2009-2013.
Influenza, Human
Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection.
Influenza, Human
Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks.
Influenza, Human
Neuraminidase in avin influenza A virus antigenically related to that of human A0 and A1 subtypes.
Influenza, Human
Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.
Influenza, Human
Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies.
Influenza, Human
Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
Influenza, Human
Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Influenza, Human
Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children.
Influenza, Human
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Influenza, Human
Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
Influenza, Human
Neuraminidase inhibitor susceptibility and evolutionary analysis of human influenza B isolates from three Asian countries during 2012-2015.
Influenza, Human
Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
Influenza, Human
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Influenza, Human
Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999.
Influenza, Human
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Influenza, Human
Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
Influenza, Human
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Influenza, Human
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Influenza, Human
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
Influenza, Human
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Influenza, Human
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Influenza, Human
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Influenza, Human
Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo.
Influenza, Human
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Influenza, Human
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
Influenza, Human
Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Influenza, Human
Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
Influenza, Human
Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials.
Influenza, Human
Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.
Influenza, Human
Neuraminidase inhibitors beneficial for treatment and prevention of influenza in children.
Influenza, Human
Neuraminidase inhibitors for influenza A and B: antivirals need to be protected from adverse conditions to retain effectiveness.
Influenza, Human
Neuraminidase inhibitors for influenza A and B: PROSE may be as useful as POEMs.
Influenza, Human
Neuraminidase inhibitors for influenza A and B: study showed benefits of treatment are marginal.
Influenza, Human
Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance.
Influenza, Human
Neuraminidase inhibitors for influenza in healthy adults: what we don't know.
Influenza, Human
Neuraminidase inhibitors for influenza treatment and prevention in healthy adults.
Influenza, Human
Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.
Influenza, Human
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
Influenza, Human
Neuraminidase inhibitors for influenza: fully evaluating benefits and harms.
Influenza, Human
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
Influenza, Human
Neuraminidase inhibitors for preventing and treating influenza in children.
Influenza, Human
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Influenza, Human
Neuraminidase inhibitors for preventing and treating influenza in healthy adults.
Influenza, Human
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review.
Influenza, Human
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.
Influenza, Human
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.
Influenza, Human
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials.
Influenza, Human
Neuraminidase inhibitors for treatment of equine influenza - when all else fails?
Influenza, Human
Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
Influenza, Human
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
Influenza, Human
Neuraminidase Inhibitors in Influenza Treatment and Prevention?Is It Time to Call It a Day?
Influenza, Human
Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy.
Influenza, Human
Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice.
Influenza, Human
Neuraminidase inhibitors in the treatment of influenza A and B--overview and case reports.
Influenza, Human
Neuraminidase inhibitors produce a small reduction in duration of seasonal influenza in children and reduce transmission in affected households, but effects on serious complications unclear.
Influenza, Human
Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages.
Influenza, Human
Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Influenza, Human
Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
Influenza, Human
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Influenza, Human
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.
Influenza, Human
Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
Influenza, Human
Neuraminidase mutations conferring resistance to oseltamivir in influenza A(H7N9) viruses.
Influenza, Human
Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.
Influenza, Human
Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture.
Influenza, Human
Neuraminidase Receptor Binding Variants of Human Influenza A(H3N2) Viruses due to Substitution of Aspartic acid 151 in the Catalytic Site - Role in Virus Attachment?
Influenza, Human
Neuraminidase Resistant Sialosides for the Detection of Influenza Viruses.
Influenza, Human
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
Influenza, Human
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.
Influenza, Human
Neuraminidase subtyping of human influenza a viruses by RT-PCR and its application to clinical isolates.
Influenza, Human
Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection.
Influenza, Human
Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
Influenza, Human
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Influenza, Human
Neuraminidase-inhibition assay for the identification of influenza A virus neuraminidase subtype or neuraminidase antibody specificity.
Influenza, Human
Neuraminidase-inhibition assay for the identification of influenza A virus neuraminidase virus subtype or neuraminidase antibody specificity.
Influenza, Human
Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.
Influenza, Human
Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site.
Influenza, Human
Neuraminidase-mediated, NKp46-dependent immune-evasion mechanism of influenza viruses.
Influenza, Human
Neuraminidase-producing oral mitis group streptococci potentially contribute to influenza viral infection and reduction in antiviral efficacy of zanamivir.
Influenza, Human
Neuraminidase-specific antibody responses are generated in naive and vaccinated newborn nonhuman primates following virus infection.
Influenza, Human
Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.
Influenza, Human
Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae.
Influenza, Human
Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody.
Influenza, Human
Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A/H3N2 outbreak among unvaccinated military recruits.
Influenza, Human
New avian influenza A virus subtype combination H5N7 identified in Danish mallard ducks.
Influenza, Human
New genotype of avian influenza H5N1 viruses isolated from tree sparrows in China.
Influenza, Human
New insights into the nonconserved noncoding region of the subtype-determinant hemagglutinin and neuraminidase segments of influenza A viruses.
Influenza, Human
New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors.
Influenza, Human
New point of care test is highly specific but less sensitive for influenza virus A and B in children and adults.
Influenza, Human
New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
Influenza, Human
New stilbenoid with inhibitory activity on viral neuraminidases from Erythrina addisoniae.
Influenza, Human
New, azide-free transformation of epoxides into 1,2-diamino compounds: synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu).
Influenza, Human
New, efficient synthesis of oseltamivir phosphate (Tamiflu) via enzymatic desymmetrization of a meso-1,3-cyclohexanedicarboxylic acid diester.
Influenza, Human
New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions.
Influenza, Human
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Influenza, Human
NH2-terminal hydrophobic region of influenza virus neuraminidase provides the signal function in translocation.
Influenza, Human
Nonlinkage of neurovirulence exclusively to viral hemagglutinin or neuraminidase in genetic recombinants of A-NWS (HON1) influenza virus.
Influenza, Human
Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.
Influenza, Human
Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.
Influenza, Human
Novel antiviral activity of neuraminidase inhibitors against an avian influenza A virus.
Influenza, Human
Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
Influenza, Human
Novel correlates of protection against pandemic H1N1 influenza A virus infection.
Influenza, Human
Novel fucolipids of human adenocarcinoma: disialosyl Lea antigen (III4FucIII6NeuAcIV3NeuAcLc4) of human colonic adenocarcinoma and the monoclonal antibody (FH7) defining this structure.
Influenza, Human
Novel influenza A viruses isolated from Canadian feral ducks: including strains antigenically related to swine influenza (Hsw1N1) viruses.
Influenza, Human
Novel linear polymers bearing thiosialosides as pendant-type epitopes for influenza neuraminidase inhibitors.
Influenza, Human
Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies.
Influenza, Human
Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode.
Influenza, Human
Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase.
Influenza, Human
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.
Influenza, Human
Novel Piperine compound AB05 (N-5-(3,4-dimethoxyphenyl) -2E,4E pentadienylpiperidine) inhibits H1N1 influenza virus propagation in vitro.
Influenza, Human
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
Influenza, Human
Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.
Influenza, Human
NS-gene based phylogenetic analysis of equine influenza viruses isolated in Poland.
Influenza, Human
Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses.
Influenza, Human
Nucleotide and deduced amino acid sequence of the influenza neuraminidase genes of two equine serotypes.
Influenza, Human
Nucleotide sequence of the influenza virus A/USSR/90/77 neuraminidase gene.
Influenza, Human
Nucleotide sequences of the neuraminidase genes of influenza A/Leningrad/134/57 (H2N2) virus and two of its live, attenuated, cold-adapted variants.
Influenza, Human
Observations on the relationship between hemagglutinin and neuraminidase of influenza viruses.
Influenza, Human
On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9.
Influenza, Human
On the role of electrostatic interactions in the design of protein-protein interfaces.
Influenza, Human
On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Influenza, Human
On three-dimensional holographic vector of atomic interaction field analysis for influenza neuraminidase inhibitors.
Influenza, Human
Optimal Charges in Lead Progression: A Structure-Based Neuraminidase Case Study.
Influenza, Human
Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.
Influenza, Human
Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations.
Influenza, Human
Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors.
Influenza, Human
Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
Influenza, Human
Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene.
Influenza, Human
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Influenza, Human
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Influenza, Human
Oral clarithromycin enhances airway IgA immunity through induction of IgA class switching recombination and B-cell activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.
Influenza, Human
Oral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral Infection.
Influenza, Human
Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958.
Influenza, Human
Origins and Evolutionary Genomics of the Novel Swine-Origin Influenza A (H1N1) Virus in Humans -Past and Present Perspectives.
Influenza, Human
Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations.
Influenza, Human
Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs.
Influenza, Human
Ortho- and paramyxoviruses from migrating feral ducks: characterization of a new group of influenza A viruses.
Influenza, Human
Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex.
Influenza, Human
Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
Influenza, Human
Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan.
Influenza, Human
Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
Influenza, Human
Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors.
Influenza, Human
Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets.
Influenza, Human
Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.
Influenza, Human
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
Influenza, Human
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.
Influenza, Human
Oseltamivir Resistance in Influenza A(H6N2) Caused by an R292K Substitution in Neuraminidase Is Not Maintained in Mallards without Drug Pressure.
Influenza, Human
Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study.
Influenza, Human
Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.
Influenza, Human
Oseltamivir susceptibility in south-western France during the 2007-8 and 2008-9 influenza epidemics and the ongoing influenza pandemic 2009.
Influenza, Human
Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Influenza, Human
Oseltamivir use in adolescents and adults: clinical and economic considerations.
Influenza, Human
Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Influenza, Human
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Influenza, Human
Oseltamivir-Resistant Influenza A (H1N1) Virus Strain with an H274Y Mutation in Neuraminidase Persists without Drug Pressure in Infected Mallards.
Influenza, Human
Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients.
Influenza, Human
Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.
Influenza, Human
Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post-pandemic 2010-2011 season.
Influenza, Human
Oseltamivir-resistant influenza A(H1N1) pdm09 virus: first reported case from India.
Influenza, Human
Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013-14.
Influenza, Human
Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance.
Influenza, Human
Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.
Influenza, Human
Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
Influenza, Human
Oseltamivir-resistant influenza viruses get by with a little help from permissive mutations.
Influenza, Human
Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.
Influenza, Human
Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets.
Influenza, Human
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets.
Influenza, Human
Oseltamivir-resistant seasonal A(H1N1) and A(H1N1)pdm09 influenza viruses from the 2007/2008 to 2012/2013 season in Nara Prefecture, Japan.
Influenza, Human
Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Influenza, Human
Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
Influenza, Human
Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation.
Influenza, Human
Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
Influenza, Human
Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.
Influenza, Human
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.
Influenza, Human
Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Influenza, Human
Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.
Influenza, Human
Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness.
Influenza, Human
Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine.
Influenza, Human
Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects.
Influenza, Human
Pandemic Swine H1N1 Influenza Viruses with Almost Undetectable Neuraminidase Activity Are Not Transmitted via Aerosols in Ferrets and Are Inhibited by Human Mucus but Not Swine Mucus.
Influenza, Human
Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?
Influenza, Human
Panorama phylogenetic diversity and distribution of Type A influenza virus.
Influenza, Human
Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors.
Influenza, Human
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains.
Influenza, Human
Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
Influenza, Human
Patchouli alcohol: in vitro direct anti-influenza virus sesquiterpene in Pogostemon cablin Benth.
Influenza, Human
Pathogenesis and Transmission of Genetically Diverse Swine-Origin H3N2 Variant Influenza A Viruses from Multiple Lineages Isolated in the United States, 2011-2016.
Influenza, Human
Pathogenic studies and antigenic and sequence comparisons of A/equine/Alaska/1/91 (H3N8) influenza virus.
Influenza, Human
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus.
Influenza, Human
Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.
Influenza, Human
Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice.
Influenza, Human
Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
Influenza, Human
Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
Influenza, Human
Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza.
Influenza, Human
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
Influenza, Human
Peramivir binding affinity with influenza A neuraminidase and research on its mutations using an induced-fit docking approach.
Influenza, Human
Peramivir conjugates as orally available agents against influenza H275Y mutant.
Influenza, Human
Peramivir injection in the treatment of acute influenza: a review of the literature.
Influenza, Human
Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
Influenza, Human
Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
Influenza, Human
Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Influenza, Human
Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.
Influenza, Human
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
Influenza, Human
Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Influenza, Human
Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment.
Influenza, Human
Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].
Influenza, Human
Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
Influenza, Human
Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.
Influenza, Human
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.
Influenza, Human
Phage surface presentation and secretion of antibody fragments using an adaptable phagemid vector.
Influenza, Human
Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.
Influenza, Human
Pharmacoeconomics of Antiviral Therapy for Influenza in a Japanese Hospital Setting.
Influenza, Human
Pharmacokinetic behavior of peramivir in the plasma and lungs of rats after trans-nasal aerosol inhalation and intravenous injection.
Influenza, Human
Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
Influenza, Human
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
Influenza, Human
Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.
Influenza, Human
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
Influenza, Human
Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
Influenza, Human
Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
Influenza, Human
Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
Influenza, Human
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Influenza, Human
Pharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration.
Influenza, Human
Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
Influenza, Human
Pharmacological activities and structure-modification of resveratrol analogues.
Influenza, Human
Pharmacophore model of influenza neuraminidase inhibitors--a systematic review.
Influenza, Human
Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Influenza, Human
Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Influenza, Human
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Influenza, Human
Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.
Influenza, Human
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
Influenza, Human
Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.
Influenza, Human
Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.
Influenza, Human
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
Influenza, Human
Phenotypic expression of HA-NA combinations in human-avian influenza A virus reassortants.
Influenza, Human
Photodegradation and inhibition of drug-resistant influenza virus neuraminidase using anthraquinone-sialic acid hybrids.
Influenza, Human
Phylogenetic analysis of hemagglutinin and neuraminidase genes of H9N2 viruses isolated from migratory ducks.
Influenza, Human
Phylogenetic analysis of neuraminidase gene of H9N2 influenza viruses prevalent in chickens in China during 1995-2002.
Influenza, Human
Phylogenetic analysis of the neuraminidase gene of pandemic H1N1 influenza A virus circulating in the South American region.
Influenza, Human
Phylogenetic analysis of the neuraminidase segment gene of Influenza A/H1N1 strains isolated from Monastir Region (Tunisia) during the 2017-2018 outbreak.
Influenza, Human
Phylogenetic relationships of the HA and NA genes between vaccine and seasonal influenza A(H3N2) strains in Korea.
Influenza, Human
Phylogenetic, molecular and drug-sensitivity analysis of HA and NA genes of human H3N2 influenza A viruses in Guangdong, China, 2007-2011.
Influenza, Human
PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
Influenza, Human
Plant expression systems for production of hemagglutinin as a vaccine against influenza virus.
Influenza, Human
Plant polyphenolic complex inhibits the reproduction of influenza and herpes simplex viruses.
Influenza, Human
Plant-Produced Recombinant Influenza Vaccine Based on Virus-Like HBc Particles Carrying an Extracellular Domain of M2 Protein.
Influenza, Human
Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin independent of the viral neuraminidase.
Influenza, Human
Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase.
Influenza, Human
Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus.
Influenza, Human
Plasticity of 150-loop in influenza neuraminidase explored by Hamiltonian replica exchange molecular dynamics simulations.
Influenza, Human
Plasticity of the 340-Loop in Influenza Neuraminidase Offers New Insight for Antiviral Drug Development.
Influenza, Human
Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
Influenza, Human
PNA FIT-Probes for the Dual Color Imaging of Two Viral mRNA Targets in Influenza H1N1 Infected Live Cells.
Influenza, Human
Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.
Influenza, Human
Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection.
Influenza, Human
Polarization of allogeneic T-cell responses by influenza virus-infected dendritic cells.
Influenza, Human
Polyclonal B-cell activation by influenza A/Texas virus-specific human T-cell clones.
Influenza, Human
Polymerase-assisted fluorescence resonance energy transfer (FRET) assay for simultaneous detection of binary viral sequences.
Influenza, Human
Polyphenolic glycosides isolated from Pogostemon cablin (Blanco) Benth. as novel influenza neuraminidase inhibitors.
Influenza, Human
Polyunsaturated fatty acids from Phyllocaulis boraceiensis mucus block the replication of influenza virus.
Influenza, Human
Polyuridylated mRNA synthesized by a recombinant influenza virus is defective in nuclear export.
Influenza, Human
Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.
Influenza, Human
Population dynamics at neuraminidase position 151 of influenza A (H1N1)pdm09 virus in clinical specimens.
Influenza, Human
Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza.
Influenza, Human
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
Influenza, Human
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
Influenza, Human
Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.
Influenza, Human
Population-wide emergence of antiviral resistance during pandemic influenza.
Influenza, Human
Porous gold nanoparticles for attenuating infectivity of influenza A virus.
Influenza, Human
Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses.
Influenza, Human
Positive selection on the H3 hemagglutinin gene of human influenza virus A.
Influenza, Human
Possible Reason for Cross-Species and Cross-Subtype Reassortment in Polymerase Basic Protein 2 from Influenza A Virus.
Influenza, Human
Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK.
Influenza, Human
Post-Exposure Prophylaxis for Influenza in Pediatric Wards: Oseltamivir or Zanamivir After Rapid Antigen Detection.
Influenza, Human
Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
Influenza, Human
Postreassortment changes in a model system: HA-NA adjustment in an H3N2 avian-human reassortant influenza virus.
Influenza, Human
Postreassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match.
Influenza, Human
Potency of an inactivated influenza vaccine prepared from A/duck/Hong Kong/960/1980 (H6N2) against a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice.
Influenza, Human
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.
Influenza, Human
Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.
Influenza, Human
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Influenza, Human
Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.
Influenza, Human
Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic.
Influenza, Human
Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design.
Influenza, Human
Potential for hepatic and renal dysfunction during influenza B infection, convalescence, and after induction of secondary viremia.
Influenza, Human
Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Influenza, Human
Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza.
Influenza, Human
Potentiation of the immune response to influenza virus subunit vaccines.
Influenza, Human
Practising evidence-based occupational health in workers' groups: how to prevent sickness absence caused by influenza.
Influenza, Human
Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol.
Influenza, Human
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Influenza, Human
Pre-existing anti-neuraminidase antibodies are associated with shortened duration of influenza A (H1N1)pdm virus shedding and illness in naturally infected adults.
Influenza, Human
Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit.
Influenza, Human
Predicting Influenza Antigenicity by Matrix Completion With Antigen and Antiserum Similarity.
Influenza, Human
Predicting the emergence of H3N2 influenza viruses reveals contrasted modes of evolution of HA and NA antigens.
Influenza, Human
Prediction of Biological Functions on Glycosylation Site Migrations in Human Influenza H1N1 Viruses.
Influenza, Human
Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development.
Influenza, Human
Prediction of mutations in H1 neuraminidases from North America influenza A virus engineered by internal randomness.
Influenza, Human
Prediction of the Inhibition of Influenza Virus Neuraminidase Various Strains by Means of a Generalized Model Constructed Using the Data on the Position of Known Ligands.
Influenza, Human
Prediction of zanamivir efficiency over the possible 2009 Influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations.
Influenza, Human
Predictors of Influenza Diagnosis Among Patients With Laboratory-Confirmed Influenza.
Influenza, Human
Predictors of mortality and length of stay in hospitalized cases of 2009 influenza A (H1N1): Experiences of a tertiary care center.
Influenza, Human
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
Influenza, Human
Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study.
Influenza, Human
Preliminary crystallographic analysis of neuraminidase N2 from a new influenza A virus.
Influenza, Human
Preliminary crystallographic data for influenza virus neuraminidase "heads".
Influenza, Human
Preparation and characterization of a purified influenza virus neuraminidase vaccine.
Influenza, Human
Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine.
Influenza, Human
Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine.
Influenza, Human
Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration.
Influenza, Human
Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus.
Influenza, Human
Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP.
Influenza, Human
Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.
Influenza, Human
Preparation-conditioned changes of the antigenicity of influenza virus neuraminidases.
Influenza, Human
Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic.
Influenza, Human
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.
Influenza, Human
Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.
Influenza, Human
Prevalence and risk factors for H1N1 and H3N2 influenza A virus infections in Minnesota turkey premises.
Influenza, Human
Prevalence and subtypes of Influenza A Viruses in Wild Waterfowl in Norway 2006-2007.
Influenza, Human
Primarily oseltamivir resistant influenza A (H1N1pdm09) virus evolving into a multi-drug resistant virus carrying H275Y and I223R neuraminidase substitutions.
Influenza, Human
Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice.
Influenza, Human
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.
Influenza, Human
Primer development to obtain complete coding sequence of HA and NA genes of influenza A/H3N2 virus.
Influenza, Human
Principles of rational classification and nomenclature of human influenza A viruses.
Influenza, Human
Principles of selective inactivation of viral genome. I. UV-induced inactivation of influenza virus.
Influenza, Human
Prion Protein is a Novel Modulator of Influenza: Potential Implications for Anti-Influenza Therapeutics.
Influenza, Human
Probable association of plaque size with neuraminidase subtype among H3N2 influenza A viruses. Brief report.
Influenza, Human
Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods.
Influenza, Human
Probing the effect of quercetin 3-glucoside from Dianthus superbus L against influenza virus infection- In vitro and in silico biochemical and toxicological screening.
Influenza, Human
Probing the Neuraminidase Activity of Influenza Virus Using a Cytolysin A Protein Nanopore.
Influenza, Human
Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Influenza, Human
Production of neuraminidase in cell monolayers infected with influenza virus.
Influenza, Human
Professional oral health care by dental hygienists reduced respiratory infections in elderly persons requiring nursing care.
Influenza, Human
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Influenza, Human
Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors.
Influenza, Human
Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine.
Influenza, Human
Progress of small molecular inhibitors in the development of anti-influenza virus agents.
Influenza, Human
Prolonged Influenza Virus Infection during Lymphocytopenia and Frequent Detection of Drug-Resistant Viruses.
Influenza, Human
Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant.
Influenza, Human
Prolonged shedding of influenza A(H1N1)v virus: two case reports from France 2009.
Influenza, Human
Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study.
Influenza, Human
Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation.
Influenza, Human
Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1).
Influenza, Human
Prospective Cohort Study Comparing Seasonal and H1N1(2009)-Pandemic Influenza Virus Illnesses in HIV-Infected Children During 2009.
Influenza, Human
Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
Influenza, Human
Protease-Activated Receptor 2 Agonist as Adjuvant: Augmenting Development of Protective Memory CD8 T Cell Responses Induced by Influenza Virosomes.
Influenza, Human
Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents.
Influenza, Human
Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
Influenza, Human
Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model.
Influenza, Human
Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.
Influenza, Human
Protection against influenza B virus infection by immunization with DNA vaccines.
Influenza, Human
Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
Influenza, Human
Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes.
Influenza, Human
Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.
Influenza, Human
Protection of chickens against challenge with virulent influenza A viruses of Hav5 subtype conferred by prior infection with influenza A viruses of Hsw1 subtype.
Influenza, Human
Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase.
Influenza, Human
Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective interfering virus.
Influenza, Human
Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.
Influenza, Human
Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model.
Influenza, Human
Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice.
Influenza, Human
Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Influenza, Human
Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
Influenza, Human
Protective Immunity Afforded by Inactivated H5N1 (NIBRG-14) Vaccine Requires Antibodies against Both Hemagglutinin and Neuraminidase in Mice.
Influenza, Human
Protective immunity against influenza H5N1 virus challenge in chickens by oral administration of recombinant Lactococcus lactis expressing neuraminidase.
Influenza, Human
Protective immunity and safety of a genetically modified influenza virus vaccine.
Influenza, Human
Protein-lipid interactions critical to replication of the influenza A virus during infection.
Influenza, Human
Proteinquakes in the Evolution of Influenza Virus Hemagglutinin (A/H1N1) under Opposing Migration and Vaccination Pressures.
Influenza, Human
Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity.
Influenza, Human
Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.
Influenza, Human
Pterocarpans and flavanones from Sophora flavescens displaying potent neuraminidase inhibition.
Influenza, Human
Pterodontic acid isolated from Laggera pterodonta suppressed RIG-I/NF-KB/STAT1/Type I interferon and programmed death-ligand 1/2 activation induced by influenza A virus in vitro.
Influenza, Human
Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.
Influenza, Human
Punctuated evolution of influenza virus neuraminidase (A/H1N1) under opposing migration and vaccination pressures.
Influenza, Human
Purification and properties of cloned Salmonella typhimurium LT2 sialidase with virus-typical kinetic preference for sialyl alpha 2----3 linkages.
Influenza, Human
Purification of antibodies to influenza A virus structural proteins by affinity chromatography, and their participation in haemagglutination-inhibition, neutralization and enzyme-linked immunosorbent assay.
Influenza, Human
Purification of haemagglutinin and neuraminidase from influenza virus strain 3QB and isolation of a peptide from an antigenic region of haemagglutinin.
Influenza, Human
Purification of neuraminidase from influenza viruses by affinity chromatography.
Influenza, Human
Purification of viral neuraminidase from inclusion bodies produced by recombinant Escherichia coli.
Influenza, Human
Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans.
Influenza, Human
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.
Influenza, Human
Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.
Influenza, Human
Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.
Influenza, Human
Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity.
Influenza, Human
QSAR model for predicting neuraminidase inhibitors of influenza A viruses (H1N1) based on adaptive grasshopper optimization algorithm.
Influenza, Human
QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors.
Influenza, Human
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
Influenza, Human
Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences.
Influenza, Human
Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry.
Influenza, Human
Quantification of influenza virus structural proteins using rocket immunoelectrophoresis.
Influenza, Human
Quantification of Multivalent Interactions between Sialic Acid and Influenza A Virus Spike Proteins by Single-Molecule Force Spectroscopy.
Influenza, Human
Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry.
Influenza, Human
Quantification of peramivir in dog plasma by liquid chromatography/tandem mass spectrometry employing precolumn derivatization.
Influenza, Human
Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.
Influenza, Human
Quantification of Viral Proteins of the Avian H7 Subtype of Influenza Virus: An Isotope Dilution Mass Spectrometry Method Applicable for Producing more Rapid Vaccines in the Case of an Influenza Pandemic.
Influenza, Human
Quantifying relative within-host replication fitness in influenza virus competition experiments.
Influenza, Human
Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.
Influenza, Human
Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
Influenza, Human
Quantitative predictions of binding free energy changes in drug-resistant influenza neuraminidase.
Influenza, Human
Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Influenza, Human
Radiation inactivation analysis of influenza virus reveals different target sizes for fusion, leakage, and neuraminidase activities.
Influenza, Human
Radioimmunoassay of influenza A virus haemagglutinin. I. Preparation and properties of radioactive 125I-labelled bromelain-released haemagglutinin.
Influenza, Human
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.
Influenza, Human
Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis.
Influenza, Human
Rapid detection of influenza A neuraminidase subtypes by cDNA amplification coupled to a simple DNA enzyme immunoassay.
Influenza, Human
Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR.
Influenza, Human
Rapid detection of the S247N neuraminidase mutation in influenza A(H1N1)pdm09 virus by one-step duplex RT-PCR assay.
Influenza, Human
Rapid diagnostics: the detection of neuraminidase activity as a technology for high-specificity targets.
Influenza, Human
Rapid Differentiation of Seasonal and Pandemic H1N1 Influenza through Proteotyping of Viral Neuraminidase with Mass Spectrometry.
Influenza, Human
Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.
Influenza, Human
Rapid identification and isolation of neuraminidase inhibitors from mockstrawberry (Duchesnea indica Andr.) based on ligand fishing combined with HR-ESI-Q-TOF-MS.
Influenza, Human
Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis.
Influenza, Human
Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay.
Influenza, Human
Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses.
Influenza, Human
Rapid molecular subtyping by reverse transcription polymerase chain reaction of the neuraminidase gene of avian influenza A viruses.
Influenza, Human
Rapid multiplex reverse transcription-PCR typing of influenza A and B virus, and subtyping of influenza A virus into H1, 2, 3, 5, 7, 9, N1 (human), N1 (animal), N2, and N7, including typing of novel swine origin influenza A (H1N1) virus, during the 2009 outbreak in Milwaukee, Wisconsin.
Influenza, Human
Rapid preparation of mutated influenza hemagglutinins for influenza virus pandemic prevention.
Influenza, Human
Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Influenza, Human
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.
Influenza, Human
Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues.
Influenza, Human
Rational design of potent sialidase-based inhibitors of influenza virus replication.
Influenza, Human
Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1.
Influenza, Human
Re-assorted pandemic (H1N1) 2009 influenza A virus discovered from pigs in Germany.
Influenza, Human
Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.
Influenza, Human
Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children.
Influenza, Human
Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
Influenza, Human
Reassortant Eurasian Avian-Like Influenza A(H1N1) Virus from a Severely Ill Child, Hunan Province, China, 2015.
Influenza, Human
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys.
Influenza, Human
Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature.
Influenza, Human
Reassortment and interspecies transmission of North American H6N2 influenza viruses.
Influenza, Human
Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.
Influenza, Human
Reassortment between Avian H5N1 and Human Influenza Viruses Is Mainly Restricted to the Matrix and Neuraminidase Gene Segments.
Influenza, Human
Reassortment patterns of avian influenza virus internal segments among different subtypes.
Influenza, Human
Recent Advances in Neuraminidase Inhibitor Development as Anti-influenza Drugs.
Influenza, Human
Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery.
Influenza, Human
Recent Advances in the Structure-based Design of Neuraminidase Inhibitors as Anti-influenza Agents.
Influenza, Human
Recent advances in the study, prevention, and treatment of infectious diseases.
Influenza, Human
Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches.
Influenza, Human
Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses.
Influenza, Human
Recent Patents on development of nucleic acid-based antiviral drugs against seasonal and pandemic influenza virus infections.
Influenza, Human
Recent progress and challenges in the discovery of new neuraminidase inhibitors.
Influenza, Human
Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range.
Influenza, Human
Receptor recognition mechanism of human influenza A H1N1 (1918), avian influenza A H5N1 (2004), and pandemic H1N1 (2009) neuraminidase.
Influenza, Human
Recognition of dual targets by a molecular beacon-based sensor: subtyping of influenza A virus.
Influenza, Human
Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes.
Influenza, Human
Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants.
Influenza, Human
Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus.
Influenza, Human
Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Influenza, Human
Recombinant Influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines.
Influenza, Human
Recombinant Influenza Virus Carrying the Respiratory Syncytial Virus (RSV) F85-93 CTL Epitope Reduces RSV Replication in Mice.
Influenza, Human
Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes.
Influenza, Human
Recombinant influenza-virus vaccines. IV. Segregation of antigenic and some biological properties of Influenza virus neuraminidase by recombination.
Influenza, Human
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Influenza, Human
Recombinant neuraminidase pseudotyped baculovirus: a dual vector for delivery of Angiotensin II peptides and DNA vaccine.
Influenza, Human
Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge.
Influenza, Human
Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro.
Influenza, Human
Recommendations for Treatment with Neuraminidase Inhibitors in Emergency Department Patients Infected with Influenza Virus.
Influenza, Human
Recommended hospital preparations for future cases and outbreaks of novel influenza viruses.
Influenza, Human
Reconstitution of functional influenza virus envelopes and fusion with membranes and liposomes lacking virus receptors.
Influenza, Human
Reconstructing the household transmission of influenza in the suburbs of Tokyo based on clinical cases.
Influenza, Human
Recovery of Drug-Resistant Influenza Virus from Immunocompromised Patients: A Case Series.
Influenza, Human
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.
Influenza, Human
Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity.
Influenza, Human
Reduced Effectiveness of Oseltamivir in Children Infected With Oseltamivir-Resistant Influenza A(H1N1) Viruses With His275Tyr Mutation.
Influenza, Human
Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice.
Influenza, Human
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
Influenza, Human
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.
Influenza, Human
Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
Influenza, Human
Reduction in Sympathetic Nerve Activity as a Possible Mechanism for the Hypothermic Effect of Oseltamivir, an Anti-influenza Virus Drug, in Normal Mice.
Influenza, Human
Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.
Influenza, Human
Reduction of neuraminidase activity exacerbates disease in 2009 pandemic influenza virus-infected mice.
Influenza, Human
Reductive amination assistance for quantification of oseltamivir phosphate and oseltamivir carboxylate by HPLC-MS/MS.
Influenza, Human
Redundancy of signal and anchor functions in the NH2-terminal uncharged region of influenza virus neuraminidase, a class II membrane glycoprotein.
Influenza, Human
Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants.
Influenza, Human
Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex.
Influenza, Human
Regulation of primary metabolic pathways in oyster mushroom mycelia induced by blue light stimulation: accumulation of shikimic Acid.
Influenza, Human
Relation of sialidase of influenza A viruses to viral particles as determined by electron microscopy.
Influenza, Human
Relationship between surface antigens of two variants of influenza A (H3N2) virus, as revealed by hemagglutination inhibition, kinetic neutralization, and neuraminidase inhibition.
Influenza, Human
Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.
Influenza, Human
Release of influenza virus neuraminidase by caseinase C of Streptomyces albus G.
Influenza, Human
Release of neuraminidase from hemagglutinins caused by treatment of influenza viruses with ether. (Brief report).
Influenza, Human
Remarkable Structural Diversity of N-Glycan Sulfation on Influenza Vaccines.
Influenza, Human
Remote-site stimulation of influenza antibodies in monkeys following intestinal stimulation.
Influenza, Human
REMOVED: Physicochemical properties of the potent influenza neuraminidase inhibitor, peramivir (BCX-1812).
Influenza, Human
Replacement of neuraminidase inhibitor susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.
Influenza, Human
Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro.
Influenza, Human
Replication of H9 influenza viruses in the human ex vivo respiratory tract, and the influence of neuraminidase on virus release.
Influenza, Human
Replication of influenza B virus: biological functions of viral neuraminidase.
Influenza, Human
Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant viruses.
Influenza, Human
Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity.
Influenza, Human
Rescue of synthetic RNAs into thogoto and influenza A virus particles using core proteins purified from Thogoto virus.
Influenza, Human
Residue 41 of the Eurasian avian-like swine influenza a virus matrix protein modulates virion filament length and efficiency of contact transmission.
Influenza, Human
Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza.
Influenza, Human
Resistance Mutation R292K Is Induced in Influenza A(H6N2) Virus by Exposure of Infected Mallards to Low Levels of Oseltamivir.
Influenza, Human
Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
Influenza, Human
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Influenza, Human
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Influenza, Human
Resistant influenza A viruses in children treated with oseltamivir: descriptive study.
Influenza, Human
Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study.
Influenza, Human
Respiratory syncytial virus envelope glycoprotein (G) has a novel structure.
Influenza, Human
Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.
Influenza, Human
Respiratory viral infections occurring after hematopoietic stem cell transplantation.
Influenza, Human
Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
Influenza, Human
Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine.
Influenza, Human
Response to: Recommendations for Treatment with Neuraminidase Inhibitors in Emergency Department Patients Infected with Influenza Virus.
Influenza, Human
Restricted infectivity of a human-Lineage H3N2 influenza A virus in pigs is hemagglutinin and neuraminidase gene dependent.
Influenza, Human
Retrospective Analysis of the Equine Influenza Virus A/Equine/Kirgizia/26/1974 (H7N7) Isolated in Central Asia.
Influenza, Human
Reverse design of an influenza neutralizing spiky nano-inhibitor with a dual mode of action.
Influenza, Human
Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009 H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory.
Influenza, Human
Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Influenza, Human
Review of the use of neuraminidase inhibitors for prophylaxis of influenza.
Influenza, Human
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations.
Influenza, Human
Review: Oseltamivir relieves symptoms but does not reduce hospitalizations in influenza.
Influenza, Human
Risk factors for poor outcomes and therapeutic strategies for seasonal and pandemic influenza.
Influenza, Human
RNA Polymerase II Inhibitors Dissociate Antigenic Peptide Generation from Normal Viral Protein Synthesis: A Role for Nuclear Translation in Defective Ribosomal Product Synthesis?
Influenza, Human
Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.
Influenza, Human
Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study.
Influenza, Human
Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses.
Influenza, Human
Role of phosphatidylserine exposure and sugar chain desialylation at the surface of influenza virus-infected cells in efficient phagocytosis by macrophages.
Influenza, Human
Role of Pneumococcal NanC in the Severe Disease of Streptococcus pneumoniae Superinfection with Influenza.
Influenza, Human
Role of proteases in the release of porcine epidemic diarrhea virus from infected cells.
Influenza, Human
Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study.
Influenza, Human
Role of secondary sialic acid binding sites in influenza N1 neuraminidase.
Influenza, Human
Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding.
Influenza, Human
Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.
Influenza, Human
Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses.
Influenza, Human
Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
Influenza, Human
Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection.
Influenza, Human
Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Influenza, Human
Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
Influenza, Human
Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children.
Influenza, Human
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Influenza, Human
Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.
Influenza, Human
Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model.
Influenza, Human
Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
Influenza, Human
Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.
Influenza, Human
SARS-CoV-2 and influenza: a comparative overview and treatment implications.
Influenza, Human
Scoring binding affinity of multiple ligands using implicit solvent and a single molecular dynamics trajectory: application to influenza neuraminidase.
Influenza, Human
Scoring ensembles of docked protein:ligand interactions for virtual lead optimization.
Influenza, Human
Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs.
Influenza, Human
Screening for H7N9 influenza A by matrix gene-based real-time reverse-transcription PCR.
Influenza, Human
Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza.
Influenza, Human
Screening of influenza mutations using base-specific cleavage and MALDI mass spectrometry.
Influenza, Human
Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines.
Influenza, Human
Seasonality of influenza A(H3N2) virus: a Hong Kong perspective (1997-2006).
Influenza, Human
Second sialic acid-binding site of influenza A virus neuraminidase: binding receptors for efficient release.
Influenza, Human
Second-generation nitazoxanide derivatives: thiazolides are effective inhibitors of the influenza A virus.
Influenza, Human
Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
Influenza, Human
Selection and analysis of antigenic variants of the neuraminidase of N2 influenza viruses with monoclonal antibodies.
Influenza, Human
Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes.
Influenza, Human
Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.
Influenza, Human
Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.
Influenza, Human
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
Influenza, Human
Selective solubilization of hemagglutinin and neuraminidase from influenza viruses.
Influenza, Human
Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Influenza, Human
Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.
Influenza, Human
Separation of hemagglutinin and neuraminidase from influenza virus membrane by column displacement electrophoresis (isotachophoresis) with preservation of their activities.
Influenza, Human
Sequence analysis of haemagglutinin and neuraminidase of H1N1 strain from a patient coinfected with Mycobacterium tuberculosis.
Influenza, Human
Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase.
Influenza, Human
Sequence and phylogenetic analyses of neuraminidase gene of Iranian seasonal influenza H1N1 viruses from 2005-2009 and corresponding vaccine strains.
Influenza, Human
Sequence and structure alignment of Paramyxoviridae attachment proteins and discovery of enzymatic activity for a morbillivirus hemagglutinin.
Influenza, Human
Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.
Influenza, Human
Sequence of the influenza A/Udorn/72 (H3N2) virus neuraminidase gene as determined from cloned full-length DNA.
Influenza, Human
Sequence of the neuraminidase gene of an avian influenza A virus (A/parrot/ulster/73, H7N1).
Influenza, Human
Sequence of the neuraminidase gene of influenza virus A/Tokyo/3/67 and previously uncharacterized monoclonal variants.
Influenza, Human
Sequence variation at the 3' end of the neuraminidase gene from 39 influenza type A viruses.
Influenza, Human
Sequential Influenza B Viral Load and Susceptibility in Children Treated with Oseltamivir and Zanamivir.
Influenza, Human
Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor.
Influenza, Human
Serological studies with purified neuraminidase antigens of influenza B viruses.
Influenza, Human
Serum amyloid p is a sialylated glycoprotein inhibitor of influenza a viruses.
Influenza, Human
Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic ?/California/07/2009(H1N1) influenza in healthy volunteers.
Influenza, Human
Severe abnormal behavior incidence after administration of neuraminidase inhibitors using the national database of medical claims.
Influenza, Human
Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016.
Influenza, Human
Shedding of the Pandemic Swine-Origin Influenza A Virus (H1N1) after Oseltamivir Administration.
Influenza, Human
Sheng Jiang San, a traditional multi-herb formulation, exerts anti-influenza effects in vitro and in vivo via neuraminidase inhibition and immune regulation.
Influenza, Human
Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors.
Influenza, Human
Shikimic Acid Production in Escherichia coli: From Classical Metabolic Engineering Strategies to Omics Applied to Improve Its Production.
Influenza, Human
Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus.
Influenza, Human
Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses.
Influenza, Human
Sialic acid is incorporated into influenza hemagglutinin glycoproteins in the absence of viral neuraminidase.
Influenza, Human
Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study.
Influenza, Human
Sialidase activity in rimantadine-resistant and -sensitive influenza A viruses.
Influenza, Human
Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication.
Influenza, Human
Sialidase and protease activities of commercial (RDE) receptor destroying enzyme products used for the (HI) hemagglutination inhibition test of influenza viruses]
Influenza, Human
Sialidase assay by luminescence in the low picomole-range of sialic acid. Its application to the measurement of this activity in influenza virus.
Influenza, Human
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
Influenza, Human
Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.
Influenza, Human
Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.
Influenza, Human
Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses.
Influenza, Human
Sialoglycoproteins that bind influenza A virus and resist viral neuraminidase in different animal sera.
Influenza, Human
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus.
Influenza, Human
Signal-processing-based bioinformatics approach for the identification of influenza A virus subtypes in Neuraminidase genes.
Influenza, Human
Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways.
Influenza, Human
Simple test for detection of virus neuraminidase and antineuraminidase using lectins (lectin-neuraminidase test system).
Influenza, Human
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes.
Influenza, Human
Simpterpenoid A, a Meroterpenoid with a Highly Functionalized Cyclohexadiene Moiety Featuring gem-Propane-1,2-dione and Methylformate Groups, from the Mangrove-Derived Penicillium simplicissimum MA-332.
Influenza, Human
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Influenza, Human
Simultaneous detection of hemagglutinin and neuraminidase genes of novel influenza A (H7N9) by duplex real-time reverse transcription polymerase chain reaction.
Influenza, Human
Simultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualization.
Influenza, Human
Simultaneous purification of influenza haemagglutinin and neuraminidase proteins by immunochromatography.
Influenza, Human
Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry.
Influenza, Human
Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE.
Influenza, Human
Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants.
Influenza, Human
Single Electrode Genosensor for Simultaneous Determination of Sequences Encoding Hemagglutinin and Neuraminidase of Avian Influenza Virus (AIV) type H5N1.
Influenza, Human
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus.
Influenza, Human
Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium.
Influenza, Human
Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.
Influenza, Human
Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.
Influenza, Human
Site-directed mutagenesis of a conserved hexapeptide in the paramyxovirus hemagglutinin-neuraminidase glycoprotein: effects on antigenic structure and function.
Influenza, Human
Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design.
Influenza, Human
Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism.
Influenza, Human
Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.
Influenza, Human
Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses.
Influenza, Human
Small Variations Between Species/Subtypes Attributed to Reassortment Evidenced from Polymerase Basic Protein 1 with Other Seven Proteins from Influenza A Virus.
Influenza, Human
SNP Discrimination by Tolane-Modified Peptide Nucleic Acids: Application for the Detection of Drug Resistance in Pathogens.
Influenza, Human
Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
Influenza, Human
Solid-phase synthesis of mimosine tetrapeptides and their inhibitory activities on neuraminidase and tyrosinase.
Influenza, Human
Soluble Proteins Induce Strong CD8+ T Cell and Antibody Responses through Electrostatic Association with Simple Cationic or Anionic Lipopeptides That Target TLR2.
Influenza, Human
Source of oseltamivir resistance due to single E119D and double E119D/H274Y mutations in pdm09H1N1 influenza neuraminidase.
Influenza, Human
Spatiotemporal analysis of the genetic diversity of seal influenza A(H10N7) virus, Northwestern Europe.
Influenza, Human
Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses.
Influenza, Human
Specific Sites of N-Linked Glycosylation on the Hemagglutinin of H1N1 Subtype Influenza A Virus Determine Sensitivity to Inhibitors of the Innate Immune System and Virulence in Mice.
Influenza, Human
Specific subtyping of influenza A virus using a recombinant hemagglutinin protein expressed in baculovirus.
Influenza, Human
Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates.
Influenza, Human
Specificity of the N1 and N2 sialidase subtypes of human influenza A virus for natural and synthetic gangliosides.
Influenza, Human
Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine.
Influenza, Human
Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal.
Influenza, Human
Spread of predominant neuraminidase and hemagglutinin co-mutations in the influenza A/H3N2 virus genome.
Influenza, Human
Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor.
Influenza, Human
Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
Influenza, Human
Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.
Influenza, Human
Stereoisomers of oseltamivir - synthesis, in silico prediction and biological evaluation.
Influenza, Human
Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents.
Influenza, Human
Stereospecific synthesis of a GS 4104 metabolite: determination of absolute stereochemistry and influenza neuraminidase inhibitory activity.
Influenza, Human
Stimulation of cytotoxic T cells by liposomes containing influenza virus or its components.
Influenza, Human
Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
Influenza, Human
Stimulation of phagocytosis of influenza virus-infected cells through surface desialylation of macrophages by viral neuraminidase.
Influenza, Human
Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase.
Influenza, Human
Strain identification of commercial influenza vaccines by mass spectrometry.
Influenza, Human
Strain-specific antiviral activity of iminosugars against human influenza A viruses.
Influenza, Human
Strain-specific differences in the effect of influenza A virus neuraminidase on vector-expressed hemagglutinin.
Influenza, Human
Strategies to alleviate original antigenic sin responses to influenza viruses.
Influenza, Human
Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus.
Influenza, Human
Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Influenza, Human
Structural and composition of the N2 neuraminidase of influenza virus. Effect of carbohydrate content on the validity of molecular weight estimations.
Influenza, Human
Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
Influenza, Human
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
Influenza, Human
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
Influenza, Human
Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus.
Influenza, Human
Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: receptor recognition is dependent on neuraminidase activity.
Influenza, Human
Structural and functional-group tuning in the design of neuraminidase inhibitors.
Influenza, Human
Structural basis for a class of nanomolar influenza A neuraminidase inhibitors.
Influenza, Human
Structural basis for influence of viral glycans on ligand binding by influenza hemagglutinin.
Influenza, Human
Structural basis of antigenic variation: studies of influenza virus neuraminidase.
Influenza, Human
Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.
Influenza, Human
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Influenza, Human
Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.
Influenza, Human
Structural characterization of the 1918 influenza virus H1N1 neuraminidase.
Influenza, Human
Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.
Influenza, Human
Structural modification on rupestonic acid leads to highly potent inhibitors against influenza virus.
Influenza, Human
Structural restrictions for influenza neuraminidase activity promote adaptation and diversification.
Influenza, Human
Structural similarity between binding sites in influenza sialidase and isocitrate dehydrogenase: implications for an alternative approach to rational drug design.
Influenza, Human
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Influenza, Human
Structure determination of the 1918 H1N1 neuraminidase from a crystal with lattice-translocation defects.
Influenza, Human
Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding.
Influenza, Human
Structure of an escape mutant of glycoprotein N2 neuraminidase of influenza virus A/Tokyo/3/67 at 3 A.
Influenza, Human
Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk.
Influenza, Human
Structure of an influenza neuraminidase-diabody complex by electron cryomicroscopy and image analysis.
Influenza, Human
Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle.
Influenza, Human
Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8-A resolution: implications for the catalytic mechanism.
Influenza, Human
Structure of the catalytic and antigenic sites in influenza virus neuraminidase.
Influenza, Human
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.
Influenza, Human
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution.
Influenza, Human
Structure of the lysosomal sphingolipid activator protein 1 by homology with influenza virus neuraminidase.
Influenza, Human
Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
Influenza, Human
Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
Influenza, Human
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
Influenza, Human
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
Influenza, Human
Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
Influenza, Human
Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: Molecular dynamics simulation and MM-GBSA calculation.
Influenza, Human
Structure-guided design of a novel class of benzyl-sulfonate inhibitors for influenza virus neuraminidase.
Influenza, Human
Studies on adaptation of influenza virus replicated at low temperature.IV. Sensitivity of neuraminidase and hemagglutinin to some proteolytic enzymes, detergents and chemical agents.
Influenza, Human
Studies on mutation lesions and physiology of fowl plague virus ts mutants.
Influenza, Human
Studies on neuraminidase from influenza virus A(H3N2) obtained by two procedures.
Influenza, Human
Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase.
Influenza, Human
STUDIES ON THE NEURAMINIDASE OF INFLUENZA VIRUS. II. ADDITIONAL PROPERTIES OF THE ENZYMES FROM THE ASIAN AND PR 8 STRAINS.
Influenza, Human
Studies on the Bioactive Flavonoids Isolated from Pithecellobium clypearia Benth.
Influenza, Human
Studies on the development of the charge heterogeneity of the influenza virus glycoproteins.
Influenza, Human
Studies on the inhibitory effect of concanavalin A on the neuraminidase activity of influenza A virus strains.
Influenza, Human
Studies on the neuraminidase of influenza virus. I. Separation and some properties of the enzyme from Asian and PR8 strains.
Influenza, Human
Studies on the role of myxovirus neuraminidase in virus-cell receptors interaction by means of direct determination of sialic acid split from cells. I. Experiments on influenza virus-RBC cell system.
Influenza, Human
Studies on the size, chemical composition, and partial sequence of the neuraminidase (NA) from type A influenza viruses show that the N-terminal region of the NA is not processed and serves to anchor the NA in the viral membrane.
Influenza, Human
Studies with cross-linking reagents on the oligomeric form of the paramyxovirus fusion protein.
Influenza, Human
Study of immunogenicity of recombinant proteins based on hemagglutinin and neuraminidase conservative epitopes of Influenza A virus.
Influenza, Human
Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines.
Influenza, Human
Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden.
Influenza, Human
Study of several genetic markers of two recombinants derived from autochthonous influenza virus type A strains.
Influenza, Human
Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy.
Influenza, Human
Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors.
Influenza, Human
Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin.
Influenza, Human
Study on the Mechanisms of Active Compounds in Traditional Chinese Medicine for the Treatment of Influenza Virus by Virtual Screening.
Influenza, Human
Subclinical influenza virus a infections in pigs exhibited at agricultural fairs, Ohio, USA, 2009-2011.
Influenza, Human
Substituent effects on the binding of natural product anthocyanidin inhibitors to influenza neuraminidase with mass spectrometry.
Influenza, Human
Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
Influenza, Human
Substrate Binding by the Second Sialic Acid-Binding Site of Influenza A Virus N1 Neuraminidase Contributes to Enzymatic Activity.
Influenza, Human
Substrate specificity and inhibitor studies of a membrane-bound ganglioside sialidase isolated from human brain tissue.
Influenza, Human
Substrate Specificity of Equine and Human Influenza A Virus Sialidase to Molecular Species of Sialic Acid.
Influenza, Human
Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase.
Influenza, Human
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.
Influenza, Human
Subtype identification of the novel A H1N1 and other human influenza A viruses using an oligonucleotide microarray.
Influenza, Human
Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin.
Influenza, Human
Successful treatment of influenza A virus by oseltamivir in bone marrow transplant recipients.
Influenza, Human
Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Influenza, Human
Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody.
Influenza, Human
Sulfation of the N-linked oligosaccharides of influenza virus hemagglutinin: temporal relationships and localization of sulfotransferases.
Influenza, Human
Superoxide anion production in influenza protein-activated NADPH oxidase of human polymorphonuclear leukocytes.
Influenza, Human
Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.
Influenza, Human
Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Influenza, Human
Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009-2010 H1N1 Pandemic: An Ecological Study.
Influenza, Human
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.
Influenza, Human
Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.
Influenza, Human
Suppression of influenza A virus nuclear antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids.
Influenza, Human
Suppression of influenza virus infection by an N-thioacetylneuraminic acid acrylamide copolymer resistant to neuraminidase.
Influenza, Human
Surface expression of influenza virus neuraminidase, an amino-terminally anchored viral membrane glycoprotein, in polarized epithelial cells.
Influenza, Human
Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets.
Influenza, Human
Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages.
Influenza, Human
Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014).
Influenza, Human
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Influenza, Human
Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Influenza, Human
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.
Influenza, Human
Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient.
Influenza, Human
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Influenza, Human
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.
Influenza, Human
Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
Influenza, Human
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Influenza, Human
Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs in vitro and in a Mouse Model.
Influenza, Human
Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Influenza, Human
Susceptibility of influenza viruses circulating in Western Saudi Arabia to neuraminidase inhibitors.
Influenza, Human
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Influenza, Human
Suspected Oseltamivir-induced bradycardia in a pediatric patient: A case report from King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia.
Influenza, Human
Swine Influenza Virus (H1N2) Characterization and Transmission in Ferrets, Chile.
Influenza, Human
Swine-origin influenza A (H3N2) virus infection in two children--Indiana and Pennsylvania, July-August 2011.
Influenza, Human
Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants.
Influenza, Human
Syncytium formation and HIV-1 replication are both accentuated by purified influenza and virus-associated neuraminidase.
Influenza, Human
Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro.
Influenza, Human
Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
Influenza, Human
Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.
Influenza, Human
Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
Influenza, Human
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
Influenza, Human
Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.
Influenza, Human
Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.
Influenza, Human
Synthesis and Biological Evaluation of NH2-Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors.
Influenza, Human
Synthesis and biological evaluation of oseltamivir analogues from shikimic acid.
Influenza, Human
Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors.
Influenza, Human
Synthesis and evaluation of a new series of substituted acyl(thio)urea and thiadiazolo [2,3-a] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Influenza, Human
Synthesis and evaluation of influenza A viral neuraminidase candidate inhibitors based on a bicyclo[3.1.0]hexane scaffold.
Influenza, Human
Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.
Influenza, Human
Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
Influenza, Human
Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.
Influenza, Human
Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase.
Influenza, Human
Synthesis and processing of the influenza virus neuraminidase, a type II transmembrane glycoprotein.
Influenza, Human
Synthesis of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified at the C-4 and C-9 positions and their behaviour towards sialidase from influenza virus and pig liver membrane.
Influenza, Human
Synthesis of a carbocyclic sialic acid analogue for the inhibition of influenza virus neuraminidase.
Influenza, Human
Synthesis of a cluster-forming sialylthio-D-galactose fullerene conjugate and evaluation of its interaction with influenza virus hemagglutinin and neuraminidase.
Influenza, Human
Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase.
Influenza, Human
Synthesis of an influenza neuraminidase inhibitor intermediate via a highly diastereoselective coupling reaction.
Influenza, Human
Synthesis of an STnThr analogue, structurally based on a TnThr antigen mimetic.
Influenza, Human
Synthesis of bromoindolyl 4,7-di-O-methyl-Neu5Ac: specificity toward influenza A and B viruses.
Influenza, Human
Synthesis of novel N-acetylneuraminic acid derivatives as substrates for rapid detection of influenza virus neuraminidase.
Influenza, Human
Synthesis of screening substrates for the directed evolution of sialic acid aldolase: towards tailored enzymes for the preparation of influenza A sialidase inhibitor analogues.
Influenza, Human
Synthesis of sialoglycopolypeptide for potentially blocking influenza virus infection using a rat alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm larvae.
Influenza, Human
Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase.
Influenza, Human
Synthesis of transition-state analogues as potential inhibitors of sialidase from Influenza virus.
Influenza, Human
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Influenza, Human
Synthetic inhibitors of Vibrio cholerae neuraminidase and neuraminidases of some influenza virus strains.
Influenza, Human
Synthetic long oligonucleotides to generate artificial templates for use as positive controls in molecular assays: drug resistance mutations in influenza virus as an example.
Influenza, Human
Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors.
Influenza, Human
Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus.
Influenza, Human
Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening.
Influenza, Human
Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
Influenza, Human
Systematic review of influenza resistance to the neuraminidase inhibitors.
Influenza, Human
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.
Influenza, Human
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
Influenza, Human
Systematic syntheses of influenza neuraminidase inhibitors: a series of carbosilane dendrimers uniformly functionalized with thioglycoside-type sialic acid moieties.
Influenza, Human
T cell mediated protection against lethal 2009 pandemic H1N1 influenza infection in a mouse model.
Influenza, Human
Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.
Influenza, Human
Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries.
Influenza, Human
Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: clinical and economic impact.
Influenza, Human
Targeting a cluster of arginine residues of neuraminidase to avoid oseltamivir resistance in influenza A (H1N1): a theoretical study.
Influenza, Human
Targets for the induction of protective immunity against influenza a viruses.
Influenza, Human
Targets of anti-influenza chemotherapy other than neuraminidase and proton pump.
Influenza, Human
Temperature-sensitive mutants of influenza A virus: evaluation of the A/Victoria/75-ts-1A2 temperature-sensitive recombinant virus in seronegative adult volunteers.
Influenza, Human
Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.
Influenza, Human
Tethered neuraminidase inhibitors that bind an influenza virus: a first step towards a diagnostic method for influenza.
Influenza, Human
Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase.
Influenza, Human
TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization.
Influenza, Human
The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.
Influenza, Human
The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site.
Influenza, Human
The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.
Influenza, Human
The 2nd sialic acid-binding site of influenza A virus neuraminidase is an important determinant of the hemagglutinin-neuraminidase-receptor balance.
Influenza, Human
The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.
Influenza, Human
The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery.
Influenza, Human
The accuracy and timeliness of neuraminidase inhibitor dispensing data for predicting laboratory-confirmed influenza.
Influenza, Human
The amino-terminal region of the neuraminidase protein from avian H5N1 influenza virus is important for its biosynthetic transport to the host cell surface.
Influenza, Human
The aminoshikimic acid pathway in bacteria as source of precursors for the synthesis of antibacterial and antiviral compounds.
Influenza, Human
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Influenza, Human
The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.
Influenza, Human
The antigenic relationship of the neuraminidase of Hong Kong virus to that of other human strains of influenza A virus.
Influenza, Human
The Appropriate Combination of Hemagglutinin and Neuraminidase Prompts the Predominant H5N6 Highly Pathogenic Avian Influenza Virus in Birds.
Influenza, Human
The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys.
Influenza, Human
The battle against influenza: The role of neuraminidase inhibitors in children.
Influenza, Human
The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.
Influenza, Human
The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling.
Influenza, Human
The bird flu: a new emerging pandemic threat and its pharmacological intervention.
Influenza, Human
The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance.
Influenza, Human
The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Influenza, Human
The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.
Influenza, Human
The complete neuraminidase of influenza A/PR8/34 (H0N1) is not detectable in its recombinant virus.
Influenza, Human
The complete nucleotide sequence of the influenza virus neuraminidase gene of A/NJ/8/76 strain and its evolution by segmental duplication and deletion.
Influenza, Human
The cotranslational maturation program for the type II membrane glycoprotein influenza neuraminidase.
Influenza, Human
The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology, and virulence in mice but is not essential for virus replication.
Influenza, Human
The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.
Influenza, Human
The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes.
Influenza, Human
The cytoplasmic tails of the influenza virus spike glycoproteins are required for normal genome packaging.
Influenza, Human
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
Influenza, Human
The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay.
Influenza, Human
The difference in thermostability of haemagglutinin and neuraminidase of two variants of influenza A2 virus.
Influenza, Human
The distribution of neuraminidase among the cytoplasmic membranes of HeLa cells infected with an influenza virus.
Influenza, Human
The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
Influenza, Human
The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.
Influenza, Human
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine.
Influenza, Human
The effect of ceruloplasmin on the multiplication and on some biological and physico-chemical characteristics of influenza virus A/PR8/34 (H0N1) cultivated in chorioallantoic membrane fragments. Note 2. Modifications occurring in the course of serial passages.
Influenza, Human
The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
Influenza, Human
The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
Influenza, Human
The effect of phospholipase C on influenza viruses: limited release of "soluble" V-antigens and of neuraminidase.
Influenza, Human
The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Influenza, Human
The effect of virus particle size on chemiluminescence induction by influenza and Sendai viruses in mouse spleen cells.
Influenza, Human
The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.
Influenza, Human
The emergency use authorization of peramivir IV: a view from the manufacturer.
Influenza, Human
The epitope regions of H1-subtype influenza A, with application to vaccine efficacy.
Influenza, Human
The equilibrium constant for the interaction between a monoclonal Fab fragment and an influenza virus neuraminidase.
Influenza, Human
The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle?
Influenza, Human
The evolutionary dynamics of influenza A virus adaptation to mammalian hosts.
Influenza, Human
The evolutionary genetics and emergence of avian influenza viruses in wild birds.
Influenza, Human
The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase.
Influenza, Human
The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Influenza, Human
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Influenza, Human
The H275Y Neuraminidase Mutation of the Pandemic A/H1N1 Influenza Virus Lengthens the Eclipse Phase and Reduces Viral Output of Infected Cells, Potentially Compromising Fitness in Ferrets.
Influenza, Human
The hemagglutinins of the human influenza viruses A and B recognize different receptor microdomains.
Influenza, Human
The Homologous Tripartite Viral RNA Polymerase of A/Swine/Korea/CT1204/2009(H1N2) Influenza Virus Synergistically Drives Efficient Replication and Promotes Respiratory Droplet Transmission in Ferrets.
Influenza, Human
The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.
Influenza, Human
The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors.
Influenza, Human
The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant.
Influenza, Human
The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
Influenza, Human
The impact of case diagnosis coverage and diagnosis delays on the effectiveness of antiviral strategies in mitigating pandemic influenza A/H1N1 2009.
Influenza, Human
The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
Influenza, Human
The importance of antineuraminidase antibodies in resistance to influenza A and immunologic memory for their synthesis.
Influenza, Human
The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients.
Influenza, Human
The influence of 150-cavity binders on the dynamics of influenza a neuraminidases as revealed by molecular dynamics simulations and combined clustering.
Influenza, Human
The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus.
Influenza, Human
The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging.
Influenza, Human
The influenza virus haemagglutinin gene: cloning and characterisation of a double-stranded DNA copy.
Influenza, Human
The influenza virus neuraminidase protein transmembrane and head domains have coevolved.
Influenza, Human
The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
Influenza, Human
The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
Influenza, Human
The Interferon-Inducible Proteoglycan Testican-2/SPOCK2 Functions as a Protective Barrier against Virus Infection of Lung Epithelial Cells.
Influenza, Human
The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase.
Influenza, Human
The Low-pH Resistance of Neuraminidase Is Essential for the Replication of Influenza A Virus in Duck Intestine following Infection via the Oral Route.
Influenza, Human
The low-pH stability discovered in neuraminidase of 1918 pandemic influenza A virus enhances virus replication.
Influenza, Human
The m segment of the 2009 pandemic influenza virus confers increased neuraminidase activity, filamentous morphology, and efficient contact transmissibility to a/puerto rico/8/1934-based reassortant viruses.
Influenza, Human
The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines.
Influenza, Human
The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines.
Influenza, Human
The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase.
Influenza, Human
The Medicinal Potential of Natural products for the Development of Anti-influenza Agents.
Influenza, Human
The N-terminal domain of PA from bat-derived influenza-like virus H17N10 has endonuclease activity.
Influenza, Human
The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity.
Influenza, Human
The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Influenza, Human
The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7N9) Influenza Virus in a Mouse Model of Acute Respiratory Distress Syndrome.
Influenza, Human
The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain.
Influenza, Human
The neuraminidases of the virulent and avirulent A/Chicken/Pennsylvania/83 (H5N2) influenza A viruses: sequence and antigenic analyses.
Influenza, Human
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
Influenza, Human
The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
Influenza, Human
The novel swine-origin H1N1 influenza A virus riddle: is it a domestic bird H1N1-derived virus?
Influenza, Human
The Origin of Novel Avian Influenza A (H7N9) and Mutation Dynamics for Its Human-To-Human Transmissible Capacity.
Influenza, Human
The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.
Influenza, Human
The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs.
Influenza, Human
The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
Influenza, Human
The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.
Influenza, Human
The polypeptides of influenza virus. 3. Identification of the hemagglutinin, neuraminidase and nucleocapsid proteins.
Influenza, Human
The position 4 nucleotide at the 3' end of the influenza virus neuraminidase vRNA is involved in temporal regulation of transcription and replication of neuraminidase RNAs and affects the repertoire of influenza virus surface antigens.
Influenza, Human
The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses.
Influenza, Human
The preparation and properties of 14 C-carboxamidomethylated subunits from A 2 -1957 influenza neuraminidase.
Influenza, Human
The R292K Mutation That Confers Resistance to Neuraminidase Inhibitors Leads to Competitive Fitness Loss of A/Shanghai/1/2013 (H7N9) Influenza Virus in Ferrets.
Influenza, Human
The rapid identification of human influenza neuraminidase N1 and N2 subtypes by ELISA.
Influenza, Human
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses.
Influenza, Human
THE REACTION OF RECEPTOR GLYCOPROTEIN WITH INFLUENZA VIRUS AND NEURAMINIDASE: AN ELECTRON MICROSCOPIC STUDY.
Influenza, Human
The reappearance of Victoria lineage influenza B virus in Brazil, antigenic and molecular analysis.
Influenza, Human
The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen.
Influenza, Human
The relative amount of an influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment.
Influenza, Human
The role of antigen in the localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia.
Influenza, Human
The role of antigenically different virus neuraminidases as structures implicated in receptor-binding processes.
Influenza, Human
The role of balanced haemagglutinin-neuraminidase activity in the genesis of transmissible neuraminidase inhibitor-resistant variants in seasonal and novel pandemic influenza A H1N1 viruses.
Influenza, Human
The role of cell surface expression of influenza virus neuraminidase in induction of human lymphocyte apoptosis.
Influenza, Human
The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
Influenza, Human
The role of hemagglutinin in the inhibition of neuraminidase activity of influenza virus by concanavalin A. Brief Report.
Influenza, Human
The Role of Neuraminidase Inhibitors in the Treatment and Prevention of Influenza.
Influenza, Human
The role of oseltamivir in the treatment and prevention of influenza in children.
Influenza, Human
The role of the neuraminidase of the infecting virus in the production of noninfectious (von Magnus) influenza virus.
Influenza, Human
The signal anchor and stem regions of the beta-galactoside alpha 2,6-sialyltransferase may each act to localize the enzyme to the Golgi apparatus.
Influenza, Human
The special neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1 influenza A virus.
Influenza, Human
The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody.
Influenza, Human
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.
Influenza, Human
The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.
Influenza, Human
The structures of Salmonella typhimurium LT2 neuraminidase and its complexes with three inhibitors at high resolution.
Influenza, Human
The subclass IgG responses of mice to influenza surface proteins formulated into liposomes.
Influenza, Human
The surface receptor is a major determinant of the cell tropism of influenza C virus.
Influenza, Human
The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
Influenza, Human
The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor.
Influenza, Human
The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.
Influenza, Human
The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.
Influenza, Human
The use of a radial haemolysis test for neuraminidase antibodies in the diagnosis of influenza A infection.
Influenza, Human
The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
Influenza, Human
The value of neuraminidase inhibition antibody titers in influenza seroepidemiology.
Influenza, Human
The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.
Influenza, Human
The virulence of the 1918 pandemic influenza virus: unraveling the enigma.
Influenza, Human
The war against influenza: discovery and development of sialidase inhibitors.
Influenza, Human
Theoretical analysis of the neuraminidase epitope of the Mexican A H1N1 influenza strain, and experimental studies on its interaction with rabbit and human hosts.
Influenza, Human
Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
Influenza, Human
Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.
Influenza, Human
Thiosialoside clusters using carbosilane dendrimer core scaffolds as a new class of influenza neuraminidase inhibitors.
Influenza, Human
Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.
Influenza, Human
Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin.
Influenza, Human
Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus.
Influenza, Human
Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.
Influenza, Human
Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.
Influenza, Human
Three-dimensional structure of a complex of antibody with influenza virus neuraminidase.
Influenza, Human
Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid.
Influenza, Human
Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.
Influenza, Human
Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase.
Influenza, Human
Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.
Influenza, Human
Three-dimensional structures of influenza virus neuraminidase-antibody complexes.
Influenza, Human
Three-dimensional window analysis for detecting positive selection at structural regions of proteins.
Influenza, Human
TMPRSS2 activates hemagglutinin-esterase glycoprotein of influenza C virus.
Influenza, Human
Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.
Influenza, Human
Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines.
Influenza, Human
Total synthesis of A-315675: a potent inhibitor of influenza neuraminidase.
Influenza, Human
Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
Influenza, Human
Towards the electrochemical diagnostic of influenza virus: development of a graphene-Au hybrid nanocomposite modified influenza virus biosensor based on neuraminidase activity.
Influenza, Human
Transfer of the hemagglutinin activity of influenza virus neuraminidase subtype N9 into an N2 neuraminidase background.
Influenza, Human
Transforming growth factor-?: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis.
Influenza, Human
Transmembrane domain of influenza virus neuraminidase, a type II protein, possesses an apical sorting signal in polarized MDCK cells.
Influenza, Human
Transmission of avian influenza A viruses among species in an artificial barnyard.
Influenza, Human
Transport of an influenza virus vaccine formulation (iscom) in Caco-2 cells.
Influenza, Human
Transport of influenza A virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42.
Influenza, Human
Transport of influenza virus envelope proteins from the Golgi complex to the apical plasma membrane in MDCK cells: pH-controlled interaction with a cycling receptor is not involved.
Influenza, Human
Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses.
Influenza, Human
Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results.
Influenza, Human
Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial.
Influenza, Human
Treatment and prophylaxis of influenza and the problem of resistance to neuraminidase inhibitors.
Influenza, Human
Treatment of community-acquired lower respiratory tract infections during pregnancy.
Influenza, Human
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.
Influenza, Human
Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
Influenza, Human
Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
Influenza, Human
Treatment of influenza with neuraminidase inhibitors: virological implications.
Influenza, Human
Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Influenza, Human
Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral.
Influenza, Human
Treatment of Severe Cases of Pandemic (H1N1) 2009 Influenza: Review of Antivirals and Adjuvant Therapy.
Influenza, Human
Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09.
Influenza, Human
Treatment with neuraminidase inhibitors for high-risk patients with influenza: why is adherence to antiviral treatment recommendations so low?
Influenza, Human
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Influenza, Human
Triabodies: single chain Fv fragments without a linker form trivalent trimers.
Influenza, Human
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Influenza, Human
Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice.
Influenza, Human
Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Influenza, Human
Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice.
Influenza, Human
Triplet entropy analysis of hemagglutinin and neuraminidase sequences measures influenza virus phylodynamics.
Influenza, Human
Trypanosoma vivax, stock V953: inhibitory effect of type A influenza virus anti-HAV8 serum on in vitro neuraminidase (sialidase) activity.
Influenza, Human
Two evolutionary strategies of influenza viruses to escape host non-specific inhibitors: alteration of hemagglutinin or neuraminidase specificity.
Influenza, Human
Type A influenza virus surveillance in free-flying, nonmigratory ducks residing on the eastern shore of Maryland.
Influenza, Human
Type A influenza viruses in waterfowl in Ohio and implications for domestic turkeys.
Influenza, Human
Type II transmembrane domain hydrophobicity dictates the cotranslational dependence for inversion.
Influenza, Human
Type- and subtype-specific RT-PCR assays for avian influenza A viruses (AIV).
Influenza, Human
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic.
Influenza, Human
U13???C13 mutation in the variable region of the NA gene 3'UTR of H9N2 influenza virus influences the replication and transcription of NA and enhances virus infectivity.
Influenza, Human
Ultrasensitive detection of drug-resistant pandemic 2009 (H1N1) influenza A virus by rare-variant-sensitive high-resolution melting-curve analysis.
Influenza, Human
Ultrasensitive detection of rare mutations using next-generation targeted resequencing.
Influenza, Human
Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
Influenza, Human
Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection.
Influenza, Human
Unique ability of pandemic influenza to downregulate the genes involved in neuronal disorders.
Influenza, Human
Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Influenza, Human
Unique Directional Motility of Influenza C Virus Controlled by Its Filamentous Morphology and Short-Range Motions.
Influenza, Human
Universal Anti-Neuraminidase Antibody Inhibiting all Influenza A Subtypes.
Influenza, Human
Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.
Influenza, Human
Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
Influenza, Human
Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Influenza, Human
Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines.
Influenza, Human
Unsaturated N-acetyl- D-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase.
Influenza, Human
Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
Influenza, Human
Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus.
Influenza, Human
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes.
Influenza, Human
Use of antiviral prophylaxis in influenza outbreaks in long term care facilities.
Influenza, Human
Use of HDEL-tagged Trichoderma reesei mannosyl oligosaccharide 1,2-alpha-D-mannosidase for N-glycan engineering in Pichia pastoris.
Influenza, Human
Use of hemagglutinin and neuraminidase amplicon-based high-throughput sequencing with variant analysis to detect co-infection and resolve identical consensus sequences of seasonal influenza in a university setting.
Influenza, Human
Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance.
Influenza, Human
Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09.
Influenza, Human
Use of lentiviral pseudotypes as an alternative to reassortant or Triton X-100-treated wild-type Influenza viruses in the neuraminidase inhibition enzyme-linked lectin assay.
Influenza, Human
Use of neuraminidase inhibitors for prophylaxis and treatment of pandemic influenza: summary of a Faculty of Public Health meeting.
Influenza, Human
Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies.
Influenza, Human
Use of Neuraminidase Inhibitors for Treatment of Severe Influenza: Times Are Changing.
Influenza, Human
Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
Influenza, Human
Use of oseltamivir in Dutch nursing homes during the 2004-2005 influenza season.
Influenza, Human
Use of Oseltamivir to control influenza complications after bone marrow transplantation.
Influenza, Human
Use of semiconductor-based oligonucleotide microarrays for influenza a virus subtype identification and sequencing.
Influenza, Human
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.
Influenza, Human
Use of the DNA flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses.
Influenza, Human
Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines.
Influenza, Human
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
Influenza, Human
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Influenza, Human
Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1: Preparation and characterization of disrupted virions.
Influenza, Human
Using common spatial distributions of atoms to relate functionally divergent influenza virus n10 and n11 protein structures to functionally characterized neuraminidase structures, toxin cell entry domains, and non-influenza virus cell entry domains.
Influenza, Human
Using Support Vector Machine (SVM) for Classification of Selectivity of H1N1 Neuraminidase Inhibitors.
Influenza, Human
Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.
Influenza, Human
Vaccination of an adolescent group with A (H3N2) + A(HSW1N1) bivaccine before an A (H1N1) influenza epidemic.
Influenza, Human
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice.
Influenza, Human
Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody.
Influenza, Human
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Influenza, Human
Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.
Influenza, Human
Vaccine-associated enhanced respiratory disease is influenced by hemagglutinin and neuraminidase in whole inactivated influenza virus vaccines.
Influenza, Human
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Influenza, Human
Validation of a fully integrated microfluidic array device for influenza a subtype identification and sequencing.
Influenza, Human
Variability among the neuraminidase, non-structural 1 and PB1-F2 proteins in the influenza A virus genome.
Influenza, Human
Variable ligand- and receptor-binding hot spots in key strains of influenza neuraminidase.
Influenza, Human
Variation in the divalent cation requirements of influenza a virus N2 neuraminidases.
Influenza, Human
Variation in the membrane-insertion and "stalk" sequences in eight subtypes of influenza type A virus neuraminidase.
Influenza, Human
Variation of influenza A (H3N2) viruses isolated in the G.D.R. during 1969-1980 epidemics.
Influenza, Human
VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
Influenza, Human
Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children.
Influenza, Human
Vigna radiata (L.) R. Wilczek Extract Inhibits Influenza A Virus by Targeting Viral Attachment, Penetration, Assembly, and Release.
Influenza, Human
Viral burden, inflammatory milieu and CD8+ T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study.
Influenza, Human
Viral infections in immunocompromised patients: what's new with respiratory viruses?
Influenza, Human
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).
Influenza, Human
Viral neuraminidase and cellular ectosialyltransferase in human lymphoblastoid cells infected with influenza virus.
Influenza, Human
Viral neuraminidase treatment of dendritic cells enhances antigen-specific CD8(+) T cell proliferation, but does not account for the CD4(+) T cell independence of the CD8(+) T cell response during influenza virus infection.
Influenza, Human
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.
Influenza, Human
Virological characterization of influenza H1N1pdm09 in Vietnam, 2010-2013.
Influenza, Human
Virological Methods for the Generation and Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.
Influenza, Human
Virological monitoring of influenza activity and influenza-like illness in the epidemic season 2011-2012 in poland.
Influenza, Human
Virological surveillance and phylogenetic analysis of the PB2 genes of influenza viruses isolated from wild water birds flying from their nesting lakes in Siberia to Hokkaido, Japan in autumn.
Influenza, Human
Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain.
Influenza, Human
Virosome engineering of colloidal particles and surfaces: bioinspired fusion to supported lipid layers.
Influenza, Human
Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function.
Influenza, Human
Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach.
Influenza, Human
Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.
Influenza, Human
Virus isolations from pet birds submitted for importation into the United States.
Influenza, Human
Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia.
Influenza, Human
Virus yield-reduction assays for interferon with the influenza virus neuraminidase assay.
Influenza, Human
Virus-cell interactions in the induction of type 1 interferon by influenza virus in mouse spleen cells.
Influenza, Human
Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Influenza, Human
Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
Influenza, Human
Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.
Influenza, Human
What adaptive changes in hemagglutinin and neuraminidase are necessary for emergence of pandemic influenza virus from its avian precursor?
Influenza, Human
What does the molecular structure of viruses tell us about viral functions?
Influenza, Human
What happened after the initial global spread of pandemic human influenza virus A (H1N1)? A population genetics approach.
Influenza, Human
WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008.
Influenza, Human
Whole-Genome Phylogenetic Analysis of Influenza B/Phuket/3073/2013-Like Viruses and Unique Reassortants Detected in Malaysia between 2012 and 2014.
Influenza, Human
Why was the 1918 influenza pandemic so lethal? The possible role of a neurovirulent neuraminidase.
Influenza, Human
Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry.
Influenza, Human
Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
Influenza, Human
Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Induces Gene Expression of Anti-viral Proteins and Inhibits Neuraminidase Activity.
Influenza, Human
Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
Influenza, Human
Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza.
Influenza, Human
Zanamivir for the prevention of influenza in adults and children age 5 years and older.
Influenza, Human
Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.
Influenza, Human
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
Influenza, Human
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
Influenza, Human
Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
Influenza, Human
ZstatFlu-II test: a chemiluminescent neuraminidase assay for influenza viral diagnostics.
Influenza, Human
Zwitterionic structures: from physicochemical properties toward computer-aided drug designs.
Influenza, Human
[A comparative study of the neuraminidase activity of 2 strains of influenza A2 type virus]
Influenza, Human
[A field experiment with neuraminidase influenza vaccine (author's transl)]
Influenza, Human
[A mechanism for limiting reproduction influenza A virus reassortants with incomplete functional compatibility of hemagglutinin and neuraminidase gene products]
Influenza, Human
[A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].
Influenza, Human
[A new influenza subunit vaccine: reactogenicity and antigenicity in comparison to split and whole virus vaccines (author's transl)]
Influenza, Human
[Ability of the influenza viruses and their envelope proteins to stimulates endothelial cells apoptosis in vitro].
Influenza, Human
[Accessing the features of surface neuraminidase (N1) of influenza A virus presenting on the platforms for anti-NA Abs screening].
Influenza, Human
[Action of antiviral substances on influenza viruses through the inhibition of neuraminidase production]
Influenza, Human
[Active neuraminidase constituents of Polygonum cuspidatum against influenza A(H1N1) influenza virus].
Influenza, Human
[Adaptation of freshly isolated strains of influenza viruses. I. Neuraminidase activity]
Influenza, Human
[An analysis on genetic characteristics of hemagglutinin and neuraminidase of type B influenza viruses in Guangzhou in 2006]
Influenza, Human
[An analysis on HA, NA gene/protein evolution and the variability of antigenicity sites of influenza A (H7N9) virus].
Influenza, Human
[An inhibitor of influenza virus neuraminidase isolated from Staphylococcus aureus]
Influenza, Human
[Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors]
Influenza, Human
[Analysis of etiology of four pandemic influenza A (H1N1) virus outbreaks in Shandong province, in 2009].
Influenza, Human
[Analysis of HA and NA Genes of Influenza A H1N1 Virus in Yunnan Province during 2009-2014].
Influenza, Human
[Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan].
Influenza, Human
[Analysis of the antigenic properties of strains of influenza virus that caused the epidemic of 1974-1975]
Influenza, Human
[Analysis of the antigenic specificity of the neuraminidases of influenza B viruses isolated in different years]
Influenza, Human
[Analysis of the Genetic Evolution of Neuraminidases of Influenza A Subtype N9 Viruses].
Influenza, Human
[Analysis of the Neuraminidase Amino Acid Sequences of Influenza A/H1N1pdm09, A/H3N2, and B Viruses Isolated from Influenza Patients in the 2013/14 Japanese Influenza Season].
Influenza, Human
[Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]
Influenza, Human
[Antigen production for the influenza virus neuraminidase activity inhibition reaction]
Influenza, Human
[Antigenic and biochemical analysis of the proteins of influenza virus A/USSR/Alma-Ata/13/81 with hemagglutinin H1]
Influenza, Human
[Antigenic and biological characteristics of influenza virus A strains isolated in 1985]
Influenza, Human
[Antigenic and biological characteristics of the A (H1N1) strains that caused the 1977--1978 epidemic]
Influenza, Human
[Antigenic characterization of hemagglutinin and neuraminidase in strains of influenza B virus isolated in Italy in the years 1962, 1967 and 1971]
Influenza, Human
[Antigenic properties of influenza virus type A inactivated by ultraviolet irradiation]
Influenza, Human
[Antigenic relationships of strains of the epidemic virus H1N1 isolated in November-December 1977 in the USSR to inluenza viruses of human and animal origin]
Influenza, Human
[Antigenic specificity of neuraminidase and structure of neuraminidase gene of influenza A(H1N1) serotype Hsw1N1 viruses isolated from man and animals]
Influenza, Human
[Antineuraminidase activity of inactivated influenza vaccines in elderly people]
Influenza, Human
[Antineuraminidase serum antibodies in natural influenza A and immunization with influenza vaccines]
Influenza, Human
[Antiviral agents in influenza--current recommendations. Anti-influenza agents are not a substitution for but a complement to vaccination]
Influenza, Human
[Assessment of the antiviral activity of 2HCl*H-His-Rim compound compared to the anti-influenza drug Arbidol for influenza caused by A/duck/Novosibirsk/56/05 (H5N1) (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae).]
Influenza, Human
[Assessment of the sensitivity of immunoprecipitation for the serodiagnosis of influenzal-bacterial pneumonias]
Influenza, Human
[Biological characteristics of influenza B viruses isolated during influenza B epidemics in 1976-1977]
Influenza, Human
[Biological consequences of breaks and reunions of disulfide bonds in influenza virus proteins]
Influenza, Human
[Biological properties and genome structure of recombinant strains of influenza A virus differing in their degree of human virulence]
Influenza, Human
[Biological properties of the agents of the influenza epidemic of 1972-1973 in Leningrad and other cities of the Soviet Union]
Influenza, Human
[Changes in cell membrane fluidity evoked by removal of influenza virus receptors with neuraminidase]
Influenza, Human
[Changes in the antigenicity of influenza virus neuraminidases due to various methods of preparation]
Influenza, Human
[Characteristics of complete genome of pandemic A/H1N1/2009 influenza virus isolated in Fujian Province, China].
Influenza, Human
[Characteristics of isolating influenza virus hemagglutinin using purified bromelin]
Influenza, Human
[Characteristics of measuring the neuraminidase activity and total protein in influenza virus preparations of an allantoic nature]
Influenza, Human
[Chemical Constituents from Leaves of Acanthus ilicifolius and Their Anti-influenza Virus Activities].
Influenza, Human
[Chitosan as an adjuvant for inactivated vaccines against avian influenza viruses]
Influenza, Human
[Circulation of the influenza A virus of H13 serosubtype among seagulls in the Northern Caspian (1979-1985)]
Influenza, Human
[Classical fowl plague and milder influenza infections in birds and mammals]
Influenza, Human
[Clinical Characteristics of Adult Onset RSV Infection During Two Consecutive Winter Seasons].
Influenza, Human
[Clinical evaluation of an immunochromatography test for rapid diagnosis of influenza]
Influenza, Human
[Clinical evaluation of rapid diagnostic kit detecting separately influenza A and B viruses]
Influenza, Human
[Cold-adapted strain of A/Leningrad/134/47/57 (H2N2)--a special attenuation donor of live influenza vaccine for children and the isolation of its recombinants]
Influenza, Human
[Comparative characteristics of epidemic strains of the influenza virus B isolated in 1980-1981]
Influenza, Human
[Comparative immunogenicity studies of cultural and peptide influenza vaccines].
Influenza, Human
[Comparative study of the RNA and proteins of antigenically similar human and animal influenza A viruses]
Influenza, Human
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Influenza, Human
[Comparison of the synonymous and non-synonymous substitution rates in various regions of the neuraminidase and hemagglutinin genes of the influenza A virus]
Influenza, Human
[Complement fixation, hemagglutination inhibition and neuraminidase inhibition reactions in the seroepidemiologic evaluation of an influenza A epidemic]
Influenza, Human
[Contribution of neuraminidase of influenza viruses to the sensitivity to the serum inhibitors and reassortment efficiency].
Influenza, Human
[Contribution to the antigenic study of influenza viruses in animals. I.--Neuraminidase of the equine influenza viruses (author's transl)]
Influenza, Human
[Contribution to the antigenic study of influenza viruses in animals. II.--Antibodies, antineuraminidase in horse: conditions of apparition and importance (author's transl)]
Influenza, Human
[Control of hospital infection of influenza: administration of neuraminidase inhibitor and cohort isolation of influenza patients]
Influenza, Human
[Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?]
Influenza, Human
[Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains].
Influenza, Human
[Design, synthesis and activity of a new type of influenza virus N1 neuraminidase inhibitors].
Influenza, Human
[Determination of standard conditions for the influenza virus neuraminidase inhibition test]
Influenza, Human
[Determination of the antigenic specificity of the neuraminidase of influenza viruses]
Influenza, Human
[Determination of the neuraminidase specificity of influenza A and B viruses using a modified lectin test]
Influenza, Human
[Development of a real-time reverse transcriptase PCR assay for detection of E119V amino acid change in neuraminidase of influenza A (H3N2) using the TaqMan-MGB probe].
Influenza, Human
[Differentiating markers of virulent and attenuated (cold-adapted) strains of influenza A virus]
Influenza, Human
[Disulfide maturation of the glycoproteins of influenza virus hemagglutinin and neuraminidase in infected cells]
Influenza, Human
[DNA vaccination via in vivo electroporation can elicit specific immune response against highly pathogenic H5N1 influenza viral structural antigens in mice]
Influenza, Human
[Effect of inhibitors of protein synthesis on neuraminidase and hemaglutinin of the influenza virus]
Influenza, Human
[Effect of low pH values on the infectivity and neuraminidase activity of human and animal strains of influenza virus type A]
Influenza, Human
[Effect of ultraviolet irradiation and formalin on the antigenic properties of the hemagglutinin and neuraminidase from the influenza A/-Victoria/72 virus]
Influenza, Human
[Effects of Maxing Shigan Decoction Decocted by Different Methods and Its Drug Containing Serum on Neuraminidase Activity of Influenza A Virus].
Influenza, Human
[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].
Influenza, Human
[Efficacy of inhaled zanamivir in the treatment and prevention of influenza]
Influenza, Human
[Elaboration of immune stimulating lipid-saponin subunit antigen carrier based on glycolipid monogalactosyldiacylglycerol from sea macrophytes and triterpene glycosides from Cucumaria japonica].
Influenza, Human
[Electrophoretic motility of RNA of recombinant influenza virus strains X-7 and X-9]
Influenza, Human
[Eluting and neuraminidase activity of inhibitor-resistant strains of influenza A2 virus]
Influenza, Human
[Enhancement of the immune response to surface antigens of the influenza B virus as a result of their covalent binding with a synthetic polymer carrier]
Influenza, Human
[Enzyme activity of the neuraminidase from various strains of the influenza A virus]
Influenza, Human
[Epidemiology, clinical picture, prevention and treatment of avian influenza.]
Influenza, Human
[Establishment of a cell-based 2009 H1N1 influenza neuraminidase inhibitors evaluation system].
Influenza, Human
[Etiological and molecular characteristics of pandemic influenza A (H1N1) virus during 2009-2010 in Shandong Province].
Influenza, Human
[Evaluation of Chinese traditional patent medicines against influenza virus in vitro].
Influenza, Human
[Evaluation of rapid detection kit using neuraminidase activity of influenza virus]
Influenza, Human
[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
Influenza, Human
[Evaluation of the rapid detection test for influenza A and B viruses using neuraminidase activity]
Influenza, Human
[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].
Influenza, Human
[Expression and mutagenesis of genes coding for protein synthesis in the influenza virus]
Influenza, Human
[Expression of NA of influenza virus and C3d fusion gene in replication-defective recombinant adenovirus and its immune efficacy analysis].
Influenza, Human
[Expression of neuraminidase gene of influenza virus H1N1 in baculovirus-expression system].
Influenza, Human
[Factors that cause a change in the antigenic structure of of the influenza virus hemagglutinin]
Influenza, Human
[Formation and protective functions of antibodies to neuraminidase of the influenza A virus]
Influenza, Human
[Formation of antibodies against neuraminidase of A/California/07/2009 (H1N1) influenza virus after immunization with live monovalent influenza vaccine].
Influenza, Human
[French general practitioners' perceptions and use of neuraminidase inhibitors during the pandemic A(H1N1)2009 influenza].
Influenza, Human
[Function of neuraminidase of influenza virus and anti influenza compounds by its inhibition]
Influenza, Human
[Generation high yield vaccine strain wholly derived from avian influenza viruses by reverse genetics]
Influenza, Human
[Genetic characteristics of hemagglutinin and neuraminidase of avian influenza A (H7N9) virus in Guizhou province, 2014-2017].
Influenza, Human
[Genetic characteristics of influenza A/H3N2 virus neuraminidase gene: a survey from 2010 to 2012 in Qinghai Province, China].
Influenza, Human
[Genetic markers and their interrelationships in influenza viruses. 3. The interrelationship between virulence and sensitivity to serum inhibitors, neuraminidase and eluting activity]
Influenza, Human
[Genetic variability of isolates of pandemic influenza A virus H1N1 isolated in Russia in 2009].
Influenza, Human
[Genetic variation of the hemagglutinin and neuraminidase of influenza B viruses isolated in Ningbo during 2010-2012].
Influenza, Human
[Genetic variation of the hemagglutinin and neuraminidase of influenza B viruses isolated in Zhejiang province during 1999 - 2010.]
Influenza, Human
[Genome composition analysis of the reassortant influenza viruses used in seasonal and pandemic live attenuated influenza vaccine].
Influenza, Human
[Heat sensitivity of haemagglutinin and neuraminidase of influenza A-strains]
Influenza, Human
[Heterogeneity of an influenza virus population in the manifestation of biological functions (author's transl)]
Influenza, Human
[High-yield reassortant virus containing hemagglutinin and neuraminidase genes of pandemic influenza A/Moscowl/01/2009 (H1N1) virus].
Influenza, Human
[Homologous and heterologous antibody induction in influenzal infection and immunization]
Influenza, Human
[Hypothermic Action of Oseltamivir Not Dependent on Its Anti-influenza Virus Action].
Influenza, Human
[Immunogenic activity of the influenza virus dependent on ne uraminidase (author's transl)]
Influenza, Human
[Immunogenic activity of the viral hemagglutinin and neuraminidase from live and inactivated influenza vaccines]
Influenza, Human
[Immunologic analysis of the antigenic properties of neuraminidase from drift-variants of influenza virus B]
Influenza, Human
[Immunologic characteristics of the neuraminidase of influenza A viruses serologic subtype 2]
Influenza, Human
[Immunologic response of mice to influenza virus strains with different neuraminidase activity]
Influenza, Human
[Immunological analysis of the surface components of the influenza virus similar to the serovariant A (Hsw1N1) isolated in Alma-Ata 1984-1985]
Influenza, Human
[In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
Influenza, Human
[Incidence of circulating antibodies against hemagglutinin and neuraminidase of influenza viruses in the epidemic season 1991/92 in Poland]
Influenza, Human
[Influence of normal inhibitors of allantoic fluid on hemagglutinin and sialidase in influenza virus]
Influenza, Human
[Influenza vaccination: antibodies against hemagglutinin and neuraminidase after administration of common Al2O3 and Al(OH)3 vaccines in man]
Influenza, Human
[Inhibition of the infectivity of enveloped viruses while retaining the specific biological activity of the viral proteins]
Influenza, Human
[Inhibitory activity of blood group antigens M and N in inhibition of virus hemagglutination reactions of influenza viruses]
Influenza, Human
[Isolation and crystallization of neuraminidase of the influenza B virus strain B/Leningrad/179/86]
Influenza, Human
[Isolation of preparative amounts of influenza virus neuraminidase by affinity chromatography]
Influenza, Human
[Isolation of surface antigens of influenza virus A/Hong Kong 1/68 (H3N2) by density gradient fractionation with a new carboxypolypeptidase (author's transl)]
Influenza, Human
[Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. II. Neuraminidase inhibiting antibodies (author's transl)]
Influenza, Human
[Maturation of the hemagglutinin and neuraminidase polypeptides of the influenza virus in infected cells]
Influenza, Human
[Mechanism of the modifying effect of neuraminidase of the influenza virus on the development of Rauscher leukemia]
Influenza, Human
[Mechanism underlying the anterograde transport of the influenza A virus transmembrane proteins and genome in host cytoplasm].
Influenza, Human
[Method for evaluating the neuraminidase activity of receptordestroying enzyme (RDE) compounds using the influenza virus.]
Influenza, Human
[Molecular and genetic analysis of influenza A viruses isolated in Russia, based on the neuraminidase and M2 protein gene sequence]
Influenza, Human
[Molecular characterization of human influenza viruses--a look back on the last 10 years]
Influenza, Human
[Molecular genetic analysis of a cold-adapted donor attenuation strain for a pediatric liver influenza vaccine, of recombinants based on it and of isolates from vaccinated children]
Influenza, Human
[Molecular genetic studies of the susceptibility of epidemic influenza A(H1N1) virus strains isolated in the 2006-2009 seasons in Russia to oseltamivir (Tamiflu)].
Influenza, Human
[Molecular mechanism of the variation of influenza virus hemagglutinin and neuraminidase, and their recognition of sialylglycoconjugates]
Influenza, Human
[Monitoring of the sensitivity of epidemic influenza virus strains isolated in Russia to etiotropic chemical agents]
Influenza, Human
[Mutations in the genes coding for hemagglutinin and neuraminidase in cold-adapted variants of the influenza virus A/Leningrad/134/57 (H2N2)]
Influenza, Human
[Mutations in the Neuraminidase Gene of the Epidemic Influenza Virus Strain Isolated in the 2012-2013 Season and Improvement of a PCR Assay for the Detection of Influenza Virus].
Influenza, Human
[Neuraminidase antigenic erythrocytic diagnostic agent in determining antibodies to the neuraminidase of influenza A viruses]
Influenza, Human
[Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically]
Influenza, Human
[Neuraminidase inhibitors and high risk of influenza complications: considered and widely-supported recommendations]
Influenza, Human
[Neuraminidase inhibitors in the general practice management of influenza: who prescribe them, when and with which results?]
Influenza, Human
[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]
Influenza, Human
[Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
Influenza, Human
[Neuraminidase-Inhibiting Antibodies to Avian Influenza Virus Subtypes in Human Sera (author's transl)]
Influenza, Human
[Oligonucleotide microarray for subtyping of influenza virus A neuraminidase].
Influenza, Human
[Oral neuraminidase inhibitor and an early warning system. New weapons against influenza]
Influenza, Human
[Oseltamivir resistance depends on the position 273 amino acid of neuraminidase of the type A influenza virus (H1N1), circulating in human population].
Influenza, Human
[Peculiarity of reassortment of current wild type influenza viruses with master donor viruses for live influenza vaccine].
Influenza, Human
[Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza]
Influenza, Human
[pH-dependent hemolytic and neuraminidase activity of remantadine-sensitive and -resistant variants of influenza virus]
Influenza, Human
[Pharmacoeconomic evaluation of oseltamivir as prophylaxis against influenza infection]
Influenza, Human
[Phylogenetic analysis based on hemagglutinin and neuraminidase genes between swine influenza virus and human influenza A/H3N2 virus strains isolated in Zhejiang province]
Influenza, Human
[Phylogenetic analysis of human/swine/avian gene reassortant H1N2 influenza A virus isolated from a pig in China]
Influenza, Human
[Prediction of inhibition of influenza virus neuraminidase of various strains by using a generalized model constructed using the data on the position of known ligands].
Influenza, Human
[Prediction of selective inhibition of neuraminidase from various influenza virus strains by potential inhibitors].
Influenza, Human
[Preliminary results of the comparative study of the hemagglutinin and neuraminidase antigens of strains of influenza virus A isolated in Leningrad in 1972-1973]
Influenza, Human
[Preparative isolation of neuraminidase from influenza viruses A (Singapore) 1-57, A (Hongkong) 1-68 and A (Leningrad) 99-71]
Influenza, Human
[Present data on influenza virus isolated from ducks and chickens, and influenza virus C. Anti-influenza drugs]
Influenza, Human
[Prevention and care management of influenza infection in institutions for the elderly and high risk groups]
Influenza, Human
[Primary structure of a full-size DNA copy of the influenza virus A/Kiev/59/79 (H1N1) neuraminidase gene]
Influenza, Human
[Primary structure of the full-length DNA copy of the neuraminidase gene in the avian influenza virus of the N7 antigenic subtype]
Influenza, Human
[Properties of current influenza A (H1N1) virus strains and the characteristics of the epidemics they induce]
Influenza, Human
[Properties of the influenza viruses isolated in 1976 from gulls in Astrakhan Province]
Influenza, Human
[Protective action of liposome-incorporated surface antigens of the influenza virus by different methods of immunization]
Influenza, Human
[Radioimmunological analysis of the neuraminidase of influenza virus subtype N2]
Influenza, Human
[Recognition mechanisms of receptor sialooligosaccharides by influenza virus hemagglutinin and sialidase]
Influenza, Human
[Reduction of the functional match of influenza virus hemagglutinin and neuraminidase after reassortation of genes]
Influenza, Human
[Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]
Influenza, Human
[Research progress in molecular determinants of neuraminidase, polymerase basic protein 2 and nonstructural protein 1, related to virulence of influenza A virus--a review].
Influenza, Human
[Respiratory viruses: epidemiologic features, clinical impact, and management]
Influenza, Human
[Role of carbohydrates in the manifestation of the hemagglutinating and neuraminidase activities of the influenza virus]
Influenza, Human
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections]
Influenza, Human
[Screening based on response surface methodology of multi-fractions traditional Chinese medicine with anti-influenza virus neuraminidase activity: take shuanghuanglian injection as an example].
Influenza, Human
[Sensitivity of influenza A2 virus to the non-specific alpha-inhibitor of Francis (the thermoresistance of the sialidase of several variants of influenza A2 virus)]
Influenza, Human
[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]
Influenza, Human
[Serological study of the neuraminidase activity of cholera filtrate and influenza virus]
Influenza, Human
[Significance of the neuraminidase inhibitor oseltamivir for the management of seasonal influenza]
Influenza, Human
[Speed and intensity of the immune response to the administration of inactivated influenza vaccine in relation to neuraminidase activity]
Influenza, Human
[Studies of adaptation of influenza viruses to their replication in low temperature. I. Biological properties]
Influenza, Human
[Studies on the adaptation of freshly isolated strains of influenza virus. 3. Comparative determination of neuraminidase activity]
Influenza, Human
[Studies on the determination of neuraminidase subtypes of influenza A viruses using ovomucoid]
Influenza, Human
[Study on immunogenicity of a recombinant adenovirus vaccine containing neuraminidase gene of H5N1 influenza virus (A/Anhui/1/2005) in mice]
Influenza, Human
[Study on the role of influenza viral neuraminidase in the early stages of the growth cycle by means fo quantitative hemadsorption (author's transl)]
Influenza, Human
[Successive isolation of hemagglutinin and neuraminidase from influenza virus A/Kransnodar/101/59 (H2N2) using bromelain]
Influenza, Human
[Susceptibility of human influenza A (H3N2) viruses to neuraminidase inhibitors isolated during 2011-2012 in China].
Influenza, Human
[Susceptibility of Influenza B Viruses to Neuraminidase Inhibitors Isolated during 2013-2014 Influenza Season in Mainland China].
Influenza, Human
[Synthesis, cloning and determination of the primary structure of a full-size DNA copy of the neuraminidase gene from influenza virus type A subtype H1N1]
Influenza, Human
[The 2001/2002 influenza season and the vaccine composition for the 2002/2003 season]
Influenza, Human
[The antigenic specificity of the hemagglutinin and neuraminidase of influenza B virus reproducing in different cell systems]
Influenza, Human
[The characteristics of various substrates in the determination of neuraminidase activity in influenza virus]
Influenza, Human
[The immunomodulating action of the surface antigens of the influenza A virus in experimental staphylococcal infection]
Influenza, Human
[The induction by the influenza virus A/H1N1 (serovariant Hsw1N1) and its glycoproteins of congenital pathology in mice]
Influenza, Human
[The mechanisms of the antiviral action of the bora-adamantane derivative preparation BG-12]
Influenza, Human
[The model of prediction of the inhibition of neuraminidases of influenza A and B based on a reduced set of energy terms].
Influenza, Human
[The nature of amino acid substitution in antigenic drift of hemagglutinin N3 and neuraminidase N2 from the influenza virus]
Influenza, Human
[The rapid detection kit based on neuraminidase activity of influenza virus]
Influenza, Human
[The receptor destroying enzyme of influenza viruses. The role of the receptor destroying enzyme on the budding and the release of influenza viruses from the host cells]
Influenza, Human
[The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand]
Influenza, Human
[The structure of carbohydrate chains of hemagglutinin and neuraminidase of influenza virus B/Leningrad/179/86]
Influenza, Human
[The structure of oligosaccharide fragments of glycoproteins from influenza virus A/Krasnodar/101/59/(H2N2)--heavy and light chains of hemagglutinin and neuraminidase]
Influenza, Human
[The threatening influenza pandemic: a national store ofoseltamivir is a waste of money]
Influenza, Human
[The use of the Soviet detergents dezintegron-O and dezintegron-B for the solubilization of influenza virus glycoproteins]
Influenza, Human
[Two recombinant adenovirus vaccine candidates containing neuraminidase Gene of H5N1 influenza virus (A/Anhui/1/2005) elicited effective cell-mediated immunity in mice]
Influenza, Human
[Vaccination of infants and schoolchildren with an influenza subunit vaccine (author's transl)]
Influenza, Human
[Variation of influenza viruses and their recognition of the receptor sialo-sugar chains]
Influenza, Human
[Various sides of influenza. Part II--epidemiology, influenza surveillance and prophylaxis]
Influenza, Human
[Virological impact of stalk region of neuraminidase in influenza A/Anhui/1/05 (H5N1) and A/Ohio/07/2009 (H1N1) viruses].
Insulin Resistance
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.
Insulin Resistance
Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis.
Insulin Resistance
Elastin-derived peptides, new regulators of insulin resistance development in mice.
Insulin Resistance
Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice.
Insulin Resistance
NEU3 sialidase as a marker of insulin sensitivity: Regulation by fatty acids.
Insulin Resistance
Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice.
Intellectual Disability
Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Intellectual Disability
Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Intellectual Disability
Neuraminidase deficiency in the original patient with the Goldberg syndrome.
Intestinal Diseases
Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease.
Keratitis
Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.
Kidney Failure, Chronic
Immune response to influenza vaccine in hemodialysis patients with chronic renal failure.
Kidney Neoplasms
Arylamidase from human renal cancer tissue in comparison with normal kidney and placental enzymes.
Laboratory Infection
Serum neuraminidase activity and hematological alterations in acute human Chagas' disease.
Leber Congenital Amaurosis
Altered expression of ?-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.
Leishmaniasis
The Role of Sialic Acids in the Establishment of Infections by Pathogens, With Special Focus on Leishmania.
Leishmaniasis, Visceral
Trans-sialidase neutralizing antibodies detection in Trypanosoma cruzi infected domestic reservoirs.
Leprosy, Lepromatous
Macrophage membrane alterations in leprosy as determined by change in sialic acid level.
Leprosy, Tuberculoid
Macrophage membrane alterations in leprosy as determined by change in sialic acid level.
Leukemia
Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
Leukemia
Characterization of a 75,000 mol. wt glycoprotein synthesized by guinea-pig T-lymphocytes: a possible homologue of Lyt-1 antigen.
Leukemia
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Leukemia
Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.
Leukemia
Human leukemia cells and mature lymphocytes induce platelet aggregation after removal of cell surface sialic acid.
Leukemia
Human T-cell leukemia-associated cell surface glycoprotein GP37: studies with three monoclonal antibodies and a rabbit antiserum.
Leukemia
Immune response-associated antigens on mouse leukemia cells. I. Detection of Ia antigens on GRSL cells.
Leukemia
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
Leukemia
Membrane type sialidase inhibits the megakaryocytic differentiation of human leukemia K562 cells.
Leukemia
Monoclonal antibodies to carbohydrate antigens in autologous bone marrow transplantation.
Leukemia
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
Leukemia
New monoclonal antibodies SN3, SN3a, and SN3b directed to sialic acid of glycoprotein on human non-T leukemia cells.
Leukemia
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Leukemia
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus.
Leukemia
Stimulation of sialidase activity during cell differentiation of human promyelocytic leukemia cell line HL-60.
Leukemia
The presence of anti-leukoblast antibodies as complement fixation agents in leukemia patients imm-nized with leukoblats treated with neuraminidase and radiation.
Leukemia
[Establishing a high-titer infectious avian influenza A (H5N1) pseudotyped viral particle].
Leukemia
[Evaluation of leukemogenic and immunogenic properties of leukemic cells modified by neuraminidase of non-cholera Vibrios on the model of Rauscher leukemia]
Leukemia
[Inhibitory effect of combined administration of neuraminidase and interferon in mice with Rauscher leukemia]
Leukemia
[Mechanism of the modifying effect of neuraminidase of the influenza virus on the development of Rauscher leukemia]
Leukemia L1210
Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
Leukemia, Erythroblastic, Acute
A novel series of anti-human glycophorin A (CD235a) antibodies defining five extra- and intracellular epitopes.
Leukemia, Erythroblastic, Acute
Biogenesis of glycophorin A in K562 human erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Evidence for sialidase activity in K 562 cells: inhibition by adriamycin treatment.
Leukemia, Erythroblastic, Acute
Monoclonal antibodies recognizing normal and retrovirus-transformed chicken hematopoietic cells.
Leukemia, Erythroblastic, Acute
Synthesis of sialoglycoconjugates during dimethylsulfoxide-induced erythrodifferentiation of friend leukemia cells.
Leukemia, Erythroblastic, Acute
Transport of surface mannose 6-phosphate receptor to the Golgi complex in cultured human cells.
Leukemia, Erythroblastic, Acute
Tunicamycin modulates binding of 125I-erythropoietin to Friend erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Sodium periodate stimulation of normal and chronic lymphocytic leukemia lymphocytes. II. The use of neuraminidase and trypsin to probe the nature of the response.
Leukemia, Megakaryoblastic, Acute
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regeneration of membrane sialic acid after neuraminidase treatment of leukemic granulocytes.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3.
Leukemia, Myeloid
FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis(x) hapten.
Leukemia, Myeloid
Monoclonal antibodies to carbohydrate antigens in autologous bone marrow transplantation.
Leukemia, Myeloid, Acute
Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
Leukemia, Myeloid, Acute
Detection of the granulocyte-specific antigen 3-fucosyl-N-acetyl-lactosamine on leukemic cells after neuraminidase treatment.
Leukemia, Myeloid, Acute
Monoclonal antibodies to carbohydrate antigens in autologous bone marrow transplantation.
Leukemia, Myeloid, Acute
Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris.
Leukemia, T-Cell
Neuraminidase enhances the initial steps of human T-cell leukemia virus type 1 replication.
Leukemoid Reaction
The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation.
Leukemoid Reaction
The Sialidase NanS Enhances Non-TcsL Mediated Cytotoxicity of Clostridium sordellii.
Leukostasis
Recruitment of murine neutrophils in vivo through endogenous sialidase activity.
Liver Abscess
Entamoeba histolytica: identification of a major surface antigen in liver abscess pus using a monoclonal antibody.
Liver Cirrhosis
A side effect of neuraminidase inhibitor in a patient with liver cirrhosis.
Liver Cirrhosis
Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.
Liver Cirrhosis
[Hemostatic studies on acquired abnormal fibrinogenemia in severe liver diseases and umbilical cord blood]
Liver Diseases
Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase.
Liver Diseases
Neuraminidase activity in human peripheral lymphocytes: its increase in chronic active liver disease.
Liver Diseases, Alcoholic
Effect of ethanol on sialidase activity of peripheral lymphocytes.
Liver Neoplasms
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.
Liver Neoplasms, Experimental
The impact of neuraminidase on apoptosis in cultures of blood lymphocytes isolated from rats bearing morris hepatoma.
Lung Neoplasms
An altered lectin binding to mucus glycoprotein in goblet cells of human tracheobronchial epithelium among former mustard-gas workers.
Lung Neoplasms
Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.
Lung Neoplasms
Expression of CD44 variants in lung cancer and its relationship to hyaluronan binding.
Lung Neoplasms
Monoclonal antibody that distinguishes small-cell lung cancer from non-small-cell lung cancer.
Lung Neoplasms
Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Lung Neoplasms
Noncatalytic Endosialidase Enables Surface Capture of Small-Cell Lung Cancer Cells Utilizing Strong Dendrimer-Mediated Enzyme-Glycoprotein Interactions.
Lung Neoplasms
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
Lung Neoplasms
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1.
Lupus Erythematosus, Systemic
Desialylation of dying cells with catalytically active antibodies possessing sialidase activity facilitates their clearance by human macrophages.
Lupus Erythematosus, Systemic
Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study.
Lupus Erythematosus, Systemic
[Immunoenzyme analysis and complement fixation test used for detection of antibodies to neuraminidase in patients with systemic lupus erythematosus]
Lupus Nephritis
Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.
Lupus Nephritis
The role of neuraminidase 1 (NEU1) in cytokine release by primary mouse mesangial cells and disease outcomes in murine lupus nephritis.
Lymphatic Metastasis
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Lymphatic Metastasis
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Lymphocytosis
Elevated Expression of NEU1 Sialidase in Idiopathic Pulmonary Fibrosis Provokes Pulmonary Collagen Deposition, Lymphocytosis, and Fibrosis.
Lymphogranuloma Venereum
Effect of polycations, polyanions and neuraminidase on the infectivity of trachoma-inclusin conjunctivitis and lymphogranuloma venereum organisms HeLa cells: sialic acid residues as possible receptors for trachoma-inclusion conjunction.
Lymphoma
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
Lymphoma
Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma.
Lymphoma
Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction.
Lymphoma
Combination of cytokine-induced killer and dendritic cells pulsed with antigenic ?-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
Lymphoma
Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: Regulatory roles of cell surface glycans.
Lymphoma
Glycosidases from the interferon producing lymphoid cell line Namalva and from three other lymphoid cell lines.
Lymphoma
Modification of blood-borne arrest properties of lymphoma cells by inhibitors of protein glycosylation suggests the existence of endogenous lectins.
Lymphoma
Neuraminidase "unmasking" and failure of trypsin to "unmask" -D-galactose-like sites on erythrocyte, lymphoma, and normal and virus-transformed fibroblast cell membranes.
Lymphoma
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes.
Lymphoma
Radiation-induced lymphoblastic lymphomas/leukemias and sarcomas of mice express conserved, immunogenic 44-kilodalton oncofetal antigen.
Lymphoma
Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma.
Lymphoma
Regulatory roles of cell surface sialylation in susceptibility to sphingomyelinase in human diffuse large B cell lymphoma.
Lymphoma
Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma.
Lymphoma
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia.
Lymphoma
Sialylation by ?-galactoside ?-2,6-sialyltransferase and N-glycans regulate cell adhesion and invasion in human anaplastic large cell lymphoma.
Lymphoma
The effect of specific glycosidases on Ricinus communis agglutinin binding to cell surfaces of two tumor sublines. A comparative flow-cytometric study.
Lymphoma
[The morphofunctional characteristics of lymphoma NK/LY cells treated with concanavalin A and Vibrio cholerae neuraminidase]
Lymphoma
[Transplantability and immunogenicity in mice of lymphoma Nk/Ly cells modified by concanavalin A and neuraminidase]
Lymphoma, B-Cell
Caspase-dependent drug-induced apoptosis is regulated by cell surface sialylation in human B-cell lymphoma.
Lymphoma, B-Cell
Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma.
Lymphoma, B-Cell
Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction.
Lymphoma, B-Cell
Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Lymphoma, B-Cell
Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B-cell lymphoma and its relevance to the patient's clinical outcome: lectin histochemistry and lectin blot analysis.
Lymphoma, B-Cell
Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma.
Lymphoma, B-Cell
Regulatory roles of cell surface sialylation in susceptibility to sphingomyelinase in human diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Caspase-dependent drug-induced apoptosis is regulated by cell surface sialylation in human B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
Lymphoma, Large B-Cell, Diffuse
Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B-cell lymphoma and its relevance to the patient's clinical outcome: lectin histochemistry and lectin blot analysis.
Lymphoma, Large B-Cell, Diffuse
Regulatory roles of cell surface sialylation in sphingolipid-induced cell death in human B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Regulatory roles of cell surface sialylation in susceptibility to sphingomyelinase in human diffuse large B cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
Sialylation by ?-galactoside ?-2,6-sialyltransferase and N-glycans regulate cell adhesion and invasion in human anaplastic large cell lymphoma.
Lymphoma, Non-Hodgkin
Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
Lymphoma, T-Cell
Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma.
Lysosomal Storage Diseases
A case of galactosialidosis with a homozygous Q49R point mutation.
Lysosomal Storage Diseases
A case of galactosialidosis with novel mutations of the protective protein/cathepsin a gene: diagnosis prompted by trophoblast vacuolization on placental examination.
Lysosomal Storage Diseases
A new heterozygous compound mutation in the CTSA gene in galactosialidosis.
Lysosomal Storage Diseases
A Turkish case of galactosialidosis with a new homozygous mutation in CTSA gene.
Lysosomal Storage Diseases
An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca2+ dynamics.
Lysosomal Storage Diseases
Cathepsin A deficiency in galactosialidosis: studies of patients and carriers in 16 families.
Lysosomal Storage Diseases
Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Lysosomal Storage Diseases
Chemical chaperone treatment for galactosialidosis: Effect of NOEV on ?-galactosidase activities in fibroblasts.
Lysosomal Storage Diseases
Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Lysosomal Storage Diseases
Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation.
Lysosomal Storage Diseases
Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Lysosomal Storage Diseases
Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Lysosomal Storage Diseases
Enhanced proteolytic degradation of normal beta-galactosidase in the lysosomal storage disease with combined beta-galactosidase and neuraminidase deficiency.
Lysosomal Storage Diseases
Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Lysosomal Storage Diseases
Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings.
Lysosomal Storage Diseases
Inheritance of an ovine lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase.
Lysosomal Storage Diseases
Inherited lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase in sheep.
Lysosomal Storage Diseases
Inhibition of CatA: an emerging strategy for the treatment of heart failure.
Lysosomal Storage Diseases
Intermittent enzyme replacement therapy prevents Neu1 deficiency.
Lysosomal Storage Diseases
Interspecific genetic complementation analysis of human and sheep fibroblasts with beta-galactosidase deficiency.
Lysosomal Storage Diseases
Isolated acid neuraminidase deficiency: a distinct lysosomal storage disease.
Lysosomal Storage Diseases
Lectin histochemistry of an ovine lysosomal storage disease with deficiencies of beta-galactosidase and alpha-neuraminidase.
Lysosomal Storage Diseases
Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation.
Lysosomal Storage Diseases
Molecular pathology of galactosialidosis in a patient affected with two new frameshift mutations in the cathepsin A/protective protein gene.
Lysosomal Storage Diseases
New mutations in two Dutch patients with early infantile galactosialidosis.
Lysosomal Storage Diseases
Optical coherence tomography features in a case of Type I sialidosis.
Lysosomal Storage Diseases
Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.
Lysosomal Storage Diseases
Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase.
Lysosomal Storage Diseases
Sialidosis type I presenting with a novel mutation and advanced neuroimaging features.
Lysosomal Storage Diseases
The cherry red spot-myoclonus syndrome: a newly recognized inherited lysosomal storage disease due to acid neuraminidase deficiency.
Lysosomal Storage Diseases
Transient neonatal hyperparathyroidism: a presenting feature of sialidosis type II.
Lysosomal Storage Diseases
Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.
Lysosomal Storage Diseases
Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients.
Lysosomal Storage Diseases
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1- deficient mice.
Lysosomal Storage Diseases
[Screening methods for the diagnosis of lysosomal storage disease]
Macular Degeneration
Comparison of lectin binding of drusen, RPE, Bruch's membrane, and photoreceptors.
Macular Degeneration
Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration.
Malaria
A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.
Malaria
Analysis of Erythrocyte Invasion Mechanisms of Plasmodium falciparum Clinical Isolates Across 3 Malaria-Endemic Areas in Ghana.
Malaria
Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens.
Malaria
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form.
Malaria
Erythrocyte invasion and merozoite ligand gene expression in severe and mild Plasmodium falciparum malaria.
Malaria
Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity.
Malaria
Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide.
Malaria
Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria.
Malaria
Merozoite surface protein-1 genetic diversity in Plasmodium malariae and Plasmodium brasilianum from Brazil.
Malaria
Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens.
Malaria
Plasmodium falciparum heterochromatin protein 1 marks genomic loci linked to phenotypic variation of exported virulence factors.
Malaria
Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection.
Malaria
Rapid antigen diversification through mitotic recombination in the human malaria parasite Plasmodium falciparum.
Malaria
T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.
Malaria
The human immune response against the major merozoite surface antigen of Plasmodium falciparum.
Malaria
The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area.
Malnutrition
Neonatal undernutrition and short term administration of hydrocortisone and thyroxine: effects on rat brain hydrolases.
Marek Disease
Adenovirus-mediated co-expression of the TRAIL and HN genes inhibits growth and induces apoptosis in Marek's disease tumor cell line MSB-1.
Marek Disease
Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase.
Mastocytoma
Induction of lymphocyte cytotoxicity by modification of the effector or target cells with periodate or with neuraminidase and galactose oxidase.
Mastocytoma
Some effects of neuraminidase on the in vitro interactions between spleen and mastocytoma (P815) cells.
Mastocytoma
The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes.
Measles
Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn's disease.
Measles
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Measles
Individual N-Glycans Added at Intervals along the Stalk of the Nipah Virus G Protein Prevent Fusion but Do Not Block the Interaction with the Homologous F Protein.
Measles
Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae.
Measles
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Measles
Secretion of immunoglobulins by human lymphocytes after infection with influenza virus.
Measles
Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating.
Melanoma
A correlation between cell surface sialyltransferase, sialic acid, and glycosidase activities and the implantability of B16 murine melanoma.
Melanoma
CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells.
Melanoma
Cell surface glycoproteins of human tumor cell lines: unusual characteristics of malignant melanoma.
Melanoma
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Melanoma
Correlation between plasminogen activator activity of immunizing tumor cells and complement-mediated cytotoxic antibodies secreted by cloned hybrid cells.
Melanoma
Cytotoxicity reactions during immunotherapy of melanoma with neuraminidase altered autologous tumor cells.
Melanoma
Differing lectin-binding patterns of malignant melanoma and nevocellular and Spitz nevi.
Melanoma
Electrophoretic profile of tyrosinase treated with neuraminidase in various subcellular fractions from mouse melanoma.
Melanoma
Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens.
Melanoma
Identification of a structure on human melanoma cells recognized by CTL exhibiting anomalous killer cell function.
Melanoma
Inhibition of b16 melanoma metastasis by administration of g(m3)- or gg3- liposomes - blocking adhesion of melanoma-cells to endothelial-cells (antiadhesion therapy) via inhibition of g(m3)-gg3cer or g(m3)-laccer interaction.
Melanoma
Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides.
Melanoma
Organization and neuraminidase susceptibility of sialic acid residues in human melanoma cell lines with different heterotransplantabilities in nude mice.
Melanoma
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Melanoma
Proceedings: Increase in antigenicity of syngeneic murine melanoma by neuraminidase.
Melanoma
Prolonged inhibition of protein and glycoprotein synthesis in tumor cells treated with muconomycin A.
Melanoma
Simultaneous silencing of lysophosphatidylcholine acyltransferases 1-4 by nucleic acid nanoparticles (NANPs) improves radiation response of melanoma cells.
Melanoma
The surface glycoproteins of a mouse melanoma growing in culture and as a solid tumor in vivo.
Melanoma, Experimental
Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
Melanoma, Experimental
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Melanoma, Experimental
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.
Memory Disorders
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Meningitis
Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein.
Meningitis
Effect of pneumococcal neuraminidase on canine cerebral cortex in experimental meningitis.
Meningitis
Experimental pneumococcal meningitis. Effects of neuraminidase and other pneumococcal constituents on cerebrospinal fluid in the intact dog.
Meningitis
The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease.
Meningitis, Bacterial
Purification and properties of a bacteriophage-induced endo-N-acetylneuraminidase specific for poly-alpha-2,8-sialosyl carbohydrate units.
Meningitis, Pneumococcal
A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs.
Meningitis, Pneumococcal
Experimental pneumococcal meningitis. Effects of neuraminidase and other pneumococcal constituents on cerebrospinal fluid in the intact dog.
Meningitis, Pneumococcal
Histochemical demonstration of neuraminidase effects in pneumococcal meningitis.
Meningitis, Pneumococcal
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Meningoencephalitis
The substantia nigra is a major target for neurovirulent influenza A virus.
Mesothelioma
Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.
Mesothelioma, Malignant
Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Mesothelioma, Malignant
Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125.
Metabolic Diseases
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
Metabolic Diseases
[Inherited metabolic diseases caused by the genetic defect of protective protein/cathepsin A and lysosomal sialidase]
Monoclonal Gammopathy of Undetermined Significance
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Mouth Neoplasms
"Aberrant sialylation plays a significant role in oral squamous cell carcinoma progression".
Mucocutaneous Lymph Node Syndrome
[Analysis of blood neuraminidase activities and free sialic acid, with special reference to the fluctuations in Kawasaki disease]
Mucolipidoses
A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine.
Mucolipidoses
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.
Mucolipidoses
A point mutation in the neu-1 locus causes the neuraminidase defect in the SM/J mouse.
Mucolipidoses
A sialidosis type I cohort and a quantitative approach to multimodal ophthalmic imaging of the macular cherry-red spot.
Mucolipidoses
Abnormal pattern electroretinograms with macular cherry-red spots: evidence for selective ganglion cell damage.
Mucolipidoses
Activated sialidase activity in transformed lymphocytes by Epstein-Barr (EB) virus of sialidosis type I (cherry-red spot-myoclonus syndrome).
Mucolipidoses
Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.
Mucolipidoses
Adult type mucolipidosis with beta-galactosidase and sialidase deficiency. Histological and biochemical studies.
Mucolipidoses
An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca2+ dynamics.
Mucolipidoses
Anesthetic management for mastectomy and total hysterectomy in a 49-year-old woman with type 1 sialidosis: a case report.
Mucolipidoses
Bergmeister's papilla in a young patient with type 1 sialidosis: case report.
Mucolipidoses
beta-Galactosidase deficient-type mucolipidosis: a complementation study of neuraminidase in somatic cell hybrids.
Mucolipidoses
Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Mucolipidoses
Cardiovascular involvement in alpha-n-acetyl neuraminidase deficiency syndromes (sialidosis type I and II).
Mucolipidoses
Carrier detection of sialidosis with partial beta-galactosidase deficiency by the assay of lysosomal sialidase in lymphocytes.
Mucolipidoses
Cell disease: desialylation of beta-hexosaminidase and its effect on uptake by fibroblasts.
Mucolipidoses
Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Mucolipidoses
Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.
Mucolipidoses
Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex.
Mucolipidoses
Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.
Mucolipidoses
Cleavage of oligosaccharides by rat kidney sialidase. Influence of substrate structure.
Mucolipidoses
Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Mucolipidoses
Clinical Exome Sequencing Enables Congenital Sialidosis Type II Diagnosis in Two Siblings Presenting with Unreported Clinical Features from a Rare Homozygous Sequence Variant p.(Tyr370Cys) in NEU1.
Mucolipidoses
Clinical presentation of congenital sialidosis in a patient with a neuraminidase gene frameshift mutation.
Mucolipidoses
Cloning of the cDNA and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse SM/J fibroblasts.
Mucolipidoses
Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis.
Mucolipidoses
Coincident neuraminidase and aspartoacylase deficiency associated with chromosome 9Q paracentric inversion in a Saudi family.
Mucolipidoses
Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases).
Mucolipidoses
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
Mucolipidoses
Compound heterozygous mutations in the neuraminidase 1 gene in type 1 sialidosis: A case report and review of literature.
Mucolipidoses
Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Mucolipidoses
Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition.
Mucolipidoses
Deficiency of methylumbelliferyl-alpha-Neuraminic acid neuraminidase in the sialidoses and mucolipidosis II and III.
Mucolipidoses
Degradation of gangliosides by the lysosomal sialidase requires an activator protein.
Mucolipidoses
Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients.
Mucolipidoses
Effect of the co-existence of galactosyl and phosphomannosyl residues on beta-hexosaminidase on the processing and transport of the enzyme in mucolipidosis I fibroblasts.
Mucolipidoses
Effects of neuraminidase of the phenotype of sindbis virus grown in fibroblasts obtained from patients with I-cell disease.
Mucolipidoses
Electrophoretic analysis of glycoprotein enzymes in the sialidoses and mucolipidoses.
Mucolipidoses
Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Mucolipidoses
Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Mucolipidoses
Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis.
Mucolipidoses
Exclusion of NEU1 and PPGB from candidate genes for a lysosomal storage disease in Japanese Black cattle
Mucolipidoses
Exclusion of NEU1 and PPGB from candidate genes for a lysosomal storage disease in Japanese Black cattle.
Mucolipidoses
Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression.
Mucolipidoses
Fundus autofluorescence and optical coherence tomography of a macular cherry-red spot in a case report of sialidosis.
Mucolipidoses
Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV. Subcellular distribution and and some properties.
Mucolipidoses
Ganglioside sialidase distribution in mucolipidosis type IV cultured fibroblasts.
Mucolipidoses
Generation of human induced pluripotent stem cells (hIPSCs) from sialidosis types I and II patients with pathogenic neuraminidase 1 mutations.
Mucolipidoses
Generation of novel induced pluripotent stem cell (iPSC) line from a 16-year-old sialidosis patient with NEU-1 gene mutation.
Mucolipidoses
Human beta-galactosidase and alpha-neuraminidase deficient mucolipidosis: genetic complementation analysis of the neuraminidase deficiency.
Mucolipidoses
I-cell disease. A hypothesis for the structure of the carbohydrate recognition site on beta-D-N-acetylhexosaminidase.
Mucolipidoses
I-cell disease: intracellular desialylation of lysosomal enzymes using an influenza virus vector.
Mucolipidoses
Identification of a homozygous deletion of the NEU1 gene in a patient with type II sialidosis presenting isolated fetal ascites and central nervous system hypoplasia.
Mucolipidoses
Increased levels of sialic acid associated with a sialidase deficiency in I-cell disease (mucolipidosis II) fibroblasts.
Mucolipidoses
Increased lung surfactant phosphatidylcholine in patients affected by lysosomal storage diseases.
Mucolipidoses
Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings.
Mucolipidoses
Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail.
Mucolipidoses
Km defect in neuraminidase of dysmorphic type sialidosis with and without beta-galactosidase deficiency.
Mucolipidoses
Lysosomal and plasma membrane ganglioside GM3 sialidases of cultured human fibroblasts. Differentiation by detergents and inhibitors.
Mucolipidoses
Lysosomal localization of Japanese medaka (Oryzias latipes) Neu1 sialidase and its highly conserved enzymatic profiles with human.
Mucolipidoses
Lysosomal multienzymatic complex-related diseases: a genetic study among Portuguese patients.
Mucolipidoses
Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly.
Mucolipidoses
Lysosomal sialidase deficiency in sialidosis with partial beta-galactosidase deficiency.
Mucolipidoses
Lysosomal sialidase deficiency: increased ganglioside content in autopsy tissues of a sialidosis patient.
Mucolipidoses
Metabolic disorders characterized by angiokeratomas and neurologic dysfunction.
Mucolipidoses
Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Mucolipidoses
Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.
Mucolipidoses
Mucolipidosis I (acid neuraminidase deficiency). Three cases and delineation of the variability of the phenotype.
Mucolipidoses
Mucolipidosis I, the cherry red-spot--myoclonus syndrome and neuraminidase deficiency.
Mucolipidoses
Multimodality evoked potentials and EEG in a case of cherry red spot-myoclonus syndrome and alpha-neuraminidase deficiency (sialidosis type 1)
Mucolipidoses
Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex.
Mucolipidoses
Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Mucolipidoses
Neuraminidase activity in the mucolipidoses (types I, II and III) and the cherry-red spot myoclonus syndrome.
Mucolipidoses
Neuraminidase deficiency and accumulation of sialic acid in lymphocytes in adult type sialidosis with partial beta-galactosidase deficiency.
Mucolipidoses
Neuraminidase in cultured fibroblasts and leucocytes of homozygotes and heterozygotes for the mucolipidosis II gene (I-cell disease).
Mucolipidoses
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Mucolipidoses
Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.
Mucolipidoses
Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes.
Mucolipidoses
Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis.
Mucolipidoses
Novel mutations in the neuraminidase-1 (NEU1) gene in two patients of sialidosis in India.
Mucolipidoses
Oligosaccharide and ganglioside neuraminidase activities of mucolipidosis I (sialidosis) and mucolipidosis II (I-cell disease) fibroblasts.
Mucolipidoses
Partial characterization and studies of fibroblast and leucocyte neuraminidase activities towards sialyloligosaccharides in adult sialidosis and mucolipidosis II and III.
Mucolipidoses
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Mucolipidoses
Prenatal diagnosis and fetal pathology in a Turkish family harboring a novel nonsense mutation in the lysosomal alpha-N-acetyl-neuraminidase (sialidase) gene.
Mucolipidoses
Prenatal diagnosis of sialidosis with combined neuraminidase and beta-galactosidase deficiency.
Mucolipidoses
Radioassay method of neuraminidase towards N-acetylneuraminosyl hexasaccharides.
Mucolipidoses
Sialidase in brain and fibroblasts in three patients with different types of sialidosis.
Mucolipidoses
Sialidosis and galactosialidosis: chromosomal assignment of two genes associated with neuraminidase-deficiency disorders.
Mucolipidoses
Sialidosis presenting as severe nonimmune fetal hydrops is associated with two novel mutations in lysosomal alpha-neuraminidase.
Mucolipidoses
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobilities of some enzymes known to be glycoproteins. 1. Clinical findings.
Mucolipidoses
Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobility of some enzymes known to be glycoproteins. II. Enzymes studies.
Mucolipidoses
Sialidosis type 2 (acid neuraminidase deficiency): clinical and biochemical features of a further case.
Mucolipidoses
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia.
Mucolipidoses
Sialidosis type I presenting with a novel mutation and advanced neuroimaging features.
Mucolipidoses
Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.
Mucolipidoses
Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient.
Mucolipidoses
Stimulation of GM3 ganglioside sialidase activity by an activator protein in patients with mucolipidosis IV and controls.
Mucolipidoses
Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan.
Mucolipidoses
Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis.
Mucolipidoses
The cherry red spot-myoclonus syndrome: a newly recognized inherited lysosomal storage disease due to acid neuraminidase deficiency.
Mucolipidoses
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
Mucolipidoses
The structure of sialyl-glycopeptides of the O-glycosidic type, isolated from sialidosis (mucolipidosis I) urine.
Mucolipidoses
The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis.
Mucolipidoses
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Mucolipidoses
Transient neonatal hyperparathyroidism: a presenting feature of sialidosis type II.
Mucolipidoses
Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A.
Mucolipidoses
Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.
Mucolipidoses
Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.
Mucolipidoses
Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients.
Mucolipidoses
Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1- deficient mice.
Mucolipidoses
[A new type of sialidosis with kidney disease: nephrosialidosis. I. Clinical, radiological and nosological study]
Mucolipidoses
[Genetic disorders of N-acetylneuraminic acid metabolism: sialurias and sialidoses]
Mucolipidoses
[Morphological and functional alterations of ear in lysosomal neuraminidase gene deficient mouse]
Mucolipidoses
[Mucolipidosis type I. Sialidosis due to alpha-2-6-neuraminidase deficiency with neurological symptoms]
Mucolipidoses
[Prenatal diagnosis of sialidosis, a defect of the lysosomal enzyme neuraminidase]
Mucolipidoses
[Studies on sialidosis and mucolipidosis. Properties of neuraminidase in cultured skin fibroblasts]
Mucolipidoses
[Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]
Mucopolysaccharidoses
Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds.
Mucopolysaccharidosis III
Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID.
Mucopolysaccharidosis III
Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre.
Mucopolysaccharidosis IV
An Autophagic Vacuolar Myopathy-Like Disorder Presenting as Non-Immune Hydrops in a Female Fetus.
Mucopolysaccharidosis IV
An autophagic vacuolar myopathy-like disorder presenting as nonimmune hydrops in a female fetus.
Mucopolysaccharidosis IV
Partial deficiency of glycoprotein neuraminidase in some patients with Morquio disease type A.
Multiple Myeloma
Antibody-mediated sialidase activity in blood serum of patients with multiple myeloma.
Multiple Myeloma
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Multiple Myeloma
Desialylation of dying cells with catalytically active antibodies possessing sialidase activity facilitates their clearance by human macrophages.
Mumps
A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.
Mumps
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
Mumps
Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity.
Mumps
Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein.
Mumps
Amino acid substitution at position 464 in the haemagglutinin-neuraminidase protein of a mumps virus Urabe strain enhanced the virus growth in neuroblastoma SH-SY5Y cells.
Mumps
Analysis of the fusion protein gene of the porcine rubulavirus LPMV: comparative analysis of paramyxovirus F proteins.
Mumps
Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines.
Mumps
Antigenic relationships between six genotypes of the small hydrophobic protein gene of mumps virus.
Mumps
Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T-cell and B-cell epitopes? An immunoinformatic analysis.
Mumps
Complete nucleotide sequence of the hemagglutinin-neuraminidase (HN) mRNA of mumps virus and comparison of paramyxovirus HN proteins.
Mumps
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein.
Mumps
Disruption of the Dimer-Dimer Interaction of the Mumps Virus Attachment Protein Head Domain, Aided by an Anion Located at the Interface, Compromises Membrane Fusion Triggering.
Mumps
Expression of mumps virus glycoproteins in mammalian cells from cloned cDNAs: both F and HN proteins are required for cell fusion.
Mumps
Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain.
Mumps
Functional properties and genetic relatedness of the fusion and hemagglutinin-neuraminidase proteins of a mumps virus-like bat virus.
Mumps
Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine.
Mumps
Genomic characterization of mumps viruses from a large-scale mumps outbreak in Arkansas, 2016.
Mumps
Hemagglutinin-neuraminidase (HN) amino acid alterations in neutralization escape mutants of Kilham mumps virus.
Mumps
Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.
Mumps
Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore.
Mumps
Identification of amino acids involved in the sialidase activity of the mumps virus hemagglutinin-neuraminadase protein.
Mumps
Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies.
Mumps
Large-Scale Expression and Purification of Mumps Virus Hemagglutinin-Neuraminidase for Structural Analyses and Glycan-Binding Assays.
Mumps
Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein.
Mumps
Molecular characterization of two genotypes of mumps virus circulated in Korea during 1998-2001.
Mumps
Mumps virus infection of the developing mouse brain--appearance of structural virus proteins demonstrated with monoclonal antibodies.
Mumps
Mumps Virus Matrix, Fusion, and Nucleocapsid Proteins Cooperate for Efficient Production of Virus-Like Particles.
Mumps
Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain.
Mumps
Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps virus Urabe vaccine strain.
Mumps
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.
Mumps
Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae.
Mumps
Postembedding immunocytochemical localization of paramyxovirus antigens by light and electron microscopy.
Mumps
Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence.
Mumps
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.
Mumps
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Mumps
Recombinant mumps viruses expressing the batMuV fusion glycoprotein are highly fusion-active and neurovirulent.
Mumps
Selection of mutants of mumps virus with altered structure and pathogenicity by passage in vivo.
Mumps
Simple detection of mumps virus neuraminidase and anti-neuraminidase with the lectin neuraminidase test.
Mumps
Simple differentiation method of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP).
Mumps
Simple test for detection of virus neuraminidase and antineuraminidase using lectins (lectin-neuraminidase test system).
Mumps
Single amino acid changes in the mumps virus HN and L proteins are associated with neuroattenuation.
Mumps
Single genotype of measles virus is dominant whereas several genotypes of mumps virus are co-circulating.
Mumps
Structural basis for Glycan-receptor binding by mumps virus hemagglutinin-neuraminidase.
Mumps
Structure-function analysis of two variants of mumps virus hemagglutinin-neuraminidase protein.
Mumps
The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease.
Mumps
Transcripts of simian virus 41 (SV41) matrix gene are exclusively dicistronic with the fusion gene which is also transcribed as a monocistron.
Mumps
Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains.
Mumps
[Epitope analysis of mumps virus proteins in a persistent cell culture infection: changes in the hemagglutinin-neuraminidase polypeptide]
Mumps
[Genetic characteristics on the small hydrophobic protein and hemagglutinin-neuraminidase genes of mumps virus in Yunnan province, China from 2007 to 2009.]
Muscular Dystrophies
Decreased surface sialic acid content is a sensitive indicator of muscle damage.
Myocardial Infarction
Serum total and lipid-bound sialic acid levels following acute myocardial infarction.
Myoclonus
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Myoclonus
Cherry-red spot myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult.
Myoclonus
Macular cherry-red spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies.
Myoclonus
Neuraminidase activity in the mucolipidoses (types I, II and III) and the cherry-red spot myoclonus syndrome.
Myoclonus
Neuraminidase in mucolipidoses: normal activity in frozen autopsy tissues from three patients with I-cell disease and adult beta-galactosidase deficiency.
Myoclonus
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Myoclonus
Sialidase (alpha-n-acetyl neuraminidase) deficiency: the enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia.
Myoclonus
[Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]
Myotonic Dystrophy
Carbohydrate composition of erythrocyte membranes and glycosidase activities in serum in patients with myotonic dystrophy, limb-girdle dystrophy and congenital myotonia.
Nasopharyngeal Carcinoma
A study of glycoconjugates in nasopharyngeal carcinoma with correlation to clinical transformation.
Neoplasm Metastasis
A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
Neoplasm Metastasis
A successful liver metastasis model in mice with neuraminidase treated colon 26.
Neoplasm Metastasis
Altered saccharide sequences in two groups of patients with metastatic prostatic carcinoma.
Neoplasm Metastasis
Clustering of murine lung metastases reflects fractal nonuniformity in regional lung blood flow.
Neoplasm Metastasis
Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
Neoplasm Metastasis
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4.
Neoplasm Metastasis
Defensive role of pleural mesothelial cell sialomucins in tumor metastasis.
Neoplasm Metastasis
Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.
Neoplasm Metastasis
ELEVATION OF LIVER NEURAMINIDASE ACTIVITY IN THE TUMOR-BEARING HOST. A BIOCHEMICAL APPROACH TO THE MECHANISM OF CANCER INVASION AND METASTASIS FORMATION.
Neoplasm Metastasis
Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Neoplasm Metastasis
Inhibition of b16 melanoma metastasis by administration of g(m3)- or gg3- liposomes - blocking adhesion of melanoma-cells to endothelial-cells (antiadhesion therapy) via inhibition of g(m3)-gg3cer or g(m3)-laccer interaction.
Neoplasm Metastasis
Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen-Friedenreich-specific monoclonal antibody.
Neoplasm Metastasis
LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway.
Neoplasm Metastasis
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Neoplasm Metastasis
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Neoplasm Metastasis
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression.
Neoplasm Metastasis
Significance of platelets in an antimetastatic activity of bacterial lipopolysaccharide.
Neoplasm Metastasis
Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA.
Neoplasm Metastasis
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Neoplasm Metastasis
Variation of leukocyte neuraminidase with Duke stage in patients with adenocarcinoma of the colon and rectum.
Neoplasm Metastasis
[Pseudomyxoma peritonei: a case with multiple metastases. Ultrastructural study and chemical analysis of the mucoid substance]
Neoplasm Metastasis
[Successful liver metastasis model with neuraminidase treated colon 26 adenocarcinoma via portal vein: preliminary report]
Neoplasms
A biotechnological tool for glycoprotein desialylation based on immobilized neuraminidase from Clostridium perfringens.
Neoplasms
A Chemical Biology Solution to Problems with Studying Biologically Important but Unstable 9-O-Acetyl Sialic Acids.
Neoplasms
A comparative study of peanut agglutinin and amaranthin binding to human urinary bladder tumor glycoproteins.
Neoplasms
A correlation between cell surface sialyltransferase, sialic acid, and glycosidase activities and the implantability of B16 murine melanoma.
Neoplasms
A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells.
Neoplasms
A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
Neoplasms
A novel method for detection of Newcastle disease virus with a fluorescent sialidase substrate.
Neoplasms
A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach.
Neoplasms
Accessibility of plasma membrane sialoglycoconjugates of Novikoff tumor cells to exogenous neuraminidase and proteases.
Neoplasms
Action of pronase and neuraminidase on the electrophoretic mobility of erythrocytes from normal cats and those with spontaneous tumours.
Neoplasms
Activation of host lymphocytes cultured with cancer cells treated with neuraminidase.
Neoplasms
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
Neoplasms
Adenovirus-mediated co-expression of the TRAIL and HN genes inhibits growth and induces apoptosis in Marek's disease tumor cell line MSB-1.
Neoplasms
Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis.
Neoplasms
Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene.
Neoplasms
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Neoplasms
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Neoplasms
Analysis of carbohydrate composition and sialidase activity in oral secretions of patients with tumors in the upper aerodigestive tract.
Neoplasms
Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.
Neoplasms
Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
Neoplasms
Antitumor immune response following injection of neuraminidase-treated sarcoma cells.
Neoplasms
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity.
Neoplasms
Approaches to effective tumor immunotherapy with cells and the enzyme neuraminidase.
Neoplasms
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Neoplasms
Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
Neoplasms
Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Neoplasms
Blocking of lymphokine activated killer (LAK) cell mediated cytotoxicity by cell-sized beads bearing tumor cell proteins.
Neoplasms
Cell surface modification in the treatment of experimental cancer: neuraminidase or concanavalin A.
Neoplasms
Cell-mediated immunity to tumor antigen in Marek's disease: susceptibility of effector cells to antithymocyte serum and enhancement of cytotoxic activity by Vibrio cholerae neuraminidase.
Neoplasms
Cells of rhabdomyosarcoma PA-23 tumor clones with high and low metastatic potential differ by activity of lysosomal sialidase.
Neoplasms
Cervicovaginal cytokines, sialidase activity and bacterial load in reproductive-aged women with intermediate vaginal flora.
Neoplasms
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Neoplasms
Characteristics of immunity induced by neuraminidase-treated lymphosarcoma cells in C3H (MTV+) and C3H (MTV-) mice.
Neoplasms
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
Neoplasms
Characterization of the lymphokine responsible for migration-inhibitory activity against tumor cells.
Neoplasms
Characterization of variant gamma-glutamyl transpeptidase produced by pancreatocholangiocarcinoma cell lines in a protein-free, chemically defined medium.
Neoplasms
CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.
Neoplasms
Chitinase 3-like-1 deficient donor splenocytes accentuated the pathogenesis of acute graft-versus-host diseases through regulating T cell expansion and type I inflammation.
Neoplasms
Clinical and experimental studies on inflammatory mediators during AIDS-associated Pneumocystis carinii pneumonia.
Neoplasms
Cloning, Expression, and Characterization of Capra hircus Golgi ?-Mannosidase II.
Neoplasms
Combination of cytokine-induced killer and dendritic cells pulsed with antigenic ?-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
Neoplasms
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Neoplasms
Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors.
Neoplasms
Combined immunostimulation (Propionibacterium avidum KP 40) and anticoagulation (heparin) prevents metastatic lung and liver colonization in mice.
Neoplasms
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4.
Neoplasms
Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer.
Neoplasms
Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase.
Neoplasms
Curcumin's effects on sialic acid level and sialidase activity in Ehrlich ascites tumor bearing mice.
Neoplasms
Cytotoxicity reactions during immunotherapy of melanoma with neuraminidase altered autologous tumor cells.
Neoplasms
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin.
Neoplasms
Design, Synthesis, Molecular Docking, and Biological Evaluation of New Emodin Anthraquinone Derivatives as Potential Antitumor Substances.
Neoplasms
Detection of 4-O-acetyl-N-glycolylneuraminyl lactosylceramide as one of tumor-associated antigens in human colon cancer tissues by specific antibody.
Neoplasms
Differences between the O-acetylated sialic acids of the epithelial mucins of human colonic tumors and normal controls: a correlative chemical and histochemical study.
Neoplasms
Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer.
Neoplasms
Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.
Neoplasms
Differences in the isoelectric focusing patterns of gamma-glutamyl transpeptidase from normal and cancerous rat mammary tissue.
Neoplasms
Differences in the peripheries of Lewis lung tumor cells growing in different sites in the mouse.
Neoplasms
Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody.
Neoplasms
Dimethyl sulfoxide (DMSO) increases expression of sialyl Lewis x antigen and enhances adhesion of human gastric carcinoma (NUGC4) cells to activated endothelial cells.
Neoplasms
Effect of enzymic removal of cell surface constituents on metastatic colonisation potential of mouse mammary tumour cells.
Neoplasms
Effect of neuraminidase and papain treatment on lectin-induced agglutination of Novikoff tumor cells and assay of lectin receptor activity of the glycopeptides released from the cell surface by papain.
Neoplasms
Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas.
Neoplasms
Effects of neuraminidase on apoptosis of blood lymphocytes in rats with implanted Morris tumor.
Neoplasms
ELEVATION OF LIVER NEURAMINIDASE ACTIVITY IN THE TUMOR-BEARING HOST. A BIOCHEMICAL APPROACH TO THE MECHANISM OF CANCER INVASION AND METASTASIS FORMATION.
Neoplasms
Elicitation of anti-viral cytotoxic T lymphocytes with purified viral and H-2 antigens.
Neoplasms
Endothelial cell membrane vesicles in the study of organ preference of metastasis.
Neoplasms
Establishment and characterization of Neu1-knockout zebrafish and its abnormal clinical phenotypes.
Neoplasms
Exosomes Secreted by HeLa Cells Shuttle on Their Surface the Plasma Membrane-Associated Sialidase NEU3.
Neoplasms
Experimental cancer immunotherapy: modification of tumor cells to increase immunogenicity.
Neoplasms
Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy.
Neoplasms
Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
Neoplasms
Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase.
Neoplasms
Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
Neoplasms
Failure of neuraminidase treatment to influence tumorigenicity or immunogenicity of syngeneically transplanted rat tumour cells.
Neoplasms
Flow cytometric evaluation of Thomsen-Friedenreich antigen on transitional cell cancer using monoclonal antibody.
Neoplasms
Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants.
Neoplasms
Functional studies of H-2k-like epitopes on DTIC treated and untreated L1210 (H-2d) clones.
Neoplasms
Glycosphingolipid expression on murine L1-fibrosarcoma cells: analysis of clonal in vivo and in vitro selected sublines with different lung colonisation potential.
Neoplasms
Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody.
Neoplasms
Histochemistry of mucin secreting components in mucoepidermoid and adenosquamous carcinoma of the oesophagus.
Neoplasms
Human macrophage responses to vaccine strains of influenza virus: synthesis of viral proteins, interleukin-1 beta, interleukin-6, tumour necrosis factor-alpha and interleukin-1 inhibitor.
Neoplasms
Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids.
Neoplasms
Identification of internally sialylated carbohydrate tumor marker candidates, including Sda/CAD antigens, by focused glycomic analyses utilizing the substrate specificity of neuraminidase.
Neoplasms
Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium.
Neoplasms
Immuno-therapy of methyl cholanthrene induced and spontaneous tumors in mice by use of tumor vaccine, neuraminidase and BCG.
Neoplasms
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Neoplasms
Immunological properties of and neuraminidase action on aminopeptidases and arylamidases in human normal and cancer tissues.
Neoplasms
Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.
Neoplasms
Immunotherapy of L1210 leukemia using neuraminidase-modified plasma membranes combined with chemotherapy.
Neoplasms
In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell - endothelial cell interaction.
Neoplasms
Increased binding and killing of neuraminidase-galactose oxidase-treated tumor cells by normal macrophages.
Neoplasms
Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma.
Neoplasms
Increased sialidase activity in serum of cancer patients: Identification of sialidase and inhibitor activities in human serum.
Neoplasms
Increased tumor immunity in mice inoculated with muconomycin A-treated B16 melanoma cells.
Neoplasms
Increased tumorigenicity of polyploid Ehrlich variants during growth in vivo is associated with karyotypic changes.
Neoplasms
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus.
Neoplasms
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Neoplasms
Inhibition of growth of rat Yoshida sarcoma using a neuraminidase treated tumour vaccine.
Neoplasms
Inhibition of tumor cell adhesion to lymph nodes by laminin-related peptide and neuraminidase.
Neoplasms
Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages: in vitro analysis of tumor cell binding and cytostasis.
Neoplasms
Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content.
Neoplasms
Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Neoplasms
Isolation and characterization of Rana catesbeiana lectin and demonstration of the lectin-binding glycoprotein of rodent and human tumor cell membranes.
Neoplasms
Lectin binding and expression of blood group-related antigens in carcinoma-in-situ and invasive carcinoma of urinary bladder.
Neoplasms
Lectin binding in murine tumour lines with different malignant characteristics. Effect of enzyme (pronase, neuraminidase) treatment on lectin labelling.
Neoplasms
LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway.
Neoplasms
Localization of glycoconjugates on the surfaces of pronephric tumor cells in vitro.
Neoplasms
Low mobility T cells in the peripheral blood of cancer patients: surface modification and mobility.
Neoplasms
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Neoplasms
Lymphoblastic lymphoma of convoluted or acid phosphatase type-a tumor of T precursor cells.
Neoplasms
Lymphocyte blastogenic response to autologous tumor cells pretreated with neuraminidase in patients with gastric carcinoma.
Neoplasms
Metastatic cancer cell attachment to endothelium is promoted by endothelial glycocalyx sialic acid degradation.
Neoplasms
Metastatic sarcoma. Combined surgical and immunotherapeutic approach. Neuraminidase treated tumor cells as tumor vaccine.
Neoplasms
Modification of sialidase levels and sialoglycoconjugate pattern during erythroid and erytroleukemic cell differentiation.
Neoplasms
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
Neoplasms
Modulation of K562 cells with sodium butyrate. Association of impaired NK susceptibility with sialic acid and analysis of other parameters.
Neoplasms
Modulation of the immunosuppressive effects of splenic macrophages in Fischer rats bearing adenocarcinoma 13762.
Neoplasms
Monoclonal antibodies to the human mammary gland: III. Monoclonal antibody LICR-LON-M18 identifies impaired expression and excess sialylation of the I(Ma) cell-surface antigen by primary breast carcinoma cells.
Neoplasms
MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 ?1,6-N-acetylglucosaminyltransferase and ?-galactoside ?2,3-sialyltransferase.
Neoplasms
NEU3 sialidase strictly modulates GM3 levels in skeletal myoblasts C2C12 thus favoring their differentiation and protecting them from apoptosis.
Neoplasms
Neuraminidase 1 regulates proliferation, apoptosis and the expression of Cadherins in mammary carcinoma cells.
Neoplasms
Neuraminidase effect on the growth of a transplantable nickel sulfide-induced rat tumor.
Neoplasms
Neuraminidase induced immunospecific destruction of transplantable experimental tumors.
Neoplasms
Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins.
Neoplasms
Neuraminidase-mediated augmentation of in vitro immune response of patients with solid tumors.
Neoplasms
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.
Neoplasms
Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent.
Neoplasms
Observations on the effect of neuraminidase on the distribution of intravenously injected Walker tumor cells in rats.
Neoplasms
On the lysosomal occurrence and the properties of the neuraminidase of rat liver and of Ehrlich ascites tumor cells.
Neoplasms
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.
Neoplasms
Oseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platform.
Neoplasms
Overexpression of lysosomal-type sialidase leads to suppression of metastasis associated with reversion of malignant phenotype in murine B16 melanoma cells.
Neoplasms
Overexpression of ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits glioma growth in vivo.
Neoplasms
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
Neoplasms
Phosphatidic acid-mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration.
Neoplasms
Plasma membrane-associated sialidase as a crucial regulator of transmembrane signalling.
Neoplasms
Plasma membrane-associated sialidase confers cancer initiation, promotion and progression.
Neoplasms
Platelet aggregating material (PAM) of two virally-transformed tumors: SV3T3 mouse fibroblast and PW20 rat renal sarcoma. Role of cell surface sialylation.
Neoplasms
Possible immunological action of Vibrio cholerae neuraminidase (VCN) in tumor immunotherapy.
Neoplasms
Possible mechanism of inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid: nucleoside conjugate.
Neoplasms
Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation.
Neoplasms
Pseudopsammoma bodies in meningotheliomatous meningioma. A histochemical and ultrastructural study.
Neoplasms
Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine.
Neoplasms
Recognition of a high molecular weight glycoprotein (HMW-GP) associated with rat colon cancer cells by rat monoclonal antibodies.
Neoplasms
Regeneration of the surface glycoproteins of a transplantable mouse tumor cell after treatment with neuraminidase.
Neoplasms
Regression of established methylcholanthrene tumors by intratumor injections of Vbrio cholerae neuraminidase.
Neoplasms
Related glycoproteins from normal secretory and malignant breast cells. Purification and initial comparative characterizations.
Neoplasms
Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia.
Neoplasms
Sequential combination chemoimmunotherapy for various malignant tumors: clinical and laboratory results.
Neoplasms
Sialic acid metabolism in rats undergoing chemically-induced mammary gland carcinogenesis in specific dietary states.
Neoplasms
Sialidase of Glaesserella parasuis Augments Inflammatory Response via Desialylation and Abrogation of Negative Regulation of Siglec-5.
Neoplasms
Sialyl Lewisx-dependent binding of human monocyte-derived dendritic cells to selectins.
Neoplasms
Sialyl ligands facilitate lymphocyte accumulation during inflammation of the central nervous system.
Neoplasms
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus.
Neoplasms
Sialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide.
Neoplasms
Sialylation of 3-Methylcholanthrene-Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting.
Neoplasms
Significance of glycosylation patterns of rat Zajdela ascitic hepatocellular carcinoma: effect of enzymatic removal of surface sialic acid on humoral response.
Neoplasms
Significance of platelets in an antimetastatic activity of bacterial lipopolysaccharide.
Neoplasms
Specific lysis of human colon tumor cells by antibodies to CEA and isoantigen A: dependence on rabbit serum or neuraminidase.
Neoplasms
Specific modifications of hepatoma cell-surface glycoproteins with enzymes. Effects on in vitro growth as investigated by the use of lectins.
Neoplasms
Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines.
Neoplasms
Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase.
Neoplasms
Systematic analysis of the human tumor cell binding to human vs. murine E- and P-selectin under static vs. dynamic conditions.
Neoplasms
T-antigen. A prognostic indicator of high recurrence index in transitional carcinoma of the bladder.
Neoplasms
Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase.
Neoplasms
The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
Neoplasms
The binding of peroxidase-labelled lectins to human breast epithelium. IV--The reactivity of breast carcinomas to peanut, soy bean and Dolichos biflorus agglutinins.
Neoplasms
The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
Neoplasms
The comparison of different rosette assay systems for the determination of T-lymphocytes in patients with solid malignant tumors.
Neoplasms
The effect of neuraminidase on the immunogenicity of the Landschütz ascites tumour: site and mode of action.
Neoplasms
The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes.
Neoplasms
The effect of trypsin and neuraminidase on the circulation and organ distribution of tumor cells.
Neoplasms
The effects of inflammatory mediators, polyamines, antisera, neuraminidase and heparin on the cell-surface charge of BP8 tumour cells and allergised lymph-node cells.
Neoplasms
The electrophoretic mobility of BP8 ascites tumour cells and allergized lymph-node cells after treatment with inflammatory mediators, ptomaines, polyamines, antisera and neuraminidase or heparin.
Neoplasms
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
Neoplasms
The impact of neuraminidase on apoptosis in cultures of blood lymphocytes isolated from rats bearing morris hepatoma.
Neoplasms
The in vitro growth, heterotransplantation, and immunohistochemical characterization of the blastemal component of Wilms' tumor.
Neoplasms
The influence of host immunity on the arrest of circulating cancer cells, and its modification by neuraminidase.
Neoplasms
The modification of the growth characteristics of the Landschütz ascites tumour by neuraminidase.
Neoplasms
The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling ?1 integrin internalization and recycling.
Neoplasms
The Reed-Sternberg cell/lymphocyte rosette. I. Properties of rosettes formed between Hodgkin's cell lines and allogeneic lymphocytes.
Neoplasms
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.
Neoplasms
Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guérin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
Neoplasms
Thomsen-Friedenreich antigen in bladder cancer tissues detected by monoclonal antibody.
Neoplasms
Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: a possible marker of recurrence.
Neoplasms
Thomsen-Friedenreich-related antigen in non-neoplastic ureter urothelium and transitional cell tumours of the urinary bladder. An immunohistochemical study employing the monoclonal antibody 49H.8.
Neoplasms
Tissue distribution, immunochemical characterization, and biosynthesis of 47D10, a tumor-associated surface glycoprotein.
Neoplasms
Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma.
Neoplasms
Transmembrane Peptides as Inhibitors of Protein-Protein Interactions: An Efficient Strategy to Target Cancer Cells?
Neoplasms
Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells.
Neoplasms
Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guérin and neuraminidase.
Neoplasms
Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors.
Neoplasms
Tumor therapy of neoplastic diseases with tumor cells and neuraminidase: experimental studies on chessboard vaccination in transplantation tumors.
Neoplasms
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Neoplasms
Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression.
Neoplasms
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.
Neoplasms
Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression.
Neoplasms
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Neoplasms
Use of the lectin from Amaranthus caudatus as a histochemical probe of proliferating colonic epithelial cells.
Neoplasms
Variation of leukocyte neuraminidase with Duke stage in patients with adenocarcinoma of the colon and rectum.
Neoplasms
Vase mini-exon usage by NCAM is not restricted to tumours of neuroectodermal origin.
Neoplasms
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
Neoplasms
Visualization of sialidase activity in Mammalian tissues and cancer detection with a novel fluorescent sialidase substrate.
Neoplasms
[Action of x-rays and neuraminidase on pinocytotic activity and microtubule-microfilament system of Ehrlich ascites tumor cells in monolayer culture (author's transl)]
Neoplasms
[Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene]
Neoplasms
[Distribution of lectin-receptors in normal, dysplastic and neoplastic cervical epithelium]
Neoplasms
[Effect of neuraminidase and x-rays (2 Gy and 8 Gy) on microvilli and membrane invaginations of Ehrlich ascites tumor cells in monolayer culture]
Neoplasms
[Effects of treatment with neuraminidase on the immunogenicity of ATPC tumor cells]
Neoplasms
[Expression of a cloned hemagglutinin-neuraminidase gene from Newcastle disease virus in murine myeloma cells]
Neoplasms
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
Neoplasms
[Lymphocyte cytotoxicity against autologous tumor cells and the effect of interferon-beta on their activities. (1) Evaluation by modification of target tumor cells]
Neoplasms
[MODIFICATIONS INDUCED BY NEURAMINIDASE ON THE ALPHA-1 GLYCOPROTEIN ISOLATED FROM YOSHIDA ACITES TUMOR.]
Neoplasms
[Modulating effect of immunotherapy with modified tumor cells in transplantable lymphoma]
Neoplasms
[Multidimensional Analysis of Hippocampal Excitatory Neurotransmission and Development of Analytical Tools for Glycans].
Neoplasms
[Sensitivity of human glial tumor cells of different grade of anaplasia to lysis due to natural killers depending on some characteristics of the glycoprotein structure of tumor cell membranes]
Neoplasms
[The effect of vibrio-cholerae neuraminidase (VCN) on the NK activity of peripheral blood lymphocytes in patients with cancer]
Neoplasms
[Use of the enzyme neuraminidase for immunotherapeutic treatment of chemically induced carcinogenesis]
Nephritis
Extracellular neuraminidase production of streptococci associated with acute nephritis.
Nephritis
Histological evidence of neuraminidase involvement in acute nephritis: desialized leukocytes infiltrate the kidney in acute post-streptococcal glomerulonephritis.
Nephritis
Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis.
Nephritis
The role of neuraminidase in TLR4-MAPK signalling and the release of cytokines by lupus serum-stimulated mesangial cells.
Nephrosis
Altered glomerular permeability as a result of focal detachment of the visceral epithelium.
Nephrotic Syndrome
Effects of the aminonucleoside of puromycin on glomerular epithelial cells in vitro.
Nephrotic Syndrome
Renal neuraminidase. Characterization in normal rat kidney and measurement in experimentally induced nephrotic syndrome.
Nervous System Diseases
Molecular characterization of the hemagglutinin-neuraminidase gene of porcine rubulavirus isolates associated with neurological disorders in fattening and adult pigs.
Nervous System Diseases
Molecular heterogeneity in human beta-galactosidase and neuraminidase deficiency.
Neurilemmoma
Lectin histochemistry of normal and neoplastic peripheral nerve sheath. 2. Lectin binding patterns of schwannoma and neurofibroma.
Neuroblastoma
Activation of acetyl- and butyrylcholinesterase by enzymatic removal of sialic acid from intact neuroblastoma and astroblastoma cells in culture.
Neuroblastoma
Amino acid substitution at position 464 in the haemagglutinin-neuraminidase protein of a mumps virus Urabe strain enhanced the virus growth in neuroblastoma SH-SY5Y cells.
Neuroblastoma
Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines.
Neuroblastoma
Density-dependent changes in gangliosides and sialidase activity of murine neuroblastoma cells.
Neuroblastoma
Desialylation of extracellular GD1a-neoganglioprotein suggests cell surface orientation of the plasma membrane-bound ganglioside sialidase activity in human neuroblastoma cells.
Neuroblastoma
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin.
Neuroblastoma
Differential functional relevance of a plasma membrane ganglioside sialidase in cholinergic and adrenergic neuroblastoma cell lines.
Neuroblastoma
Effects of cell surface ganglioside sialidase inhibition on growth control and differentiation of human neuroblastoma cells.
Neuroblastoma
Effects of GM1 and 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (NeuAc2en) on neuroblastoma (Neuro 2a) and human glioma cells (U1242 MG).
Neuroblastoma
Expression of the cluster 1 antigen (neural cell adhesion molecule) in neuroectodermal tumours.
Neuroblastoma
Fluorescent cytochemical detection of sialidase activity using 5-bromo-4-chloroindol-3-yl-alpha- D- N-acetylneuraminic acid as the substrate.
Neuroblastoma
Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture.
Neuroblastoma
Glycan Chains of Gangliosides: Functional Ligands for Tissue Lectins (Siglecs/Galectins).
Neuroblastoma
Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells.
Neuroblastoma
Hydroxyl free radicals induce cell differentiation in SK-N-MC neuroblastoma cells.
Neuroblastoma
Induced and spontaneous neuritogenesis are associated with enhanced expression of ganglioside GM1 in the nuclear membrane.
Neuroblastoma
Induction of axonal differentiation by silencing plasma membrane-associated sialidase Neu3 in neuroblastoma cells.
Neuroblastoma
Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content.
Neuroblastoma
Modulation of neuritogenesis by ganglioside-specific sialidase (Neu 3) in human neuroblastoma NB-1 cells.
Neuroblastoma
Molecular cloning and biochemical characterization of two novel Neu3 sialidases, neu3a and neu3b, from medaka (Oryzias latipes).
Neuroblastoma
Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3.
Neuroblastoma
NEU4L sialidase overexpression promotes ?-catenin signaling in neuroblastoma cells, enhancing stem-like malignant cell growth.
Neuroblastoma
Oseltamivir Blocks Human Neuronal Nicotinic Acetylcholine Receptor-Mediated Currents.
Neuroblastoma
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
Neuroblastoma
Role of plasma membrane ganglioside sialidase of human neuroblastoma cells in growth control and differentiation.
Neuroblastoma
Selective ganglioside desialylation in the plasma membrane of human neuroblastoma cells.
Neuroblastoma
Stimulation of neurite outgrowth in neuroblastoma cells by neuraminidase: putative role of GM1 ganglioside in differentiation.
Neuroblastoma
Structural and functional characteristics of insulin receptors in rat neuroblastoma cells.
Neuroblastoma
The plasma membrane ganglioside sialidase cofractionates with markers of lipid rafts.
Neuroblastoma
[Surface charge of mouse neuroblastoma cells and changes during growth and morphologic differentiation of the cell population]
Neurofibroma
Lectin histochemistry of normal and neoplastic peripheral nerve sheath. 2. Lectin binding patterns of schwannoma and neurofibroma.
Neuroinflammatory Diseases
Microglia activated by microbial neuraminidase contributes to ependymal cell death.
Neuroinflammatory Diseases
Microglial activation by microbial neuraminidase through TLR2 and TLR4 receptors.
Neuroinflammatory Diseases
Microglial Morphometric Parameters Correlate With the Expression Level of IL-1?, and Allow Identifying Different Activated Morphotypes.
Neuroinflammatory Diseases
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Neuroinflammatory Diseases
Neuroinflammation induced by intracerebroventricular injection of microbial neuraminidase.
Neuroinflammatory Diseases
SVCT2 Expression and Function in Reactive Astrocytes Is a Common Event in Different Brain Pathologies.
Nevus
Differing lectin-binding patterns of malignant melanoma and nevocellular and Spitz nevi.
Newcastle Disease
'a'-Position-mutated and G4-mutated hemagglutinin-neuraminidase proteins of Newcastle disease virus impair fusion and hemagglutinin-neuraminidase-fusion interaction by different mechanisms.
Newcastle Disease
2?-3,4-Unsaturated sialic acid derivatives: Synthesis optimization, and biological evaluation as Newcastle disease virus hemagglutinin-neuraminidase inhibitors.
Newcastle Disease
A comparison of the onset of protection induced by Newcastle disease virus strain B1 and a fowl poxvirus recombinant Newcastle disease vaccine to a viscerotropic velogenic Newcastle disease virus challenge.
Newcastle Disease
A differential scanning calorimetric study of Newcastle disease virus: identification of proteins involved in thermal transitions.
Newcastle Disease
A mutation in the stalk of the newcastle disease virus hemagglutinin-neuraminidase (HN) protein prevents triggering of the F protein despite allowing efficient HN-F complex formation.
Newcastle Disease
A novel chimeric oncolytic virus vector for improved safety and efficacy in hepatocellular carcinoma.
Newcastle Disease
A novel method for detection of Newcastle disease virus with a fluorescent sialidase substrate.
Newcastle Disease
A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV.
Newcastle Disease
A single amino acid substitution in the haemagglutinin-neuraminidase protein of Newcastle disease virus results in increased fusion promotion and decreased neuraminidase activities without changes in virus pathotype.
Newcastle Disease
A single amino acid substitution in the hemagglutinin-neuraminidase of Newcastle disease virus results in a protein deficient in both functions.
Newcastle Disease
A temperature-sensitive mutant of Newcastle disease virus which is affected in both haemagglutinin-neuraminidase and matrix proteins.
Newcastle Disease
A Y526Q mutation in the Newcastle disease virus HN protein reduces its functional activities and attenuates virus replication and pathogenicity.
Newcastle Disease
Aberrant membrane insertion of a cytoplasmic tail deletion mutant of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Newcastle Disease
Abnormal surface expression of sialoglycans on B lymphocyte cell lines from patients with carbohydrate deficient glycoprotein syndrome I A (CDGS I A).
Newcastle Disease
Accidental persistent infection of cell lines by Newcastle disease virus, showing three unusual features--defective neuraminidase, temperature sensitivity and intranuclear inclusions.
Newcastle Disease
Action of ortho- and paramyxovirus neuraminidase on gangliosides. Hydrolysis of ganglioside GM1 by Sendai virus neuraminidase.
Newcastle Disease
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
Newcastle Disease
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction.
Newcastle Disease
Agglutination-separation reactions of red blood cells sensitized with Newcastle disease virus: quantities, agglutination characteristics, and serology of altered virus and HN spikes released following neuraminidase reactivation.
Newcastle Disease
Alpha-2,6-sialylation of L-PHA reactive oligosaccharides and expression of N-acetylglucosaminyltransferase V in human diffuse large B cell lymphoma.
Newcastle Disease
Amino acid esters substituted phosphorylated emtricitabine and didanosine derivatives as antiviral and anticancer agents.
Newcastle Disease
Amino acid substitutions in a conserved region in the stalk of the Newcastle disease virus HN glycoprotein spike impair its neuraminidase activity in the globular domain.
Newcastle Disease
Amino acid substitutions in the F-specific domain in the stalk of the newcastle disease virus HN protein modulate fusion and interfere with its interaction with the F protein.
Newcastle Disease
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Newcastle Disease
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Newcastle Disease
Analysis of synonymous codon usage in Newcastle disease virus hemagglutinin-neuraminidase (HN) gene and fusion protein (F) gene.
Newcastle Disease
Analysis of the protective effect of the haemagglutinin-neuraminidase protein in Newcastle disease virus infection.
Newcastle Disease
Anomalous behaviour of Newcastle disease virus haemagglutinin-neuraminidase protein in Western blotting analysis of monoclonal antibody binding sites.
Newcastle Disease
Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo.
Newcastle Disease
Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV.
Newcastle Disease
Antigenic validation of recombinant hemagglutinin-neuraminidase protein of Newcastle disease virus expressed in Saccharomyces cerevisiae.
Newcastle Disease
Antitumor effect of the Newcastle disease viral hemagglutinin-neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells.
Newcastle Disease
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity.
Newcastle Disease
Antiviral action of interferon-beta on Newcastle disease virus: selectivity to the hemagglutinin-neuraminidase gene expression.
Newcastle Disease
Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes.
Newcastle Disease
Avian adeno-associated virus-based expression of Newcastle disease virus hemagglutinin-neuraminidase protein for poultry vaccination.
Newcastle Disease
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Newcastle Disease
Avian paramyoxvirus-8 immunization reduces viral shedding after homologous APMV-8 challenge but fails to protect against Newcastle disease.
Newcastle Disease
Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
Newcastle Disease
Biological activities of monoclonal antibodies to the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus.
Newcastle Disease
Biological consequences of neuraminidase deficiency in Newcastle disease virus.
Newcastle Disease
Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein.
Newcastle Disease
Biosynthesis of the O-glycosidically linked oligosaccharide chains of fetuin. Indications for an alpha-N-acetylgalactosaminide alpha 2 leads to 6 sialyltransferase with a narrow acceptor specificity in fetal calf liver.
Newcastle Disease
Biosynthesis of Vicia graminea lectin- and Vicia unijuga lectin-binding glycoproteins in human tumor and nontumor cells and an estimation of its epitope structure.
Newcastle Disease
Cells persistently infected with Newcastle disease virus. 3. Thermal stability of hemagglutinin and neuraminidase of a mutant isolated from persistently infected L cells.
Newcastle Disease
Characterization of a carbohydrate epitope defined by the monoclonal antibody H185: sialic acid O-acetylation on epithelial cell-surface mucins.
Newcastle Disease
Characterization of Newcastle disease virus envelope glycoproteins expressed in insect cells.
Newcastle Disease
Characterization of Newcastle disease virus vaccines by biological properties and sequence analysis of the hemagglutinin-neuraminidase protein gene.
Newcastle Disease
Characterization of terminal NeuNAcalpha2-3Galbeta1-4GlcNAc sequence in lipooligosaccharides of Neisseria meningitidis.
Newcastle Disease
Chicken galectin-1B inhibits Newcastle disease virus adsorption and replication through binding to hemagglutinin-neuraminidase (HN) glycoprotein.
Newcastle Disease
Chimeric Newcastle disease virus nucleocapsid with parts of viral hemagglutinin-neuraminidase and fusion proteins.
Newcastle Disease
Chimeric Newcastle disease virus-vectored vaccine protects chickens against H9N2 avian influenza virus in the presence of pre-existing NDV immunity.
Newcastle Disease
Cloning and expression of NDV hemagglutinin-neuraminidase cDNA in a baculovirus expression vector system.
Newcastle Disease
Cloning and nucleotide sequence of Newcastle disease virus hemagglutinin-neuraminidase mRNA: identification of a putative sialic acid binding site.
Newcastle Disease
Cloning of a novel alpha 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups.
Newcastle Disease
Co-expression of the Hemagglutinin and Neuraminidase by Heterologous Newcastle Disease Virus Vectors Protected Chickens against H5 Clade 2.3.4.4 HPAI Viruses.
Newcastle Disease
Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens.
Newcastle Disease
Comparative analysis of sialidase protein in velogenic and lentogenic strains of Newcastle disease virus.
Newcastle Disease
Comparative characteristics of the Israeli Newcastle disease virus field strains by means of a wide panel of monoclonal antibodies against hemagglutinin-neuraminidase glycoprotein.
Newcastle Disease
Conformationally sensitive antigenic determinants on the HN glycoprotein of Newcastle disease virus form with different kinetics.
Newcastle Disease
Construction and expression of a single-chain variable fragment antibody against chicken DEC 205 for targeting the bacterial expressed hemagglutinin-neuraminidase of Newcastle disease virus.
Newcastle Disease
Construction of a camelid VHH yeast two-hybrid library and the selection of VHH against haemagglutinin-neuraminidase protein of the Newcastle disease virus.
Newcastle Disease
Construction of Recombinant Marek's Disease Virus (rMDV) Co-Expressing AIV-H9N2-NA and NDV-F Genes under Control of MDV's Own Bi-Directional Promoter.
Newcastle Disease
Contribution of HN protein length diversity to Newcastle disease virus virulence, replication and biological activities.
Newcastle Disease
Crystallization of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.
Newcastle Disease
Decreased dependence on receptor recognition for the fusion promotion activity of L289A-mutated newcastle disease virus fusion protein correlates with a monoclonal antibody-detected conformational change.
Newcastle Disease
Deduced amino acid sequences surrounding the fusion glycoprotein cleavage site and of the carboxyl-terminus of haemagglutinin-neuraminidase protein of the avirulent thermostable vaccine strain I-2 of Newcastle disease virus.
Newcastle Disease
Detection and differentiation of four poultry diseases using asymmetric reverse transcription polymerase chain reaction in combination with oligonucleotide microarrays.
Newcastle Disease
Determination of the disulfide bond arrangement of Newcastle disease virus hemagglutinin neuraminidase. Correlation with a beta-sheet propeller structural fold predicted for paramyxoviridae attachment proteins.
Newcastle Disease
Development of a candidate vaccine for Newcastle disease virus by epitope display in the Cucumber mosaic virus capsid protein.
Newcastle Disease
Different Origins of Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein Modulate the Replication Efficiency and Pathogenicity of the Virus.
Newcastle Disease
Differential action of Aspergillus glycosidases on the hemagglutinating and neuraminidase activities of influenza and Newcastle disease viruses.
Newcastle Disease
Disulfide bond formation is a determinant of glycosylation site usage in the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Newcastle Disease
Dynamic properties of Newcastle Disease Virus envelope and their relations with viral hemagglutinin-neuraminidase membrane glycoprotein.
Newcastle Disease
E. coli expression and immunological assessment of expressed recombinant Newcastle disease virus hemagglutinin-neuraminidase protein in chickens.
Newcastle Disease
Effect of inhibitors of proteases and glycosidases on functional lability of newly synthesized hemagglutinin-neuraminidase glycoprotein in avirulent NDV strain-infected cells.
Newcastle Disease
Effects of the HN gene C-terminal extensions on the Newcastle disease virus virulence.
Newcastle Disease
Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge.
Newcastle Disease
Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants.
Newcastle Disease
Engineered intermonomeric disulfide bonds in the globular domain of Newcastle disease virus hemagglutinin-neuraminidase protein: implications for the mechanism of fusion promotion.
Newcastle Disease
Enhanced Reliability of Avian Influenza Virus (AIV) and Newcastle Disease Virus (NDV) Identification Using Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry (MALDI-MS).
Newcastle Disease
Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa.
Newcastle Disease
Estimation of Newcastle disease virus concentration by using a sandwich ELISA and measuring neuraminidase activity.
Newcastle Disease
Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone.
Newcastle Disease
Evaluation of the hemagglutination-inhibition assay using a baculovirus-expressed hemagglutinin-neuraminidase protein for detection of Newcastle disease virus antibodies.
Newcastle Disease
Exoglycosidase purity and linkage specificity: assessment using oligosaccharide substrates and high-pH anion-exchange chromatography with pulsed amperometric detection.
Newcastle Disease
Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy.
Newcastle Disease
Expression of a secreted version of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: its evaluation as a diagnostic reagent.
Newcastle Disease
Expression of Hemagglutinin-Neuraminidase glycoprotein of Newcastle Disease Virus in agroinfiltrated Nicotiana benthamiana plants.
Newcastle Disease
Flexibility of the head-stalk linker domain of paramyxovirus HN glycoprotein is essential for triggering virus fusion.
Newcastle Disease
Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent viral attachment.
Newcastle Disease
Further characterization of the interaction between L-selectin and its endothelial ligands.
Newcastle Disease
Fusion deficiency induced by mutations at the dimer interface in the Newcastle disease virus hemagglutinin-neuraminidase is due to a temperature-dependent defect in receptor binding.
Newcastle Disease
Fusion mutants of Newcastle disease virus selected with monoclonal antibodies to the hemagglutinin-neuraminidase.
Newcastle Disease
Fusogenic activity of reconstituted newcastle disease virus envelopes: a role for the hemagglutinin-neuraminidase protein in the fusion process.
Newcastle Disease
Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.
Newcastle Disease
Glycosylation within an antigenic site on the HN glycoprotein of Newcastle disease virus interferes with its role in the promotion of membrane fusion.
Newcastle Disease
GMP-140 binds to a glycoprotein receptor on human neutrophils: evidence for a lectin-like interaction.
Newcastle Disease
Heat inactivation of the neuraminidase and haemagglutinin estimated in the agglutination-separation reactions using red blood cells sensitized with Newcastle disease virus.
Newcastle Disease
Hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus cooperatively disturb fusion-fission homeostasis to enhance mitochondrial function by activating the unfolded protein response of endoplasmic reticulum and mitochondrial stress.
Newcastle Disease
Hemagglutinin-neuraminidase Sequence and Phylogenetic Analysis of Two Newcastle Disease Virus Isolated from Chickens in Iran.
Newcastle Disease
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules.
Newcastle Disease
HN gene C-terminal extension of Newcastle disease virus is not the determinant of the enteric tropism.
Newcastle Disease
HN Protein of Newcastle Disease Virus Induces Apoptosis Through SAPK/JNK Pathway.
Newcastle Disease
HN protein of Newcastle disease virus sensitizes HeLa cells to TNF-?-induced apoptosis by downregulating NF-?B expression.
Newcastle Disease
Identification and characterization of the Sda beta 1,4,N-acetylgalactosaminyltransferase from pig large intestine.
Newcastle Disease
Identification of a potential neutralizing linear epitope of hemagglutinin-neuraminidase in Newcastle disease virus.
Newcastle Disease
Identification of a variable epitope on the Newcastle disease virus hemagglutinin-neuraminidase protein.
Newcastle Disease
Identification of amino acid residues important to the neuraminidase activity of the HN glycoprotein of Newcastle disease virus.
Newcastle Disease
Identification of novel E347Q and G362K amino acid substitutions in HN neutralization epitope and major antigenic difference in novel sub-genotype VIIj isolates.
Newcastle Disease
Identification of the amino acids residues involved in hemagglutinin-neuraminidase of Newcastle disease virus binding to sulfated Chuanmingshen violaceum polysaccharides.
Newcastle Disease
Immunogenic properties of recombinant ectodomain of Newcastle disease virus hemagglutinin-neuraminidase protein expressed in Escherichia coli.
Newcastle Disease
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Newcastle Disease
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus.
Newcastle Disease
Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes.
Newcastle Disease
In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.
Newcastle Disease
Increase in the Neuraminidase Activity of a Nonpathogenic Newcastle Disease Virus Isolate during Passaging in Chickens.
Newcastle Disease
Individual N-Glycans Added at Intervals along the Stalk of the Nipah Virus G Protein Prevent Fusion but Do Not Block the Interaction with the Homologous F Protein.
Newcastle Disease
Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240.
Newcastle Disease
Induction of Immune Response in Animal Model Using Recombinant Anti-NDV Vaccine.
Newcastle Disease
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus.
Newcastle Disease
Influence of insertion site of the avian influenza virus haemagglutinin (HA) gene within the Newcastle disease virus genome on HA expression.
Newcastle Disease
Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites.
Newcastle Disease
Integration of membrane proteins into the endoplasmic reticulum requires GTP.
Newcastle Disease
Intracellular processing of the vesicular stomatitis virus glycoprotein and the Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.
Newcastle Disease
Intracellular synthesis of myxovirus neuraminidase in chick embryo cell monolayer culture. I. Neuraminidase activity, hemagglutinin synthesis, and content of cellbound sialic acid in Newcastle disease virus-infected cells.
Newcastle Disease
Ionic dependence of the sialidase activity of hemagglutinin-neuraminidase glycoprotein in Newcastle disease virus membrane.
Newcastle Disease
Isolation and characterization of defective interfering particle of Newcastle disease virus.
Newcastle Disease
Killing Effects of IFN R-/- Mouse NK Cells Activated by HN Protein of NDV on Mouse Hepatoma Cells and Possible Mechanism with Syk and NF-?B.
Newcastle Disease
Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus.
Newcastle Disease
Mapping of three antigenic sites on the haemagglutinin-neuraminidase protein of Newcastle disease virus.
Newcastle Disease
Maturation of the hemagglutinin-neuraminidase and fusion glycoproteins of two biologically distinct strains of Newcastle disease virus.
Newcastle Disease
Mature, cell-associated HN protein of Newcastle disease virus exists in two forms differentiated by posttranslational modifications.
Newcastle Disease
Membrane glycoproteins of Newcastle disease virus: nucleotide sequence of the hemagglutinin-neuraminidase cloned gene and structure/function relationship of predicted amino acid sequence.
Newcastle Disease
Methanolic soluble fractions of lingzhi or reishi medicinal mushroom, Ganoderma lucidum (higher Basidiomycetes) extract inhibit neuraminidase activity in Newcastle disease virus (LaSota).
Newcastle Disease
Modulation of the activities of HN protein of Newcastle disease virus by nonconserved cysteine residues.
Newcastle Disease
Modulation of the neuraminidase activity of HN protein from Newcastle disease virus by substrate binding and conformational change: kinetic and thermal denaturation studies.
Newcastle Disease
Molecular characterization of chicken-derived genotype VIId Newcastle disease virus isolates in China during 2005-2012 reveals a new length in hemagglutinin-neuraminidase.
Newcastle Disease
Molecular characterization of hemagglutinin-neuraminidase fragment gene of Newcastle disease virus isolated from periodically-vaccinated farms.
Newcastle Disease
Monoclonal antibodies as functional probes of the HN glycoprotein of Newcastle disease virus: antigenic separation of the hemagglutinating and neuraminidase sites.
Newcastle Disease
Monoclonal antibodies identify a strain-specific epitope on the HN glycoprotein of Newcastle disease virus strain Australia-Victoria.
Newcastle Disease
Monoclonal antibodies specific for the hemagglutinin-neuraminidase protein define neutralizing epitopes specific for Newcastle disease virus genotype 2.VII from Egypt.
Newcastle Disease
Monoclonal antibodies to hemagglutinin-neuraminidase and fusion glycoproteins of Newcastle disease virus: relationship between glycosylation and reactivity.
Newcastle Disease
Monoclonal antibody routinely used to identify avirulent strains of Newcastle disease virus binds to an epitope at the carboxy terminus of the hemagglutinin-neuraminidase protein and recognizes individual mesogenic and velogenic strains.
Newcastle Disease
Mutated form of the Newcastle disease virus hemagglutinin-neuraminidase interacts with the homologous fusion protein despite deficiencies in both receptor recognition and fusion promotion.
Newcastle Disease
Mutations in the Newcastle disease virus hemagglutinin-neuraminidase protein that interfere with its ability to interact with the homologous F protein in the promotion of fusion.
Newcastle Disease
Neuraminidase as an enzymatic marker for detecting airborne Influenza virus and other viruses.
Newcastle Disease
Neuraminidase content of strains of Newcastle disease virus which differ in virulence.
Newcastle Disease
Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition.
Newcastle Disease
Neutralization of Newcastle disease virus by monoclonal antibodies to the hemagglutinin-neuraminidase glycoprotein: requirement for antibodies to four sites for complete neutralization.
Newcastle Disease
Newcastle disease virus (NDV) vaccine based on immunization with avian cells expressing the NDV hemagglutinin-neuraminidase glycoprotein.
Newcastle Disease
Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
Newcastle Disease
Newcastle disease virus contains a linkage-specific glycoprotein sialidase. Application to the localization of sialic acid residues in N-linked oligosaccharides of alpha 1-acid glycoprotein.
Newcastle Disease
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.
Newcastle Disease
Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene.
Newcastle Disease
Newcastle disease virus F and HN proteins contribute to its macrophage host range.
Newcastle Disease
Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent.
Newcastle Disease
Newcastle disease virus neuraminidase primes neutrophils for stimulation by galectin-3 and formyl-Met-Leu-Phe.
Newcastle Disease
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Newcastle Disease
Nucleotide and predicted amino acid sequence analysis of the fusion protein and hemagglutinin-neuraminidase protein genes among Newcastle disease virus isolates. Phylogenetic relationships among the Paramyxovirinae based on attachment glycoprotein sequences.
Newcastle Disease
Nucleotide sequence and phylogenetic analysis of Newcastle disease virus isolates from recent outbreaks in Taiwan.
Newcastle Disease
Nucleotide sequence of the envelope protein genes of a highly virulent, neurotropic strain of Newcastle disease virus.
Newcastle Disease
Nucleotide sequence of the gene encoding the Newcastle disease virus hemagglutinin-neuraminidase protein and comparisons of paramyxovirus hemagglutinin-neuraminidase protein sequences.
Newcastle Disease
Nucleotide sequence of the hemagglutinin-neuraminidase gene of Newcastle disease virus avirulent strain D26: evidence for a longer coding region with a carboxyl terminal extension as compared to virulent strains.
Newcastle Disease
On the inhibition mechanism of the sialidase activity from Newcastle disease virus.
Newcastle Disease
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.
Newcastle Disease
Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-neuraminidase antigens.
Newcastle Disease
Over-expression of mammalian sialidase NEU3 reduces Newcastle disease virus entry and propagation in COS7 cells.
Newcastle Disease
Partial Antiviral Activities Detection of Chicken Mx Jointing with Neuraminidase Gene (NA) against Newcastle Disease Virus.
Newcastle Disease
Pathotyping isolates of Newcastle disease virus using antipeptide antibodies to pathotype-specific regions of their fusion and hemagglutinin-neuraminidase proteins.
Newcastle Disease
Positive selection in the hemagglutinin-neuraminidase gene of Newcastle disease virus and its effect on vaccine efficacy.
Newcastle Disease
Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.
Newcastle Disease
Potential use of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed in Rachiplusia nu larvae as an immunogen for chickens.
Newcastle Disease
Preparation and diagnostic utility of a hemagglutination inhibition test antigen derived from the baculovirus-expressed hemagglutinin-neuraminidase protein gene of Newcastle disease virus.
Newcastle Disease
Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion.
Newcastle Disease
Prokaryotic recombinant hemagglutinin-neuraminidase protein enhances the humoral response and efficacy of commercial Newcastle disease vaccines in chickens.
Newcastle Disease
Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein.
Newcastle Disease
Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus.
Newcastle Disease
Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutininneuraminidase proteins.
Newcastle Disease
Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene.
Newcastle Disease
Protective effect of individual glycoproteins of Newcastle disease virus expressed in insect cells: the fusion protein derived from an avirulent strain had lower protective efficacy.
Newcastle Disease
Proteins of Newcastle disease virus envelope: interaction between the outer hemagglutinin-neuraminidase glycoprotein and the inner non-glycosylated matrix protein.
Newcastle Disease
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
Newcastle Disease
Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses.
Newcastle Disease
Recombinant haemagglutinin neuraminidase antigen-based single serum dilution ELISA for rapid serological profiling of Newcastle disease virus.
Newcastle Disease
Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge.
Newcastle Disease
Recombinant infectious bursal disease virus expressing Newcastle disease virus (NDV) neutralizing epitope confers partial protection against virulent NDV challenge in chickens.
Newcastle Disease
Recombinant Newcastle disease virus (NDV) La Sota expressing the haemagglutinin-neuraminidase protein of genotype VII NDV shows improved protection efficacy against NDV challenge.
Newcastle Disease
Reducing agent-sensitive dimerization of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus correlates with the presence of cysteine at residue 123.
Newcastle Disease
Regioselective transglycosylation in the synthesis of oligosaccharides: comparison of beta-galactosidases and sialidases of various origins.
Newcastle Disease
Requirement for sialic acid on neutrophils in a GMP-140 (PADGEM) mediated adhesive interaction with activated platelets.
Newcastle Disease
Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.
Newcastle Disease
Retraction notice: Role of C596 in the C-terminal extension of the haemagglutinin-neuraminidase protein in replication and pathogenicity of a highly virulent Indonesian strain of Newcastle disease virus.
Newcastle Disease
Retroviral expressed hemagglutinin-neuraminidase protein protects chickens from Newcastle disease virus induced disease.
Newcastle Disease
Role of C596 in the C-terminal extension of the haemagglutinin-neuraminidase protein in replication and pathogenicity of a highly virulent Indonesian strain of Newcastle disease virus.
Newcastle Disease
Role of carbohydrate processing and calnexin binding in the folding and activity of the HN protein of Newcastle disease virus.
Newcastle Disease
Role of cotranslational disulfide bond formation in the folding of the hemagglutinin-neuraminidase protein of Newcastle disease virus.
Newcastle Disease
Role of the cytoplasmic tail amino acid sequences of Newcastle disease virus hemagglutinin-neuraminidase protein in virion incorporation, cell fusion, and pathogenicity.
Newcastle Disease
Role of the two sialic acid binding sites on the newcastle disease virus HN protein in triggering the interaction with the F protein required for the promotion of fusion.
Newcastle Disease
Role of untranslated regions of the hemagglutinin-neuraminidase gene in replication and pathogenicity of newcastle disease virus.
Newcastle Disease
Screening and mechanistic study of key sites of the hemagglutinin-neuraminidase protein related to the virulence of Newcastle disease virus.
Newcastle Disease
Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion.
Newcastle Disease
Selection of unique antigenic variants of Newcastle disease virus with neutralizing monoclonal antibodies and anti-immunoglobulin.
Newcastle Disease
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.
Newcastle Disease
Sialidase, receptor-binding and fusion-promotion activities of Newcastle disease virus haemagglutinin-neuraminidase glycoprotein: a mutational and kinetic study.
Newcastle Disease
Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction.
Newcastle Disease
Strain-specific degradation of a viral glycoprotein in Newcastle disease virus-infected cells.
Newcastle Disease
Structural analysis and functional role of the carbohydrate component of somatostatin receptors.
Newcastle Disease
Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus.
Newcastle Disease
Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: receptor recognition is dependent on neuraminidase activity.
Newcastle Disease
Structural features unique to each of the three antigenic sites on the hemagglutinin-neuraminidase protein of Newcastle disease virus.
Newcastle Disease
Structure and function of a membrane anchor-less form of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Newcastle Disease
Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III.
Newcastle Disease
Structure of the Newcastle disease virus hemagglutinin-neuraminidase (HN) ectodomain reveals a four-helix bundle stalk.
Newcastle Disease
Structure of the ulster strain newcastle disease virus hemagglutinin-neuraminidase reveals auto-inhibitory interactions associated with low virulence.
Newcastle Disease
Subunits of NDV. Hemagglutinin and neuraminidase subunits of Newcastle disease virus.
Newcastle Disease
Syncytia generated by hemagglutinin-neuraminidase and fusion proteins of virulent Newcastle disease virus induce complete autophagy by activating AMPK-mTORC1-ULK1 signaling>.
Newcastle Disease
Synergistic effects of adjuvants interferon-gamma and levamisole on DNA vaccination against infection with Newcastle disease virus.
Newcastle Disease
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Newcastle Disease
Terminal glycosylation of bovine uroplakin III, one of the major integral-membrane glycoproteins of mammalian bladder.
Newcastle Disease
The attachment function of the Newcastle disease virus hemagglutinin-neuraminidase protein can be separated from fusion promotion by mutation.
Newcastle Disease
The carboxyterminus of the hemagglutinin-neuraminidase of Newcastle disease virus is exposed at the surface of the viral envelope.
Newcastle Disease
The comparative antigenic characterization of Newcastle disease virus strains isolated in Kenya and Kazakhstan.
Newcastle Disease
The differences in significance of alpha 2,3Gal-linked and alpha 2,6GalNAc-linked sialic acid residues in blood group M- and N-related epitopes recognized by various monoclonal antibodies.
Newcastle Disease
The fusion promotion activity of the NDV HN protein does not correlate with neuraminidase activity.
Newcastle Disease
The hemagglutinin-neuraminidase (HN) gene of Newcastle disease virus strain Italien (ndv Italien): comparison with HNs of other strains and expression by a vaccinia recombinant.
Newcastle Disease
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
Newcastle Disease
The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence.
Newcastle Disease
The major gangliosides of human peripheral blood monocytes/macrophages: absence of ganglio series structures.
Newcastle Disease
The neuraminidase of Newcastle disease virus inhibited in the elution-inhibition reaction.
Newcastle Disease
The pathogenesis of Newcastle disease: A comparison of selected Newcastle disease virus wild-type strains and their infectious clones.
Newcastle Disease
The regulatory roles of cell surface sialylation and N-glycans in human B cell lymphoma cell adhesion to galectin-1.
Newcastle Disease
The role of individual oligosaccharide chains in the activities of the HN glycoprotein of Newcastle disease virus.
Newcastle Disease
The role of the individual cysteine residues in the formation of the mature, antigenic HN protein of Newcastle disease virus.
Newcastle Disease
The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion.
Newcastle Disease
The site of bluetongue virus attachment to glycophorins from a number of animal erythrocytes.
Newcastle Disease
The synergistic neutralization of Newcastle disease virus by two monoclonal antibodies to its haemagglutinin-neuraminidase protein.
Newcastle Disease
The use of in situ hybridization and immunohistochemistry to study the pathogenesis of various Newcastle disease virus strains and recombinants in embryonated chicken eggs.
Newcastle Disease
Therapeutic targeting of liver cancer with a recombinant DNA vaccine containing the hemagglutinin-neuraminidase gene of Newcastle disease virus via apoptotic-dependent pathways.
Newcastle Disease
Thermal inactivation of Newcastle disease virus. I. Coupled inactivation rates of hemagglutinating and neuraminidase activities.
Newcastle Disease
Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein.
Newcastle Disease
Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation. Skeletal muscle alpha-dystroglycan is a latent receptor for Vicia villosa agglutinin b4 masked by sialic acid modification.
Newcastle Disease
Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements.
Newcastle Disease
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25.
Newcastle Disease
Transfection of the Newcastle disease virus hemagglutinin-neuraminidase gene into murine myeloma cells for induction of host-versus-tumor immune response.
Newcastle Disease
Translation and membrane insertion of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.
Newcastle Disease
Two single mutations in the fusion protein of Newcastle disease virus confer hemagglutinin-neuraminidase independent fusion promotion and attenuate the pathogenicity in chickens.
Newcastle Disease
Use of conformationally restricted pyridinium alpha-D-N-acetylneuraminides to probe specificity in bacterial and viral sialidases.
Newcastle Disease
Vaccination against Newcastle disease with a recombinant baculovirus hemagglutinin-neuraminidase subunit vaccine.
Newcastle Disease
Vaccination of chickens with a recombinant fowlpox virus containing the hemagglutinin-neuraminidase gene of Newcastle disease virus under the control of the fowlpox virus thymidine kinase promoter.
Newcastle Disease
Variation of a newcastle disease virus hemagglutinin-neuraminidase linear epitope.
Newcastle Disease
Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein.
Newcastle Disease
Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3.
Newcastle Disease
[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
Newcastle Disease
[Antigenic differences in the glycoproteins of the Newcastle disease virus]
Newcastle Disease
[Evaluation of Newcastle disease virus with derivated hemagglutinin-neuraminidase gene of mesogenic strain]
Newcastle Disease
[Expression of a cloned hemagglutinin-neuraminidase gene from Newcastle disease virus in murine myeloma cells]
Newcastle Disease
[Lability of neuraminidase and hemagglutinin in cells of a primary culture of chick embryo fibroblasts infected with Newcastle disease virus]
Newcastle Disease
[Restoration of the biological activity of hemagglutinin--neuraminidase in NDV with phospholipids]
Newcastle Disease
[Role of intracellular proteinases and glycosidases in the degradation of the 'large glycoprotein' responsible for the neuraminidase and hemagglutinating activity of the Newcastle disease virus]
Obesity
Arterial Stiffening in Western Diet-Fed Mice Is Associated with Increased Vascular Elastin, Transforming Growth Factor-?, and Plasma Neuraminidase.
Obstetric Labor, Premature
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora.
Orthomyxoviridae Infections
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Orthomyxoviridae Infections
Characterization of a newly emerged genetic cluster of H1N1 and H1N2 swine influenza virus in the United States.
Orthomyxoviridae Infections
Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
Orthomyxoviridae Infections
Comparison of the pathogenesis of two genetically different H3N2 influenza A viruses in pigs.
Orthomyxoviridae Infections
Complete sequences of the neuraminidase genes of swine influenza viruses (H1N1) associated with the respiratory disease in pigs.
Orthomyxoviridae Infections
Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains.
Orthomyxoviridae Infections
Evolution and antigenic advancement of N2 neuraminidase of swine influenza A viruses circulating in the United States following two separate introductions from human seasonal viruses.
Orthomyxoviridae Infections
Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.
Orthomyxoviridae Infections
Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus.
Orthomyxoviridae Infections
Influenza A Virus in Backyard Pigs and Poultry in Rural Cambodia.
Orthomyxoviridae Infections
Large outbreak of swine influenza in southern Japan caused by reassortant (H1N2) influenza viruses: its epizootic background and characterization of the causative viruses.
Orthomyxoviridae Infections
Locally Acquired Human Infection with Swine-Origin Influenza A(H3N2) Variant Virus, Australia, 2018.
Orthomyxoviridae Infections
Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza.
Orthomyxoviridae Infections
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Orthomyxoviridae Infections
Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Orthomyxoviridae Infections
Population susceptibility to a variant swine-origin influenza virus A(H3N2) in Vietnam, 2011-2012.
Orthomyxoviridae Infections
Reassortant Eurasian Avian-Like Influenza A(H1N1) Virus from a Severely Ill Child, Hunan Province, China, 2015.
Orthomyxoviridae Infections
Reassortant Pandemic (H1N1) 2009 virus in pigs, United Kingdom.
Orthomyxoviridae Infections
Sialidase of swine influenza A viruses: variation of the recognition specificities for sialyl linkages and for the molecular species of sialic acid with the year of isolation.
Orthomyxoviridae Infections
Single-step multiplex conventional and real-time reverse transcription polymerase chain reaction assays for simultaneous detection and subtype differentiation of Influenza A virus in swine.
Orthomyxoviridae Infections
Studies on antigenic variations of the haemagglutinin and neuraminidase of swine influenza virus isolates.
Orthomyxoviridae Infections
The first Swedish H1N2 swine influenza virus isolate represents an uncommon reassortant.
Orthomyxoviridae Infections
The Origin of Novel Avian Influenza A (H7N9) and Mutation Dynamics for Its Human-To-Human Transmissible Capacity.
Orthomyxoviridae Infections
The possible origin H1N1 (Hsw1N1) virus in the swine population of Japan and antigenic analysis of the isolates.
Orthomyxoviridae Infections
[Origin of hemagglutinin and neuraminidase gene of swine influenza A H1N1 viruses]
Orthomyxoviridae Infections
[Phylogenetic analysis based on hemagglutinin and neuraminidase genes between swine influenza virus and human influenza A/H3N2 virus strains isolated in Zhejiang province]
Orthomyxoviridae Infections
[Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]
Osteonecrosis
Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion.
Osteosarcoma
Antitumor effect of the Newcastle disease viral hemagglutinin-neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells.
Osteosarcoma
[Effect of attenuated expression of neuraminidase 3 via RNA interference on the proliferation and apoptosis of osteosarcoma MG-63 cells].
Otitis
Effect of lacto-N-neotetraose, asialoganglioside-GM1 and neuraminidase on adherence of otitis media-associated serotypes of Streptococcus pneumoniae to chinchilla tracheal epithelium.
Otitis
Pneumococcal Neuraminidase A (NanA) Promotes Biofilm Formation and Synergizes with Influenza A Virus in Nasal Colonization and Middle Ear Infection.
Otitis Media
Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model.
Otitis Media
Experimental alteration of chinchilla middle ear mucosae by bacterial neuraminidase.
Otitis Media
Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model.
Otitis Media
Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.
Otitis Media with Effusion
Experimental alteration of chinchilla middle ear mucosae by bacterial neuraminidase.
Otitis Media with Effusion
Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model.
Otitis Media with Effusion
Purification and properties of Streptococcus pneumoniae neuraminidase.
Ovarian Neoplasms
Desialylation of Atg5 by sialidase (Neu2) enhances autophagosome formation to induce anchorage-dependent cell death in ovarian cancer cells.
Ovarian Neoplasms
Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer.
Ovarian Neoplasms
Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
Ovarian Neoplasms
Factors effecting the measurement of tumor-associated MUC1 mucins in serum.
Ovarian Neoplasms
Pregnancy-associated beta 1-macroglobulin: detection on the surface of ovarian cancer cell lines.
Ovarian Neoplasms
[Multidimensional Analysis of Hippocampal Excitatory Neurotransmission and Development of Analytical Tools for Glycans].
Pancreatic Neoplasms
Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.
Pancreatic Neoplasms
Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
Pancreatic Neoplasms
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.
Pancreatitis
[Flow cytometry detection of erythrocyte antigens and antibodies. Technical aspects and new clinical applications]
Papilloma
Assessment of cell surface glycoconjugates in normal, benign and malignant human nasal mucosa.
Papilloma
Immunohistochemical localization of peanut lectin binding sites on human brain tumors as determined by peroxidase-antiperoxidase technique in paraffin sections.
Papilloma, Inverted
Assessment of cell surface glycoconjugates in normal, benign and malignant human nasal mucosa.
Paramyxoviridae Infections
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid analogs structurally modified by thiocarbamoylalkyl groups at the C-4 position: Synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
Paramyxoviridae Infections
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid analogues structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
Paramyxoviridae Infections
2beta,3beta-Difluorosialic acid derivatives structurally modified at the C-4 position: synthesis and biological evaluation as inhibitors of human parainfluenza virus type 1.
Paramyxoviridae Infections
A cell fusion-inhibiting monoclonal antibody binds to the presumed stalk domain of the human parainfluenza type 2 virus hemagglutinin-neuraminidase protein.
Paramyxoviridae Infections
A fluorometric procedure for measuring the neuraminidase activity: its application to the determination of this activity in influenza and parainfluenza viruses.
Paramyxoviridae Infections
A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
Paramyxoviridae Infections
A I131V Substitution in the Fusion Glycoprotein of Human Parainfluenza Virus Type 1 Enhances Syncytium Formation and Virus Growth.
Paramyxoviridae Infections
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Paramyxoviridae Infections
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Paramyxoviridae Infections
A probable model of the inhibitory action of ceruloplasmin on the multiplication of some myxo- and paramyxoviruses.
Paramyxoviridae Infections
A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3.
Paramyxoviridae Infections
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.
Paramyxoviridae Infections
A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
Paramyxoviridae Infections
A role for caveolin 1 in assembly and budding of the paramyxovirus parainfluenza virus 5.
Paramyxoviridae Infections
A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.
Paramyxoviridae Infections
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.
Paramyxoviridae Infections
A single amino acid changes enhances the fusion promotion activity of human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.
Paramyxoviridae Infections
A single amino acid mutation at position 170 of human parainfluenza virus type 1 fusion glycoprotein induces obvious syncytium formation and caspase-3-dependent cell death.
Paramyxoviridae Infections
Amino acid substitutions contributing to ?2,6-sialic acid linkage binding specificity of human parainfluenza virus type 3 hemagglutinin-neuraminidase.
Paramyxoviridae Infections
An oligosaccharide at the C-terminus of the F-specific domain in the stalk of the human parainfluenza virus 3 hemagglutinin-neuraminidase modulates fusion.
Paramyxoviridae Infections
Analysis of parainfluenza virus-5 hemagglutinin-neuraminidase protein mutants that are blocked in internalization and degradation.
Paramyxoviridae Infections
Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
Paramyxoviridae Infections
Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities.
Paramyxoviridae Infections
Antigenic structure, function, and evolution of the hemagglutinin-neuraminidase protein of human parainfluenza virus type 1.
Paramyxoviridae Infections
Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus.
Paramyxoviridae Infections
Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces.
Paramyxoviridae Infections
Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Paramyxoviridae Infections
Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
Paramyxoviridae Infections
Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins.
Paramyxoviridae Infections
Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Paramyxoviridae Infections
Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies.
Paramyxoviridae Infections
Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo.
Paramyxoviridae Infections
Crystallization of biologically active hemagglutinin-neuraminidase glycoprotein dimers proteolytically cleaved from human parainfluenza virus type 1.
Paramyxoviridae Infections
Crystals of hemagglutinin-neuraminidase of parainfluenza virus contain triple-stranded helices.
Paramyxoviridae Infections
Delineation of four antigenic sites on a paramyxovirus glycoprotein via which monoclonal antibodies mediate distinct antiviral activities.
Paramyxoviridae Infections
Detailed genetic analysis of hemagglutinin-neuraminidase glycoprotein gene in human parainfluenza virus type 1 isolates from patients with acute respiratory infection between 2002 and 2009 in Yamagata prefecture, Japan.
Paramyxoviridae Infections
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
Paramyxoviridae Infections
Differences in bovine parainfluenza 3 virus variants studied by sequencing of the genes of viral envelope proteins.
Paramyxoviridae Infections
Distinct hemagglutinin and neuraminidase epitopes involved in antigenic variation of recent human parainfluenza virus type 2 isolates.
Paramyxoviridae Infections
Down-regulation of paramyxovirus hemagglutinin-neuraminidase glycoprotein surface expression by a mutant fusion protein containing a retention signal for the endoplasmic reticulum.
Paramyxoviridae Infections
Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.
Paramyxoviridae Infections
Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virus.
Paramyxoviridae Infections
Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
Paramyxoviridae Infections
Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.
Paramyxoviridae Infections
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Paramyxoviridae Infections
Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery.
Paramyxoviridae Infections
Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.
Paramyxoviridae Infections
Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase.
Paramyxoviridae Infections
Expression and characterization of soluble human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.
Paramyxoviridae Infections
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.
Paramyxoviridae Infections
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Paramyxoviridae Infections
Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies.
Paramyxoviridae Infections
Fixation of oligosaccharides to a surface may increase the susceptibility to human parainfluenza virus 1, 2, or 3 hemagglutinin-neuraminidase.
Paramyxoviridae Infections
Flexibility of the head-stalk linker domain of paramyxovirus HN glycoprotein is essential for triggering virus fusion.
Paramyxoviridae Infections
Full conversion of the hemagglutinin-neuraminidase specificity of the parainfluenza virus 5 fusion protein by replacement of 21 amino acids in its head region with those of the simian virus 41 fusion protein.
Paramyxoviridae Infections
Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses.
Paramyxoviridae Infections
Functional analysis of amino acids at stalk/head interface of human parainfluenza virus type 3 hemagglutinin-neuraminidase protein in the membrane fusion process.
Paramyxoviridae Infections
Functional characterization of bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins expressed by adenovirus recombinants.
Paramyxoviridae Infections
Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses.
Paramyxoviridae Infections
Fusion activation by a headless parainfluenza virus 5 hemagglutinin-neuraminidase stalk suggests a modular mechanism for triggering.
Paramyxoviridae Infections
Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II.
Paramyxoviridae Infections
Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion.
Paramyxoviridae Infections
Genetic variation and evolution of human parainfluenza virus type 1 hemagglutinin neuraminidase: analysis of 12 clinical isolates.
Paramyxoviridae Infections
Glycosylation of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 1 affects its functional but not its antigenic properties.
Paramyxoviridae Infections
Hemagglutinin-neuraminidase gene sequence-based reclassification of human parainfluenza virus 3 variants.
Paramyxoviridae Infections
Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.
Paramyxoviridae Infections
Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy.
Paramyxoviridae Infections
Homooligomerization of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 occurs before the acquisition of correct intramolecular disulfide bonds and mature immunoreactivity.
Paramyxoviridae Infections
Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
Paramyxoviridae Infections
Human parainfluenza virus 3 neuraminidase activity contributes to dendritic cell maturation.
Paramyxoviridae Infections
Human parainfluenza virus infection of the airway epithelium: the viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity.
Paramyxoviridae Infections
Human parainfluenza virus type 1 evolution combines cocirculation of strains and development of geographically restricted lineages.
Paramyxoviridae Infections
Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant.
Paramyxoviridae Infections
Human parainfluenza virus type 3: analysis of the cytoplasmic tail and transmembrane anchor of the hemagglutinin-neuraminidase protein in promoting cell fusion.
Paramyxoviridae Infections
Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin.
Paramyxoviridae Infections
Identification of regions on the hemagglutinin-neuraminidase protein of human parainfluenza virus type 2 important for promoting cell fusion.
Paramyxoviridae Infections
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Paramyxoviridae Infections
Infection of human airway epithelium by human and avian strains of influenza a virus.
Paramyxoviridae Infections
Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based HPIV3 vaccines.
Paramyxoviridae Infections
Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein.
Paramyxoviridae Infections
Inhibition of human parainfluenza virus type 1 sialidase by analogs of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid.
Paramyxoviridae Infections
Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites.
Paramyxoviridae Infections
Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position.
Paramyxoviridae Infections
Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo.
Paramyxoviridae Infections
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
Paramyxoviridae Infections
Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.
Paramyxoviridae Infections
Intracellular processing and transport of NH2-terminally truncated forms of a hemagglutinin-neuraminidase type II glycoprotein.
Paramyxoviridae Infections
Live bivalent vaccine for parainfluenza and influenza virus infections.
Paramyxoviridae Infections
Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.
Paramyxoviridae Infections
Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.
Paramyxoviridae Infections
Mechanism of interference mediated by human parainfluenza virus type 3 infection.
Paramyxoviridae Infections
Membrane fusion promoted by increasing surface densities of the paramyxovirus F and HN proteins: comparison of fusion reactions mediated by simian virus 5 F, human parainfluenza virus type 3 F, and influenza virus HA.
Paramyxoviridae Infections
Molecular cloning and sequence analysis of the human parainfluenza 3 virus genes encoding the surface glycoproteins, F and HN.
Paramyxoviridae Infections
Monoclonal antibodies reveal extensive antigenic differences between the hemagglutinin-neuraminidase glycoproteins of human and bovine parainfluenza 3 viruses.
Paramyxoviridae Infections
Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.
Paramyxoviridae Infections
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir).
Paramyxoviridae Infections
Mutations in the HRB linker of human parainfluenza virus type 3 fusion protein reveal its importance for fusion activity.
Paramyxoviridae Infections
N-glycosylation contributes to the limited cross-reactivity between hemagglutinin neuraminidase proteins of human parainfluenza virus type 4A and 4B.
Paramyxoviridae Infections
N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.
Paramyxoviridae Infections
Neuraminidase activity and syncytial formation in variants of parainfluenza 3 virus.
Paramyxoviridae Infections
Neuraminidase activity of a bovine strain of parainfluenza 3 virus.
Paramyxoviridae Infections
Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983.
Paramyxoviridae Infections
Nucleotide sequence of the coding and flanking regions of the human parainfluenza virus 3 hemagglutinin-neuraminidase gene: comparison with other paramyxoviruses.
Paramyxoviridae Infections
O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.
Paramyxoviridae Infections
Outbreak of Human Parainfluenza Virus Type 1 in a Kindergarten from China, 2018.
Paramyxoviridae Infections
Parainfluenza 3 virus: plaque-type variants lacking neuraminidase activity.
Paramyxoviridae Infections
Parainfluenza virus surface projections: glycoproteins with haemagglutinin and neuraminidase activities.
Paramyxoviridae Infections
Parainfluenza virus type 1 reduces the affinity of agonists for muscarinic receptors in guinea-pig lung and heart.
Paramyxoviridae Infections
Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
Paramyxoviridae Infections
Paramyxovirus fusion (F) protein and hemagglutinin-neuraminidase (HN) protein interactions: intracellular retention of F and HN does not affect transport of the homotypic HN or F protein.
Paramyxoviridae Infections
Paramyxovirus mediated cell fusion requires co-expression of both the fusion and hemagglutinin-neuraminidase glycoproteins.
Paramyxoviridae Infections
Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.
Paramyxoviridae Infections
Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase.
Paramyxoviridae Infections
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Paramyxoviridae Infections
Quantitative comparison of human parainfluenza virus hemagglutinin-neuraminidase receptor binding and receptor cleavage.
Paramyxoviridae Infections
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
Paramyxoviridae Infections
Receptor-Binding Specificity of the Human Parainfluenza Virus Type 1 Hemagglutinin-Neuraminidase Glycoprotein.
Paramyxoviridae Infections
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Paramyxoviridae Infections
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Paramyxoviridae Infections
Regions on the hemagglutinin-neuraminidase proteins of human parainfluenza virus type-1 and Sendai virus important for membrane fusion.
Paramyxoviridae Infections
Relative affinity of the human parainfluenza virus type 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity.
Paramyxoviridae Infections
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Paramyxoviridae Infections
Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study.
Paramyxoviridae Infections
Respiratory viruses predisposing to bacterial infections: role of neuraminidase.
Paramyxoviridae Infections
Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.
Paramyxoviridae Infections
Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein.
Paramyxoviridae Infections
Roles of conserved residues in the receptor binding sites of human parainfluenza virus type 3 HN protein.
Paramyxoviridae Infections
Sequence determination of the hemagglutinin-neuraminidase (HN) gene of human parainfluenza type 2 virus and the construction of a phylogenetic tree for HN proteins of all the paramyxoviruses that are infectious to humans.
Paramyxoviridae Infections
Sequence of the hemagglutinin-neuraminidase gene of human parainfluenza virus type 1.
Paramyxoviridae Infections
Structural Insights into Human Parainfluenza Virus 3 Hemagglutinin-Neuraminidase Using Unsaturated 3- N-Substituted Sialic Acids as Probes.
Paramyxoviridae Infections
Structural studies of the parainfluenza virus 5 hemagglutinin-neuraminidase tetramer in complex with its receptor, sialyllactose.
Paramyxoviridae Infections
Structure and mutagenesis of the parainfluenza virus 5 hemagglutinin-neuraminidase stalk domain reveals a four-helix bundle and the role of the stalk in fusion promotion.
Paramyxoviridae Infections
Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein.
Paramyxoviridae Infections
Structure of the Parainfluenza Virus 5 (PIV5) Hemagglutinin-Neuraminidase (HN) Ectodomain.
Paramyxoviridae Infections
Syncytium formation by recombinant vaccinia viruses carrying bovine parainfluenza 3 virus envelope protein genes.
Paramyxoviridae Infections
Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by ?-acylaminoamido groups at the C-4 position using isocyanide-based four-component coupling and biological evaluation as inhibitors of human parainfluenza virus type 1.
Paramyxoviridae Infections
Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfluenza virus type 1.
Paramyxoviridae Infections
Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity.
Paramyxoviridae Infections
The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.
Paramyxoviridae Infections
The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion.
Paramyxoviridae Infections
The Fusion Protein Specificity of the Parainfluenza Virus Hemagglutinin-Neuraminidase Protein Is Not Solely Defined by the Primary Structure of Its Stalk Domain.
Paramyxoviridae Infections
The Hemagglutinin-Neuraminidase (HN) Head Domain and the Fusion (F) Protein Stalk Domain of the Parainfluenza Viruses Affect the Specificity of the HN-F Interaction.
Paramyxoviridae Infections
The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity.
Paramyxoviridae Infections
The human parainfluenza virus type-1 prototypic strain contains a heat-labile hemagglutinin-neuraminidase protein.
Paramyxoviridae Infections
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
Paramyxoviridae Infections
The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
Paramyxoviridae Infections
The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.
Paramyxoviridae Infections
Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion.
Paramyxoviridae Infections
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Paramyxoviridae Infections
Wheat germ cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 for generation and characterization of monoclonal antibody.
Paramyxoviridae Infections
[Inhibition of the infectivity of enveloped viruses while retaining the specific biological activity of the viral proteins]
Paramyxoviridae Infections
[Prokaryotic expression of HN gene of bovine parainfluenza virus type 3 and the establishment of indirect ELISA method].
Paramyxoviridae Infections
[Study on functions of N-carbohydrate chains in human parainfluenza virus type 3 hemagglutinin-neuraminidase protein].
Paramyxoviridae Infections
[The rapid detection kit based on neuraminidase activity of influenza virus]
Paraproteinemias
Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Parasitemia
A bloodstream Trypanosoma congolense sialidase could be involved in anemia during experimental trypanosomiasis.
Parasitemia
Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants.
Parasitemia
Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection.
Parasitemia
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Parkinson Disease
Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Parotitis
Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore.
Pasteurella Infections
Serological response to Pasteurella multocida NanH sialidase in persistently colonized rabbits.
Periodontal Diseases
Structural Significance of the ?1K396 Residue Found in the Porphyromonas gingivalis Sialidase ?-Propeller Domain: A Computational Study with Implications for Novel Therapeutics Against Periodontal Disease.
Periodontal Diseases
The use of a rapid assay to detect the neuraminidase production in oral Porphyromonas spp. isolated from dogs and humans.
Periodontitis
A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola.
Periodontitis
Glycosidase activities in gingival crevicular fluid in subjects with adult periodontitis or gingivitis.
Periodontitis
Structural Significance of the ?1K396 Residue Found in the Porphyromonas gingivalis Sialidase ?-Propeller Domain: A Computational Study with Implications for Novel Therapeutics Against Periodontal Disease.
Periodontitis
The sialidase inhibitor, DANA, reduces Porphyromonas gingivalis pathogenicity and exerts anti-inflammatory effects: An in vitro and in vivo experiment.
Periodontitis
The use of a rapid assay to detect the neuraminidase production in oral Porphyromonas spp. isolated from dogs and humans.
Periodontitis
[Cloning and sequence analysis of a sialidase gene (siaHI) from Bacteroides forsythus ATCC 43037]
Peritonitis
Survey of neuraminidase production by Clostridium butyricum, Clostridium beijerinckii, and Clostridium difficile strains from clinical and nonclinical sources.
Persistent Infection
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa.
Persistent Infection
Accidental persistent infection of cell lines by Newcastle disease virus, showing three unusual features--defective neuraminidase, temperature sensitivity and intranuclear inclusions.
Persistent Infection
Fusion properties of cells infected with human parainfluenza virus type 3: receptor requirements for viral spread and virus-mediated membrane fusion.
Persistent Infection
Investigation of T-cell responses and viral mRNA persistence in lymph nodes of pigs infected with porcine rubulavirus.
Persistent Infection
Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.
Persistent Infection
Production of the Pseudomonas aeruginosa neuraminidase is increased under hyperosmolar conditions and is regulated by genes involved in alginate expression.
Persistent Infection
Restriction of cell surface expression of Sendai virus hemagglutinin-neuraminidase glycoprotein correlates with its higher instability in persistently and standard plus defective interfering virus infected BHK-21 cells.
Persistent Infection
[Persistent influenza virus infection. Molecular genetic characteristics of ts mutants selected during persistence]
Peste-des-Petits-Ruminants
Competitive enzyme-linked immunosorbent assay based on monoclonal antibody and recombinant hemagglutinin for serosurveillance of rinderpest virus.
Peste-des-Petits-Ruminants
Cytotoxic T cell epitope in cattle from the attachment glycoproteins of rinderpest and peste des petits ruminants viruses.
Peste-des-Petits-Ruminants
Expression of biologically active Hemagglutinin-neuraminidase protein of Peste des petits ruminants virus in transgenic pigeonpea [Cajanus cajan (L) Millsp.].
Peste-des-Petits-Ruminants
Immune responses in goats to recombinant hemagglutinin-neuraminidase glycoprotein of Peste des petits ruminants virus: identification of a T cell determinant.
Peste-des-Petits-Ruminants
Immune responses to hemagglutinin-neuraminidase protein of peste des petits ruminants virus expressed in transgenic peanut plants in sheep.
Peste-des-Petits-Ruminants
Mapping of B-cell epitopic sites and delineation of functional domains on the hemagglutinin-neuraminidase protein of peste des petits ruminants virus.
Peste-des-Petits-Ruminants
The fusion protein of Peste des petits ruminants virus mediates biological fusion in the absence of hemagglutinin-neuraminidase protein.
Peste-des-Petits-Ruminants
The hemagglutinin-neuraminidase protein of peste des petits ruminants virus is biologically active when transiently expressed in mammalian cells.
Phaeohyphomycosis
Exploring the genomic diversity of black yeasts and relatives (Chaetothyriales, Ascomycota).
Plague
Cell surface sialic acid inhibits Cx43 gap junction functions in constructed Hela cancer cells involving in sialylated N-cadherin.
Plague
Conserved hydrophobic clusters on the surface of the Caf1A usher C-terminal domain are important for F1 antigen assembly.
Plague
Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase.
Plague
[pH-dependent hemolytic and neuraminidase activity of remantadine-sensitive and -resistant variants of influenza virus]
Plasmacytoma
Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins.
Pneumococcal Infections
Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A.
Pneumococcal Infections
Investigating the role of pneumococcal neuraminidase A activity in isolates from pneumococcal haemolytic uraemic syndrome.
Pneumococcal Infections
Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae.
Pneumococcal Infections
Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.
Pneumococcal Infections
The NanA neuraminidase of Streptococcus pneumoniae is involved in biofilm formation.
Pneumococcal Infections
[The virulence of Streptococcus pneumoniae strains--the causative agents of pneumococcal infection at different sites]
Pneumonia
Behavior of hospitalized severe influenza cases according to the outcome variable in Catalonia, Spain, during the 2017-2018 season.
Pneumonia
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.
Pneumonia
DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.
Pneumonia
Extracellular neuraminidase production by a Pasteurella multocida A:3 strain associated with bovine pneumonia.
Pneumonia
Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion.
Pneumonia
Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study.
Pneumonia
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.
Pneumonia
Influence of age on symptoms and laboratory findings at presentation in patients with influenza-associated pneumonia.
Pneumonia
Influenza A virus derived from persistently virus-infected cells shows attenuated cytotoxicity in cultured cells but virulent pathogenicity in mice.
Pneumonia
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.
Pneumonia
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Pneumonia
Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study.
Pneumonia
Neuraminidase production by a Pasteurella haemolytica A1 strain associated with bovine pneumonia.
Pneumonia
Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.
Pneumonia
Retrospective survey for sialidase activity in Mycoplasma pneumoniae isolates from cases of community-acquired pneumonia.
Pneumonia
Streptococcus pneumoniae-induced hemolytic uremic syndrome: a case for early diagnosis.
Pneumonia
The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
Pneumonia
Virtual Screening of compounds from Tabernaemontana divaricata for potential anti-bacterial activity.
Pneumonia
[Assessment of the sensitivity of immunoprecipitation for the serodiagnosis of influenzal-bacterial pneumonias]
Pneumonia
[Clinical Characteristics of Adult Onset RSV Infection During Two Consecutive Winter Seasons].
Pneumonia
[Clinical Features of Hospitalized Cases due to Influenza Virus A Infection in the 2011/2012 Season].
Pneumonia
[Severe pneumonia with hemolysis caused by neuraminidase. Detection of cryptantigens by indirect immunofluorescent technic]
Pneumonia, Bacterial
Deletions in the Neuraminidase Stalk Region of H2N2 and H9N2 Avian Influenza Virus Subtypes Do Not Affect Postinfluenza Secondary Bacterial Pneumonia.
Pneumonia, Bacterial
Influenza virus neuraminidase contributes to secondary bacterial pneumonia.
Pneumonia, Bacterial
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.
Pneumonia, Bacterial
[Clinical features and outcome in 84 patients with influenza pneumonia]
Pneumonia, Necrotizing
Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children.
Pneumonia, Pneumococcal
Deacetylation of sialic acid by esterases potentiates pneumococcal neuraminidase activity for mucin utilization, colonization and virulence.
Pneumonia, Viral
Efficacy of a Cap-Dependent Endonuclease Inhibitor and Neuraminidase Inhibitors against H7N9 Highly Pathogenic Avian Influenza Virus Causing Severe Viral Pneumonia in Cynomolgus Macaques.
Pneumonia, Viral
Functional analysis of amino acids at stalk/head interface of human parainfluenza virus type 3 hemagglutinin-neuraminidase protein in the membrane fusion process.
Pneumonia, Viral
Review of Non-Bacterial Infections in Respiratory Medicine: Viral Pneumonia.
Polycystic Kidney Diseases
Cloning and expression of a chitinase gene from Sanguibacter sp. C4.
Polycystic Kidney Diseases
Functional expression and characterization of a chitinase from the marine archaeon Halobacterium salinarum CECT 395 in Escherichia coli.
Polycystic Kidney Diseases
Genomic analysis and initial characterization of the chitinolytic system of Microbulbifer degradans strain 2-40.
Polycythemia Vera
[Glycoprotein sialylation and NEU1 and ST6GAL1 expressions in erythremia].
Pre-Eclampsia
Alpha 2,6-sialyltransferase I expression in the placenta of patients with preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Electrophoretic mobility distributions of normal human T and B lymphocytes and of peripheral blood lymphoblasts in acute lymphocytic leukemia: effects of neuraminidase and of solvent ionic strength.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland.
Pregnancy Complications
Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.
Premature Birth
Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.
Premature Birth
Combination of vaginal pH with vaginal sialidase and prolidase activities for prediction of low birth weight and preterm birth.
Premature Birth
High sialidase levels increase preterm birth risk among women who are bacterial vaginosis-positive in early gestation.
Premature Birth
Inhibition of sialidase activity and cellular invasion by the bacterial vaginosis pathogen Gardnerella vaginalis.
Premature Birth
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta-analysis of cohort studies.
Premature Birth
The preterm prediction study: failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth.
Premature Birth
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora.
Prostatic Hyperplasia
Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium.
Prostatic Hyperplasia
T antigen expression in benign hyperplasia and adenocarcinoma of the prostate.
Prostatic Neoplasms
Effects of a human plasma membrane-associated sialidase siRNA on prostate cancer invasion.
Prostatic Neoplasms
Human cytosolic sialidase NEU2-low general tissue expression but involvement in PC-3 prostate cancer cell survival.
Prostatic Neoplasms
Increased sialidase activity in serum of cancer patients: Identification of sialidase and inhibitor activities in human serum.
Prostatic Neoplasms
Isoenzyme-Selective Inhibitors of Human Neuraminidases Reveal Distinct Effects on Cell Migration.
Prostatic Neoplasms
Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling.
Prostatic Neoplasms
[Enzyme activity of neuraminidase 1 correlated with the biological behavior of prostate cancer PC3 and DU145 cell lines].
Proteinuria
In vivo enzymatic removal of alpha 2-->6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury.
Proteinuria
Renal neuraminidase. Characterization in normal rat kidney and measurement in experimentally induced nephrotic syndrome.
Pseudomyxoma Peritonei
[Pseudomyxoma peritonei: a case with multiple metastases. Ultrastructural study and chemical analysis of the mucoid substance]
Puerperal Infection
[Relationship between vaginal sialidase bacteria vaginosis and chorioammionitis]
Pulmonary Aspergillosis
Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.
Pulmonary Aspergillosis
Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis.
Pulmonary Disease, Chronic Obstructive
[Metabolism of the main substance of the connective tissue in chronic obstructive pulmonary disease]
Pulmonary Edema
Neuraminidase Reprograms Lung Tissue and Potentiates Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Pulmonary Fibrosis
High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice Are Reduced by Inhibiting Sialidases.
Pulmonary Fibrosis
Inhibiting Sialidase-Induced TGF-?1 Activation Attenuates Pulmonary Fibrosis in Mice.
Pulmonary Fibrosis
Reduced Sialylation and Bioactivity of the Antifibrotic Protein Serum Amyloid P in the Sera of Patients with Idiopathic Pulmonary Fibrosis.
Pulmonary Fibrosis
Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.
Purpura, Thrombocytopenic, Idiopathic
Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Purpura, Thrombocytopenic, Idiopathic
Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia.
Pyelonephritis
Pyelonephritis: renal urokinase and sialidase (neuraminidase) activity in rats fed a standard laboratory diet.
Renal Insufficiency
In vivo enzymatic removal of alpha 2-->6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury.
Renal Insufficiency
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Respiratory Distress Syndrome
Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study.
Respiratory Distress Syndrome
The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7N9) Influenza Virus in a Mouse Model of Acute Respiratory Distress Syndrome.
Respiratory Insufficiency
DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.
Respiratory Syncytial Virus Infections
Respiratory viral infections occurring after hematopoietic stem cell transplantation.
Respiratory Tract Diseases
Influenza virus-related critical illness: prevention, diagnosis, treatment.
Respiratory Tract Infections
Analysis of delays in the prescription of oseltamivir in hospitals and potential for improvement.
Respiratory Tract Infections
Comparison of a new neuraminidase detection assay with an enzyme immunoassay, immunofluorescence, and culture for rapid detection of influenza A and B viruses in nasal wash specimens.
Respiratory Tract Infections
Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
Respiratory Tract Infections
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.
Respiratory Tract Infections
Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses.
Respiratory Tract Infections
The role of antigenically different virus neuraminidases as structures implicated in receptor-binding processes.
Respiratory Tract Infections
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Retinal Degeneration
Altered expression of ?-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.
Rhabdomyolysis
Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma.
Rhabdomyosarcoma
Cells of rhabdomyosarcoma PA-23 tumor clones with high and low metastatic potential differ by activity of lysosomal sialidase.
Rhabdomyosarcoma
Defective myogenic differentiation of human rhabdomyosarcoma cells is characterized by sialidase Neu2 loss of expression.
Rheumatic Fever
Neuraminidase production by streptococci from patients with glomerulonephritis.
Rinderpest
A newly identified horseshoe crab lectin with specificity for blood group A antigen recognizes specific O-antigens of bacterial lipopolysaccharides.
Rinderpest
The hemagglutinin-neuraminidase protein of peste des petits ruminants virus is biologically active when transiently expressed in mammalian cells.
Rotavirus Infections
Productive penetration of rotavirus in cultured cells induces coentry of the translation inhibitor alpha-sarcin.
Salmonella Infections
Implication of Sialidases in Salmonella Infection: Genome Release of Sialidase Knockout Strains from Salmonella enterica Serovar Typhimurium LT2.
Sandhoff Disease
Increased lung surfactant phosphatidylcholine in patients affected by lysosomal storage diseases.
Sarcoidosis
Anticarbohydrate autoantibodies to sialidase-treated erythrocytes and thymocytes in serum from patients with pulmonary sarcoidosis.
Sarcoidosis
Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis.
Sarcoidosis, Pulmonary
Sialidase activity and antibodies to sialidase-treated autologous erythrocytes in bronchoalveolar lavages from patients with idiopathic pulmonary fibrosis or sarcoidosis.
Sarcoma
Antitumor immune response following injection of neuraminidase-treated sarcoma cells.
Sarcoma
Comparative immunogenicity of irradiated, neuraminidase treated, and fused cells of a strain-restricted sarcoma.
Sarcoma
In vitro evidence that Vibrio Cholerae neuraminidase increases antigenicity of sarcoma cells.
Sarcoma
Metastatic sarcoma. Combined surgical and immunotherapeutic approach. Neuraminidase treated tumor cells as tumor vaccine.
Sarcoma
The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes.
Sarcoma
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.
Sarcoma
[Use of the enzyme neuraminidase for immunotherapeutic treatment of chemically induced carcinogenesis]
Sarcoma, Avian
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Sarcoma, Avian
Neuraminidase activity and cell surface sialic acid turnover in Rous sarcoma virus transformed chick embryo fibroblasts.
Sarcoma, Yoshida
Inhibition of growth of rat Yoshida sarcoma using a neuraminidase treated tumour vaccine.
Scrub Typhus
Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi).
Seizures
Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis.
Seizures
The effect of neuraminidase blocker on gabazine-induced seizures in rat hippocampus.
Seizures
Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency.
Seminoma
Electrophoretic heterogeneity of alkaline phosphatase isozymes in seminoma and normal testis.
Sepsis
Accelerated Aging and Clearance of Host Anti-inflammatory Enzymes by Discrete Pathogens Fuels Sepsis.
Sepsis
Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma.
Sepsis
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.
Sepsis
Bacterial neuraminidase-mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure.
Sepsis
Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment.
Sepsis
Crystal structure of the catalytic domain of Clostridium perfringens neuraminidase in complex with a non-carbohydrate-based inhibitor, 2-(cyclohexylamino)ethanesulfonic acid.
Sepsis
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
Sepsis
Neuraminidase activity in Streptococcus sanguis and in the viridans group, and occurrence of acylneuraminate lyase in viridans organisms isolated from patients with septicemia.
Sepsis
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19.
Sepsis
Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis.
Sepsis
Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets.
Sepsis
Potent inhibition of bacterial neuraminidase activity by pterocarpans isolated from the roots of Lespedeza bicolor.
Sepsis
Red blood cell T-activation and hemolysis in surgical intensive care patients with severe infections.
Sepsis
Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors.
Severe Acute Respiratory Syndrome
Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein.
Severe Acute Respiratory Syndrome
De Novo Drug Design of Targeted Chemical Libraries Based on Artificial Intelligence and Pair-Based Multiobjective Optimization.
Severe Acute Respiratory Syndrome
The potential antiviral effect of major royal jelly protein2 and its isoform X1 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Insight on their sialidase activity and molecular docking.
Severe Combined Immunodeficiency
Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
Shock, Septic
Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma.
Sialic Acid Storage Disease
Comparison of sialic acids excretion in spot urines and 24-hour-urines of children and adults.
Sialic Acid Storage Disease
Salla disease variants. Sialoylaciduric encephalopathy with increased sialidase activity in two non-Finnish children.
Small Cell Lung Carcinoma
Cellular site of synthesis and dynamics of cell surface re-expression of polysialic acid of the neural cell adhesion molecule.
Small Cell Lung Carcinoma
P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.
Smallpox
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Spinal Cord Injuries
Sialidase, chondroitinase ABC and combination therapy after spinal cord contusion injury.
Sporotrichosis
[Occurrence of neuraminidase in Sporothrix schenckii and Ceratocystis stenoceras and its role in ecology and pathomechanism of these fungi (author's transl)]
Spotted Fever Group Rickettsiosis
Genomic comparison of virulent Rickettsia rickettsii Sheila Smith and avirulent Rickettsia rickettsii Iowa.
Squamous Cell Carcinoma of Head and Neck
Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma.
Squamous Cell Carcinoma of Head and Neck
Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis.
Staphylococcal Infections
[The immunomodulating action of the surface antigens of the influenza A virus in experimental staphylococcal infection]
Starvation
Glycosyl hydrolases of cell wall are induced by sugar starvation in Arabidopsis.
Status Epilepticus
Neuroaminidase reduces interictal spikes in a rat temporal lobe epilepsy model.
Status Epilepticus
Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency.
steroid 21-monooxygenase deficiency
The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: possible linkage between HLA and the neuraminidase deficiency gene.
Stomach Neoplasms
Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.
Stomach Neoplasms
Expression of Forssman glycolipid and blood group-related antigens A, Le(x), and Le(y) in human gastric cancer and in fetal tissues.
Stomach Neoplasms
Lymph node metastasis-related carbohydrate epitopes of gastric cancer with submucosal invasion.
Stomach Neoplasms
The effect of sialidase inhibitors on hyaluronan-mediated escape from apoptosis induced by anti-cancer drugs in gastric cancer.
Stomach Neoplasms
Tumor-associated antigen defined by a monoclonal antibody against neuraminidase-treated human cancer cells.
Streptococcal Infections
Extracellular neuraminidase production of streptococci associated with acute nephritis.
Streptococcal Infections
Streptococcus pneumoniae Sialidase SpNanB-Catalyzed One-Pot Multienzyme (OPME) Synthesis of 2,7-Anhydro-Sialic Acids as Selective Sialidase Inhibitors.
Superinfection
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Superinfection
Neuraminidase-deficient Sendai virus HN mutants provide protection from homologous superinfection.
Superinfection
Retroviral infection of Syrian hamster BHK cells depends on age and susceptibility toward sialidase.
Swine Erysipelas
[Neuraminidase neutralizing and precipitating antibodies in commercial swine erysipelas antiserums]
Syncope
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Tachypnea
Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
Tay-Sachs Disease
Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.
Tay-Sachs Disease
Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
Tay-Sachs Disease
Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
Tetanus
Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure.
Tetanus
Evidence for the functional role of monosialoganglioside GM1 in synaptic transmission in the rat hippocampus.
Tetanus
Excitability and ion content of cerebral tissues treated with alkylating agents, tetanus toxin, or a neuraminidase.
Tetanus
Possible role of sialocompounds in the uptake of choline into synaptosomes and nerve cell cultures.
Tetanus
Preparation of affinity-purified, biotinylated tetanus toxin, and characterization and localization of cell surface binding sites on nerve growth factor-treated PC12 cells.
Tetanus
Temperature-mediated interaction of tetanus toxin with cerebral neuron cultures: characterization of a neuraminidase-insensitive toxin-receptor complex.
Tetanus
Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain.
Tetanus
Tetanus toxin binds with high affinity to neuroblastoma x glioma hybrid cells NG 108-15 and impairs their stimulated acetylcholine release.
Tetanus
Tetanus toxin inhibits the evoked outflow of an inhibitory (GABA) and an excitatory (D-aspartate) amino acid from particulate brain cortex.
Thrombocytopenia
Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia.
Thrombocytopenia
Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants.
Thrombocytopenia
Hepatocellular injury in Streptococcus pneumoniae-associated hemolytic uremic syndrome in children.
Thrombocytopenia
Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content.
Thrombocytopenia
Neuraminidase injections in rabbits. Reduced platelet surface charge, aggregation and thrombocytopenia.
Thrombocytopenia
Oral exposure to Phytomonas serpens attenuates thrombocytopenia and leukopenia during acute infection with Trypanosoma cruzi.
Thrombocytopenia
Pneumococcal meningitis complicated with hemolytic uremic syndrome: report of two cases.
Thrombocytopenia
Possible role of neuraminidase in the pathogenesis of arteritis and thrombocytopenia induced in rats by Erysipelothrix rhusiopathiae.
Thrombocytopenia
Protective effect of pantethine on experimental thrombocytopenia in the rat.
Thrombocytopenia
Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia.
Thrombocytopenia
Significance of platelets in an antimetastatic activity of bacterial lipopolysaccharide.
Thrombocytopenia
The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents.
Thrombosis
Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.
Thrombotic Microangiopathies
Atypical presentation of post infectious glomerulonephritis as malignant hypertension and thrombotic microangiopathy.
Toxoplasmosis
Computational probing of Toxoplasma gondii major surface antigen 1 (SAG1) for enhanced vaccine design against toxoplasmosis.
Toxoplasmosis
High expression of water-soluble recombinant antigenic domains of Toxoplasma gondii secretory organelles.
Toxoplasmosis
High Seroprevalence of Toxoplasmosis Detected by RDT among the Residents of Seokmo-do (Island) in Ganghwa-Gun, Incheon City, Korea.
Toxoplasmosis
Seroprevalence of Toxoplasmosis Detected by RDT in Residents near the DMZ (demilitarized zone) of Cheorwon-gun, Gangwon-do, Korea.
Trichomonas Infections
Bovine trichomoniasis as a model for development of vaccines against sexually-transmitted disease.
Triple Negative Breast Neoplasms
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Trypanosomiasis
A bloodstream Trypanosoma congolense sialidase could be involved in anemia during experimental trypanosomiasis.
Trypanosomiasis
Trypanosoma evansi sialidase: surface localization, properties and hydrolysis of ghost red blood cells and brain cells-implications in trypanosomiasis.
Trypanosomiasis, African
Biochemical characterization of trans-sialidase TS1 variants from Trypanosoma congolense.
Trypanosomiasis, African
Biochemical diversity in the Trypanosoma congolense trans-sialidase family.
Trypanosomiasis, African
Production, purification and crystallization of a trans-sialidase from Trypanosoma vivax.
Trypanosomiasis, African
Regulation of Antigenic Variation by Trypanosoma brucei Telomere Proteins Depends on Their Unique DNA Binding Activities.
Trypanosomiasis, African
Silencing subtelomeric VSGs by Trypanosoma brucei RAP1 at the insect stage involves chromatin structure changes.
Trypanosomiasis, African
Suppression of subtelomeric VSG switching by Trypanosoma brucei TRF requires its TTAGGG repeat-binding activity.
Trypanosomiasis, African
Telomerase activity is required for the telomere G-overhang structure in Trypanosoma brucei.
Trypanosomiasis, African
Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis.
Trypanosomiasis, African
Trans-sialidase Protein as a Potential Serological Marker for African Trypanosomiasis.
Trypanosomiasis, African
Trypanosoma brucei Orc1 is essential for nuclear DNA replication and affects both VSG silencing and VSG switching.
Trypanosomiasis, African
Trypanosoma brucei RAP1 Has Essential Functional Domains That Are Required for Different Protein Interactions.
Trypanosomiasis, African
Trypanosoma brucei RAP1 maintains telomere and subtelomere integrity by suppressing TERRA and telomeric RNA:DNA hybrids.
Trypanosomiasis, African
Trypanosoma brucei TIF2 and TRF Suppress VSG Switching Using Overlapping and Independent Mechanisms.
Tuberculosis
Effects of Biomolecular Flexibility on Alchemical Calculations of Absolute Binding Free Energies.
Tuberculosis
Sequence analysis of haemagglutinin and neuraminidase of H1N1 strain from a patient coinfected with Mycobacterium tuberculosis.
Tuberculosis
The Mycobacterium tuberculosis phagosome in human macrophages is isolated from the host cell cytoplasm.
Urinary Bladder Neoplasms
Increase of the in vitro complement-dependent cytotoxicity against autologous invasive human bladder tumor cells by neuraminidase treatment.
Urinary Bladder Neoplasms
Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin ?5?1 interaction and Akt signaling pathway.
Urinary Bladder Neoplasms
T-antigen. A prognostic indicator of high recurrence index in transitional carcinoma of the bladder.
Urolithiasis
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Urolithiasis
In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity.
Urolithiasis
The effect of calcium and magnesium ions on urinary urokinase and sialidase activity.
Vaccinia
A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.
Vaccinia
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
Vaccinia
Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein.
Vaccinia
Biological activity of paramyxovirus fusion proteins: factors influencing formation of syncytia.
Vaccinia
Biosynthesis, intracellular transport and enzymatic activity of an avian influenza A virus neuraminidase: role of unpaired cysteines and individual oligosaccharides.
Vaccinia
Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Vaccinia
Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity.
Vaccinia
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
Vaccinia
Differences in the role of the cytoplasmic domain of human parainfluenza virus fusion proteins.
Vaccinia
Expression of cDNA encoding the Sendai virus hemagglutinin-neuraminidase gene: characterization of wild-type and mutant gene products.
Vaccinia
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Vaccinia
Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses.
Vaccinia
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Vaccinia
Immunobiological properties of influenza A (H7N9) hemagglutinin and neuraminidase proteins.
Vaccinia
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
Vaccinia
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Vaccinia
Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein.
Vaccinia
Loss of glycosylation at Asn144 alters the substrate preference of the N8 influenza A virus neuraminidase.
Vaccinia
Mice lacking CD8+ T cells develop greater numbers of IgA-producing cells in response to a respiratory virus infection.
Vaccinia
Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Vaccinia
Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.
Vaccinia
Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.
Vaccinia
Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes.
Vaccinia
Regions on the hemagglutinin-neuraminidase proteins of human parainfluenza virus type-1 and Sendai virus important for membrane fusion.
Vaccinia
Sialic acid is cleaved from glycoconjugates at the cell surface when influenza virus neuraminidases are expressed from recombinant vaccinia viruses.
Vaccinia
The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion.
Vaccinia
The hemagglutinin-neuraminidase (HN) gene of Newcastle disease virus strain Italien (ndv Italien): comparison with HNs of other strains and expression by a vaccinia recombinant.
Vaccinia
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
Vaginal Discharge
[Relationship between vaginal sialidase bacteria vaginosis and chorioammionitis]
Vaginal Diseases
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Vaginitis
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China.
Vaginitis
Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis.
Vaginitis
[Interaction between vaginal micro-environment alterations and HPV16 infection in cervical intraepithelial neoplasia].
Vaginosis, Bacterial
A Biochemiluminescent Sialidase Assay for Diagnosis of Bacterial Vaginosis.
Vaginosis, Bacterial
A tetravalent sialic acid-coated tetraphenylethene luminogen with aggregation-induced emission characteristics: design, synthesis and application for sialidase activity assay, high-throughput screening of sialidase inhibitors and diagnosis of bacterial vaginosis.
Vaginosis, Bacterial
Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta.
Vaginosis, Bacterial
Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial.
Vaginosis, Bacterial
Bacterial vaginosis in pregnant adolescents: proinflammatory cytokine and bacterial sialidase profile. Cross-sectional study.
Vaginosis, Bacterial
Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.
Vaginosis, Bacterial
BVBLUE test for diagnosis of bacterial vaginosis in pregnant women attending antenatal care at Phramongkutklao Hospital.
Vaginosis, Bacterial
Cervicovaginal cytokines, sialidase activity and bacterial load in reproductive-aged women with intermediate vaginal flora.
Vaginosis, Bacterial
Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis.
Vaginosis, Bacterial
Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes.
Vaginosis, Bacterial
Gardnerella vaginalis comprises three distinct genotypes of which only two produce sialidase.
Vaginosis, Bacterial
Gardnerella vaginalis Subgroups Defined by cpn60 Sequencing and Sialidase Activity in Isolates from Canada, Belgium and Kenya.
Vaginosis, Bacterial
Immunoglobulin A response against Gardnerella vaginalis hemolysin and sialidase activity in bacterial vaginosis.
Vaginosis, Bacterial
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis.
Vaginosis, Bacterial
Inhibition of sialidase activity and cellular invasion by the bacterial vaginosis pathogen Gardnerella vaginalis.
Vaginosis, Bacterial
Prevalence of vaginolysin, sialidase and phospholipase genes in Gardnerella vaginalis isolates between bacterial vaginosis and healthy individuals.
Vaginosis, Bacterial
Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis.
Vaginosis, Bacterial
Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora.
Vaginosis, Bacterial
The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal Fluid.
Vaginosis, Bacterial
The presence of the putative Gardnerella vaginalis sialidase A gene in vaginal specimens is associated with bacterial vaginosis biofilm.
Vaginosis, Bacterial
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
Vaginosis, Bacterial
The preterm prediction study: failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth.
Vaginosis, Bacterial
Use of 5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid in a novel spot test To identify sialidase activity in vaginal swabs from women with bacterial vaginosis.
Vaginosis, Bacterial
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora.
Vaginosis, Bacterial
Vaginal microflora associated with bacterial vaginosis in nonpregnant women: reliability of sialidase detection.
Vaginosis, Bacterial
[Relationship between vaginal sialidase bacteria vaginosis and chorioammionitis]
Vascular System Injuries
Dual Specificity of Human Plasma Lactose-Binding Immunoglobulin to Anomers of Terminal Galactose Enables Recognition of Desialylated Lipoprotein(a) and Xenoantigens.
Vesicular Stomatitis
A novel chimeric oncolytic virus vector for improved safety and efficacy in hepatocellular carcinoma.
Vesicular Stomatitis
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
Vesicular Stomatitis
Cellular adsorption function of the sialoglycoprotein of vesicular stomatitis virus and its neuraminic acid.
Vesicular Stomatitis
Cross-reactive anti-vesicular stomatitis virus (VSV) cytotoxic T lymphocytes recognize the major surface glycoprotein.
Vesicular Stomatitis
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
Vesicular Stomatitis
Influenza vaccine: progress in a vaccine that elicits a broad immune response.
Vesicular Stomatitis
Integration of membrane proteins into the endoplasmic reticulum requires GTP.
Vesicular Stomatitis
Intracellular processing of the vesicular stomatitis virus glycoprotein and the Newcastle disease virus hemagglutinin-neuraminidase glycoprotein.
Vesicular Stomatitis
Role of viral envelope sialic acid in membrane fusion mediated by the vesicular stomatitis virus envelope glycoprotein.
Virus Diseases
4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus.
Virus Diseases
A Cost-Effectiveness Analysis of Neuraminidase Inhibitors for Influenza Virus Infections in an Adult-Outpatient Setting in Japan.
Virus Diseases
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
Virus Diseases
A glycosyl hydrolase activity of mammalian reovirus sigma1 protein can contribute to viral infection through a mucus layer.
Virus Diseases
A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
Virus Diseases
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens.
Virus Diseases
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
Virus Diseases
A novel genotyping and quantitative analysis of neuraminidase inhibitor-resistance associated mutations in influenza A viruses by single nucleotide polymorphism analysis.
Virus Diseases
A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture.
Virus Diseases
A randomized study of standard versus double dose oseltamivir for treating influenza in the community.
Virus Diseases
A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK.
Virus Diseases
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.
Virus Diseases
A Sero-Survey of Subtype H3 Influenza A Virus Infection in Dogs and Cats in Japan.
Virus Diseases
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Virus Diseases
A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
Virus Diseases
Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity.
Virus Diseases
Amide-sialoside protein conjugates as neomucin bioshields prevent influenza virus infection.
Virus Diseases
An enzymatic assay reveals that proteins destined for the apical or basolateral domains of an epithelial cell line share the same late Golgi compartments.
Virus Diseases
Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein.
Virus Diseases
Analysis of the protective effect of the haemagglutinin-neuraminidase protein in Newcastle disease virus infection.
Virus Diseases
Anti-Influenza Activity of an Ethyl Acetate Fraction of a Rhus verniciflua Ethanol Extract by Neuraminidase Inhibition.
Virus Diseases
Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.
Virus Diseases
Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
Virus Diseases
Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding.
Virus Diseases
Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
Virus Diseases
Antigenic validation of recombinant hemagglutinin-neuraminidase protein of Newcastle disease virus expressed in Saccharomyces cerevisiae.
Virus Diseases
Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Virus Diseases
Antiviral activity of the plant extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii against influenza virus A/PR/8/34.
Virus Diseases
Aromatic sialic acid analogues as potential inhibitors of influenza virus neuraminidase.
Virus Diseases
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Virus Diseases
Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Virus Diseases
Avian cells expressing the Newcastle disease virus hemagglutinin-neuraminidase protein are resistant to Newcastle disease virus infection.
Virus Diseases
Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor.
Virus Diseases
Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Virus Diseases
Characterization of SA-11 rotavirus receptorial structures on human colon carcinoma cell line HT-29.
Virus Diseases
Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity.
Virus Diseases
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Virus Diseases
Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.
Virus Diseases
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Virus Diseases
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
Virus Diseases
Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.
Virus Diseases
Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: A phase III randomized, double-blind study.
Virus Diseases
Comprehensive profiling of translation initiation in influenza virus infected cells.
Virus Diseases
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.
Virus Diseases
Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.
Virus Diseases
Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.
Virus Diseases
Current and future antiviral therapy of severe seasonal and avian influenza.
Virus Diseases
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.
Virus Diseases
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.
Virus Diseases
Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice.
Virus Diseases
Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
Virus Diseases
Design of fluorinated sialic acid analog inhibitor to H5 hemagglutinin of H5N1 influenza virus through molecular dynamics simulation study.
Virus Diseases
Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections.
Virus Diseases
Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1.
Virus Diseases
Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.
Virus Diseases
Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Virus Diseases
Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.
Virus Diseases
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
Virus Diseases
Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
Virus Diseases
Diverse and Unexpected Roles of Human Monocytes/Macrophages in the Immune Response to Influenza Virus.
Virus Diseases
Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.
Virus Diseases
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.
Virus Diseases
Dynamics of viral growth, viral enzymatic activity, and antigenicity in murine lungs during the course of influenza pneumonia.
Virus Diseases
Effect of inflammatory cell mediators on M2 muscarinic receptors in the lungs.
Virus Diseases
Effect of specific immunity to viral neuraminidase on subsequent influenza virus infection in man.
Virus Diseases
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Virus Diseases
Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
Virus Diseases
Efficacy of a high-yield attenuated vaccine strain wholly derived from avian influenza viruses by use of reverse genetics.
Virus Diseases
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Virus Diseases
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Virus Diseases
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.
Virus Diseases
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
Virus Diseases
Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
Virus Diseases
Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection.
Virus Diseases
Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.
Virus Diseases
Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival.
Virus Diseases
Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery.
Virus Diseases
Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.
Virus Diseases
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
Virus Diseases
Functional balance between haemagglutinin and neuraminidase in influenza virus infections.
Virus Diseases
Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination.
Virus Diseases
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Virus Diseases
Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus.
Virus Diseases
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
Virus Diseases
H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.
Virus Diseases
H9N2 Influenza Virus Infections in Human Cells Require a Balance between Neuraminidase Sialidase Activity and Hemagglutinin Receptor Affinity.
Virus Diseases
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Virus Diseases
Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.
Virus Diseases
Homo- and heterosubtypic low pathogenic avian influenza exposure on H5N1 highly pathogenic avian influenza virus infection in wood ducks (Aix sponsa).
Virus Diseases
Human genetics and responses to influenza vaccination: clinical implications.
Virus Diseases
Human parainfluenza virus 3 neuraminidase activity contributes to dendritic cell maturation.
Virus Diseases
Identification of a linear epitope on the haemagglutinin protein of pandemic A/H1N1 2009 influenza virus using monoclonal antibodies.
Virus Diseases
Identification of antigenic epitopes in the hemagglutinin protein of H7 avian influenza virus.
Virus Diseases
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
Virus Diseases
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.
Virus Diseases
Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking.
Virus Diseases
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection.
Virus Diseases
Immunohistochemical Findings of an Autopsied Lung Specimen from a Patient with Pandemic Influenza (A/H1N1pdm) Virus Infection.
Virus Diseases
Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice.
Virus Diseases
Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
Virus Diseases
In silico biology of H1N1: molecular modelling of novel receptors and docking studies of inhibitors to reveal new insight in flu treatment.
Virus Diseases
In vitro and in vivo characterization of novel neuraminidase substitutions in influenza A(H1N1)pdm09 identified using Laninamivir-mediated in vitro selection.
Virus Diseases
In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.
Virus Diseases
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Virus Diseases
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
Virus Diseases
Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104.
Virus Diseases
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
Virus Diseases
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
Virus Diseases
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Virus Diseases
Influenza virus changes cell-surface glycoproteins including major histocompatibility complex determinants on lymphocytes.
Virus Diseases
Influenza virus infection of mouse lymphoblasts alters the binding affinity of anti-H-2 antibody: requirement for viral neuraminidase.
Virus Diseases
Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections.
Virus Diseases
Inhibition of Influenza A Virus Infection by Fucoidan Targeting Viral Neuraminidase and Cellular EGFR Pathway.
Virus Diseases
Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Virus Diseases
Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion.
Virus Diseases
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Virus Diseases
Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Virus Diseases
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Virus Diseases
In Vitro Evaluation of Synergistic Inhibitory Effects of Neuraminidase Inhibitors and Methylglyoxal Against Influenza Virus Infection.
Virus Diseases
Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
Virus Diseases
L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo.
Virus Diseases
Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.
Virus Diseases
Laninamivir Octanoate and Artificial Surfactant Combination Therapy Significantly Increases Survival of Mice Infected with Lethal Influenza H1N1 Virus.
Virus Diseases
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Virus Diseases
Locking the 150-cavity open: in silico design and verification of influenza neuraminidase inhibitors.
Virus Diseases
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection.
Virus Diseases
Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Virus Diseases
Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.
Virus Diseases
Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids Confers Neuraminidase Resistance and Inhibits Influenza Reproduction.
Virus Diseases
Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.
Virus Diseases
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
Virus Diseases
Molecular docking analysis of zanamavir with haem agglutinin neuraminidase of human para influenza virus type 3.
Virus Diseases
Molecular Docking, 3D-QSAR studies and in-silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Virus Diseases
Morin Hydrate Inhibits Influenza Virus entry into Host Cells and Has Anti-inflammatory Effect in Influenza-infected Mice.
Virus Diseases
Mouse Saliva Inhibits Transit of Influenza Virus to the Lower Respiratory Tract by Efficiently Blocking Influenza Virus Neuraminidase Activity.
Virus Diseases
Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
Virus Diseases
Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child.
Virus Diseases
Mutants of an influenza A reassortant which are cold-sensitive (cs) as well as temperature-sensitive (ts): on the role of the neuraminidase activity for influenza virus infection.
Virus Diseases
N1 neuraminidase of H5N1 avian influenza A virus complexed with sialic acid and zanamivir - A study by molecular docking and molecular dynamics simulation.
Virus Diseases
Neuraminidase activity of influenza virus-infected cells: localization and properties.
Virus Diseases
Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection.
Virus Diseases
Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection.
Virus Diseases
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
Virus Diseases
Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
Virus Diseases
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.
Virus Diseases
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.
Virus Diseases
Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses.
Virus Diseases
Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.
Virus Diseases
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Virus Diseases
Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex.
Virus Diseases
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Virus Diseases
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains.
Virus Diseases
Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
Virus Diseases
Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Virus Diseases
Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection.
Virus Diseases
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Virus Diseases
Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
Virus Diseases
Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.
Virus Diseases
Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Virus Diseases
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.
Virus Diseases
Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.
Virus Diseases
Recent Advances in Neuraminidase Inhibitor Development as Anti-influenza Drugs.
Virus Diseases
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.
Virus Diseases
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Virus Diseases
Respiratory viral infections occurring after hematopoietic stem cell transplantation.
Virus Diseases
Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
Virus Diseases
Sequence and phylogenetic analyses of neuraminidase gene of Iranian seasonal influenza H1N1 viruses from 2005-2009 and corresponding vaccine strains.
Virus Diseases
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
Virus Diseases
Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design.
Virus Diseases
Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor.
Virus Diseases
Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus.
Virus Diseases
Suppression of influenza virus infection by an N-thioacetylneuraminic acid acrylamide copolymer resistant to neuraminidase.
Virus Diseases
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Virus Diseases
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Virus Diseases
Swine-origin influenza A (H3N2) virus infection in two children--Indiana and Pennsylvania, July-August 2011.
Virus Diseases
Synthesis and chemical characterization of several perfluorinated sialic acid glycals and evaluation of their in vitro antiviral activity against Newcastle disease virus.
Virus Diseases
Synthesis of a carbocyclic sialic acid analogue for the inhibition of influenza virus neuraminidase.
Virus Diseases
Synthesis of novel pentacyclic triterpene-Neu5Ac2en derivatives and investigation of their in vitro anti-influenza entry activity.
Virus Diseases
Synthesis of Pyrazine-1,3-thiazine Hybrid Analogues as Antiviral Agent Against HIV-1, Influenza A (H1N1), Enterovirus 71 (EV71), and Coxsackievirus B3 (CVB3).
Virus Diseases
Synthesis of sialoglycopolypeptide for potentially blocking influenza virus infection using a rat alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm larvae.
Virus Diseases
Targets for the induction of protective immunity against influenza a viruses.
Virus Diseases
The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.
Virus Diseases
The amino-terminal region of the neuraminidase protein from avian H5N1 influenza virus is important for its biosynthetic transport to the host cell surface.
Virus Diseases
The Detection of a Low Pathogenicity Avian Influenza Virus Subtype H9 Infection in a Turkey Breeder Flock in the United Kingdom.
Virus Diseases
The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.
Virus Diseases
The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures.
Virus Diseases
The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses.
Virus Diseases
Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.
Virus Diseases
Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.
Virus Diseases
Transforming growth factor-?: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis.
Virus Diseases
Treatment of community-acquired lower respiratory tract infections during pregnancy.
Virus Diseases
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice.
Virus Diseases
Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody.
Virus Diseases
Viral neuraminidase treatment of dendritic cells enhances antigen-specific CD8(+) T cell proliferation, but does not account for the CD4(+) T cell independence of the CD8(+) T cell response during influenza virus infection.
Virus Diseases
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.
Virus Diseases
[Antigenic and biochemical analysis of the proteins of influenza virus A/USSR/Alma-Ata/13/81 with hemagglutinin H1]
Virus Diseases
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Virus Diseases
[Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
Virus Diseases
[Role of neuraminidase inhibitors for the treatment of influenza A virus infections]
Virus Diseases
[The induction by the influenza virus A/H1N1 (serovariant Hsw1N1) and its glycoproteins of congenital pathology in mice]
Virus Diseases
[The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand]
Vitamin E Deficiency
[Activation of lipoxygenase, neuraminidase and phospholipase A in cellular and subcellular membranes in carbon tetrachloride poisoning and vitamin E deficiency]
Whooping Cough
Adhesion of Bordetella pertussis to sulfatides and to the GalNAc beta 4Gal sequence found in glycosphingolipids.
Whooping Cough
Histamine release, an undesired effect of thrombin inhibitors with basic character, is mediated through direct activation of G(i) proteins.
Whooping Cough
Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli.
Whooping Cough
Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein.
Whooping Cough
Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action.
Whooping Cough
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Whooping Cough
Trichinella spiralis: histamine secretion induced by TSL-1 antigens from unsensitized mast cells.
Zika Virus Infection
Cell surface ?2,3-linked sialic acid facilitates Zika virus internalization.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.078
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid
-
in 50 mM Tris-HCl pH7.5, at 25°C
0.018
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant H277F, pH 5.0, 37°C
0.021
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant A160G, pH 5.0, 37°C
0.032
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant R48S, pH 5.0, 37°C
0.033
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant R48N, pH 5.0, 37°C
0.038
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant E51S, pH 5.0, 37°C
0.045
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant wild-type enzyme, pH 5.0, 37°C
0.14
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant M87G, pH 5.0, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
8
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant M87G, pH 5.0, 37°C
23
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant wild-type enzyme, pH 5.0, 37°C
27
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutants A160G and H277F, pH 5.0, 37°C
32
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant R48N, pH 5.0, 37°C
44
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant R48S, pH 5.0, 37°C
51
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid
recombinant mutant E51S, pH 5.0, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
5
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
Homo sapiens
IC50 above 5 mM, isoform NEU3
0.058
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(acetylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.013
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(benzoylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.032
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(butyrylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.68
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-[(cyclopropylcarbonyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.76
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
1,8-dihydroxyanthracene-9,10-dione
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.034
2,6-anhydro-3,5-dideoxy-5-glycolylamido-D-glycero-D-galactonon-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
0.0083
2,6-anhydro-5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
0.15 - 0.19
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
0.013
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
1
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.23
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.055
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.07
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.57
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.89
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.38
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.01
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-(pentanoylamino)-L-glycero-L-altro-non-2-enonic acid
Homo sapiens
-
0.565
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-[(3-methylbutanoyl)amino]-L-glycero-L-altro-non-2-enonic acid
Homo sapiens
-
0.135
5-(acetylamino)-2,6-anhydro-9-[(cyclopentylcarbonyl)amino]-3,5,9-trideoxy-L-glycero-L-altro-non-2-enonic acid
Homo sapiens
-
0.041 - 1.1
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
0.018
5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galactonon-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
0.031 - 0.043
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
2.4 - 10
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
1
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-methyl-4-methylidene-2-phenyl-4H-chromene
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.1
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.47
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.8
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.15
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.19
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.013
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.013
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.13
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.16
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.018
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.032
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.552
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
Homo sapiens
isoform NEU2
5
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
Homo sapiens
IC50 above 5 mM, isoform NEU4
0.041
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
1.1
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.031
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.043
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
2.4
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
10
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
IC50 above 10 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.89
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
3.5 - 5
-
pH 3.5: about 30% of maximal activity, pH 5.0: about 60% of maximal activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
only lysosomal Neu1 and plasma membrane-associated Neu3 are detected in freshly isolated and activated human T lymphocytes. Activity of Neu3 changes minimally in activated lymphocytes. Sialidase activity in activated T lymphocytes contributes to the hyposialylation of specific cell surface glycoconjugates and to the production of IFN-gamma
brenda
additional information
-
tissue distribution of the 3 isozymes, Neu-1 is ubiquitously expressed at higher level, except for neutrophils
brenda
-
expressing human tyrosinase under the transcriptional control of the T-RExTM. The expression level of Neu4L is dramatically decreased prior to apoptosis. Neu4L and its substrate ganglioside GD3 may act as key molecules in the mitochondrial apoptotic pathway in neuronal cells
brenda
only lysosomal Neu1 and plasma membrane-associated Neu3 are detected in freshly isolated and activated human T lymphocytes. Activation of lymphocytes by exposure to anti-CD3 and anti-CD28 IgG results in a ninefold increase in Neu1-specific activity after growth of cells in culture for 5 days. The increase in Neu1 enzyme activity correlates with increased synthesis of Neu1-specific mRNA. Neu1 is present on the surface of freshly isolated and activated CD4 and CD8 T lymphocytes. Cell surface Neu1 is tightly associated with a subunit of protective protein/cathepsin A. Sialidase activity in activated T lymphocytes contributes to the hyposialylation of specific cell surface glycoconjugates and to the production of IFN-gamma
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
additional information
-
intracellular distribution, enzyme contains a signal for internalization in form of a C-terminal tetrapeptide Y412GTL415, Y412 and L415 are essential for endocytosis of the enzyme, mechanism, targeting from lysosomal membrane to endosomes via clathrin-coated pits, enzyme pattern in AP3-deficient cells
-
brenda
NEU3 is able to mobilize to membrane ruffles in response to growth stimuli and activate the Rac-1 signaling by co-localization with Rac-1, leading to increased cell motility
brenda
Neu3 is localized in the inner membrane of the nuclear envelope
brenda
Neu1 is localized in the outer membrane of the nuclear envelope
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
mutations of residues expected to interact directly with the sialic acid N5-acetyl (A160, M87, I105) and C7-C9 glycerol side-chain (E113, Y179, Y181) reduce enzymatic activity. Truncations at the N- or C-terminus of more than 10 residues abolish enzyme activity
metabolism
NEU3 regulates the detergent resistant membranes ganglioside content and is as a modulator of Akt phosphorylation
malfunction
mutations in the NEU1 gene are causative of sialidosis, a severe lysosomal storage disorder showing autosomal recessive mode of inheritance
metabolism
-
NEU4 long is a downstream component of the PI3K/Akt signaling pathway required for retinoic acid-induced differentiation of neuroblastoma SK-N-BE cells
physiological function
physiological function
isoform NEU1 restrains the endothelial migratory response to wounding
physiological function
-
the proline-rich region of NEU4 long can enhance cell proliferation and retinoic acid-induced neuronal differentiation and it is also involved in NEU4 interaction with Akt, as well as in substrate recognition, modifying directly or through the interaction with other protein(s) the enzyme specificity toward sialylated glycoprotein(s)
physiological function
-
isoform NEU3 is involved in the fine-tuning of sialic acid-containing glycans directly on the cell surface and plays relevant roles in important biological phenomena such as cell differentiation, molecular recognition, and cancer transformation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). NEUR3_HUMAN
428
0
48252
Swiss-Prot
other Location (Reliability: 2)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
48000
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
modeling of three-dimensional structures of NEU3 based on the crystal structure of NEU2 using a homology modeling program
hanging drop method, high resolution X-ray structures of human sialidase Neu2, in its apo form and in complex with the inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. The structure shows the canonical six-blade beta-propeller observed in viral and bacterial sialidases with its active site in a shallow crevice. In the complex structure, the inhibitor lies in the catalytic crevice surrounded by ten amino acids
modeling of three-dimensional structures of NEU1, NEU3 and NEU4 based on the crystal structure of NEU2 using a homology modeling program
modeling of three-dimensional structures of NEU4 based on the crystal structure of NEU2 using a homology modeling program
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
A160G
site-directed mutagenesis, the mutant shows slightly reduced activity compared to the wild-type enzyme
D50S
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
E51D
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
E51S
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
G162A
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
G419STOP
site-directed mutagenesis, the C-terminal 10-residue truncation leads to an increase in activity compared to the wild-type enzyme
H277F
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
I105G
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
L408STOP
site-directed mutagenesis, the large deletion leads to inactivation of the mutant
M87G
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
N88D
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
R114A
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
R114Q
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
R25H
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
V107M
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
Y370C
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
Y370F
D234N
the mutation results in significantly lower levels of sialidase activity (25%) compared to the wild type and is associated with sialosis
G413A
-
site-directed mutagenesis, activity and localization in the cell similar to the wild-type enzyme
K45A
the mutant shows about 3fold increased activity towards 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid compared to the wild type
L415A
-
site-directed mutagenesis, 30-50% reduced activity compared to the wild-type enzyme, no internalization due to impaired endocytosis, location in the plasma membrane and the cytosol
Q112A
the mutant shows nearly 4fold increased activity towards 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid compared to the wild type
Q270A
the mutant shows about 4fold increased activity towards 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid compared to the wild type
V217A
the mutation results in significantly lower levels of sialidase activity (44%) compared to the wild type and is associated with sialosis
Y412A
-
site-directed mutagenesis, 55-70% reduced activity compared to the wild-type enzyme, no internalization due to impaired endocytosis, location in the plasma membrane and the cytosol
additional information
additional information
mutations of residues expected to interact directly with the sialic acid N5-acetyl (A160, M87, I105) and C7-C9 glycerol side-chain (E113, Y179, Y181) reduce enzymatic activity. Truncations at the N- or C-terminus of more than 10 residues abolish enzyme activity
additional information
-
mutations of residues expected to interact directly with the sialic acid N5-acetyl (A160, M87, I105) and C7-C9 glycerol side-chain (E113, Y179, Y181) reduce enzymatic activity. Truncations at the N- or C-terminus of more than 10 residues abolish enzyme activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
the enzyme is unstable upon freezing at -20°C, 50% loss of activity after one cycle of freezing-thawing
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant wild-type and mutant enzymes as MBP-fusion proteins from Escherichia coli strain TB1 by amylose affinity chromatography, the tag is cleaved off by Factor Xa
SP Sepharose column chromatography, His-Trap HP column chromatography, and Superdex 200 gel filtration
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
adenoviral-mediated gene transfer is used to overexpress hNeu3 in the livers of male mice. hepatic Neu3 overexpression improves insulin sensitivity and glucose tolerance through modification of ganglioside composition and peroxisome proliferator-activated receptor gamma signaling
overexpression in mouse aortic vascular smooth muscle cells. Overexpression of this gene has no effect on DNA synthesis and ERK phosphorylation in cultured vascular smooth muscle cells in the presence of TNF-alpha. The expression of the Neu3 gene leads to the inhibition of TNF-alpha induced matrix metalloproteinase-9 (MMP-9) expression in vascular smooth muscle cells. Neu3 gene expression strongly decreases MMP-9 promoter activity in response to TNF-alpha
recombinant expression of wild-type and mutant A160G, E51S, H277F, R48N, R48S, M87G, D50S, and Y370F enzymes as MBP-fusion proteins in Escherichia coli strain TB1
gene neu-1 located in the major histocompatibility complex locus, expression of wild-type and mutant in COS-7 cells
-
isozyme NEU2, DNA and amino acid sequence determination and analysis, overexpression as soluble active enzyme in Escherichia coli
-
isozymes Neu-1 and Neu-3, DNA sequence determination and analysis, expression of the enzymes in COS-7 cells, stably in JURKAT cells, and as His-tagged proteins in Spodoptera frugiperda Sf9 insect cells
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
medicine
in fibroblasts from patients with sialidosis, oversialylated lysosomal membrane protein Lamp-1 enhances lysosomal exocytosis. Silencing of Lamp-1 reverts this phenotype by interfering with the docking of lysosomes at the plasma membrane
medicine
-
neuraminidase activity is significantly higher in septic patients compared with nonseptic patients and healthy volunteers. Desialylation by increased neuramindase activity may contribute to the alternations in red blood cell rheology
medicine
-
study on susceptibility of Neu3 transgenic mice to induction of colonic aberrant crypt foci by azoxymethane. Injection of with azoxymethane results in decreased GM3 and increased lactosylceramide content in transgenic colon mucosa. Up-regulation of Neu3 is important to the promotion stage of colorectal carcinogenesis
medicine
-
the induction of hST3Gal V, which synthesizes ganglioside GM3 and reduction of Neu3 by PMA, are linked for the expression of differentiation marker protein, CD41b surface antigen. Neu3 overexpression inhibits the PMA-induced ERK1/2 and p38 MAPK phosphorylation in the K-562 cells. Down-regulation of expression of CD41b surface antigen is dependent on expression of Neu3 gene. Neu3 inhibitor 2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid induces morphological changes, showing megakaryocytic differentiation of K562 cells, with expression of CD41b surface antigen, while specific glucosylceramide synthase inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol inhibits megakaryocytic differentiation of K-562 cells. Molecular mechanisms involved in Neu3-involved inhibition of CD41b surface antigen expression in K-562 cells include that Neu3 degrades membrane sialic acids and the resulting signaling pathway of the PKC/ERKs/p38 MAPK is down-regulated, causing a decrease in CD41b surface antigen expression and inhibition of megakaryocytic differentiation of K562 cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Schauer, R.; Wember, M.
Isolation and characterization of a sialidase from the starfish Asterias rubens
Biol. Chem. Hoppe-Seyler
370
183-190
1989
Asterias rubens, Homo sapiens
brenda
Lieser, M.; Harms, E.; Kern, H.; Bach, G.; Cantz, M.
Ganglioside GM3 sialidase activity in fibroblasts of normal individuals and of patients with sialidosis and mucolipidosis IV
Biochem. J.
260
69-74
1989
Homo sapiens
brenda
Hiraiwa, M.; Uda, Y.; Nishizawa, M.; Miyatake, T.
Human placental sialidase: partial purification and characterization
J. Biochem.
101
1273-1279
1987
Homo sapiens
brenda
Michalski, J.C.; Corfield, A.P.; Schauer, R.
Properties of human liver lysosomal sialidase
Biol. Chem. Hoppe-Seyler
367
715-722
1986
Homo sapiens
brenda
Hiraiwa, M.; Uda, Y.; Nishizawa, M.; Uda, Y.; Nakajima, T.; Miyatake, T.
Human placental sialidase: further purification and characterization
J. Biochem.
103
86-90
1988
Homo sapiens
brenda
Verheuen, F.W.; Palmeri, S.; Galjaard, H.
Purification and partial characterization of lysosomal neuraminidase from human placenta
Eur. J. Biochem.
162
63-67
1987
Homo sapiens
brenda
Schauer, R.; Wember, M.; Tschetsche, H.
Isolation and characterization of an oligosaccharide- and glycoprotein-specific sialidase from human leucocytes
Hoppe-Seyler's Z. Physiol. Chem.
365
419-426
1984
Homo sapiens
brenda
Michalski, J.C.; Corfield, A.P.; Schauer, R.
Solubilization and affinity chromatography of a sialidase from human liver
Hoppe-Seyler's Z. Physiol. Chem.
363
1097-1102
1982
Homo sapiens
brenda
Meyer, D.M.; Lemmonier, M.; Bourrillon, R.
Human liver neuraminidase
Biochem. Biophys. Res. Commun.
103
1302-1309
1981
Homo sapiens
brenda
Thomas, G.H.; Reynolds, L.W.; Miller, C.S.
Characterization of neuraminidase activity of cultured human fibroblasts
Biochim. Biophys. Acta
568
39-48
1979
Homo sapiens
brenda
Ray, P.K.
Bacterial neuraminidase and altered immunological behavior of treated mammalian cells
Adv. Appl. Microbiol.
21
227-267
1977
Bos taurus, Oryctolagus cuniculus, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Tallman J.F.; Brady, R.O.
The purification and properties of a mammalian neuraminidase (sialidase)
Biochim. Biophys. Acta
293
434-443
1973
Homo sapiens
brenda
Waters, P.J.; Corfield, A.P.; Eisenthal, R.; Pennok, C.A.
Freeze-stable sialidase activity in human leucocytes: substrate specificity, inhibitor susceptibility, detergent requirements and subcellular localization
Biochem. J.
301
777-784
1994
Homo sapiens
-
brenda
Hiraiwa, M.; Uda, Y.; Tsuji, S.; Miyatake, T.; Martin, B.M.; Tayama, M.; O. Brien, J.S.; Kishimoto, Y.
Human placental sialidase complex: characterization of the 60 kda protein that cross-reacts with anti-saposin antibodies
Biochem. Biophys. Res. Commun.
177
1211-1216
1991
Homo sapiens
brenda
Martinez-Zorzano, V.S.; Feijoo, C.; de la Cadena, M.P.; Butron, M.; Fernandez-Briera, A.; Rodriguez-Berrocal, F.J.
Human colon sialidase: characterization and activity levels in normal mucosa and colonic adenocarcinoma
Enzyme Protein
48
282-290
1996
Homo sapiens
brenda
Wang, P.; Zhang, J.; Bian, H.; Wu, P.; Kuvelkar, R.; Kung, T.T.; Crawley, Y.; Egan, R.W.; Billah, M.M.
Induction of lysosomal and plasma membrane-bound sialidases in human T-cells via T-cell receptor
Biochem. J.
380
425-433
2004
Homo sapiens, Mus musculus
brenda
Nagaoka, M.; Shiraishi, T.; Furuhata, K.; Uda, Y.
Effects of inorganic anions on the activation of acid sialidases
Biol. Pharm. Bull.
26
295-298
2003
Homo sapiens, Sus scrofa
brenda
Lukong, K.E.; Seyrantepe, V.; Landry, K.; Trudel, S.; Ahmad, A.; Gahl, W.A.; Lefrancois, S.; Morales, C.R.; Pshezhetsky, A.V.
Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail
J. Biol. Chem.
276
46172-46181
2001
Homo sapiens
brenda
Monti, E.; Bassi, M.T.; Bresciani, R.; Civini, S.; Croci, G.L.; Papini, N.; Riboni, M.; Zanchetti, G.; Ballabio, A.; Preti, A.; Tettamanti, G.; Venerando, B.; Borsani, G.
Molecular cloning and characterization of NEU4, the fourth member of the human sialidase gene family
Genomics
83
445-453
2004
Homo sapiens
brenda
Tringali, C.; Papini, N.; Fusi, P.; Croci, G.; Borsani, G.; Preti, A.; Tortora, P.; Tettamanti, G.; Venerando, B.; Monti, E.
Properties of recombinant human cytosolic sialidase HsNEU2: The enzyme hydrolyzes monomerically dispersed GM1 ganglioside molecules
J. Biol. Chem.
279
3169-3179
2004
Homo sapiens
brenda
Chavas, L.M.; Tringali, C.; Fusi, P.; Venerando, B.; Tettamanti, G.; Kato, R.; Monti, E.; Wakatsuki, S.
Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition
J. Biol. Chem.
280
469-475
2005
Homo sapiens (Q9Y3R4), Homo sapiens
brenda
Ha, K.; Cho, S.; Kang, S.; Kim, Y.; Kim, J.; Kim, C.
Cloning of human liver cytosolic sialidase from genomic DNA using splicing by overlap extension and its characterization
J. Microbiol. Biotechnol.
15
722-727
2005
Homo sapiens
-
brenda
Ha, K.T.; Lee, Y.C.; Cho, S.H.; Kim, J.K.; Kim, C.H.
Molecular characterization of membrane type and ganglioside-specific sialidase (Neu3) expressed in E. coli
Mol. Cell
17
267-273
2004
Homo sapiens
brenda
Yamaguchi, K.; Hata, K.; Wada, T.; Moriya, S.; Miyagi, T.
Epidermal growth factor-induced mobilization of a ganglioside-specific sialidase (NEU3) to membrane ruffles
Biochem. Biophys. Res. Commun.
346
484-490
2006
Homo sapiens (Q9UQ49), Homo sapiens
brenda
Moon, S.K.; Cho, S.H.; Kim, K.W.; Jeon, J.H.; Ko, J.H.; Kim, B.Y.; Kim, C.H.
Overexpression of membrane sialic acid-specific sialidase Neu3 inhibits matrix metalloproteinase-9 expression in vascular smooth muscle cells
Biochem. Biophys. Res. Commun.
356
542-547
2007
Homo sapiens (Q9UQ49)
brenda
Magesh, S.; Moriya, S.; Suzuki, T.; Miyagi, T.; Ishida, H.; Kiso, M.
Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: selective inhibitors of lysosomal sialidase (NEU1)
Bioorg. Med. Chem. Lett.
18
532-537
2008
Homo sapiens (Q99519), Homo sapiens
brenda
Aksenov, D.V.; Kaplun, V.V.; Tertov, V.V.; Sobenin, I.A.; Orekhov, A.N.
Effect of plant extracts on trans-sialidase activity in human blood plasma
Bull. Exp. Biol. Med.
143
46-50
2007
Homo sapiens
brenda
Hasegawa, T.; Sugeno, N.; Takeda, A.; Matsuzaki-Kobayashi, M.; Kikuchi, A.; Furukawa, K.; Miyagi, T.; Itoyama, Y.
Role of Neu4L sialidase and its substrate ganglioside GD3 in neuronal apoptosis induced by catechol metabolites
FEBS Lett.
581
406-412
2007
Homo sapiens
brenda
Nan, X.; Carubelli, I.; Stamatos, N.M.
Sialidase expression in activated human T lymphocytes influences production of IFN-gamma
J. Leukoc. Biol.
81
284-296
2007
Homo sapiens (Q99519), Homo sapiens (Q9UQ49), Homo sapiens
brenda
Magesh, S.; Suzuki, T.; Miyagi, T.; Ishida, H.; Kiso, M.
Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors
J. Mol. Graph. Model.
25
196-207
2006
Homo sapiens (Q8WWR8), Homo sapiens (Q9UQ49), Homo sapiens (Q9Y3R4), Homo sapiens
brenda
Yoshizumi, S.; Suzuki, S.; Hirai, M.; Hinokio, Y.; Yamada, T.; Yamada, T.; Tsunoda, U.; Aburatani, H.; Yamaguchi, K.; Miyagi, T.; Oka, Y.
Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice
Metab. Clin. Exp.
56
420-429
2007
Homo sapiens (Q9UQ49)
brenda
Hinek, A.; Bodnaruk, T.D.; Bunda, S.; Wang, Y.; Liu, K.
Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2
Am. J. Pathol.
173
1042-1056
2008
Clostridium perfringens, Homo sapiens
brenda
Jin, U.H.; Ha, K.T.; Kim, K.W.; Chang, Y.C.; Lee, Y.C.; Ko, J.H.; Kim, C.H.
Membrane type sialidase inhibits the megakaryocytic differentiation of human leukemia K562 cells
Biochim. Biophys. Acta
1780
757-763
2008
Homo sapiens
brenda
Shiozaki, K.; Yamaguchi, K.; Sato, I.; Miyagi, T.
Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice
Cancer Sci.
100
588-594
2009
Homo sapiens
brenda
Piagnerelli, M.; Boudjeltia, K.Z.; Rapotec, A.; Richard, T.; Brohee, D.; Babar, S.; Bouckaert, V.; Simon, A.C.; Toko, J.P.; Walravens, T.; Vincent, J.L.; Vanhaeverbeek, M.
Neuraminidase alters red blood cells in sepsis
Crit. Care Med.
37
1244-1250
2009
Clostridium perfringens, Homo sapiens
brenda
Yogalingam, G.; Bonten, E.J.; van de Vlekkert, D.; Hu, H.; Moshiach, S.; Connell, S.A.; dAzzo, A.
Neuraminidase 1 is a negative regulator of lysosomal exocytosis
Dev. Cell
15
74-86
2008
Mus musculus (O35657), Homo sapiens (Q99519), Homo sapiens
brenda
Gadhoum, S.Z.; Sackstein, R.
CD15 expression in human myeloid cell differentiation is regulated by sialidase activity
Nat. Chem. Biol.
4
751-757
2008
Homo sapiens
brenda
Uchihara, T.; Ohashi, K.; Kitagawa, M.; Kurata, M.; Nakamura, A.; Hirokawa, K.; Kasuga, T.; Kobayashi, T.
Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia
Acta Neuropathol.
119
135-145
2010
Homo sapiens
brenda
Magesh, S.; Savita, V.; Moriya, S.; Suzuki, T.; Miyagi, T.; Ishida, H.; Kiso, M.
Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids
Bioorg. Med. Chem.
17
4595-4603
2009
Homo sapiens (Q8WWR8), Homo sapiens (Q99519), Homo sapiens (Q9UQ49), Homo sapiens (Q9Y3R4), Homo sapiens
brenda
Arioka, S.; Sakagami, M.; Uematsu, R.; Yamaguchi, H.; Togame, H.; Takemoto, H.; Hinou, H.; Nishimura, S.
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase
Bioorg. Med. Chem.
18
1633-1640
2010
Homo sapiens, Trypanosoma cruzi
brenda
Bigi, A.; Morosi, L.; Pozzi, C.; Forcella, M.; Tettamanti, G.; Venerando, B.; Monti, E.; Fusi, P.
Human sialidase NEU4 long and short are extrinsic proteins bound to outer mitochondrial membrane and the endoplasmic reticulum, respectively
Glycobiology
20
148-157
2010
Homo sapiens
brenda
Bonten, E.J.; Campos, Y.; Zaitsev, V.; Nourse, A.; Waddell, B.; Lewis, W.; Taylor, G.; dAzzo, A.
Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization
J. Biol. Chem.
284
28430-28441
2009
Homo sapiens
brenda
Wang, J.; Wu, G.; Miyagi, T.; Lu, Z.H.; Ledeen, R.W.
Sialidase occurs in both membranes of the nuclear envelope and hydrolyzes endogenous GD1a
J. Neurochem.
111
547-554
2009
Homo sapiens (Q99519), Homo sapiens (Q9UQ49)
brenda
Sandbhor, M.S.; Soya, N.; Albohy, A.; Zheng, R.B.; Cartmell, J.; Bundle, D.R.; Klassen, J.S.; Cairo, C.W.
Substrate recognition of the membrane-associated sialidase NEU3 requires a hydrophobic aglycone
Biochemistry
50
6753-6762
2011
Homo sapiens
brenda
Albohy, A.; Li, M.D.; Zheng, R.B.; Zou, C.; Cairo, C.W.
Insight into substrate recognition and catalysis by the human neuraminidase 3 (NEU3) through molecular modeling and site-directed mutagenesis
Glycobiology
20
1127-1138
2010
Homo sapiens (Q9UQ49), Homo sapiens
brenda
Li, Y.; Cao, H.; Yu, H.; Chen, Y.; Lau, K.; Qu, J.; Thon, V.; Sugiarto, G.; Chen, X.
Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies
Mol. Biosyst.
7
1060-1072
2011
Homo sapiens
brenda
Bigi, A.; Tringali, C.; Forcella, M.; Mozzi, A.; Venerando, B.; Monti, E.; Fusi, P.
A proline-rich loop mediates specific functions of human sialidase NEU4 in SK-N-BE neuronal differentiation
Glycobiology
23
1499-1509
2013
Homo sapiens
brenda
Albohy, A.; Richards, M.R.; Cairo, C.W.
Mapping substrate interactions of the human membrane-associated neuraminidase, NEU3, using STD NMR
Glycobiology
25
284-293
2015
Homo sapiens (Q9UQ49), Homo sapiens
brenda
Cross, A.S.; Hyun, S.W.; Miranda-Ribera, A.; Feng, C.; Liu, A.; Nguyen, C.; Zhang, L.; Luzina, I.G.; Atamas, S.P.; Twaddell, W.S.; Guang, W.; Lillehoj, E.P.; Puche, A.C.; Huang, W.; Wang, L.X.; Passaniti, A.; Goldblum, S.E.
NEU1 and NEU3 sialidase activity expressed in human lung microvascular endothelia: NEU1 restrains endothelial cell migration, whereas NEU3 does not
J. Biol. Chem.
287
15966-15980
2012
Homo sapiens (Q99519), Homo sapiens (Q9UQ49), Homo sapiens
brenda
Khedri, Z.; Li, Y.; Cao, H.; Qu, J.; Yu, H.; Muthana, M.M.; Chen, X.
Synthesis of selective inhibitors against V. cholerae sialidase and human cytosolic sialidase NEU2
Org. Biomol. Chem.
10
6112-6120
2012
Streptococcus pneumoniae, Vibrio cholerae (P0C6E9), Vibrio cholerae, Clostridium perfringens (P10481), Salmonella enterica subsp. enterica serovar Typhimurium (P29768), Homo sapiens (Q9Y3R4), Homo sapiens
brenda
Bonardi, D.; Ravasio, V.; Borsani, G.; dAzzo, A.; Bresciani, R.; Monti, E.; Giacopuzzi, E.
In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization
PLoS ONE
9
e104229
2014
Homo sapiens (Q99519), Homo sapiens
brenda
Bonardi, D.; Papini, N.; Pasini, M.; Dileo, L.; Orizio, F.; Monti, E.; Caimi, L.; Venerando, B.; Bresciani, R.
Sialidase NEU3 dynamically associates to different membrane domains specifically modifying their ganglioside pattern and triggering Akt phosphorylation
PLoS ONE
9
e99405
2014
Homo sapiens (Q9UQ49)
brenda
Mozzi, A.; Mazzacuva, P.; Zampella, G.; Forcella, M.E.; Fusi, P.A.; Monti, E.
Molecular insight into substrate recognition by human cytosolic sialidase NEU2
Proteins
80
1123-1132
2012
Homo sapiens (Q9Y3R4), Homo sapiens
brenda
Hunter, C.D.; Khanna, N.; Richards, M.R.; Rezaei Darestani, R.; Zou, C.; Klassen, J.S.; Cairo, C.W.
Human neuraminidase isoenzymes show variable activities for 9-O-acetyl-sialoside substrates
ACS Chem. Biol.
13
922-932
2018
Homo sapiens
brenda
Paolini, L.; Orizio, F.; Busatto, S.; Radeghieri, A.; Bresciani, R.; Bergese, P.; Monti, E.
Exosomes secreted by hela cells shuttle on their surface the plasma membrane-associated sialidase NEU3
Biochemistry
56
6401-6408
2017
Homo sapiens
brenda
Hata, K.; Tochigi, T.; Sato, I.; Kawamura, S.; Shiozaki, K.; Wada, T.; Takahashi, K.; Moriya, S.; Yamaguchi, K.; Hosono, M.; Miyagi, T.
Increased sialidase activity in serum of cancer patients Identification of sialidase and inhibitor activities in human serum
Cancer Sci.
106
383-389
2015
Homo sapiens
brenda
EXTERNAL LINKS (specific for EC-Number 3.2.1.18)
Transporter Classification Database (TCDB): 1.A.32.1.3
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
